{"docstore/data": {"38dd1a7d-27ba-4335-9402-e03734054c3c": {"__data__": {"id_": "38dd1a7d-27ba-4335-9402-e03734054c3c", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n02-Feb-2021  \nMcKesson Corp.   (MCK ) \nQ3 2021 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n02-Feb-2021  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ce41d2b-3372-41ec-8dc6-18355fe24e8d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cb0620b4eb3c32156d5ab9c9941e10b0c7c3cc1b4c6a92ecdf52fb517b02ae4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa318a10-2b17-45a0-a4c7-11ca0eb5030d", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n02-Feb-2021  \nMcKesson Corp.   (MCK ) \nQ3 2021 Earnings Call    ", "original_text": "(MCK ) \nQ3 2021 Earnings Call    "}, "hash": "44ec2a6a4b4554736496a7b660d37a2a533cf0e7837c96b76fe222ede0ed37e2", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n02-Feb-2021  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa318a10-2b17-45a0-a4c7-11ca0eb5030d": {"__data__": {"id_": "aa318a10-2b17-45a0-a4c7-11ca0eb5030d", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n02-Feb-2021  \nMcKesson Corp.   (MCK ) \nQ3 2021 Earnings Call    ", "original_text": "(MCK ) \nQ3 2021 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ce41d2b-3372-41ec-8dc6-18355fe24e8d", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cb0620b4eb3c32156d5ab9c9941e10b0c7c3cc1b4c6a92ecdf52fb517b02ae4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38dd1a7d-27ba-4335-9402-e03734054c3c", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n02-Feb-2021  \nMcKesson Corp.   (MCK ) \nQ3 2021 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n02-Feb-2021  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37a3b76798f75310100252bbcc92e76e708b4833a342b78e722bf99da47fb5c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b545ce81-cc7e-4fa9-a7b7-bfc56d248bd8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  "}, "hash": "e8330c358d8c5da3206df570b6efc951e4971e5bf0b00f7c6049bce2addd030d", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call    ", "start_char_idx": 165, "end_char_idx": 198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b545ce81-cc7e-4fa9-a7b7-bfc56d248bd8": {"__data__": {"id_": "b545ce81-cc7e-4fa9-a7b7-bfc56d248bd8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0976cb6edb49aec4c30371a1955e58856efff00a6f4e807250d905be3229625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa318a10-2b17-45a0-a4c7-11ca0eb5030d", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n02-Feb-2021  \nMcKesson Corp.   (MCK ) \nQ3 2021 Earnings Call    ", "original_text": "(MCK ) \nQ3 2021 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bcbeeed735215ee7b91b075d9ef6ef109dd5427cbe08c23767421d816d2b355", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71877390-36c8-461c-b0a1-96a746e9ea03", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n"}, "hash": "14e025a8e0709d2d576070ebe6b95d283b36e67c1283d3359540eeaeaa25e7c1", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71877390-36c8-461c-b0a1-96a746e9ea03": {"__data__": {"id_": "71877390-36c8-461c-b0a1-96a746e9ea03", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0976cb6edb49aec4c30371a1955e58856efff00a6f4e807250d905be3229625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b545ce81-cc7e-4fa9-a7b7-bfc56d248bd8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2349f472989e261a2ee02bf67c5fc4115d7f917f33189d829baa5175d2fba653", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48c17cbb-eb22-4ffe-8efd-c1227a965b57", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "d6f6d865bfca8d36c86a72a94812fcaac1edd47d1ac4b7454c43b04a40ef05a6", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48c17cbb-eb22-4ffe-8efd-c1227a965b57": {"__data__": {"id_": "48c17cbb-eb22-4ffe-8efd-c1227a965b57", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0976cb6edb49aec4c30371a1955e58856efff00a6f4e807250d905be3229625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71877390-36c8-461c-b0a1-96a746e9ea03", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "976188d7c592fa267e15cffad687f3967ad178aa40130e43ef8c25ffc259766d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6071895-5869-40fb-b13a-d38dd1a512d8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co. ", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n "}, "hash": "594edcab59bf5e9c43d018d21fd5c08ea43e7d29b21b1ba07944f84a47cf5cf0", "class_name": "RelatedNodeInfo"}}, "text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 313, "end_char_idx": 385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6071895-5869-40fb-b13a-d38dd1a512d8": {"__data__": {"id_": "d6071895-5869-40fb-b13a-d38dd1a512d8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co. ", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0976cb6edb49aec4c30371a1955e58856efff00a6f4e807250d905be3229625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48c17cbb-eb22-4ffe-8efd-c1227a965b57", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74a1ecfebd11ae55b5a5831432d3836c09dd57e990a54a4c068faf6479f9b63e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b83f4e1-444a-42b3-874e-a7787747e24f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n"}, "hash": "b7b80fd42a62710e7a7d2338ef943ea204720af30d9c677fd106f1285f9e5c81", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "start_char_idx": 385, "end_char_idx": 475, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b83f4e1-444a-42b3-874e-a7787747e24f": {"__data__": {"id_": "7b83f4e1-444a-42b3-874e-a7787747e24f", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0976cb6edb49aec4c30371a1955e58856efff00a6f4e807250d905be3229625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6071895-5869-40fb-b13a-d38dd1a512d8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co. ", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c41dc29cdc97fb9a4ff2b3dab4e0ff42b8824612c1e98ab2afc634681e7e5c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70197d07-7432-4104-8330-93d4f97f51b7", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n"}, "hash": "5de696a425f510980ff3a6842319ad866e1535d2eb7881472129b2abf39445a3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "start_char_idx": 475, "end_char_idx": 807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70197d07-7432-4104-8330-93d4f97f51b7": {"__data__": {"id_": "70197d07-7432-4104-8330-93d4f97f51b7", "embedding": null, "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0976cb6edb49aec4c30371a1955e58856efff00a6f4e807250d905be3229625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b83f4e1-444a-42b3-874e-a7787747e24f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b76a76af83196624d76b18910d66c58cb92f67c5be9e8d9ab0232f55a9a3cb84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b286532c-a62d-461a-be8b-78fb9bf58770", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ", "original_text": "Robert P. Jo nes \nAnalyst, Goldman Sachs & Co. "}, "hash": "ec94f98ab20368d86fd6b94b75f207547667322aae8969a3ef73f9affdaa536d", "class_name": "RelatedNodeInfo"}}, "text": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "start_char_idx": 807, "end_char_idx": 918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b286532c-a62d-461a-be8b-78fb9bf58770": {"__data__": {"id_": "b286532c-a62d-461a-be8b-78fb9bf58770", "embedding": null, "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ", "original_text": "Robert P. Jo nes \nAnalyst, Goldman Sachs & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0976cb6edb49aec4c30371a1955e58856efff00a6f4e807250d905be3229625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70197d07-7432-4104-8330-93d4f97f51b7", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54dd96334c2621683971e7abfe803261bcbd61f838b82a7ab9f24fe35b1e6a6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecc443c4-d1f3-4098-aebd-dca88772981e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ", "original_text": "LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "5a64e35cf180af13d1b969178f0899696aa20956d8adaa27ce9fb90dcc57d5b0", "class_name": "RelatedNodeInfo"}}, "text": "Robert P. Jo nes \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 918, "end_char_idx": 965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecc443c4-d1f3-4098-aebd-dca88772981e": {"__data__": {"id_": "ecc443c4-d1f3-4098-aebd-dca88772981e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ", "original_text": "LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0976cb6edb49aec4c30371a1955e58856efff00a6f4e807250d905be3229625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b286532c-a62d-461a-be8b-78fb9bf58770", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ", "original_text": "Robert P. Jo nes \nAnalyst, Goldman Sachs & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3c15a3a6d7fbf56401e0dc364b437c5b2157b9436356b3b9c7b7834882494e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba51a396-2c18-4f9b-94a0-4233194e9be8", "node_type": "1", "metadata": {"window": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ", "original_text": "LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "b96e639841a58c7d2f68d1625586a42ee1101f921b41bf8562a6daadde92c255", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 965, "end_char_idx": 1008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba51a396-2c18-4f9b-94a0-4233194e9be8": {"__data__": {"id_": "ba51a396-2c18-4f9b-94a0-4233194e9be8", "embedding": null, "metadata": {"window": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ", "original_text": "LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0976cb6edb49aec4c30371a1955e58856efff00a6f4e807250d905be3229625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecc443c4-d1f3-4098-aebd-dca88772981e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ", "original_text": "LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "934674c5adb20c17ea0864d48b611394606304b3a2fc10c5e8cdbeadb82a66a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d094fb8-dace-4cba-a878-9a43d07bcebf", "node_type": "1", "metadata": {"window": "Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ", "original_text": "LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  "}, "hash": "e6fc38587443414bac10e562a72d6fb9452e7f052ba487f4bf9d8ee440e28a05", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 1008, "end_char_idx": 1231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d094fb8-dace-4cba-a878-9a43d07bcebf": {"__data__": {"id_": "7d094fb8-dace-4cba-a878-9a43d07bcebf", "embedding": null, "metadata": {"window": "Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ", "original_text": "LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0976cb6edb49aec4c30371a1955e58856efff00a6f4e807250d905be3229625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba51a396-2c18-4f9b-94a0-4233194e9be8", "node_type": "1", "metadata": {"window": "Lisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ", "original_text": "LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34fe01b1a534a06b3f006f7944b657ed4ffb23f2c401b9fc92c6685d0c16abe0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78eb8fd5-0524-4b07-b320-1f7af98185f6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "original_text": "McKesson Corp.  "}, "hash": "d10730899751bc1886a640126f32b711ffe8467821f164c026ab6a5a18ce1d93", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ", "start_char_idx": 1231, "end_char_idx": 1295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78eb8fd5-0524-4b07-b320-1f7af98185f6": {"__data__": {"id_": "78eb8fd5-0524-4b07-b320-1f7af98185f6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d094fb8-dace-4cba-a878-9a43d07bcebf", "node_type": "1", "metadata": {"window": "Robert P. Jo nes \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ", "original_text": "LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f61da0f2d71f1f975aa3f96acb63e83986d8833fdb7a5b5ae0b68b862a4b30d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82bd315a-fbaa-4d21-a386-2c46c7d0feb0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n"}, "hash": "1c2e3bacfb34f809c381eedc5565542980303bb47dc94aea0324a981368439d4", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82bd315a-fbaa-4d21-a386-2c46c7d0feb0": {"__data__": {"id_": "82bd315a-fbaa-4d21-a386-2c46c7d0feb0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78eb8fd5-0524-4b07-b320-1f7af98185f6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5b293b7b817b4a52951904b73cb95560f5372d6795e9a9927b367c097c57671", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55b759ef-c781-4fec-ac9f-7b52c205d702", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "original_text": "Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call. "}, "hash": "2720dcc1e9335faebccb3d2f859642d1a702c9ca3c4b05aa7668ba8828d451d2", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55b759ef-c781-4fec-ac9f-7b52c205d702": {"__data__": {"id_": "55b759ef-c781-4fec-ac9f-7b52c205d702", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "original_text": "Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82bd315a-fbaa-4d21-a386-2c46c7d0feb0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e2f79ae5e149d74095d877955b824f1787e6c41da7f3eea0e45d0016fb1895e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72f54f0b-0978-4278-8f7b-0f1b7008ed0a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. "}, "hash": "440e08565be4081f80f871f4802f56c6e365ac613eb8c09cd43e407005294c7c", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call. ", "start_char_idx": 319, "end_char_idx": 412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72f54f0b-0978-4278-8f7b-0f1b7008ed0a": {"__data__": {"id_": "72f54f0b-0978-4278-8f7b-0f1b7008ed0a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55b759ef-c781-4fec-ac9f-7b52c205d702", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "original_text": "Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6846dfe877b0948f16ff37e3d7e9fbb84a5f35cd67dd466ead11f4425db1daa9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "731545b3-a454-44d6-a58f-dd7ae2b8e975", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n"}, "hash": "aa82fda132e97d68cb6c90655f69a0ec782c6bb07160fc9e198fe5ad31cbadd3", "class_name": "RelatedNodeInfo"}}, "text": "Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "start_char_idx": 412, "end_char_idx": 525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "731545b3-a454-44d6-a58f-dd7ae2b8e975": {"__data__": {"id_": "731545b3-a454-44d6-a58f-dd7ae2b8e975", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72f54f0b-0978-4278-8f7b-0f1b7008ed0a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6049d9cbf4fa79fab275dee51c79cafb1c2c3d6723d3d9837297661477c66408", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f20d1cfc-94d8-496b-be4d-6a6860a1f210", "node_type": "1", "metadata": {"window": "Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n", "original_text": "Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. "}, "hash": "7f602241e77396f7e6606f73daa490e7f5fdb48a2c851e26ed6f9e2e12810156", "class_name": "RelatedNodeInfo"}}, "text": "Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n", "start_char_idx": 525, "end_char_idx": 628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f20d1cfc-94d8-496b-be4d-6a6860a1f210": {"__data__": {"id_": "f20d1cfc-94d8-496b-be4d-6a6860a1f210", "embedding": null, "metadata": {"window": "Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n", "original_text": "Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "731545b3-a454-44d6-a58f-dd7ae2b8e975", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3703ea312b73bf991be3c95fd5399fe890dffd3dcc653e3742e2c64580bfe432", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "336706fe-f05e-497c-98c1-1c06fb3c86bb", "node_type": "1", "metadata": {"window": "Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n"}, "hash": "048ee4f76acabceb560840b2a25f231db28f103a9a424e4d8af77869afc97780", "class_name": "RelatedNodeInfo"}}, "text": "Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "start_char_idx": 628, "end_char_idx": 755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "336706fe-f05e-497c-98c1-1c06fb3c86bb": {"__data__": {"id_": "336706fe-f05e-497c-98c1-1c06fb3c86bb", "embedding": null, "metadata": {"window": "Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f20d1cfc-94d8-496b-be4d-6a6860a1f210", "node_type": "1", "metadata": {"window": "Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n", "original_text": "Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09bcda42c3257f1ee4dd0213a512e287d843c7077b4e375a61ffdccb63966d64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a94b739-6aef-4e25-a694-41137a34bb1a", "node_type": "1", "metadata": {"window": "Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. "}, "hash": "fb15bf78722d2325035a4cee0d038e42a0250decc796f69d27d0d87b32959032", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "start_char_idx": 755, "end_char_idx": 1070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a94b739-6aef-4e25-a694-41137a34bb1a": {"__data__": {"id_": "9a94b739-6aef-4e25-a694-41137a34bb1a", "embedding": null, "metadata": {"window": "Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "336706fe-f05e-497c-98c1-1c06fb3c86bb", "node_type": "1", "metadata": {"window": "Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5589f908cf0d4e4ae9ed88d1ed2548bba682bf108a4d1e4953159f33fdf84b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "228d66c9-2eef-40a6-9187-8678403993b7", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody. ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n"}, "hash": "3ab53fcbd2dc551bdcd24d41c26004bcf1529c0d8d585ec27e8e3aab21a5bd10", "class_name": "RelatedNodeInfo"}}, "text": "During this call, we will discuss non -GAAP financial measures. ", "start_char_idx": 1070, "end_char_idx": 1134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "228d66c9-2eef-40a6-9187-8678403993b7": {"__data__": {"id_": "228d66c9-2eef-40a6-9187-8678403993b7", "embedding": null, "metadata": {"window": "Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody. ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a94b739-6aef-4e25-a694-41137a34bb1a", "node_type": "1", "metadata": {"window": "Brian will lead off, \nfollowed by Britt, and then we will move to a qu estion -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9d7abec2f962784c90011ae954eb5d4eb61655ba1f7188bf977207b61bd9617", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db6795b3-6d96-4dee-91d4-db0d010009a3", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n", "original_text": "With that, let me turn it over to Brian.  \n "}, "hash": "b9f6a29d1586e6f2fc64526a7a7ae213be281eda59b987dd0c5ee7790dc6f964", "class_name": "RelatedNodeInfo"}}, "text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n", "start_char_idx": 1134, "end_char_idx": 1389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db6795b3-6d96-4dee-91d4-db0d010009a3": {"__data__": {"id_": "db6795b3-6d96-4dee-91d4-db0d010009a3", "embedding": null, "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "228d66c9-2eef-40a6-9187-8678403993b7", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements, such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody. ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e88d9c368979ac57db86760832fe6166fefa07955bc5ebc6a3edd0134d66c4ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bf2f928-5cc0-4e76-8ede-441a43167d80", "node_type": "1", "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "b0005f40a1473e18cde69b75e43276b4f698fbba5ff828ab85479f8307943fb8", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it over to Brian.  \n ", "start_char_idx": 1389, "end_char_idx": 1433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bf2f928-5cc0-4e76-8ede-441a43167d80": {"__data__": {"id_": "0bf2f928-5cc0-4e76-8ede-441a43167d80", "embedding": null, "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db6795b3-6d96-4dee-91d4-db0d010009a3", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "faa81611bf3f794d2d0f51acbdef5eefa1661691938c929db0dd7ce03b1bdd74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74725430-9b72-4525-bf0e-e524b3b7ea14", "node_type": "1", "metadata": {"window": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis. ", "original_text": "Thank you, Holly, and good morning, everybody. "}, "hash": "9394e7a4937e02a76407fd2cb4f1c6cca3e6ea32bf9a568538415168affefcf5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 1433, "end_char_idx": 1763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74725430-9b72-4525-bf0e-e524b3b7ea14": {"__data__": {"id_": "74725430-9b72-4525-bf0e-e524b3b7ea14", "embedding": null, "metadata": {"window": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis. ", "original_text": "Thank you, Holly, and good morning, everybody. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bf2f928-5cc0-4e76-8ede-441a43167d80", "node_type": "1", "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64e5f42b382dd54cd95b9a289aa346eae3512bbe760de0707cebc21c5df97ce9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4809b82a-5848-4f80-af25-d50cd72838c0", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability. ", "original_text": "I appreciate you joining us on our call today.  \n \n"}, "hash": "ee9cd6fd46633b719c1dee2bd117deceea67f0491fc9e46d98fcbc9726c594c3", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Holly, and good morning, everybody. ", "start_char_idx": 1763, "end_char_idx": 1810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4809b82a-5848-4f80-af25-d50cd72838c0": {"__data__": {"id_": "4809b82a-5848-4f80-af25-d50cd72838c0", "embedding": null, "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability. ", "original_text": "I appreciate you joining us on our call today.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74725430-9b72-4525-bf0e-e524b3b7ea14", "node_type": "1", "metadata": {"window": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mck esson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis. ", "original_text": "Thank you, Holly, and good morning, everybody. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3728c0a3fa25a8c1dc37a8166634ea8b1d0f09090b01ddc6182d3d5e3f8f622b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f90bcae-b99f-4f50-ae35-afabb9c6b57f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n", "original_text": "Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims. "}, "hash": "ed47d8095eb144b6279de834f92af66769b475402f951949926d9a78d5ba2a0d", "class_name": "RelatedNodeInfo"}}, "text": "I appreciate you joining us on our call today.  \n \n", "start_char_idx": 1810, "end_char_idx": 1861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f90bcae-b99f-4f50-ae35-afabb9c6b57f": {"__data__": {"id_": "6f90bcae-b99f-4f50-ae35-afabb9c6b57f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n", "original_text": "Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4809b82a-5848-4f80-af25-d50cd72838c0", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability. ", "original_text": "I appreciate you joining us on our call today.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11600bf568401e5f7d6c20e07a889ff3cb7ace4a0f50e1df8856deb3c1ede20b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fa3900c-7811-452b-9c1e-4b3a086ff437", "node_type": "1", "metadata": {"window": "Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results. ", "original_text": "In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis. "}, "hash": "965360df9e2d806a0fd2c775d6acacd8726c5d26da9e2a501804717aba90c2c4", "class_name": "RelatedNodeInfo"}}, "text": "Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims. ", "start_char_idx": 1861, "end_char_idx": 2072, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fa3900c-7811-452b-9c1e-4b3a086ff437": {"__data__": {"id_": "7fa3900c-7811-452b-9c1e-4b3a086ff437", "embedding": null, "metadata": {"window": "Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results. ", "original_text": "In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f90bcae-b99f-4f50-ae35-afabb9c6b57f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n", "original_text": "Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46377a4bb3351d30436b02746589978c35d198bdfa8111658c0972d011a252e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6d0dbb3-be71-4cbb-9e49-82565ac4a6a7", "node_type": "1", "metadata": {"window": "I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November. ", "original_text": "We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability. "}, "hash": "089b862ad690b12ae3b48b9f7b0df70d3c31c1255319dd9a7b6069ffda39fa93", "class_name": "RelatedNodeInfo"}}, "text": "In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis. ", "start_char_idx": 2072, "end_char_idx": 2332, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6d0dbb3-be71-4cbb-9e49-82565ac4a6a7": {"__data__": {"id_": "d6d0dbb3-be71-4cbb-9e49-82565ac4a6a7", "embedding": null, "metadata": {"window": "I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November. ", "original_text": "We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fa3900c-7811-452b-9c1e-4b3a086ff437", "node_type": "1", "metadata": {"window": "Thank you, Holly, and good morning, everybody.  I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results. ", "original_text": "In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a07bb2ea16bcf0dc9dc61cfa2b76f2525dedaeea6089a8d75c5ec48fa45e310", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8359b3ff-1fdc-455c-b629-162a697b904a", "node_type": "1", "metadata": {"window": "Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic. ", "original_text": "Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n"}, "hash": "885d062efb2b15999e0190b7baaad93a48f4492d594c1d7da30e028bb3e30b55", "class_name": "RelatedNodeInfo"}}, "text": "We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability. ", "start_char_idx": 2332, "end_char_idx": 2577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8359b3ff-1fdc-455c-b629-162a697b904a": {"__data__": {"id_": "8359b3ff-1fdc-455c-b629-162a697b904a", "embedding": null, "metadata": {"window": "Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic. ", "original_text": "Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6d0dbb3-be71-4cbb-9e49-82565ac4a6a7", "node_type": "1", "metadata": {"window": "I appreciate you joining us on our call today.  \n \n Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November. ", "original_text": "We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4922dac66997f91bdd725f23564321070af54f143341b9566c5acb8fccc25130", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bea181dd-df31-4a25-bca7-0880cbab7b4e", "node_type": "1", "metadata": {"window": "In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n", "original_text": "Now let's get to the results. "}, "hash": "4c5e4108652a2e91cfbb1601924798ce24f3f28df4530caf80cf7d701383843c", "class_name": "RelatedNodeInfo"}}, "text": "Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n", "start_char_idx": 2577, "end_char_idx": 2807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bea181dd-df31-4a25-bca7-0880cbab7b4e": {"__data__": {"id_": "bea181dd-df31-4a25-bca7-0880cbab7b4e", "embedding": null, "metadata": {"window": "In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n", "original_text": "Now let's get to the results. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8359b3ff-1fdc-455c-b629-162a697b904a", "node_type": "1", "metadata": {"window": "Before I get to our third quarter re sults, I'd like to update you on the status of discussions related to a framework \nproposed by a group of attorneys general for a broad resolution of opioid -related claims.  In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic. ", "original_text": "Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd6dd637746f2cea4023447dcf2302e237393de0dabfa642067fdf30e4da427a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c95631b-be0f-46a2-b842-11b065048fd0", "node_type": "1", "metadata": {"window": "We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad. ", "original_text": "We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November. "}, "hash": "d91445446dbb25a1246d8ab1891440b2ed8f2ff3b9f1dd104de2806af7a42e6c", "class_name": "RelatedNodeInfo"}}, "text": "Now let's get to the results. ", "start_char_idx": 2807, "end_char_idx": 2837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c95631b-be0f-46a2-b842-11b065048fd0": {"__data__": {"id_": "0c95631b-be0f-46a2-b842-11b065048fd0", "embedding": null, "metadata": {"window": "We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad. ", "original_text": "We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bea181dd-df31-4a25-bca7-0880cbab7b4e", "node_type": "1", "metadata": {"window": "In the third quarter, we \nmade an accrual of approximately $8.1 billion, reflecting t he amount we would expect to pay over a period of 18 \nyears for opioid -related claims of governmental entities, with more than 90% intended to remediate the opioid \ncrisis.  We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n", "original_text": "Now let's get to the results. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "744ea20ebe459ef9e4c3064a9aa5e6b9cdb369da19799f10f57d411c7fdeb3b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1684d46-5827-4295-90f4-26eb2038a823", "node_type": "1", "metadata": {"window": "Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad.  Our fundamentals remain strong and we continue to see success across the differentiated \nassets i n our broad portfolio.  \n ", "original_text": "The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic. "}, "hash": "19a13320fe723aa31ad7efedfef8376a0ac05c4afa50d99a10dbb9bd70b946c1", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November. ", "start_char_idx": 2837, "end_char_idx": 3058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1684d46-5827-4295-90f4-26eb2038a823": {"__data__": {"id_": "f1684d46-5827-4295-90f4-26eb2038a823", "embedding": null, "metadata": {"window": "Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad.  Our fundamentals remain strong and we continue to see success across the differentiated \nassets i n our broad portfolio.  \n ", "original_text": "The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c95631b-be0f-46a2-b842-11b065048fd0", "node_type": "1", "metadata": {"window": "We continue to be in ongoing advanced discussions with state attorneys general and co unsel for plaintiffs; \nand based on the substantial progress we have made toward a settlement, we determined it was appropriate to \naccrue for this liability.  Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad. ", "original_text": "We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e542511ac2eae5a885d575b271c5401e11a35a6cf202a6a680d14f54eb45bff2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b78783a0-259e-4a47-a841-bb9110ebdd7e", "node_type": "1", "metadata": {"window": "Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad.  Our fundamentals remain strong and we continue to see success across the differentiated \nassets i n our broad portfolio.  \n ", "original_text": "W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n"}, "hash": "7741f29b4298077be69619d14c9e5727d99a02077dcbeda1b5135d093dcba8cf", "class_name": "RelatedNodeInfo"}}, "text": "The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic. ", "start_char_idx": 3058, "end_char_idx": 3197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b78783a0-259e-4a47-a841-bb9110ebdd7e": {"__data__": {"id_": "b78783a0-259e-4a47-a841-bb9110ebdd7e", "embedding": null, "metadata": {"window": "Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad.  Our fundamentals remain strong and we continue to see success across the differentiated \nassets i n our broad portfolio.  \n ", "original_text": "W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1684d46-5827-4295-90f4-26eb2038a823", "node_type": "1", "metadata": {"window": "Although we're prepared to defend ourselves vigorously, we remain hopeful that a broad \nresolution c an be achieved, which would accelerate relief efforts for the people and communities impacted by this \npublic health crisis.  \n \n Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad.  Our fundamentals remain strong and we continue to see success across the differentiated \nassets i n our broad portfolio.  \n ", "original_text": "The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0230d499b25dd66b32a75962686ca55160311e3abea1a1f4a78d7d233c2590d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b85a0100-79ab-446e-a517-c41cd67dda83", "node_type": "1", "metadata": {"window": "We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad.  Our fundamentals remain strong and we continue to see success across the differentiated \nassets i n our broad portfolio.  \n ", "original_text": "Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad. "}, "hash": "fe729097a7cf79e59b542d9c0c671f25bf8e426d23dad6e5141b0c3faee0535b", "class_name": "RelatedNodeInfo"}}, "text": "W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n", "start_char_idx": 3197, "end_char_idx": 3374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b85a0100-79ab-446e-a517-c41cd67dda83": {"__data__": {"id_": "b85a0100-79ab-446e-a517-c41cd67dda83", "embedding": null, "metadata": {"window": "We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad.  Our fundamentals remain strong and we continue to see success across the differentiated \nassets i n our broad portfolio.  \n ", "original_text": "Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b78783a0-259e-4a47-a841-bb9110ebdd7e", "node_type": "1", "metadata": {"window": "Now let's get to the results.  We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad.  Our fundamentals remain strong and we continue to see success across the differentiated \nassets i n our broad portfolio.  \n ", "original_text": "W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d8cd676ee72d0cbd35abc6581a049a1151def72f0c2054fa8601aa6c81b2cd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5a6e967-fe33-4f7e-8e6d-b24dc8994b8b", "node_type": "1", "metadata": {"window": "The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad.  Our fundamentals remain strong and we continue to see success across the differentiated \nassets i n our broad portfolio.  \n ", "original_text": "Our fundamentals remain strong and we continue to see success across the differentiated \nassets i n our broad portfolio.  \n "}, "hash": "9f55c43f425cd3fbf8dbd5ecc1928026e770532d51bd821cd1870ffdf191f1b8", "class_name": "RelatedNodeInfo"}}, "text": "Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad. ", "start_char_idx": 3374, "end_char_idx": 3624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5a6e967-fe33-4f7e-8e6d-b24dc8994b8b": {"__data__": {"id_": "a5a6e967-fe33-4f7e-8e6d-b24dc8994b8b", "embedding": null, "metadata": {"window": "The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad.  Our fundamentals remain strong and we continue to see success across the differentiated \nassets i n our broad portfolio.  \n ", "original_text": "Our fundamentals remain strong and we continue to see success across the differentiated \nassets i n our broad portfolio.  \n ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2f4f7892f3d54edc14f1c921caf05c7bfe19a877d86254e61f2accb7e76742", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b85a0100-79ab-446e-a517-c41cd67dda83", "node_type": "1", "metadata": {"window": "We're pleased to report third quarter total company revenues of $62.6 billion and an \nadjusted earning s per diluted share of $4.60, which is ahead of the prior year and the revised expectations we laid \nout in November.  The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad.  Our fundamentals remain strong and we continue to see success across the differentiated \nassets i n our broad portfolio.  \n ", "original_text": "Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad. ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7af67149bb039601decd6e0bbd23174a6abc72b95f5f30da99b75af4401b27b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d3cfddc-4c1e-4c96-808b-9baaae2713db", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share.  This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "48eb5f4e12f0565587601426c0ce95712f51516765cd93b08542b613563fee17", "class_name": "RelatedNodeInfo"}}, "text": "Our fundamentals remain strong and we continue to see success across the differentiated \nassets i n our broad portfolio.  \n ", "start_char_idx": 3624, "end_char_idx": 3748, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d3cfddc-4c1e-4c96-808b-9baaae2713db": {"__data__": {"id_": "6d3cfddc-4c1e-4c96-808b-9baaae2713db", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share.  This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5a6e967-fe33-4f7e-8e6d-b24dc8994b8b", "node_type": "1", "metadata": {"window": "The third quarter was yet another example of the often unpredictable and dynamic nature of the \nrecovery from the effects of the pandemic.  W hile heightened demand persisted for products like COVID -19 tests \nand PPE, medical visits and prescription volume trends did show some signs of softness in the quarter.  \n \n Despite those macro trends, we're pleased to have grown adjusted operating profit acro ss each of our segments, \nand our third quarter results reflect the important role McKesson plays in the response to the COVID -19 pandemic \nin the US and abroad.  Our fundamentals remain strong and we continue to see success across the differentiated \nassets i n our broad portfolio.  \n ", "original_text": "Our fundamentals remain strong and we continue to see success across the differentiated \nassets i n our broad portfolio.  \n ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcf351114ddf3454c86e14392fe735272a84382a935b6323b610ec546d3d426e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d104eef-e398-47a3-abe6-0533b9efe8bc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share.  This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share. "}, "hash": "5d2956a5b1aa2686fdfc9048c993328f0c6e560292a137698154b01a76ec488c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d104eef-e398-47a3-abe6-0533b9efe8bc": {"__data__": {"id_": "5d104eef-e398-47a3-abe6-0533b9efe8bc", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share.  This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d3cfddc-4c1e-4c96-808b-9baaae2713db", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share.  This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2631f1bcf845837dbfa298ed49acc863578b7760f9a5d57c60bafef06a0afeca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b375ff6-850e-4f61-b00b-56cbe781c5b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share.  This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship. ", "original_text": "This is up from our previous range of $16 to $16.50 per diluted share. "}, "hash": "caab171ff92aa8cfd62deea44466d7ed08fcc5d259e6a69d0de8427b18b4eed7", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share. ", "start_char_idx": 16, "end_char_idx": 322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b375ff6-850e-4f61-b00b-56cbe781c5b7": {"__data__": {"id_": "6b375ff6-850e-4f61-b00b-56cbe781c5b7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share.  This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship. ", "original_text": "This is up from our previous range of $16 to $16.50 per diluted share. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d104eef-e398-47a3-abe6-0533b9efe8bc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share.  This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ba984b20c729114e891301f853d0827dede37090a36c49681c41333a5688ea2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0915b0c5-28f3-461c-b871-5ed14b2295c6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share.  This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n", "original_text": "This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n"}, "hash": "447e2ac1e042f6e9694a6d491069f7519ca278b0dbc29d117eaa12c7f7616803", "class_name": "RelatedNodeInfo"}}, "text": "This is up from our previous range of $16 to $16.50 per diluted share. ", "start_char_idx": 322, "end_char_idx": 393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0915b0c5-28f3-461c-b871-5ed14b2295c6": {"__data__": {"id_": "0915b0c5-28f3-461c-b871-5ed14b2295c6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share.  This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n", "original_text": "This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b375ff6-850e-4f61-b00b-56cbe781c5b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share.  This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship. ", "original_text": "This is up from our previous range of $16 to $16.50 per diluted share. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a057051c0d811c75e46a2138c7b723e7a35d1c47ca11a7e82887da5383b0e8b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1410ec46-cdb1-46df-bc5a-793e520f19f2", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share.  This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work. ", "original_text": "Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US. "}, "hash": "1273cda855683441a000481bf38d0e547a4039c3ec1ecf17c3ff8e06617da796", "class_name": "RelatedNodeInfo"}}, "text": "This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n", "start_char_idx": 393, "end_char_idx": 643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1410ec46-cdb1-46df-bc5a-793e520f19f2": {"__data__": {"id_": "1410ec46-cdb1-46df-bc5a-793e520f19f2", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share.  This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work. ", "original_text": "Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0915b0c5-28f3-461c-b871-5ed14b2295c6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share.  This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n", "original_text": "This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02085464e3962d416f0df0d360c7d0873540f234bed2f3234856334eaf963071", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2551dd1c-b3b3-4177-a1ba-2bd472d9e297", "node_type": "1", "metadata": {"window": "This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part. ", "original_text": "In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship. "}, "hash": "cc04521338230481717269715a66106afdba587ee48e61054f0da30f32f244a6", "class_name": "RelatedNodeInfo"}}, "text": "Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US. ", "start_char_idx": 643, "end_char_idx": 794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2551dd1c-b3b3-4177-a1ba-2bd472d9e297": {"__data__": {"id_": "2551dd1c-b3b3-4177-a1ba-2bd472d9e297", "embedding": null, "metadata": {"window": "This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part. ", "original_text": "In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1410ec46-cdb1-46df-bc5a-793e520f19f2", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share.  This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work. ", "original_text": "Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f58fb02bffbf3eb44ad4b5d5cc053ba15223806d67bf558f25c93d053a22a8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37cbd0c5-42dc-4e62-ba1c-d9114fe303c8", "node_type": "1", "metadata": {"window": "This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution. ", "original_text": "The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n"}, "hash": "400d4e89190539c9af97d67f3698d0a5f079325e364cd1fcc53bbadcf8be1e33", "class_name": "RelatedNodeInfo"}}, "text": "In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship. ", "start_char_idx": 794, "end_char_idx": 945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37cbd0c5-42dc-4e62-ba1c-d9114fe303c8": {"__data__": {"id_": "37cbd0c5-42dc-4e62-ba1c-d9114fe303c8", "embedding": null, "metadata": {"window": "This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution. ", "original_text": "The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2551dd1c-b3b3-4177-a1ba-2bd472d9e297", "node_type": "1", "metadata": {"window": "This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part. ", "original_text": "In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f0652b0a11335eb92bd28da30d9db768ea445cb963b0147becb3962e9c7fc848", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb141e98-deb4-4dcc-abf1-79b213a9d1f0", "node_type": "1", "metadata": {"window": "Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work. ", "original_text": "Our team immediately got to work. "}, "hash": "f2fdf39f5444892da1bd103db91c5781ec1eb07a1594805342a9bfcac12df32d", "class_name": "RelatedNodeInfo"}}, "text": "The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n", "start_char_idx": 945, "end_char_idx": 1220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb141e98-deb4-4dcc-abf1-79b213a9d1f0": {"__data__": {"id_": "bb141e98-deb4-4dcc-abf1-79b213a9d1f0", "embedding": null, "metadata": {"window": "Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work. ", "original_text": "Our team immediately got to work. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37cbd0c5-42dc-4e62-ba1c-d9114fe303c8", "node_type": "1", "metadata": {"window": "This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution. ", "original_text": "The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc7bea54ea7f9f9724d8299e32bcbb7162de155350fe5b2ee3c0db464435dbc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3491bef1-5fc2-4917-92da-f170209f7fd7", "node_type": "1", "metadata": {"window": "In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n", "original_text": "Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part. "}, "hash": "c9d964a7ff9980bfca3bf8c9d93ff875245d085206e8cbc84968d27c659fa982", "class_name": "RelatedNodeInfo"}}, "text": "Our team immediately got to work. ", "start_char_idx": 1220, "end_char_idx": 1254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3491bef1-5fc2-4917-92da-f170209f7fd7": {"__data__": {"id_": "3491bef1-5fc2-4917-92da-f170209f7fd7", "embedding": null, "metadata": {"window": "In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n", "original_text": "Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb141e98-deb4-4dcc-abf1-79b213a9d1f0", "node_type": "1", "metadata": {"window": "Before turning to the business, I do want to expand on the work being done across McKesson in support of the \nCOVID -19 vaccination efforts in the US.  In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work. ", "original_text": "Our team immediately got to work. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5769c90f7718a49506b18309962a175d61013457b6e297018be412f46db72dee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22d9eb2a-fa9a-42c9-8cdd-c2bc833d2649", "node_type": "1", "metadata": {"window": "The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA. ", "original_text": "We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution. "}, "hash": "7cde7c994567f5e9c8cf2f3253a902a4d31e0127de69dda20e2b49b20b17a954", "class_name": "RelatedNodeInfo"}}, "text": "Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part. ", "start_char_idx": 1254, "end_char_idx": 1550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22d9eb2a-fa9a-42c9-8cdd-c2bc833d2649": {"__data__": {"id_": "22d9eb2a-fa9a-42c9-8cdd-c2bc833d2649", "embedding": null, "metadata": {"window": "The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA. ", "original_text": "We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3491bef1-5fc2-4917-92da-f170209f7fd7", "node_type": "1", "metadata": {"window": "In August of last year, the CDC selected McKesson to ramp up and \ndistribute future COVID -19 vaccines in the US, expanding our 14 -year partner ship.  The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n", "original_text": "Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94dcb80bae4587a95128b41e8462aa00b643fe59f077894455d44c1ac75b186d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2f8211a-6791-488e-9823-7119f462c48f", "node_type": "1", "metadata": {"window": "Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization. ", "original_text": "And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work. "}, "hash": "e903c2dbe9c79858cd90d437e953900fd0c50a7547b55a3d6aa614ae96e816e3", "class_name": "RelatedNodeInfo"}}, "text": "We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution. ", "start_char_idx": 1550, "end_char_idx": 1704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2f8211a-6791-488e-9823-7119f462c48f": {"__data__": {"id_": "b2f8211a-6791-488e-9823-7119f462c48f", "embedding": null, "metadata": {"window": "Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization. ", "original_text": "And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22d9eb2a-fa9a-42c9-8cdd-c2bc833d2649", "node_type": "1", "metadata": {"window": "The CDC exercises existing \noption within our Vaccines for Children contract, making McKesson the centralized distributor of COVID -19 \nvaccines and ancillary supplies needed to administer vaccines, similar to the role we played in the H1N1 \npandemic ove r 10 years ago.  \n \n Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA. ", "original_text": "We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a17e0b77c3f3bf2864f7994ba4aa87097e60c1e8d19af5c1748f1e94528b224", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87118209-de73-4a6f-ae04-1d608aaff662", "node_type": "1", "metadata": {"window": "Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry. ", "original_text": "In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n"}, "hash": "df6c19071cf34668235fe8078ae355ef076a127e9baa3922b88ee317f63b07c5", "class_name": "RelatedNodeInfo"}}, "text": "And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work. ", "start_char_idx": 1704, "end_char_idx": 1857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87118209-de73-4a6f-ae04-1d608aaff662": {"__data__": {"id_": "87118209-de73-4a6f-ae04-1d608aaff662", "embedding": null, "metadata": {"window": "Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry. ", "original_text": "In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2f8211a-6791-488e-9823-7119f462c48f", "node_type": "1", "metadata": {"window": "Our team immediately got to work.  Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization. ", "original_text": "And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be73f1707ccd2deb7b1b9a4f82238b43039483118fc126d1cc10d245b9f7f836", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8badf3df-0a70-4584-a279-d2bbb74d3d23", "node_type": "1", "metadata": {"window": "We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines. ", "original_text": "A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA. "}, "hash": "98e8d483d39386d7deb1c742635bd43858d466c336ede1a20ff7190b631260fc", "class_name": "RelatedNodeInfo"}}, "text": "In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n", "start_char_idx": 1857, "end_char_idx": 1959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8badf3df-0a70-4584-a279-d2bbb74d3d23": {"__data__": {"id_": "8badf3df-0a70-4584-a279-d2bbb74d3d23", "embedding": null, "metadata": {"window": "We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines. ", "original_text": "A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87118209-de73-4a6f-ae04-1d608aaff662", "node_type": "1", "metadata": {"window": "Standing up the infrastructure needed the support and initiative of this scale, \nwe quickly established new fit -for-purpose distribution centers, separate from our normal business operations so \nthat when va ccines became available for distribution, McKesson would be ready to execute our part.  We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry. ", "original_text": "In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27e11254d134bcc75dcb89f22b8b4267c32cbc4a7f7b740d1bac1363302c6560", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92005848-f674-43c7-a41b-f385e000bb14", "node_type": "1", "metadata": {"window": "And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n", "original_text": "And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization. "}, "hash": "427c9db89cb85d588605a17beb15c8afa5dd79b44e7b4770c71da176947b16d1", "class_name": "RelatedNodeInfo"}}, "text": "A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA. ", "start_char_idx": 1959, "end_char_idx": 2116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92005848-f674-43c7-a41b-f385e000bb14": {"__data__": {"id_": "92005848-f674-43c7-a41b-f385e000bb14", "embedding": null, "metadata": {"window": "And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n", "original_text": "And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8badf3df-0a70-4584-a279-d2bbb74d3d23", "node_type": "1", "metadata": {"window": "We've added \nfour new distribution centers that are highly specialized and capable of frozen and refrigerated cold chain COVID -\n19 vaccine distribution.  And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines. ", "original_text": "A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f102ef6ff43077f90d1d9594e6e124e5686380dee2d49b87264a023bf05dd96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58e27dba-0d9c-4dd6-9727-a9fd32c02945", "node_type": "1", "metadata": {"window": "In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1. ", "original_text": "Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry. "}, "hash": "348c6ef75321f492d60785418fb975e3a7f5aeed43174d9afad5cb8cd0fa3b22", "class_name": "RelatedNodeInfo"}}, "text": "And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization. ", "start_char_idx": 2116, "end_char_idx": 2270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58e27dba-0d9c-4dd6-9727-a9fd32c02945": {"__data__": {"id_": "58e27dba-0d9c-4dd6-9727-a9fd32c02945", "embedding": null, "metadata": {"window": "In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1. ", "original_text": "Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92005848-f674-43c7-a41b-f385e000bb14", "node_type": "1", "metadata": {"window": "And given our work  also includes the assembly and storage of ancillary supplies, several \nmore DCs were brought online to support this additional work.  In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n", "original_text": "And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97c291177539d78f983d94c8e0c023c24bef8c1fa8c786650c9a23c2876a1b41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e297099-a640-4ce5-8438-879911cf1455", "node_type": "1", "metadata": {"window": "A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site. ", "original_text": "From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines. "}, "hash": "ef83282fdb3e71a71ceab6d207f816b51577ff41af93a8e4c1996277ce139891", "class_name": "RelatedNodeInfo"}}, "text": "Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry. ", "start_char_idx": 2270, "end_char_idx": 2403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e297099-a640-4ce5-8438-879911cf1455": {"__data__": {"id_": "3e297099-a640-4ce5-8438-879911cf1455", "embedding": null, "metadata": {"window": "A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site. ", "original_text": "From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58e27dba-0d9c-4dd6-9727-a9fd32c02945", "node_type": "1", "metadata": {"window": "In total we've added over 3.3 million square feet of \ndedicated space to support this initiative.  \n \n A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1. ", "original_text": "Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24e7c8b43b5e30ac5d18a52d4aa1afe8a6adae250b06b0cc14e402c804db496f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89bf97d8-e7c5-4637-9696-ad8f90d1086a", "node_type": "1", "metadata": {"window": "And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities. ", "original_text": "We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n"}, "hash": "1a97f5f5bc661f71c4ad3e8901c8bcb436966c7ab967b1d202dcf0cf2ec28393", "class_name": "RelatedNodeInfo"}}, "text": "From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines. ", "start_char_idx": 2403, "end_char_idx": 2563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89bf97d8-e7c5-4637-9696-ad8f90d1086a": {"__data__": {"id_": "89bf97d8-e7c5-4637-9696-ad8f90d1086a", "embedding": null, "metadata": {"window": "And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities. ", "original_text": "We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e297099-a640-4ce5-8438-879911cf1455", "node_type": "1", "metadata": {"window": "A little over a month ago , on December 18, Moderna's COVID -19 vaccine became the second COVID -19 vaccine \ngranted emergency use authorization by the FDA.  And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site. ", "original_text": "From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9082ea9131f6096e50a32a543ffbe448877f774eaf4ee9ce6833977edbb4a3d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2339c4db-3cae-439f-bdd4-ad1da6b3836e", "node_type": "1", "metadata": {"window": "Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order. ", "original_text": "I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1. "}, "hash": "96a241b1051977a5e65f75db3d49469a1507f2ee097bab2084b08e20c1c99f92", "class_name": "RelatedNodeInfo"}}, "text": "We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n", "start_char_idx": 2563, "end_char_idx": 2661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2339c4db-3cae-439f-bdd4-ad1da6b3836e": {"__data__": {"id_": "2339c4db-3cae-439f-bdd4-ad1da6b3836e", "embedding": null, "metadata": {"window": "Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order. ", "original_text": "I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89bf97d8-e7c5-4637-9696-ad8f90d1086a", "node_type": "1", "metadata": {"window": "And given this vaccine is within the scope of our contract with \nthe CDC, McKesson began distributing this vaccine within 48 hour s of its authorization.  Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities. ", "original_text": "We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04b4dfc381fda786a83639f683e74b8a4151bb91c96fcac40a772786f0f1e76c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af70aa23-0324-485b-bb5b-30ee64ffbf45", "node_type": "1", "metadata": {"window": "From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country. ", "original_text": "The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site. "}, "hash": "566c44be5a6776008e366dfc6d78d0fbb963f027872a43865aab411aeb968dbf", "class_name": "RelatedNodeInfo"}}, "text": "I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1. ", "start_char_idx": 2661, "end_char_idx": 2842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af70aa23-0324-485b-bb5b-30ee64ffbf45": {"__data__": {"id_": "af70aa23-0324-485b-bb5b-30ee64ffbf45", "embedding": null, "metadata": {"window": "From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country. ", "original_text": "The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2339c4db-3cae-439f-bdd4-ad1da6b3836e", "node_type": "1", "metadata": {"window": "Through January, \nMcKesson has successfully distributed over 25 million doses of the COVID -19 vaccine to sites around the \ncountry.  From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order. ", "original_text": "I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3e9d4ece12e297b6591dee7f78080512bd4c715a4761928bf29b84172b3ce98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "130abf23-737f-470a-846d-dd631ec6bc3b", "node_type": "1", "metadata": {"window": "We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n", "original_text": "Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities. "}, "hash": "a6fdb42fa8b6eb4fd8ff78305089291a4c3b324e6e5f819522af07d66944ad6b", "class_name": "RelatedNodeInfo"}}, "text": "The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site. ", "start_char_idx": 2842, "end_char_idx": 3018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "130abf23-737f-470a-846d-dd631ec6bc3b": {"__data__": {"id_": "130abf23-737f-470a-846d-dd631ec6bc3b", "embedding": null, "metadata": {"window": "We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n", "original_text": "Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af70aa23-0324-485b-bb5b-30ee64ffbf45", "node_type": "1", "metadata": {"window": "From a distribution perspective, we remain on target to meet the US Government's plans to distribute \nhundreds of millions of refrigerated and frozen vaccines.  We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country. ", "original_text": "The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab1d284bd10c3abf1cceb834f04184c3ac69d9d729248e18c514d927cf042da5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f70c8135-7259-41fa-804c-0afa1adc0ddd", "node_type": "1", "metadata": {"window": "I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain. ", "original_text": "The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order. "}, "hash": "1a2a314d78078218cc3eaf35ad2736c0a1e7a5962ebff746add4ce998a97a879", "class_name": "RelatedNodeInfo"}}, "text": "Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities. ", "start_char_idx": 3018, "end_char_idx": 3158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f70c8135-7259-41fa-804c-0afa1adc0ddd": {"__data__": {"id_": "f70c8135-7259-41fa-804c-0afa1adc0ddd", "embedding": null, "metadata": {"window": "I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain. ", "original_text": "The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "130abf23-737f-470a-846d-dd631ec6bc3b", "node_type": "1", "metadata": {"window": "We are currently distributing vaccines from only two of \nthe four DCs built for this program.  \n \n I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n", "original_text": "Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ce5ded22a4a73aa9b12a6aa383ce750f53cca2eaa6af7f730c8d3a470054a78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a35e73a-bd5d-4e9f-aee8-da6633801f43", "node_type": "1", "metadata": {"window": "The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer. ", "original_text": "We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country. "}, "hash": "34fdbb4d16baef6c6d301a00129b4e58e86a46f4018bcced77b564664a0ee6bd", "class_name": "RelatedNodeInfo"}}, "text": "The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order. ", "start_char_idx": 3158, "end_char_idx": 3318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a35e73a-bd5d-4e9f-aee8-da6633801f43": {"__data__": {"id_": "8a35e73a-bd5d-4e9f-aee8-da6633801f43", "embedding": null, "metadata": {"window": "The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer. ", "original_text": "We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f70c8135-7259-41fa-804c-0afa1adc0ddd", "node_type": "1", "metadata": {"window": "I'd like to remind you that in this operation, McKesson is operating as a third -party logistics provider on behalf of \nthe US Government, which is similar to our role during H1N1.  The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain. ", "original_text": "The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4122bf078214ca1f1db1c5ddb86e5012f5e1c19024046c2d4f8e1d679396d32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf418073-1413-4f4a-add6-0255401b3432", "node_type": "1", "metadata": {"window": "Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway. ", "original_text": "We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n"}, "hash": "6ffbad827dab458adcdae3ba6bc22992a59086239d9aa58767e881a9ad97433d", "class_name": "RelatedNodeInfo"}}, "text": "We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country. ", "start_char_idx": 3318, "end_char_idx": 3473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf418073-1413-4f4a-add6-0255401b3432": {"__data__": {"id_": "cf418073-1413-4f4a-add6-0255401b3432", "embedding": null, "metadata": {"window": "Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway. ", "original_text": "We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a35e73a-bd5d-4e9f-aee8-da6633801f43", "node_type": "1", "metadata": {"window": "The US Government administers this program \nallocating vaccines to states, pharmacy chains, federal agencies, et cetera, and takes orders for the participating \nprovider site.  Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer. ", "original_text": "We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54f851ec00790cc89941caab53541c681abb19b5c597af296c9c634f63584cae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fd5df00-f307-4d7f-91fe-0e003dcd7ced", "node_type": "1", "metadata": {"window": "The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n", "original_text": "This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain. "}, "hash": "1122bb50aa80c19db544db8eb2916fc9a87998b8b9cc65be8468e98bcddd648c", "class_name": "RelatedNodeInfo"}}, "text": "We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n", "start_char_idx": 3473, "end_char_idx": 3619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fd5df00-f307-4d7f-91fe-0e003dcd7ced": {"__data__": {"id_": "2fd5df00-f307-4d7f-91fe-0e003dcd7ced", "embedding": null, "metadata": {"window": "The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n", "original_text": "This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf418073-1413-4f4a-add6-0255401b3432", "node_type": "1", "metadata": {"window": "Ultimate ly, the US Government makes all allocation decisions and decides what product is \ndistributed to what site and in what quantities.  The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway. ", "original_text": "We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "091fe93e3052e23c451b719876d66eda93e259fe9086b8d77bbf14903d84fa34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61e02dd0-6c4f-4fc7-8ec1-643521f2511f", "node_type": "1", "metadata": {"window": "We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson. ", "original_text": "Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer. "}, "hash": "ba6b210a3cd277863314fe3be8a573fb97e98c7b15e7fac6b41a4dae0ca88c63", "class_name": "RelatedNodeInfo"}}, "text": "This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain. ", "start_char_idx": 3619, "end_char_idx": 3815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61e02dd0-6c4f-4fc7-8ec1-643521f2511f": {"__data__": {"id_": "61e02dd0-6c4f-4fc7-8ec1-643521f2511f", "embedding": null, "metadata": {"window": "We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson. ", "original_text": "Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fd5df00-f307-4d7f-91fe-0e003dcd7ced", "node_type": "1", "metadata": {"window": "The orders are submitted to McKesson and when the orders are \nreceived we pick, pack and ship orders typically within one busin ess day of receiving the order.  We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n", "original_text": "This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82ad3400ed6809b503d2a063e972749fb9b54bf8753a0d9ade9fbdb9efe17b5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f75105bb-e300-42c9-80d9-3d7860047264", "node_type": "1", "metadata": {"window": "We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson.  Each week we are producing enough kits to support 10 million to 15 million doses and ", "original_text": "As I've discussed, our work as a centralized distributor is now underway. "}, "hash": "627cb6ea0e8bf5e3e39da609586bc2e01b9a20fca5bfa5230fe78bd9d45ab469", "class_name": "RelatedNodeInfo"}}, "text": "Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer. ", "start_char_idx": 3815, "end_char_idx": 3976, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f75105bb-e300-42c9-80d9-3d7860047264": {"__data__": {"id_": "f75105bb-e300-42c9-80d9-3d7860047264", "embedding": null, "metadata": {"window": "We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson.  Each week we are producing enough kits to support 10 million to 15 million doses and ", "original_text": "As I've discussed, our work as a centralized distributor is now underway. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61e02dd0-6c4f-4fc7-8ec1-643521f2511f", "node_type": "1", "metadata": {"window": "We are using the \ndepth and breadth of our experience to manage the safe distribution of hundreds of millions of doses of vaccines \nto the entire country.  We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson. ", "original_text": "Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8187b977a2ea2a70b5b75e09663342bcd725aa022299de867de899607442d1ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "983f9fb0-ab40-404b-a09a-9a5a668fba92", "node_type": "1", "metadata": {"window": "This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson.  Each week we are producing enough kits to support 10 million to 15 million doses and ", "original_text": "So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n"}, "hash": "be96c6c564f09ac9d415fc7225c7d602f6c21697b2b16ceec4ee838792e16fdd", "class_name": "RelatedNodeInfo"}}, "text": "As I've discussed, our work as a centralized distributor is now underway. ", "start_char_idx": 3976, "end_char_idx": 4050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "983f9fb0-ab40-404b-a09a-9a5a668fba92": {"__data__": {"id_": "983f9fb0-ab40-404b-a09a-9a5a668fba92", "embedding": null, "metadata": {"window": "This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson.  Each week we are producing enough kits to support 10 million to 15 million doses and ", "original_text": "So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f75105bb-e300-42c9-80d9-3d7860047264", "node_type": "1", "metadata": {"window": "We believe this distribution approach is the safest and fastest way to get COVID -19 \nvaccines into the arms of Americans across our country.  \n \n This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson.  Each week we are producing enough kits to support 10 million to 15 million doses and ", "original_text": "As I've discussed, our work as a centralized distributor is now underway. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "009a6642f7263f569e9ce8cf33dc8251042668e9be7cc68fc4200bd4726e9310", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d7cd32b-154c-4d8b-bfed-70c45ef17e61", "node_type": "1", "metadata": {"window": "Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson.  Each week we are producing enough kits to support 10 million to 15 million doses and ", "original_text": "McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson. "}, "hash": "197ce2b645e1cc02f95d03dd78a57fc966f25b9317a51ee2f97c35723a271cf1", "class_name": "RelatedNodeInfo"}}, "text": "So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n", "start_char_idx": 4050, "end_char_idx": 4173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d7cd32b-154c-4d8b-bfed-70c45ef17e61": {"__data__": {"id_": "5d7cd32b-154c-4d8b-bfed-70c45ef17e61", "embedding": null, "metadata": {"window": "Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson.  Each week we are producing enough kits to support 10 million to 15 million doses and ", "original_text": "McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "983f9fb0-ab40-404b-a09a-9a5a668fba92", "node_type": "1", "metadata": {"window": "This is a complex distribution program with several partners collaborating from end to end and McKesson takes \nextensive measures to maintain the safety and efficacy of the vaccine supply  chain.  Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson.  Each week we are producing enough kits to support 10 million to 15 million doses and ", "original_text": "So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5fadf686200973a8d88fa793315ec9b3098c92b59a4df232ccbd0e837bbea75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f729234e-bae2-490d-8521-4be6cf24c522", "node_type": "1", "metadata": {"window": "As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson.  Each week we are producing enough kits to support 10 million to 15 million doses and ", "original_text": "Each week we are producing enough kits to support 10 million to 15 million doses and "}, "hash": "676269c6eb92de773eb6e235fc7f82b1dd67d58c3ee623aae42d855c986f1ff8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson. ", "start_char_idx": 4173, "end_char_idx": 4426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f729234e-bae2-490d-8521-4be6cf24c522": {"__data__": {"id_": "f729234e-bae2-490d-8521-4be6cf24c522", "embedding": null, "metadata": {"window": "As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson.  Each week we are producing enough kits to support 10 million to 15 million doses and ", "original_text": "Each week we are producing enough kits to support 10 million to 15 million doses and ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93afebed6db8648adc91c7bb548e6c0634a39cd5555ec087fa4f223e023d7777", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d7cd32b-154c-4d8b-bfed-70c45ef17e61", "node_type": "1", "metadata": {"window": "Our goal is that every \nshipment be received at the administration site in a timely manner and within the specified guidelines established \nby the manufacturer.  As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson.  Each week we are producing enough kits to support 10 million to 15 million doses and ", "original_text": "McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson. ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "69e5d0cec8171eb1aaa4e67f7551d6438e4596171d1bbc6bbe484fbf03a8f007", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1eb451b5-bec6-44c7-b643-664b59b5a741", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses.  It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business. ", "original_text": "McKesson Corp.  "}, "hash": "bff569098f0c8892523ef6b37765db6d175757e892eeb529e808228a204cdc0f", "class_name": "RelatedNodeInfo"}}, "text": "Each week we are producing enough kits to support 10 million to 15 million doses and ", "start_char_idx": 4426, "end_char_idx": 4511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1eb451b5-bec6-44c7-b643-664b59b5a741": {"__data__": {"id_": "1eb451b5-bec6-44c7-b643-664b59b5a741", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses.  It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f729234e-bae2-490d-8521-4be6cf24c522", "node_type": "1", "metadata": {"window": "As I've discussed, our work as a centralized distributor is now underway.  So, earnings fr om \nthe COVID -19 vaccine distribution program are factored into our improved outlook for fiscal 2021.  \n \n McKesson has also been hard at work preparing and distributing the ancillary kits needed to administer all of the \nCOVID -19 vaccines, including for the Pfi zer ultra -frozen vaccine, even though Pfizer's vaccine itself is not \ndistributed by McKesson.  Each week we are producing enough kits to support 10 million to 15 million doses and ", "original_text": "Each week we are producing enough kits to support 10 million to 15 million doses and ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73b6d8799d74894144cf28da25c78737eac02797987e1f790aeceb691a4b7762", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b213a5d9-0827-4a7e-96d6-fa6c524407b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses.  It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses. "}, "hash": "b2c5257dd7d82c41b3208d62b829f3ac6feda0945a18ed1232e5609352cee5ca", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b213a5d9-0827-4a7e-96d6-fa6c524407b7": {"__data__": {"id_": "b213a5d9-0827-4a7e-96d6-fa6c524407b7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses.  It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1eb451b5-bec6-44c7-b643-664b59b5a741", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses.  It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74b2095b82b7be07359310555eaa0eb83aca6a44b05e8e3ed09633e23201d5d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dab6546f-4a4c-40fa-88a1-8ceca5315f1a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses.  It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S. ", "original_text": "It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n"}, "hash": "82f9c20c721e1ff7d748cc83934cdd037acd3e830d0ae58780458cef96286ddf", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses. ", "start_char_idx": 16, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dab6546f-4a4c-40fa-88a1-8ceca5315f1a": {"__data__": {"id_": "dab6546f-4a4c-40fa-88a1-8ceca5315f1a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses.  It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S. ", "original_text": "It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b213a5d9-0827-4a7e-96d6-fa6c524407b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses.  It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65172111609a13955359ab3d4012c6481d9129f984a620e324820737838baa7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fe71acd-c9f3-4eed-87a7-46a1410d2c3d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses.  It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S.  Pharmaceutical. ", "original_text": "Now, let's get to  the business. "}, "hash": "7dd439e6074658948250a57f4e4b2bbb0737080bfb75c206cf976ac0f82d5c04", "class_name": "RelatedNodeInfo"}}, "text": "It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n", "start_char_idx": 253, "end_char_idx": 502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fe71acd-c9f3-4eed-87a7-46a1410d2c3d": {"__data__": {"id_": "1fe71acd-c9f3-4eed-87a7-46a1410d2c3d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses.  It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S.  Pharmaceutical. ", "original_text": "Now, let's get to  the business. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dab6546f-4a4c-40fa-88a1-8ceca5315f1a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses.  It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S. ", "original_text": "It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aba259a0dda7ca40695a5af884c2d7e0bde694f155fc1bd65fdf0e1cbcd25177", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "223d73f8-5a91-44d3-b355-10b6ee1b6b82", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses.  It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S.  Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year. ", "original_text": "I'll summarize the third quarter and then turn it over to Britt to provide more details. \n"}, "hash": "e8c2a03701db10369d537606f22ddd3c36b9bd404c07938cb22eeab284f65e71", "class_name": "RelatedNodeInfo"}}, "text": "Now, let's get to  the business. ", "start_char_idx": 502, "end_char_idx": 535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "223d73f8-5a91-44d3-b355-10b6ee1b6b82": {"__data__": {"id_": "223d73f8-5a91-44d3-b355-10b6ee1b6b82", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses.  It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S.  Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year. ", "original_text": "I'll summarize the third quarter and then turn it over to Britt to provide more details. \n", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fe71acd-c9f3-4eed-87a7-46a1410d2c3d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses.  It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S.  Pharmaceutical. ", "original_text": "Now, let's get to  the business. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98201ae47d00192aaeeb03f6785d92ecd6598fd3957d57761243364a6cdcb5a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "169d44ad-5c7b-40a0-8bbe-b1c7cdea53c2", "node_type": "1", "metadata": {"window": "It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S.  Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing. ", "original_text": "Let me start with U.S. "}, "hash": "9a7e83b34cc4a6db1febdbe1115f104394ae3afcf670bdece4c663fc3223a52a", "class_name": "RelatedNodeInfo"}}, "text": "I'll summarize the third quarter and then turn it over to Britt to provide more details. \n", "start_char_idx": 535, "end_char_idx": 625, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "169d44ad-5c7b-40a0-8bbe-b1c7cdea53c2": {"__data__": {"id_": "169d44ad-5c7b-40a0-8bbe-b1c7cdea53c2", "embedding": null, "metadata": {"window": "It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S.  Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing. ", "original_text": "Let me start with U.S. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "223d73f8-5a91-44d3-b355-10b6ee1b6b82", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses.  It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S.  Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year. ", "original_text": "I'll summarize the third quarter and then turn it over to Britt to provide more details. \n", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73ffb5d88808739f0e0d111f93dc07882ba8791701ce3f09de14364bf074acd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47f9a3cb-7cc5-431a-9eee-ef6bbaeeec35", "node_type": "1", "metadata": {"window": "Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S.  Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation. ", "original_text": "Pharmaceutical. "}, "hash": "a5ef69eeb7cd61a2204cabd601aea07a2135429522f15e30b75758bdc03001f9", "class_name": "RelatedNodeInfo"}}, "text": "Let me start with U.S. ", "start_char_idx": 625, "end_char_idx": 648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47f9a3cb-7cc5-431a-9eee-ef6bbaeeec35": {"__data__": {"id_": "47f9a3cb-7cc5-431a-9eee-ef6bbaeeec35", "embedding": null, "metadata": {"window": "Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S.  Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation. ", "original_text": "Pharmaceutical. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "169d44ad-5c7b-40a0-8bbe-b1c7cdea53c2", "node_type": "1", "metadata": {"window": "It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S.  Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing. ", "original_text": "Let me start with U.S. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e8e8a597686e804f6a028f2714b51e78f6ff347274199e37d390c6fe119cbd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32fe518b-d4b9-489b-acde-1385cbf4d8db", "node_type": "1", "metadata": {"window": "I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S.  Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market. ", "original_text": "Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year. "}, "hash": "73bc77afe492e431bbfd0412ad06cc49fc4e17f211e9050a7ecb25e2f2a903d6", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical. ", "start_char_idx": 648, "end_char_idx": 664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32fe518b-d4b9-489b-acde-1385cbf4d8db": {"__data__": {"id_": "32fe518b-d4b9-489b-acde-1385cbf4d8db", "embedding": null, "metadata": {"window": "I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S.  Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market. ", "original_text": "Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47f9a3cb-7cc5-431a-9eee-ef6bbaeeec35", "node_type": "1", "metadata": {"window": "Now, let's get to  the business.  I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S.  Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation. ", "original_text": "Pharmaceutical. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "420d01adb3a3b8107afc8407b38fa8e0f9b7e173dca15c978b4187bdc2df9be7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eeeb8d89-5094-488b-b0e5-cb70571cd868", "node_type": "1", "metadata": {"window": "Let me start with U.S.  Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic. ", "original_text": "Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing. "}, "hash": "9c1cf483b2b6202dc3229ccba03bfff78aedfb1021c78d5ae34feec864d7cd40", "class_name": "RelatedNodeInfo"}}, "text": "Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year. ", "start_char_idx": 664, "end_char_idx": 987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eeeb8d89-5094-488b-b0e5-cb70571cd868": {"__data__": {"id_": "eeeb8d89-5094-488b-b0e5-cb70571cd868", "embedding": null, "metadata": {"window": "Let me start with U.S.  Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic. ", "original_text": "Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32fe518b-d4b9-489b-acde-1385cbf4d8db", "node_type": "1", "metadata": {"window": "I'll summarize the third quarter and then turn it over to Britt to provide more details. \n Let me start with U.S.  Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market. ", "original_text": "Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7c534b9982e415ae8e9762ee97dc6f6c28a22d1efb5b6104db0ab0982b1515d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd996d7c-0d4c-4812-9ccf-229b5cb55aa2", "node_type": "1", "metadata": {"window": "Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n", "original_text": "Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation. "}, "hash": "44557311327ea894038270ee01e500eea865c1998d4e3855a3793406dc0a981b", "class_name": "RelatedNodeInfo"}}, "text": "Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing. ", "start_char_idx": 987, "end_char_idx": 1106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd996d7c-0d4c-4812-9ccf-229b5cb55aa2": {"__data__": {"id_": "bd996d7c-0d4c-4812-9ccf-229b5cb55aa2", "embedding": null, "metadata": {"window": "Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n", "original_text": "Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eeeb8d89-5094-488b-b0e5-cb70571cd868", "node_type": "1", "metadata": {"window": "Let me start with U.S.  Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic. ", "original_text": "Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1888f36ed51ee3bce80564e935b52ac089d17794dc95e9fdb3758e548b733f1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cbb9807-cf80-4155-9fa6-4a06c84a559e", "node_type": "1", "metadata": {"window": "Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic. ", "original_text": "For generics, we continue to be disciplined in our approach to pricin g in the market. "}, "hash": "d32df9d522dc1ee0a4b4351b263b58c1abf4639e70be62a4cbe842d8de062321", "class_name": "RelatedNodeInfo"}}, "text": "Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation. ", "start_char_idx": 1106, "end_char_idx": 1226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cbb9807-cf80-4155-9fa6-4a06c84a559e": {"__data__": {"id_": "1cbb9807-cf80-4155-9fa6-4a06c84a559e", "embedding": null, "metadata": {"window": "Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic. ", "original_text": "For generics, we continue to be disciplined in our approach to pricin g in the market. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd996d7c-0d4c-4812-9ccf-229b5cb55aa2", "node_type": "1", "metadata": {"window": "Pharmaceutical.  Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n", "original_text": "Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b75d05d3d5e982f48344db4a2eb4895fe30bad3934fbc7b81f7c7b54bb6984a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c580e19e-e8a8-4435-9028-87c6a5fc614e", "node_type": "1", "metadata": {"window": "Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology. ", "original_text": "On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic. "}, "hash": "e85ffb2f4835bf4f1a92fe122d64145fb36646cb924ea7ed3c37d0e0a43be5c2", "class_name": "RelatedNodeInfo"}}, "text": "For generics, we continue to be disciplined in our approach to pricin g in the market. ", "start_char_idx": 1226, "end_char_idx": 1313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c580e19e-e8a8-4435-9028-87c6a5fc614e": {"__data__": {"id_": "c580e19e-e8a8-4435-9028-87c6a5fc614e", "embedding": null, "metadata": {"window": "Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology. ", "original_text": "On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cbb9807-cf80-4155-9fa6-4a06c84a559e", "node_type": "1", "metadata": {"window": "Prescription volume trends in the third quarter were again reflective of the \nnon-linear trajectory of the recover y. After seeing stability in the market trends in the second quarter, we saw \nsome volume declines in our third quarter as it progressed, driven in part by a light cold and flu season versus the \nprior year.  Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic. ", "original_text": "For generics, we continue to be disciplined in our approach to pricin g in the market. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59582a5d357a5b34552a75afea3eefb3e122d0965d4f77a6356580c8b2596394", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a141849-6c2f-4f4d-a970-afc044309af7", "node_type": "1", "metadata": {"window": "Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve. ", "original_text": "Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n"}, "hash": "4d2bf252701bb2474e5296c01f5cb823027a6c8030ab53d4b6abc7f0bc1cec40", "class_name": "RelatedNodeInfo"}}, "text": "On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic. ", "start_char_idx": 1313, "end_char_idx": 1583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a141849-6c2f-4f4d-a970-afc044309af7": {"__data__": {"id_": "0a141849-6c2f-4f4d-a970-afc044309af7", "embedding": null, "metadata": {"window": "Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve. ", "original_text": "Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c580e19e-e8a8-4435-9028-87c6a5fc614e", "node_type": "1", "metadata": {"window": "Despite some softness in volume trends within the quarter, we continue to see stability in brand and \ngeneric pricing.  Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology. ", "original_text": "On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22c9c845f414fee777af22e9afd49359d26ab4d7ac19abffe1ea145217f65114", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ad5bdb8-cb16-4475-bad3-18884107249d", "node_type": "1", "metadata": {"window": "For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n", "original_text": "While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic. "}, "hash": "d9b3c43813cbecba13b6f89a88197bf0b5e6b7c2c89cac9cc3c5ca77fa510903", "class_name": "RelatedNodeInfo"}}, "text": "Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n", "start_char_idx": 1583, "end_char_idx": 1690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ad5bdb8-cb16-4475-bad3-18884107249d": {"__data__": {"id_": "8ad5bdb8-cb16-4475-bad3-18884107249d", "embedding": null, "metadata": {"window": "For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n", "original_text": "While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a141849-6c2f-4f4d-a970-afc044309af7", "node_type": "1", "metadata": {"window": "Through the third quarter and into January, branded price inflation has tracked in line with our \noriginal expectation.  For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve. ", "original_text": "Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "530820e31f383380de7af72f30146778c1fc5b9b428887b8b3ee6d7ec1f30256", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb32dabd-b75b-46bf-93d3-43cf0dbcb18a", "node_type": "1", "metadata": {"window": "On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic. ", "original_text": "Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology. "}, "hash": "37222a1004f2f9d3280612ef4f55bf735d43b48103c40cd8e5642f6ae60faec6", "class_name": "RelatedNodeInfo"}}, "text": "While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic. ", "start_char_idx": 1690, "end_char_idx": 1852, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb32dabd-b75b-46bf-93d3-43cf0dbcb18a": {"__data__": {"id_": "bb32dabd-b75b-46bf-93d3-43cf0dbcb18a", "embedding": null, "metadata": {"window": "On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic. ", "original_text": "Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ad5bdb8-cb16-4475-bad3-18884107249d", "node_type": "1", "metadata": {"window": "For generics, we continue to be disciplined in our approach to pricin g in the market.  On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n", "original_text": "While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8736f72db5f04939403d0c7ca3d47233116a4c05326d2aa2d8ca9f5522912e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da2a37ba-51d3-4021-b240-52aaf3549d19", "node_type": "1", "metadata": {"window": "Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS. ", "original_text": "In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve. "}, "hash": "f6da2e905c83dd2d46faf8bfd2cc8b173c9b44c26926580fe2ce0ddee0be98ba", "class_name": "RelatedNodeInfo"}}, "text": "Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology. ", "start_char_idx": 1852, "end_char_idx": 2036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da2a37ba-51d3-4021-b240-52aaf3549d19": {"__data__": {"id_": "da2a37ba-51d3-4021-b240-52aaf3549d19", "embedding": null, "metadata": {"window": "Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS. ", "original_text": "In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb32dabd-b75b-46bf-93d3-43cf0dbcb18a", "node_type": "1", "metadata": {"window": "On the \nbuy side through the scale and strength of our sourcing operation with ClarusONE, we've leveraged our \nrelationship with a diverse set of manufacturers to [ph] maintain (00:08:39) stable levels of supply at low costs for \nour customer s throughout the pandemic.  Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic. ", "original_text": "Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c574b90c7fdeea88931e0356c4b2f59652af89e337037d0b9dbe61bab26fc46a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9260e91b-1c2e-493f-addb-2ad47d9676e5", "node_type": "1", "metadata": {"window": "While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n", "original_text": "US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n"}, "hash": "8fd6e681ab1e8731fd358475fa25a262a922032146c18652d58b274ac8cc0dec", "class_name": "RelatedNodeInfo"}}, "text": "In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve. ", "start_char_idx": 2036, "end_char_idx": 2263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9260e91b-1c2e-493f-addb-2ad47d9676e5": {"__data__": {"id_": "9260e91b-1c2e-493f-addb-2ad47d9676e5", "embedding": null, "metadata": {"window": "While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n", "original_text": "US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da2a37ba-51d3-4021-b240-52aaf3549d19", "node_type": "1", "metadata": {"window": "Strong pricing discipline and effective sourcing continue to allow us to \nearn spread in the business.  \n \n While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS. ", "original_text": "In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6966fbb1e42ae21f85061e0b2ba329372d1bc935a4a5631a401334c45b7715dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2829c412-cb29-4296-b726-ab922a89a8bb", "node_type": "1", "metadata": {"window": "Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment. ", "original_text": "Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic. "}, "hash": "b6882e60ec7dd9734eea4e130cb4c99229fe3de637493619ea44244d0e6b5d63", "class_name": "RelatedNodeInfo"}}, "text": "US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n", "start_char_idx": 2263, "end_char_idx": 2478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2829c412-cb29-4296-b726-ab922a89a8bb": {"__data__": {"id_": "2829c412-cb29-4296-b726-ab922a89a8bb", "embedding": null, "metadata": {"window": "Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment. ", "original_text": "Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9260e91b-1c2e-493f-addb-2ad47d9676e5", "node_type": "1", "metadata": {"window": "While total prescription volume trends fluctuated in the quarter, specialty volumes and particularly oncology have \nbeen more r esilient throughout the pandemic.  Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n", "original_text": "US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f54096b85df8d6e2a83834fa22a33d780edde3a9ed1d4e34076f44e1c866ba42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae887da4-c632-4b65-b84d-2ff58fc892d5", "node_type": "1", "metadata": {"window": "In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open. ", "original_text": "Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS. "}, "hash": "5780c0f253078aa40a5d65803fbf5b866b321ad9d2f07bd9ebe90acccc605115", "class_name": "RelatedNodeInfo"}}, "text": "Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic. ", "start_char_idx": 2478, "end_char_idx": 2581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae887da4-c632-4b65-b84d-2ff58fc892d5": {"__data__": {"id_": "ae887da4-c632-4b65-b84d-2ff58fc892d5", "embedding": null, "metadata": {"window": "In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open. ", "original_text": "Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2829c412-cb29-4296-b726-ab922a89a8bb", "node_type": "1", "metadata": {"window": "Our provider solutions and US oncology businesses have \nperformed well year -to-date and are key areas of investment as we look to further differentiate our capabilities in \noncology.  In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment. ", "original_text": "Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e9021079127a4d308356a2837aca360f6f7b4ce76fc51b2c898ab882eb0a88e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "461c251e-ca4b-46af-91f2-b79600206e97", "node_type": "1", "metadata": {"window": "US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts. ", "original_text": "Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n"}, "hash": "a0fa91df194c68dbc93a8f17895bf5074934c1f594e2f5295ed4d43d307d4127", "class_name": "RelatedNodeInfo"}}, "text": "Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS. ", "start_char_idx": 2581, "end_char_idx": 2718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "461c251e-ca4b-46af-91f2-b79600206e97": {"__data__": {"id_": "461c251e-ca4b-46af-91f2-b79600206e97", "embedding": null, "metadata": {"window": "US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts. ", "original_text": "Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae887da4-c632-4b65-b84d-2ff58fc892d5", "node_type": "1", "metadata": {"window": "In the quarter, The US Oncology Network c ontinued to expand its reach in some local communities by \nwelcoming two new practices, further strengthening the availability of advanced cancer care across the \ncommunities we serve.  US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open. ", "original_text": "Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd842598b19c56ed5f7efd6aef4030b0a464b91abccbb02680898cb022c6f246", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "023ca638-e9a0-42e6-9459-3efa8f78ae3f", "node_type": "1", "metadata": {"window": "Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients. ", "original_text": "Let's transition to our International segment. "}, "hash": "2ef9c82539e457081bfc5d494a3d96414a28ee736844a68647f36854f462cfda", "class_name": "RelatedNodeInfo"}}, "text": "Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n", "start_char_idx": 2718, "end_char_idx": 2915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "023ca638-e9a0-42e6-9459-3efa8f78ae3f": {"__data__": {"id_": "023ca638-e9a0-42e6-9459-3efa8f78ae3f", "embedding": null, "metadata": {"window": "Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients. ", "original_text": "Let's transition to our International segment. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "461c251e-ca4b-46af-91f2-b79600206e97", "node_type": "1", "metadata": {"window": "US oncology also reached a major milestone in its journey to provide high  quality value -\nbased care by enrolling its 100,000th patient in the Centers for Medicare and Medicaid Innovation Oncology Care \nmodel.  \n \n Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts. ", "original_text": "Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "894842d7c1018174c567c47459e9c3a5d1feb54fd31a6b9c68b3384e771c684d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fc3c390-2a41-41d5-9714-862183684626", "node_type": "1", "metadata": {"window": "Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses. ", "original_text": "Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open. "}, "hash": "364120a1380d9bcd45f2d139171062014e9fea23a1987c53790de4fcd3cf8e9a", "class_name": "RelatedNodeInfo"}}, "text": "Let's transition to our International segment. ", "start_char_idx": 2915, "end_char_idx": 2962, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fc3c390-2a41-41d5-9714-862183684626": {"__data__": {"id_": "3fc3c390-2a41-41d5-9714-862183684626", "embedding": null, "metadata": {"window": "Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses. ", "original_text": "Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "023ca638-e9a0-42e6-9459-3efa8f78ae3f", "node_type": "1", "metadata": {"window": "Lastly, our Health Mart franchises are expanding the role they play in the fight against the pandemic.  Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients. ", "original_text": "Let's transition to our International segment. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "589a4f71a43d125aeb2331adc1b493c6cb936b315d9e7e197433093b6791a3ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acc7369d-a4f8-49d5-9940-6cdd3c6dcd89", "node_type": "1", "metadata": {"window": "Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n", "original_text": "Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts. "}, "hash": "390f1f7e8b81a756e39086b50c76c0ca66be27f996f1855fbab4d3c009706cc4", "class_name": "RelatedNodeInfo"}}, "text": "Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open. ", "start_char_idx": 2962, "end_char_idx": 3116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acc7369d-a4f8-49d5-9940-6cdd3c6dcd89": {"__data__": {"id_": "acc7369d-a4f8-49d5-9940-6cdd3c6dcd89", "embedding": null, "metadata": {"window": "Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n", "original_text": "Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fc3c390-2a41-41d5-9714-862183684626", "node_type": "1", "metadata": {"window": "Health Mart \npharma cies have performed more than 400,000 COVID -19 test collections through a partnership with eTrueNorth \nand the HHS.  Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses. ", "original_text": "Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46b0ded51c0896f18f8e6c7482a281e68d0a369ac3067bfa114bff5575da217b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e681e1ac-99cc-422e-bba2-a417d9795e31", "node_type": "1", "metadata": {"window": "Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical. ", "original_text": "Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients. "}, "hash": "ce1cfd16d7fe1fc2fe62b6362446f1a7def6ac40a979f5b499f9b291fa69768b", "class_name": "RelatedNodeInfo"}}, "text": "Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts. ", "start_char_idx": 3116, "end_char_idx": 3240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e681e1ac-99cc-422e-bba2-a417d9795e31": {"__data__": {"id_": "e681e1ac-99cc-422e-bba2-a417d9795e31", "embedding": null, "metadata": {"window": "Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical. ", "original_text": "Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acc7369d-a4f8-49d5-9940-6cdd3c6dcd89", "node_type": "1", "metadata": {"window": "Many of our Health Mart franchise pharmacies are also preparing to serve as COVID -19 vaccine \nadministration sites in local communities when t he CDC moves into the next phase of the rollout.  \n \n Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n", "original_text": "Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ea9df4240a2d420c21462de05c1e506446d826efb5f516899173da4a97bcc0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20d1a6e6-e351-46a6-a9cd-10e589219979", "node_type": "1", "metadata": {"window": "Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines. ", "original_text": "Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses. "}, "hash": "5074657ab63d5fbf635f2f45b7e52d0d8b0ac6d93524baa4c3bd8e02193ed745", "class_name": "RelatedNodeInfo"}}, "text": "Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients. ", "start_char_idx": 3240, "end_char_idx": 3406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20d1a6e6-e351-46a6-a9cd-10e589219979": {"__data__": {"id_": "20d1a6e6-e351-46a6-a9cd-10e589219979", "embedding": null, "metadata": {"window": "Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines. ", "original_text": "Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e681e1ac-99cc-422e-bba2-a417d9795e31", "node_type": "1", "metadata": {"window": "Let's transition to our International segment.  Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical. ", "original_text": "Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "840404c284d33b5b75fbc030c5392cd819adf723f6909497d0a2495464162b2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1103d0d2-f102-4b76-b522-ae96c3dab97c", "node_type": "1", "metadata": {"window": "Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year. ", "original_text": "While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n"}, "hash": "69d5133e8806970861e3fd515138ff07d631f0cd383679210d36214aa7e8d6ee", "class_name": "RelatedNodeInfo"}}, "text": "Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses. ", "start_char_idx": 3406, "end_char_idx": 3562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1103d0d2-f102-4b76-b522-ae96c3dab97c": {"__data__": {"id_": "1103d0d2-f102-4b76-b522-ae96c3dab97c", "embedding": null, "metadata": {"window": "Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year. ", "original_text": "While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20d1a6e6-e351-46a6-a9cd-10e589219979", "node_type": "1", "metadata": {"window": "Our businesses in Europe and Canada are continuing to play their \npart in the pandemic response; and as essential businesses, our pharmacies remain open.  Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines. ", "original_text": "Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "357ae3ed4348d59ff3c692d06fd576ebca2bf790402962327282ef3e61d57259", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb4eaa02-42c7-45e1-ab7c-a1aab6a8f55a", "node_type": "1", "metadata": {"window": "Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n", "original_text": "Let's turn to Medical. "}, "hash": "ab5876e40d29212db117d4776ef2e15cbdfd5b06900a5e1ba68d9751b8d97742", "class_name": "RelatedNodeInfo"}}, "text": "While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n", "start_char_idx": 3562, "end_char_idx": 3680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb4eaa02-42c7-45e1-ab7c-a1aab6a8f55a": {"__data__": {"id_": "bb4eaa02-42c7-45e1-ab7c-a1aab6a8f55a", "embedding": null, "metadata": {"window": "Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n", "original_text": "Let's turn to Medical. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1103d0d2-f102-4b76-b522-ae96c3dab97c", "node_type": "1", "metadata": {"window": "Throug h our owned \nand banner stores abroad, we're working with local governments to accelerate COVID -19 testing efforts.  Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year. ", "original_text": "While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "add7fa72efcc1369b0e653df729ce28d4ef6cffc584b0e164f927a30beb58d1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10a9a7a3-aa73-4736-9737-cc5e03c886ba", "node_type": "1", "metadata": {"window": "Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n As our customers reopen and address COVID -19, the core business has recovered and returned to growth. ", "original_text": "When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines. "}, "hash": "2322f2b62a10156a17ba45c7b403e1513ff40293f5fb9513a97a4ef489b6d76c", "class_name": "RelatedNodeInfo"}}, "text": "Let's turn to Medical. ", "start_char_idx": 3680, "end_char_idx": 3703, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10a9a7a3-aa73-4736-9737-cc5e03c886ba": {"__data__": {"id_": "10a9a7a3-aa73-4736-9737-cc5e03c886ba", "embedding": null, "metadata": {"window": "Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n As our customers reopen and address COVID -19, the core business has recovered and returned to growth. ", "original_text": "When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb4eaa02-42c7-45e1-ab7c-a1aab6a8f55a", "node_type": "1", "metadata": {"window": "Our \ndigital offerings like well.ca in Canada and Echo by LloydsPharmacy continue to grow quickly and expand their \nservice offerings to meet t he needs of patients.  Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n", "original_text": "Let's turn to Medical. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6e1a76b6734b57cd943d52b993c0d03d04692c7941d6dc4b43c038afe596f3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cda4f07-45d5-4259-8204-59cabe4df3de", "node_type": "1", "metadata": {"window": "While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n As our customers reopen and address COVID -19, the core business has recovered and returned to growth.  With \none of the largest and most tenured sales forces in the industry, our primary and extended care teams work hard \nevery day to ensure that our customers have the products and services they need to provide patient care, \nwhether it's COVID -19 tests, PPE or pharmaceuticals.  ", "original_text": "These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year. "}, "hash": "db7283918567199115996703945008c6a650fa59fcf8a6d6c1f71cb8b1413eb6", "class_name": "RelatedNodeInfo"}}, "text": "When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines. ", "start_char_idx": 3703, "end_char_idx": 3926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cda4f07-45d5-4259-8204-59cabe4df3de": {"__data__": {"id_": "2cda4f07-45d5-4259-8204-59cabe4df3de", "embedding": null, "metadata": {"window": "While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n As our customers reopen and address COVID -19, the core business has recovered and returned to growth.  With \none of the largest and most tenured sales forces in the industry, our primary and extended care teams work hard \nevery day to ensure that our customers have the products and services they need to provide patient care, \nwhether it's COVID -19 tests, PPE or pharmaceuticals.  ", "original_text": "These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10a9a7a3-aa73-4736-9737-cc5e03c886ba", "node_type": "1", "metadata": {"window": "Also, as a reminder, on November 1, we completed the creation of \na joint venture with Walgreens Boots Alliance, combining our German wholesale businesses.  While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n As our customers reopen and address COVID -19, the core business has recovered and returned to growth. ", "original_text": "When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1cd812f226ad79dfadb203ca8a3d107356eb47819b3bc113f5a7969ad7c18652", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1072f645-1500-4d1e-b711-0689730b86d2", "node_type": "1", "metadata": {"window": "Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n As our customers reopen and address COVID -19, the core business has recovered and returned to growth.  With \none of the largest and most tenured sales forces in the industry, our primary and extended care teams work hard \nevery day to ensure that our customers have the products and services they need to provide patient care, \nwhether it's COVID -19 tests, PPE or pharmaceuticals.  ", "original_text": "The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n"}, "hash": "78f0bcfb6ea0ec00d87b2be5b3f2ec3434d4f58e7ff9c6582fd758e149ab2380", "class_name": "RelatedNodeInfo"}}, "text": "These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year. ", "start_char_idx": 3926, "end_char_idx": 4044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1072f645-1500-4d1e-b711-0689730b86d2": {"__data__": {"id_": "1072f645-1500-4d1e-b711-0689730b86d2", "embedding": null, "metadata": {"window": "Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n As our customers reopen and address COVID -19, the core business has recovered and returned to growth.  With \none of the largest and most tenured sales forces in the industry, our primary and extended care teams work hard \nevery day to ensure that our customers have the products and services they need to provide patient care, \nwhether it's COVID -19 tests, PPE or pharmaceuticals.  ", "original_text": "The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cda4f07-45d5-4259-8204-59cabe4df3de", "node_type": "1", "metadata": {"window": "While it is still early \ndays, we are excited about these teams coming together and the progress they are making.  \n \n Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n As our customers reopen and address COVID -19, the core business has recovered and returned to growth.  With \none of the largest and most tenured sales forces in the industry, our primary and extended care teams work hard \nevery day to ensure that our customers have the products and services they need to provide patient care, \nwhether it's COVID -19 tests, PPE or pharmaceuticals.  ", "original_text": "These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc174f6f52e91f00c6bed10c44f351f2ff2b7c90db2b83f1d837735bad20dba4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4519473a-5af9-4e95-ab99-d295ad23a73b", "node_type": "1", "metadata": {"window": "When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n As our customers reopen and address COVID -19, the core business has recovered and returned to growth.  With \none of the largest and most tenured sales forces in the industry, our primary and extended care teams work hard \nevery day to ensure that our customers have the products and services they need to provide patient care, \nwhether it's COVID -19 tests, PPE or pharmaceuticals.  ", "original_text": "As our customers reopen and address COVID -19, the core business has recovered and returned to growth. "}, "hash": "6da424afdba87411356b941373bc790d6849864bc24383cf05195e92a8442f4d", "class_name": "RelatedNodeInfo"}}, "text": "The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n", "start_char_idx": 4044, "end_char_idx": 4202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4519473a-5af9-4e95-ab99-d295ad23a73b": {"__data__": {"id_": "4519473a-5af9-4e95-ab99-d295ad23a73b", "embedding": null, "metadata": {"window": "When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n As our customers reopen and address COVID -19, the core business has recovered and returned to growth.  With \none of the largest and most tenured sales forces in the industry, our primary and extended care teams work hard \nevery day to ensure that our customers have the products and services they need to provide patient care, \nwhether it's COVID -19 tests, PPE or pharmaceuticals.  ", "original_text": "As our customers reopen and address COVID -19, the core business has recovered and returned to growth. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1072f645-1500-4d1e-b711-0689730b86d2", "node_type": "1", "metadata": {"window": "Let's turn to Medical.  When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n As our customers reopen and address COVID -19, the core business has recovered and returned to growth.  With \none of the largest and most tenured sales forces in the industry, our primary and extended care teams work hard \nevery day to ensure that our customers have the products and services they need to provide patient care, \nwhether it's COVID -19 tests, PPE or pharmaceuticals.  ", "original_text": "The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "954695ce3a32130480135a6d289ffd94c90765dd4181b9091f21b8881631cb2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09f93057-a4b8-4d63-bb4f-f35b78390497", "node_type": "1", "metadata": {"window": "These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n As our customers reopen and address COVID -19, the core business has recovered and returned to growth.  With \none of the largest and most tenured sales forces in the industry, our primary and extended care teams work hard \nevery day to ensure that our customers have the products and services they need to provide patient care, \nwhether it's COVID -19 tests, PPE or pharmaceuticals.  ", "original_text": "With \none of the largest and most tenured sales forces in the industry, our primary and extended care teams work hard \nevery day to ensure that our customers have the products and services they need to provide patient care, \nwhether it's COVID -19 tests, PPE or pharmaceuticals.  "}, "hash": "8820c39452aff75d992a290f1ef14a72901ba2a57019fc3ddb7c99c336936f7a", "class_name": "RelatedNodeInfo"}}, "text": "As our customers reopen and address COVID -19, the core business has recovered and returned to growth. ", "start_char_idx": 4202, "end_char_idx": 4305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09f93057-a4b8-4d63-bb4f-f35b78390497": {"__data__": {"id_": "09f93057-a4b8-4d63-bb4f-f35b78390497", "embedding": null, "metadata": {"window": "These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n As our customers reopen and address COVID -19, the core business has recovered and returned to growth.  With \none of the largest and most tenured sales forces in the industry, our primary and extended care teams work hard \nevery day to ensure that our customers have the products and services they need to provide patient care, \nwhether it's COVID -19 tests, PPE or pharmaceuticals.  ", "original_text": "With \none of the largest and most tenured sales forces in the industry, our primary and extended care teams work hard \nevery day to ensure that our customers have the products and services they need to provide patient care, \nwhether it's COVID -19 tests, PPE or pharmaceuticals.  ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a25013d0-e317-4e07-b596-16a98605d9b3", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e9b29b5b0dab94028fb5069d8f8ab7f4df8c76d99f5c06273cbf85459594bc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4519473a-5af9-4e95-ab99-d295ad23a73b", "node_type": "1", "metadata": {"window": "When we gave initial guidance for fiscal 2021, our alternate site customers were facing \nsignificant headwinds with providers and surgery centers seeing sharp declines in office visits due to shelter -in-\nplace guidelines.  These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n As our customers reopen and address COVID -19, the core business has recovered and returned to growth.  With \none of the largest and most tenured sales forces in the industry, our primary and extended care teams work hard \nevery day to ensure that our customers have the products and services they need to provide patient care, \nwhether it's COVID -19 tests, PPE or pharmaceuticals.  ", "original_text": "As our customers reopen and address COVID -19, the core business has recovered and returned to growth. ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9142c591ed2d38f9e74ebb634a44e4d5036c108c804392d86a1b262275828e70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7717ad48-7ada-4f99-a08c-849776b21e26", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions.  So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this. ", "original_text": "McKesson Corp.  "}, "hash": "d40778daca104403130b5b2a0feeaae1ee778370d75e618e6047eaf5b25e7bd6", "class_name": "RelatedNodeInfo"}}, "text": "With \none of the largest and most tenured sales forces in the industry, our primary and extended care teams work hard \nevery day to ensure that our customers have the products and services they need to provide patient care, \nwhether it's COVID -19 tests, PPE or pharmaceuticals.  ", "start_char_idx": 4305, "end_char_idx": 4585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7717ad48-7ada-4f99-a08c-849776b21e26": {"__data__": {"id_": "7717ad48-7ada-4f99-a08c-849776b21e26", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions.  So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09f93057-a4b8-4d63-bb4f-f35b78390497", "node_type": "1", "metadata": {"window": "These dynamics were clearly reflected in our first quarter results, which were significantly down \nversus prior year.  The pandemic continues to affect the needs of our customers in this market and how they \noperate today looks very diff erent than it did nine months ago.  \n \n As our customers reopen and address COVID -19, the core business has recovered and returned to growth.  With \none of the largest and most tenured sales forces in the industry, our primary and extended care teams work hard \nevery day to ensure that our customers have the products and services they need to provide patient care, \nwhether it's COVID -19 tests, PPE or pharmaceuticals.  ", "original_text": "With \none of the largest and most tenured sales forces in the industry, our primary and extended care teams work hard \nevery day to ensure that our customers have the products and services they need to provide patient care, \nwhether it's COVID -19 tests, PPE or pharmaceuticals.  ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d500a94ae937efba5f6c6b97a9ba27cfbcd214946a78334fc1da7cc24462d1f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a2b0c2e-97bd-492a-bfd6-435db8f74389", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions.  So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions. "}, "hash": "9bcbbe432166a20c24e70823aae819ff3ad57999a3945939710557010e49efe8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a2b0c2e-97bd-492a-bfd6-435db8f74389": {"__data__": {"id_": "6a2b0c2e-97bd-492a-bfd6-435db8f74389", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions.  So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7717ad48-7ada-4f99-a08c-849776b21e26", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions.  So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7181c258fddf143643e56c08739eefa49bf0e9438e7dc4b0e479a3c32715cefc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a00284f0-1b10-47f1-841d-74cd9e5cd82b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions.  So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve. ", "original_text": "So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n"}, "hash": "956e634ee5b4adf898b5c1383155eb5912f5d6486f6bb656dc13751992b874c1", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions. ", "start_char_idx": 16, "end_char_idx": 328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a00284f0-1b10-47f1-841d-74cd9e5cd82b": {"__data__": {"id_": "a00284f0-1b10-47f1-841d-74cd9e5cd82b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions.  So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve. ", "original_text": "So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a2b0c2e-97bd-492a-bfd6-435db8f74389", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions.  So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fed078f5fab28fad44416c39e17cda88f8575ca5fccee64c2d3fcbf00d2b03c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0b756d4-3a24-411a-81e5-392106092233", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions.  So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n", "original_text": "We strategically built this business to suc ceed at moments like this. "}, "hash": "61d0ac0b824f2f33b6119b2314ec482697dda8ccf1956398c6c609dc2287cbdc", "class_name": "RelatedNodeInfo"}}, "text": "So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n", "start_char_idx": 328, "end_char_idx": 500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0b756d4-3a24-411a-81e5-392106092233": {"__data__": {"id_": "f0b756d4-3a24-411a-81e5-392106092233", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions.  So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n", "original_text": "We strategically built this business to suc ceed at moments like this. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a00284f0-1b10-47f1-841d-74cd9e5cd82b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions.  So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve. ", "original_text": "So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67fe4f084e02b5bf6c4c84d08b1e1c543269c691036e84aa7d60fed50205ff19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44859863-9b82-4c5b-878e-af372dd34020", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions.  So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions. ", "original_text": "We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers. "}, "hash": "3c638464f717693fe058b91d80a36dec57ef9d511316f17ddf8ce39e4267c537", "class_name": "RelatedNodeInfo"}}, "text": "We strategically built this business to suc ceed at moments like this. ", "start_char_idx": 500, "end_char_idx": 571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44859863-9b82-4c5b-878e-af372dd34020": {"__data__": {"id_": "44859863-9b82-4c5b-878e-af372dd34020", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions.  So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions. ", "original_text": "We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0b756d4-3a24-411a-81e5-392106092233", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions.  So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n", "original_text": "We strategically built this business to suc ceed at moments like this. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d2eb22ade3f9c011c1aaf0b266f19fc2fa0309301cfaf0a57387b846e32a053", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3414d6ff-43de-42b5-9a21-5242312b758a", "node_type": "1", "metadata": {"window": "So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners. ", "original_text": "The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve. "}, "hash": "505e4ca0423abae85f037ccdddcaa66f0d7de8d4310a16821d5b0485f081f832", "class_name": "RelatedNodeInfo"}}, "text": "We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers. ", "start_char_idx": 571, "end_char_idx": 711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3414d6ff-43de-42b5-9a21-5242312b758a": {"__data__": {"id_": "3414d6ff-43de-42b5-9a21-5242312b758a", "embedding": null, "metadata": {"window": "So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners. ", "original_text": "The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44859863-9b82-4c5b-878e-af372dd34020", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions.  So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions. ", "original_text": "We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aae66c1cd666ed888d548ef450bf20d40d0de79998c684fd70c7ea1a033b9f8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5f77a77-e4cc-4f2e-a859-bfd018591c68", "node_type": "1", "metadata": {"window": "We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP. ", "original_text": "I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n"}, "hash": "1464340239c85005bff199bf862a2e82111612fabafca09ec784901cf46a08e0", "class_name": "RelatedNodeInfo"}}, "text": "The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve. ", "start_char_idx": 711, "end_char_idx": 863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5f77a77-e4cc-4f2e-a859-bfd018591c68": {"__data__": {"id_": "d5f77a77-e4cc-4f2e-a859-bfd018591c68", "embedding": null, "metadata": {"window": "We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP. ", "original_text": "I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3414d6ff-43de-42b5-9a21-5242312b758a", "node_type": "1", "metadata": {"window": "So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners. ", "original_text": "The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4229d3f1dbe206eb7ac088936e96261a58f6368a595833086771533f6524b1f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9660841a-7cb6-4b71-87e3-dc8adf067728", "node_type": "1", "metadata": {"window": "We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry. ", "original_text": "Turning now to Prescription Technology Solutions. "}, "hash": "9012c90faa962d4fd07777e475ba0a4467520e35f46f5a3ca485870dadc4fb4f", "class_name": "RelatedNodeInfo"}}, "text": "I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n", "start_char_idx": 863, "end_char_idx": 973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9660841a-7cb6-4b71-87e3-dc8adf067728": {"__data__": {"id_": "9660841a-7cb6-4b71-87e3-dc8adf067728", "embedding": null, "metadata": {"window": "We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry. ", "original_text": "Turning now to Prescription Technology Solutions. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5f77a77-e4cc-4f2e-a859-bfd018591c68", "node_type": "1", "metadata": {"window": "We strategically built this business to suc ceed at moments like this.  We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP. ", "original_text": "I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad869b272e0bc1bc41cbda9ff0bd001cfe6ced10d7620f7b0d9a8bd2658d826f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9de9ac71-c8e3-4914-974b-d699d94df8ea", "node_type": "1", "metadata": {"window": "The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n", "original_text": "We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners. "}, "hash": "54f902c4f5b5f6a033f9e7dd9daa1790a6b31e9ee3d5c1715a4b169757733b16", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to Prescription Technology Solutions. ", "start_char_idx": 973, "end_char_idx": 1023, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9de9ac71-c8e3-4914-974b-d699d94df8ea": {"__data__": {"id_": "9de9ac71-c8e3-4914-974b-d699d94df8ea", "embedding": null, "metadata": {"window": "The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n", "original_text": "We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9660841a-7cb6-4b71-87e3-dc8adf067728", "node_type": "1", "metadata": {"window": "We are the leader in distribution to the \nalternate site setting and offer a broad set of products and solutions to over 250,000 customers.  The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry. ", "original_text": "Turning now to Prescription Technology Solutions. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96e135c96bbfd2cffbe0ffd71d782b9a6eadb470cef5bb0c786388d477939519", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10abb2b2-22a2-433d-875e-30c8b1ea7c08", "node_type": "1", "metadata": {"window": "I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment. ", "original_text": "We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP. "}, "hash": "c00a6a35c5522165b8d3d3e6c71177b9922855034ec132fc5fd41afa8a71f8b6", "class_name": "RelatedNodeInfo"}}, "text": "We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners. ", "start_char_idx": 1023, "end_char_idx": 1148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10abb2b2-22a2-433d-875e-30c8b1ea7c08": {"__data__": {"id_": "10abb2b2-22a2-433d-875e-30c8b1ea7c08", "embedding": null, "metadata": {"window": "I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment. ", "original_text": "We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9de9ac71-c8e3-4914-974b-d699d94df8ea", "node_type": "1", "metadata": {"window": "The broad \ncapabilities of this business position us well to quickly take advantage of new opportunities as they emerge and \nas customer demand evolve.  I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n", "original_text": "We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "70acac1835c81d86922a5502ffabe9916b3720c70e68b0507147de9da950dd55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "389ac1cb-8ba8-4e20-bdeb-a7ab71d79ddd", "node_type": "1", "metadata": {"window": "Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure. ", "original_text": "AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry. "}, "hash": "e914ca581d8b88fd1ce457b127e97249198c74bac05c965d6ec6cd4b47226495", "class_name": "RelatedNodeInfo"}}, "text": "We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP. ", "start_char_idx": 1148, "end_char_idx": 1347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "389ac1cb-8ba8-4e20-bdeb-a7ab71d79ddd": {"__data__": {"id_": "389ac1cb-8ba8-4e20-bdeb-a7ab71d79ddd", "embedding": null, "metadata": {"window": "Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure. ", "original_text": "AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10abb2b2-22a2-433d-875e-30c8b1ea7c08", "node_type": "1", "metadata": {"window": "I continue to be impressed at how our Medical business has responded to the rapid \nchange in fiscal 2021.  \n \n Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment. ", "original_text": "We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cee85ea5bd43b505abf08dc452b17e1e601c21ff4f42d2c394445d030fa7aa9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e750f551-410a-4ae2-8b0c-54ef9df9345a", "node_type": "1", "metadata": {"window": "We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n", "original_text": "AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n"}, "hash": "dd9b4708706db23232b2eb661d05964cd1001d443511ef228d376919fb4819a4", "class_name": "RelatedNodeInfo"}}, "text": "AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry. ", "start_char_idx": 1347, "end_char_idx": 1465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e750f551-410a-4ae2-8b0c-54ef9df9345a": {"__data__": {"id_": "e750f551-410a-4ae2-8b0c-54ef9df9345a", "embedding": null, "metadata": {"window": "We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n", "original_text": "AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "389ac1cb-8ba8-4e20-bdeb-a7ab71d79ddd", "node_type": "1", "metadata": {"window": "Turning now to Prescription Technology Solutions.  We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure. ", "original_text": "AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e8b6a23df1eff35093e0d345a5c88b61b4d3542b31fdc61ebc05a5fdc1c572e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa503a1f-41ff-4234-9fd0-28d148f9a091", "node_type": "1", "metadata": {"window": "We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise. ", "original_text": "Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment. "}, "hash": "de8b5b219224f6837f62deb7babcae8f2e3dd6cb1628a0790fdebd30dd51bf1b", "class_name": "RelatedNodeInfo"}}, "text": "AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n", "start_char_idx": 1465, "end_char_idx": 1756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa503a1f-41ff-4234-9fd0-28d148f9a091": {"__data__": {"id_": "fa503a1f-41ff-4234-9fd0-28d148f9a091", "embedding": null, "metadata": {"window": "We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise. ", "original_text": "Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e750f551-410a-4ae2-8b0c-54ef9df9345a", "node_type": "1", "metadata": {"window": "We saw solid growth in the quarter, unde rpinned by the \nexpansion of our brand support programs for our biopharma partners.  We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n", "original_text": "AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "600fa9aeb3a3c663c2f6f8aadbbaeacdfe7172df7f765edcde755485da696b07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1f52b15-d6de-4226-ac59-97a810b94af2", "node_type": "1", "metadata": {"window": "AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology. ", "original_text": "We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure. "}, "hash": "f1a2e1e524644fa6f7a2c79b849428080cc3934825b31377223b130a44d0795a", "class_name": "RelatedNodeInfo"}}, "text": "Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment. ", "start_char_idx": 1756, "end_char_idx": 1952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1f52b15-d6de-4226-ac59-97a810b94af2": {"__data__": {"id_": "e1f52b15-d6de-4226-ac59-97a810b94af2", "embedding": null, "metadata": {"window": "AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology. ", "original_text": "We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa503a1f-41ff-4234-9fd0-28d148f9a091", "node_type": "1", "metadata": {"window": "We invest in innovation in this segment, \nand our results reflect positive contributions from our prior authorization solutions and newer products like Access \nfor More Patien ts, also known as AMP.  AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise. ", "original_text": "Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "abff02f6b5ce26fafa5cd13a5ebd93dd0341bfa5049d0bbcc326e9586da362d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5aebedd8-05a4-43a8-bcad-f69e2f27eda8", "node_type": "1", "metadata": {"window": "AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n", "original_text": "Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n"}, "hash": "22782cef057c0cc29d223402c4f08c65a8430bf69a3050ba780956988a81e004", "class_name": "RelatedNodeInfo"}}, "text": "We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure. ", "start_char_idx": 1952, "end_char_idx": 2101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5aebedd8-05a4-43a8-bcad-f69e2f27eda8": {"__data__": {"id_": "5aebedd8-05a4-43a8-bcad-f69e2f27eda8", "embedding": null, "metadata": {"window": "AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n", "original_text": "Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1f52b15-d6de-4226-ac59-97a810b94af2", "node_type": "1", "metadata": {"window": "AMP service offering is continuing to be recognized in the market, both by \nour biopharma customers and the industry.  AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology. ", "original_text": "We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "421486c962f6aba2ca67c4c56241cf4391cbdb22f2b9529e22b71033a920d400", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81fd99b2-1b10-4c8e-8939-6b8b497400ee", "node_type": "1", "metadata": {"window": "Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer. ", "original_text": "Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise. "}, "hash": "5dc763dee61e3bff8f54fc290a563666acbffad23b41afebd2180b2648de80b6", "class_name": "RelatedNodeInfo"}}, "text": "Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n", "start_char_idx": 2101, "end_char_idx": 2379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81fd99b2-1b10-4c8e-8939-6b8b497400ee": {"__data__": {"id_": "81fd99b2-1b10-4c8e-8939-6b8b497400ee", "embedding": null, "metadata": {"window": "Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer. ", "original_text": "Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5aebedd8-05a4-43a8-bcad-f69e2f27eda8", "node_type": "1", "metadata": {"window": "AMP recently signed on a full product portfolio for a top \npharmaceutical company and was recognized as one of 2020's  most innovative products in the healthcare and \nmedical category according to Best in the Biz Awards, an honor voted on by top reporters and editors in North \nAmerica.  \n \n Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n", "original_text": "Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "adc2ef85bcf4962445ab292d99c6e900024e1c1444ef59d491a084dba9de38ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75933a68-1c99-4d0a-a919-3fd78d93e788", "node_type": "1", "metadata": {"window": "We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n", "original_text": "Today, we are the number one distributor in community oncology. "}, "hash": "ab67a52d9effbb01db0c95763201b661119b384e6f5d6c7d628332fded9ab935", "class_name": "RelatedNodeInfo"}}, "text": "Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise. ", "start_char_idx": 2379, "end_char_idx": 2500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75933a68-1c99-4d0a-a919-3fd78d93e788": {"__data__": {"id_": "75933a68-1c99-4d0a-a919-3fd78d93e788", "embedding": null, "metadata": {"window": "We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n", "original_text": "Today, we are the number one distributor in community oncology. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81fd99b2-1b10-4c8e-8939-6b8b497400ee", "node_type": "1", "metadata": {"window": "Taking a step back to reflect, it was over two years ago that we redefined our strategy,  identifying the areas of \noncology and biopharma services as key differentiators and areas of investment.  We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer. ", "original_text": "Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0662525a9a277c21c306dc9c3ef4d9e831f99c4a7421e8833c360ca39a97a04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30548107-4cd4-4a82-8026-74ba719371eb", "node_type": "1", "metadata": {"window": "Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n", "original_text": "And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n"}, "hash": "fbc2c11d347ef5dd008b5d12987ff87c65a67c9410b07cf794bbaa1d2cd51109", "class_name": "RelatedNodeInfo"}}, "text": "Today, we are the number one distributor in community oncology. ", "start_char_idx": 2500, "end_char_idx": 2564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30548107-4cd4-4a82-8026-74ba719371eb": {"__data__": {"id_": "30548107-4cd4-4a82-8026-74ba719371eb", "embedding": null, "metadata": {"window": "Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n", "original_text": "And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75933a68-1c99-4d0a-a919-3fd78d93e788", "node_type": "1", "metadata": {"window": "We also set out to make the \nbusiness simpler and more efficient, kicking off a comprehensive review of the company's operating and cost \nstructure.  Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n", "original_text": "Today, we are the number one distributor in community oncology. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe54f3c6cd97f562d82b225554df8b1182240ab971a1c5422ceb2f0e81129269", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f41e0699-bf57-4d34-8c6c-fb0a242947e9", "node_type": "1", "metadata": {"window": "Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today. ", "original_text": "Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer. "}, "hash": "fb0f8a4dbbc0561e30b5202697e1cbf395c520d2d28fc68e1da1f1d28ab670fd", "class_name": "RelatedNodeInfo"}}, "text": "And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n", "start_char_idx": 2564, "end_char_idx": 2677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f41e0699-bf57-4d34-8c6c-fb0a242947e9": {"__data__": {"id_": "f41e0699-bf57-4d34-8c6c-fb0a242947e9", "embedding": null, "metadata": {"window": "Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today. ", "original_text": "Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30548107-4cd4-4a82-8026-74ba719371eb", "node_type": "1", "metadata": {"window": "Sin ce then, we have been methodical in our actions as we work to build a connected ecosystem of \nassets across the enterprise, with the ultimate goal of creating innovative solutions that improve patient care \ndelivery and drive incremental profit growth for th e company.  \n \n Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n", "original_text": "And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901b277a3db2dbd7868e489dd80827a26b5591ea6c89bb4f80e5bc94a1151968", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38a4a81a-0693-4137-aa1a-3f5c63f70b96", "node_type": "1", "metadata": {"window": "Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions. ", "original_text": "Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n"}, "hash": "588292e7fae512833aa443ecb259d390a07302ac1a13980b61451fa520f456ad", "class_name": "RelatedNodeInfo"}}, "text": "Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer. ", "start_char_idx": 2677, "end_char_idx": 2822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38a4a81a-0693-4137-aa1a-3f5c63f70b96": {"__data__": {"id_": "38a4a81a-0693-4137-aa1a-3f5c63f70b96", "embedding": null, "metadata": {"window": "Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions. ", "original_text": "Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f41e0699-bf57-4d34-8c6c-fb0a242947e9", "node_type": "1", "metadata": {"window": "Through internal investments in M&A, we've built a powerful and scaled specialty business with deep oncology \nexpertise.  Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today. ", "original_text": "Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "261ca2638b9fed61521b696277227f8574c49f0e5d56b36b939b55eec44ef46a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d983ffcc-a2be-42d2-94b6-7920cca7ac50", "node_type": "1", "metadata": {"window": "And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business. ", "original_text": "Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n"}, "hash": "654114c24347df19007d07a9614954c877780330e9476241f7225a272a795dd5", "class_name": "RelatedNodeInfo"}}, "text": "Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n", "start_char_idx": 2822, "end_char_idx": 3018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d983ffcc-a2be-42d2-94b6-7920cca7ac50": {"__data__": {"id_": "d983ffcc-a2be-42d2-94b6-7920cca7ac50", "embedding": null, "metadata": {"window": "And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business. ", "original_text": "Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38a4a81a-0693-4137-aa1a-3f5c63f70b96", "node_type": "1", "metadata": {"window": "Today, we are the number one distributor in community oncology.  And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions. ", "original_text": "Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "749ef2a2e375dfd7ac6870fdd8cc4aeffffa6b081f6c38f91af9d85ebabe20cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d12f354b-53ff-4b1e-a087-142a17284ca1", "node_type": "1", "metadata": {"window": "Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n", "original_text": "Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today. "}, "hash": "aeb1c9ef5c66faf2addaa61ecc6d8c306fab25d4f984dc634815edc817e2962c", "class_name": "RelatedNodeInfo"}}, "text": "Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n", "start_char_idx": 3018, "end_char_idx": 3226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d12f354b-53ff-4b1e-a087-142a17284ca1": {"__data__": {"id_": "d12f354b-53ff-4b1e-a087-142a17284ca1", "embedding": null, "metadata": {"window": "Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n", "original_text": "Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d983ffcc-a2be-42d2-94b6-7920cca7ac50", "node_type": "1", "metadata": {"window": "And The US Oncology Network is \nthe nation's largest network of its kind, with 1,400 independent physicians.  \n \n Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business. ", "original_text": "Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76e0c70e57977ffc0f183e417de31995a9aa16c4b3c1e991a9d8013b44b1bea1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f17bdc66-0d51-4ecd-8945-2f81faa4fe93", "node_type": "1", "metadata": {"window": "Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success. ", "original_text": "This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions. "}, "hash": "21ccd4c8d715c361296359c136f7e5997904e3eef4b39677be3054b5766372f6", "class_name": "RelatedNodeInfo"}}, "text": "Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today. ", "start_char_idx": 3226, "end_char_idx": 3358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f17bdc66-0d51-4ecd-8945-2f81faa4fe93": {"__data__": {"id_": "f17bdc66-0d51-4ecd-8945-2f81faa4fe93", "embedding": null, "metadata": {"window": "Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success. ", "original_text": "This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d12f354b-53ff-4b1e-a087-142a17284ca1", "node_type": "1", "metadata": {"window": "Most recently, we launched Ontada, an internally developed technology and insights business dedicated to \ntransforming the fight against cancer.  Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n", "original_text": "Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fafa9460c8b4ed054aa010d7d6040a3c5f29f07b3f4e70042af15433db4e0655", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "036207f7-043c-4c46-a61f-42afe0ee347f", "node_type": "1", "metadata": {"window": "Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA. ", "original_text": "The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business. "}, "hash": "80a7b03a8fce5b05fa9b79af0523877bdf1051698f0cb107f998e9ec9316c096", "class_name": "RelatedNodeInfo"}}, "text": "This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions. ", "start_char_idx": 3358, "end_char_idx": 3580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "036207f7-043c-4c46-a61f-42afe0ee347f": {"__data__": {"id_": "036207f7-043c-4c46-a61f-42afe0ee347f", "embedding": null, "metadata": {"window": "Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA. ", "original_text": "The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f17bdc66-0d51-4ecd-8945-2f81faa4fe93", "node_type": "1", "metadata": {"window": "Ontada builds off our existing capabilities and combines real -world data and \nresearch with the leading suite of technologies to help deliver innovative solutions that improve patient outcomes. \n Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success. ", "original_text": "This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcd390b17e50a97af9f082d984ea9fcca1cd2afb03a174330d49ba123b476398", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a847dc3-e47a-4fca-bc90-e8d5935bbd82", "node_type": "1", "metadata": {"window": "Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA.  Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization. ", "original_text": "We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n"}, "hash": "96c3bca2fd85595b8d6e27799712d159e7bacf84e6e3c0f8dd40b81f026be8e5", "class_name": "RelatedNodeInfo"}}, "text": "The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business. ", "start_char_idx": 3580, "end_char_idx": 3702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a847dc3-e47a-4fca-bc90-e8d5935bbd82": {"__data__": {"id_": "6a847dc3-e47a-4fca-bc90-e8d5935bbd82", "embedding": null, "metadata": {"window": "Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA.  Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization. ", "original_text": "We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "036207f7-043c-4c46-a61f-42afe0ee347f", "node_type": "1", "metadata": {"window": "Shortly after the launch of Ontada, Amgen and McKesson announced a strategic agreement to advance cancer \ncare and improve outc omes by accelerating the development and access to life -changing medicine.  \n \n Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA. ", "original_text": "The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b307e4ac96668d1f3920be3d4ac902291473744f5a1fe39c25942e7795198027", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34e2e5e9-c885-4150-85fe-85a9f0ac953c", "node_type": "1", "metadata": {"window": "This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA.  Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization.  But underpinning everything we do is our continued focus on growing the core business where ", "original_text": "We also continue to evaluate the portfolio and position the business for success. "}, "hash": "01ced6d1b3b4e3c6388bd6acc8ab85eecb69beadfda3a6b96230ac6652cc82d6", "class_name": "RelatedNodeInfo"}}, "text": "We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n", "start_char_idx": 3702, "end_char_idx": 3854, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34e2e5e9-c885-4150-85fe-85a9f0ac953c": {"__data__": {"id_": "34e2e5e9-c885-4150-85fe-85a9f0ac953c", "embedding": null, "metadata": {"window": "This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA.  Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization.  But underpinning everything we do is our continued focus on growing the core business where ", "original_text": "We also continue to evaluate the portfolio and position the business for success. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a847dc3-e47a-4fca-bc90-e8d5935bbd82", "node_type": "1", "metadata": {"window": "Last quarter, I talked about the evolution of our Prescription Technology Solutions assets into the exciting \nbusiness it is today.  This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA.  Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization. ", "original_text": "We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a45c7281287cb5e3a25c163c8d13e42cf2afd061492f09c6ec33645550e50e20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2313e9d9-0575-410c-aab8-578a5a0266f6", "node_type": "1", "metadata": {"window": "The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA.  Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization.  But underpinning everything we do is our continued focus on growing the core business where ", "original_text": "Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA. "}, "hash": "e2a585f86acaad396fbee30700fb3578c32383ddbb8a68f6eecc720ba1f4a8e0", "class_name": "RelatedNodeInfo"}}, "text": "We also continue to evaluate the portfolio and position the business for success. ", "start_char_idx": 3854, "end_char_idx": 3936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2313e9d9-0575-410c-aab8-578a5a0266f6": {"__data__": {"id_": "2313e9d9-0575-410c-aab8-578a5a0266f6", "embedding": null, "metadata": {"window": "The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA.  Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization.  But underpinning everything we do is our continued focus on growing the core business where ", "original_text": "Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34e2e5e9-c885-4150-85fe-85a9f0ac953c", "node_type": "1", "metadata": {"window": "This business is a powerful biopharma commercial services business that enables over $5 \nbillion in annual prescription savings for patients through innovation and next -generation patient access and \nadherence solutions.  The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA.  Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization.  But underpinning everything we do is our continued focus on growing the core business where ", "original_text": "We also continue to evaluate the portfolio and position the business for success. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "187b90967d4ef6d0868f22c9b75b027687a7012039fccbfe5a6efb7bc09cb7c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9627e903-21b1-42fe-b54a-d14c6134d457", "node_type": "1", "metadata": {"window": "We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA.  Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization.  But underpinning everything we do is our continued focus on growing the core business where ", "original_text": "Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization. "}, "hash": "a2065353863b99227d7a49047e397c6374b525bf3f1c2afa1332bc2b5b2d69f0", "class_name": "RelatedNodeInfo"}}, "text": "Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA. ", "start_char_idx": 3936, "end_char_idx": 4073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9627e903-21b1-42fe-b54a-d14c6134d457": {"__data__": {"id_": "9627e903-21b1-42fe-b54a-d14c6134d457", "embedding": null, "metadata": {"window": "We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA.  Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization.  But underpinning everything we do is our continued focus on growing the core business where ", "original_text": "Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2313e9d9-0575-410c-aab8-578a5a0266f6", "node_type": "1", "metadata": {"window": "The strategic investments I've discussed have been powered in part by the successful \nefforts to streamline the business.  We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA.  Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization.  But underpinning everything we do is our continued focus on growing the core business where ", "original_text": "Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a222e971f48fd5015d89a041f171ac001d9d485f8355f1905e1e3594463880fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1869e5c5-2127-4b7f-8a33-0df08ec856e1", "node_type": "1", "metadata": {"window": "We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA.  Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization.  But underpinning everything we do is our continued focus on growing the core business where ", "original_text": "But underpinning everything we do is our continued focus on growing the core business where "}, "hash": "ad31cfe2eab805566db5810eacc43d3b48af9da1ce93b241beb266955fea32d3", "class_name": "RelatedNodeInfo"}}, "text": "Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization. ", "start_char_idx": 4073, "end_char_idx": 4215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1869e5c5-2127-4b7f-8a33-0df08ec856e1": {"__data__": {"id_": "1869e5c5-2127-4b7f-8a33-0df08ec856e1", "embedding": null, "metadata": {"window": "We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA.  Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization.  But underpinning everything we do is our continued focus on growing the core business where ", "original_text": "But underpinning everything we do is our continued focus on growing the core business where ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ce05f017ffdb50bcf307a2aa743c55982f542186acd7e79ccd2062a172de4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9627e903-21b1-42fe-b54a-d14c6134d457", "node_type": "1", "metadata": {"window": "We've centralized many back office functions in North America and Europe and \nhave become smarter as an organization about how we spend and invest.  \n \n We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA.  Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization.  But underpinning everything we do is our continued focus on growing the core business where ", "original_text": "Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization. ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad22e5a6c01fda4cd35a019638d746f0e5df5504ac6732642047f21c44094e3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6879b280-b115-4674-b1b1-a32ae89cc63e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved.  Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers. ", "original_text": "McKesson Corp.  "}, "hash": "10e3a0fb1103d96f1ec1cbc733e14358b15df4cec620ab4f571f947f0c9ca32c", "class_name": "RelatedNodeInfo"}}, "text": "But underpinning everything we do is our continued focus on growing the core business where ", "start_char_idx": 4215, "end_char_idx": 4307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6879b280-b115-4674-b1b1-a32ae89cc63e": {"__data__": {"id_": "6879b280-b115-4674-b1b1-a32ae89cc63e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved.  Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1869e5c5-2127-4b7f-8a33-0df08ec856e1", "node_type": "1", "metadata": {"window": "We also continue to evaluate the portfolio and position the business for success.  Last year, we successfully exited \nour position in Change Healthcare and most recently we created the joint venture in Germany with WBA.  Further, \nwe re -segmented the business to better align us around our strategies and increased focus and speed th roughout \nthe organization.  But underpinning everything we do is our continued focus on growing the core business where ", "original_text": "But underpinning everything we do is our continued focus on growing the core business where ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f113453e863b4c6348583c9a573bdbeac270e7e05517519bb9580838eb5ecbea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9290e65-3492-4df4-bc14-948739c70eff", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved.  Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved. "}, "hash": "c2a6f4c2e28d4ae392049a1973fd8789601693eec2c65917effc446b6184b968", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9290e65-3492-4df4-bc14-948739c70eff": {"__data__": {"id_": "b9290e65-3492-4df4-bc14-948739c70eff", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved.  Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6879b280-b115-4674-b1b1-a32ae89cc63e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved.  Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b61c8c6cefb39c43a75ffce2ba62aa6eb5c0b929c0d2a39ae4896db8754a3e17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f610c91-11ce-4549-96e4-fbac9c666064", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved.  Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about. ", "original_text": "Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n"}, "hash": "c15b70a10f6c88ab31005e257a2024b8c2dcfbb81e198cce7b013d28a50304dc", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved. ", "start_char_idx": 16, "end_char_idx": 243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f610c91-11ce-4549-96e4-fbac9c666064": {"__data__": {"id_": "3f610c91-11ce-4549-96e4-fbac9c666064", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved.  Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about. ", "original_text": "Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9290e65-3492-4df4-bc14-948739c70eff", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved.  Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d9969860aa867647352ba2ae254a03adfc3e0c6a560237c55af0afe45155d1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2ff38a1-bca3-4c25-a365-9c385137c6bc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved.  Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns. ", "original_text": "While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers. "}, "hash": "7979b540c13ff242a40cc77cab3a5b90f260152d2395e27eff2fb34c6e04b56a", "class_name": "RelatedNodeInfo"}}, "text": "Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n", "start_char_idx": 243, "end_char_idx": 389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2ff38a1-bca3-4c25-a365-9c385137c6bc": {"__data__": {"id_": "f2ff38a1-bca3-4c25-a365-9c385137c6bc", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved.  Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns. ", "original_text": "While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f610c91-11ce-4549-96e4-fbac9c666064", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved.  Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about. ", "original_text": "Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "230df1a3c235f9a43e99b189edda669e1cfa3009b0895d7319c9e1ff367982fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "472a4687-8e10-4211-a3a2-66528be44688", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved.  Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others. ", "original_text": "This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n"}, "hash": "c7cc3e2b3acacbcad1f2632b07732a6fdd15780396eec451ef5068fe2dca2e01", "class_name": "RelatedNodeInfo"}}, "text": "While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers. ", "start_char_idx": 389, "end_char_idx": 606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "472a4687-8e10-4211-a3a2-66528be44688": {"__data__": {"id_": "472a4687-8e10-4211-a3a2-66528be44688", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved.  Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others. ", "original_text": "This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2ff38a1-bca3-4c25-a365-9c385137c6bc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved.  Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns. ", "original_text": "While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ac48c88bb7495e33f476c83e20554258ebc3d594e1040a19636540cc10f0f3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa6005d1-ab09-45d4-ae31-3cf7aba92b03", "node_type": "1", "metadata": {"window": "Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022. ", "original_text": "As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about. "}, "hash": "43891bb209ed47fcff4337bede5230ebd3b8dbc70204c44e6019de7d39453db9", "class_name": "RelatedNodeInfo"}}, "text": "This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n", "start_char_idx": 606, "end_char_idx": 782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa6005d1-ab09-45d4-ae31-3cf7aba92b03": {"__data__": {"id_": "aa6005d1-ab09-45d4-ae31-3cf7aba92b03", "embedding": null, "metadata": {"window": "Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022. ", "original_text": "As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "472a4687-8e10-4211-a3a2-66528be44688", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved.  Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others. ", "original_text": "This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee3eb0ad5fd3f94f547665a5894844d8bcebcb01045a78b1ce6306870917eaa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "873c0758-ec5d-47f7-b70d-e384c2b1cc9f", "node_type": "1", "metadata": {"window": "While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n", "original_text": "First and \nforemost, the COVID -19 pandemic continues to present many unknowns. "}, "hash": "203d5bafbeb85009b0091ba15919e559594f560b9b189bd6a1e159b0225d2424", "class_name": "RelatedNodeInfo"}}, "text": "As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about. ", "start_char_idx": 782, "end_char_idx": 888, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "873c0758-ec5d-47f7-b70d-e384c2b1cc9f": {"__data__": {"id_": "873c0758-ec5d-47f7-b70d-e384c2b1cc9f", "embedding": null, "metadata": {"window": "While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n", "original_text": "First and \nforemost, the COVID -19 pandemic continues to present many unknowns. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa6005d1-ab09-45d4-ae31-3cf7aba92b03", "node_type": "1", "metadata": {"window": "Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022. ", "original_text": "As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9bc622031e4beb60f94482f3ca512cf0fe59e9146a3f83c988815f25195e524f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "448a3708-c5ae-4f2f-bd4c-e7ebb1620afa", "node_type": "1", "metadata": {"window": "This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model. ", "original_text": "The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others. "}, "hash": "297019b728ae12231dac9b709e0eac383ff33475fecd64388c71a97bfbdd8744", "class_name": "RelatedNodeInfo"}}, "text": "First and \nforemost, the COVID -19 pandemic continues to present many unknowns. ", "start_char_idx": 888, "end_char_idx": 968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "448a3708-c5ae-4f2f-bd4c-e7ebb1620afa": {"__data__": {"id_": "448a3708-c5ae-4f2f-bd4c-e7ebb1620afa", "embedding": null, "metadata": {"window": "This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model. ", "original_text": "The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "873c0758-ec5d-47f7-b70d-e384c2b1cc9f", "node_type": "1", "metadata": {"window": "While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers.  This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n", "original_text": "First and \nforemost, the COVID -19 pandemic continues to present many unknowns. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4757508ddfe6e2574403795772a1eec99a6cfd241159ffc5d3931d62d1895cd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47f5cb84-60e1-44bc-b272-b033d15a0b27", "node_type": "1", "metadata": {"window": "As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n", "original_text": "The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022. "}, "hash": "d66c642e6350a9f5a37400881be95d8696989a4a00b4ac9d0cedcdebd63e39a4", "class_name": "RelatedNodeInfo"}}, "text": "The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others. ", "start_char_idx": 968, "end_char_idx": 1078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47f5cb84-60e1-44bc-b272-b033d15a0b27": {"__data__": {"id_": "47f5cb84-60e1-44bc-b272-b033d15a0b27", "embedding": null, "metadata": {"window": "As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n", "original_text": "The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "448a3708-c5ae-4f2f-bd4c-e7ebb1620afa", "node_type": "1", "metadata": {"window": "This has served \nus well throughout the pandemic as we responded to near -term demands from our customers, but it also positions \nthe business to succeed in the long term.  \n \n As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model. ", "original_text": "The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7274592c283e3bad8a86968c0ae04734e641521b63a0adebe9b31eb50fd585b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "168e54a3-a92a-49ad-9af5-8444f439837b", "node_type": "1", "metadata": {"window": "First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n", "original_text": "But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n"}, "hash": "f14482ff0b5b207cecd8a8ebac2fe3a3750e1c2db8af8fe9fff42c454ea246c7", "class_name": "RelatedNodeInfo"}}, "text": "The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022. ", "start_char_idx": 1078, "end_char_idx": 1169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "168e54a3-a92a-49ad-9af5-8444f439837b": {"__data__": {"id_": "168e54a3-a92a-49ad-9af5-8444f439837b", "embedding": null, "metadata": {"window": "First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n", "original_text": "But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47f5cb84-60e1-44bc-b272-b033d15a0b27", "node_type": "1", "metadata": {"window": "As we look forward to our fiscal 2022, I'd like to walk thr ough some of the things we're thinking about.  First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n", "original_text": "The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "179051e751215d647f4e4a0a3765d531645532a5862cb5e81b28aefcfb568182", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b13e458f-a59d-4dff-ab66-e322754d6aaa", "node_type": "1", "metadata": {"window": "The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022. ", "original_text": "Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model. "}, "hash": "2ad0fdc0ff27420edd1dcaa0a7e481b89d0c75304fa3ae4b477ec625f535cbc7", "class_name": "RelatedNodeInfo"}}, "text": "But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n", "start_char_idx": 1169, "end_char_idx": 1287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b13e458f-a59d-4dff-ab66-e322754d6aaa": {"__data__": {"id_": "b13e458f-a59d-4dff-ab66-e322754d6aaa", "embedding": null, "metadata": {"window": "The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022. ", "original_text": "Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "168e54a3-a92a-49ad-9af5-8444f439837b", "node_type": "1", "metadata": {"window": "First and \nforemost, the COVID -19 pandemic continues to present many unknowns.  The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n", "original_text": "But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ad7d217537935aae3c6a65ffa2e991871e0632b23c7cbc8a1c14177c2c0dbcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5dfcf625-8962-4772-966d-9500803f76b3", "node_type": "1", "metadata": {"window": "The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n", "original_text": "These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n"}, "hash": "f343db7e511cc6ffae37505a14f453a7bed83d0e2ff9ac64e077f65f7d7e5694", "class_name": "RelatedNodeInfo"}}, "text": "Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model. ", "start_char_idx": 1287, "end_char_idx": 1596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5dfcf625-8962-4772-966d-9500803f76b3": {"__data__": {"id_": "5dfcf625-8962-4772-966d-9500803f76b3", "embedding": null, "metadata": {"window": "The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n", "original_text": "These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b13e458f-a59d-4dff-ab66-e322754d6aaa", "node_type": "1", "metadata": {"window": "The trajectory of the virus can change \nquickly, accelerating in some communities and decelerating in others.  The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022. ", "original_text": "Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c10cb008ba987916fc58c93ee21904d29ad46e6030bbd83700add931d481b11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bc98567-2d2e-49b7-8efc-d347faa2bda9", "node_type": "1", "metadata": {"window": "But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners. ", "original_text": "And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n"}, "hash": "7e24c2ecce82bf64c3409cb1577871864584d9b770879a766d9ce7ea32f99cb4", "class_name": "RelatedNodeInfo"}}, "text": "These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n", "start_char_idx": 1596, "end_char_idx": 1735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bc98567-2d2e-49b7-8efc-d347faa2bda9": {"__data__": {"id_": "2bc98567-2d2e-49b7-8efc-d347faa2bda9", "embedding": null, "metadata": {"window": "But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners. ", "original_text": "And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5dfcf625-8962-4772-966d-9500803f76b3", "node_type": "1", "metadata": {"window": "The recovery from the p andemic is likely to \ncontinue to be non -linear into fiscal 2022.  But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n", "original_text": "These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52b7e18e023377f3e222bc281d195ab970ed213b676a156c5f1489e061e0ca84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70995268-93ae-4590-aa54-55cc03e1dce6", "node_type": "1", "metadata": {"window": "Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n", "original_text": "I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022. "}, "hash": "4d08bd38fa2b28021f5658ee1c4a3810ef39f9dbb4a509f03bdf91accd0c13af", "class_name": "RelatedNodeInfo"}}, "text": "And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n", "start_char_idx": 1735, "end_char_idx": 2012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70995268-93ae-4590-aa54-55cc03e1dce6": {"__data__": {"id_": "70995268-93ae-4590-aa54-55cc03e1dce6", "embedding": null, "metadata": {"window": "Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n", "original_text": "I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bc98567-2d2e-49b7-8efc-d347faa2bda9", "node_type": "1", "metadata": {"window": "But McKesson will continue to be part of the recovery, serving our \ncustomers and partners every step of the way.  \n \n Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners. ", "original_text": "And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92ddfe02675dae2b4c49cc5d67ffba2bddb5bbfce3e5ddf3bd668e2a9e752845", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fc5e98e-4ba8-4e05-a24d-b538382489f7", "node_type": "1", "metadata": {"window": "These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities. ", "original_text": "We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n"}, "hash": "2619ef964ccd809a8e66649afde8214269249555fc521c53cf003417055bfa38", "class_name": "RelatedNodeInfo"}}, "text": "I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022. ", "start_char_idx": 2012, "end_char_idx": 2160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fc5e98e-4ba8-4e05-a24d-b538382489f7": {"__data__": {"id_": "7fc5e98e-4ba8-4e05-a24d-b538382489f7", "embedding": null, "metadata": {"window": "These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities. ", "original_text": "We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70995268-93ae-4590-aa54-55cc03e1dce6", "node_type": "1", "metadata": {"window": "Secondly, our work distributing COVID -19 vaccines and ancillary supplies will  ultimately be influenced by the \nnumber of vaccines that come to market, the percentage of the population that chooses to get vaccinated, the \neffectiveness of each vaccine and the duration of the centralized distribution model.  These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n", "original_text": "I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d3a1c24433ae24e1b5b60462d43a7493ba306f235061812b174abc43827aeaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "079cb033-6767-452b-94a6-f73e3b490a85", "node_type": "1", "metadata": {"window": "And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n", "original_text": "So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners. "}, "hash": "3dcc894dea8460b70ce6219b27f26420047997820f81941e013eaae540fbff48", "class_name": "RelatedNodeInfo"}}, "text": "We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n", "start_char_idx": 2160, "end_char_idx": 2261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "079cb033-6767-452b-94a6-f73e3b490a85": {"__data__": {"id_": "079cb033-6767-452b-94a6-f73e3b490a85", "embedding": null, "metadata": {"window": "And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n", "original_text": "So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fc5e98e-4ba8-4e05-a24d-b538382489f7", "node_type": "1", "metadata": {"window": "These same dynamics are \nlikely to have an impact on the levels of demand we see for products like COVID tests and PPE in fiscal 2022.  \n \n And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities. ", "original_text": "We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b78cad15c8358f6d7c1a574eaf8898ee72367f454cfc49ebba79d444c44290c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c146540-5fe6-4e50-97ab-6a7edff81ce7", "node_type": "1", "metadata": {"window": "I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr. ", "original_text": "The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n"}, "hash": "92476fa5fcd70b541266b346e2d077083e736e9238afcb733219be179121b47d", "class_name": "RelatedNodeInfo"}}, "text": "So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners. ", "start_char_idx": 2261, "end_char_idx": 2534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c146540-5fe6-4e50-97ab-6a7edff81ce7": {"__data__": {"id_": "9c146540-5fe6-4e50-97ab-6a7edff81ce7", "embedding": null, "metadata": {"window": "I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr. ", "original_text": "The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "079cb033-6767-452b-94a6-f73e3b490a85", "node_type": "1", "metadata": {"window": "And as I mentioned earlier, we have a new administration in Washington and our teams have been working \nclosely with the new administration's transiti on team and now emerging team to ensure that the proposed reforms \nsupport solutions to improve cost, quality and access.  \n \n I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n", "original_text": "So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "548de32d25554da1e9c8b3955eebd13a23a236f70bd5bf43dd21e756cfadf6a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be270d93-59dc-4349-8cc9-0fce096699ed", "node_type": "1", "metadata": {"window": "We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact. ", "original_text": "Before I close, I also want to touch on our commitment to our local and global communities. "}, "hash": "1ea12847fd3e73d613af517a144bdf9fa70f9b7c99c069a32899643c9dcee7ec", "class_name": "RelatedNodeInfo"}}, "text": "The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n", "start_char_idx": 2534, "end_char_idx": 2709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be270d93-59dc-4349-8cc9-0fce096699ed": {"__data__": {"id_": "be270d93-59dc-4349-8cc9-0fce096699ed", "embedding": null, "metadata": {"window": "We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact. ", "original_text": "Before I close, I also want to touch on our commitment to our local and global communities. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c146540-5fe6-4e50-97ab-6a7edff81ce7", "node_type": "1", "metadata": {"window": "I'll reiterate that we continue to see stability in the core and strength in the underlying fundamentals of the \nbusiness heading into fiscal 2022.  We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr. ", "original_text": "The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffcc2af9060391cb9b5dc4857d389b94b56290af412b42fd7b793f0fcf888c4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1da4bf30-400e-41bc-b654-1f4202f69933", "node_type": "1", "metadata": {"window": "So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n", "original_text": "We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n"}, "hash": "4df341f5eaeed45c464e499c5c7d1ddab19309d41a514e75518ca72fc1683c53", "class_name": "RelatedNodeInfo"}}, "text": "Before I close, I also want to touch on our commitment to our local and global communities. ", "start_char_idx": 2709, "end_char_idx": 2801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1da4bf30-400e-41bc-b654-1f4202f69933": {"__data__": {"id_": "1da4bf30-400e-41bc-b654-1f4202f69933", "embedding": null, "metadata": {"window": "So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n", "original_text": "We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be270d93-59dc-4349-8cc9-0fce096699ed", "node_type": "1", "metadata": {"window": "We will continue to make strategic investments in the areas of oncology and \nbiopharma services.  \n \n So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact. ", "original_text": "Before I close, I also want to touch on our commitment to our local and global communities. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3262d6a137bf0f2ed263fc3d3526ddfd0b6844a1ba1fdaa58d3a798eb488b6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c1847ea-7574-4802-a972-35d19b99ffe4", "node_type": "1", "metadata": {"window": "The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people. ", "original_text": "And we recently recruited Dr. "}, "hash": "ec724be390c09c62062ad011e1fab36bb0cdf64dc769146d63db67295f195ad2", "class_name": "RelatedNodeInfo"}}, "text": "We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n", "start_char_idx": 2801, "end_char_idx": 3044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c1847ea-7574-4802-a972-35d19b99ffe4": {"__data__": {"id_": "2c1847ea-7574-4802-a972-35d19b99ffe4", "embedding": null, "metadata": {"window": "The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people. ", "original_text": "And we recently recruited Dr. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1da4bf30-400e-41bc-b654-1f4202f69933", "node_type": "1", "metadata": {"window": "So, in summary, through nine months, each quarter of the current fiscal year has proven to be different one to the \nnext, and the results we're sha ring today reflect McKesson's ability to rise to the challenge and meet the evolving \ndemands of our customers and partners.  The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n", "original_text": "We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06ea88faf2a9862f0e364d570774798da30f63f3aef4a25fe16e60b5dd02602c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1307c4e7-6f91-4010-ae15-d5d6d4a1832e", "node_type": "1", "metadata": {"window": "Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special. ", "original_text": "Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact. "}, "hash": "b4e215928ced71d7688d1f89fad3341329fed5b36e69f93cd27ae7d8ab46007d", "class_name": "RelatedNodeInfo"}}, "text": "And we recently recruited Dr. ", "start_char_idx": 3044, "end_char_idx": 3074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1307c4e7-6f91-4010-ae15-d5d6d4a1832e": {"__data__": {"id_": "1307c4e7-6f91-4010-ae15-d5d6d4a1832e", "embedding": null, "metadata": {"window": "Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special. ", "original_text": "Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c1847ea-7574-4802-a972-35d19b99ffe4", "node_type": "1", "metadata": {"window": "The pandemic has not put our strategy on hold, but HAS challenged us \nto continue to think differently and react more quickly against  the dynamic macroeconomic backdrop.  \n \n Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people. ", "original_text": "And we recently recruited Dr. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b32f06e9d0df834dab51fa038c913bf07ab5da677a61ca0d213a9327c1b199c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c593057-a76a-4a0c-ba36-a87acb0c74ab", "node_type": "1", "metadata": {"window": "We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible. ", "original_text": "We're excited to have Kelvin on the team.  \n \n"}, "hash": "563fdeef08ea0a743dc0135fca719b12ed931a0e9e5efaeccaedd3416fe7b5c3", "class_name": "RelatedNodeInfo"}}, "text": "Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact. ", "start_char_idx": 3074, "end_char_idx": 3314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c593057-a76a-4a0c-ba36-a87acb0c74ab": {"__data__": {"id_": "3c593057-a76a-4a0c-ba36-a87acb0c74ab", "embedding": null, "metadata": {"window": "We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible. ", "original_text": "We're excited to have Kelvin on the team.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1307c4e7-6f91-4010-ae15-d5d6d4a1832e", "node_type": "1", "metadata": {"window": "Before I close, I also want to touch on our commitment to our local and global communities.  We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special. ", "original_text": "Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a188ae837d729d9529b19cdffbb84d32310b43ac22f2d50d7a2627822d90f482", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab40e5b7-312a-44de-bf09-bcec33df48d0", "node_type": "1", "metadata": {"window": "And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n", "original_text": "In the end, it all comes back to our people. "}, "hash": "ec17754e50a29b5bc373322603d49ff5d6281897dd638098b35cb8db2e0c35ae", "class_name": "RelatedNodeInfo"}}, "text": "We're excited to have Kelvin on the team.  \n \n", "start_char_idx": 3314, "end_char_idx": 3360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab40e5b7-312a-44de-bf09-bcec33df48d0": {"__data__": {"id_": "ab40e5b7-312a-44de-bf09-bcec33df48d0", "embedding": null, "metadata": {"window": "And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n", "original_text": "In the end, it all comes back to our people. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c593057-a76a-4a0c-ba36-a87acb0c74ab", "node_type": "1", "metadata": {"window": "We're dedicated to \ndoing our part to eliminate bias and promote equality, and we are proud to have been recently recognized as  one \nof the Best Places to Work for LGBTQ Equality by the Human Rights Campaign for the eighth consecutive year. \n And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible. ", "original_text": "We're excited to have Kelvin on the team.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0830f9c633a4eb04ed60db473131bc667210eb40978182a58ba59c56b792537", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d0e40d5-8ee6-4b0d-8c54-b831017c4c5e", "node_type": "1", "metadata": {"window": "Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n Thank you for your time. ", "original_text": "The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special. "}, "hash": "c627aa4ba4a67299c83eb1b97e07e60f597a6d0114800b1191ec4bad1a14a538", "class_name": "RelatedNodeInfo"}}, "text": "In the end, it all comes back to our people. ", "start_char_idx": 3360, "end_char_idx": 3405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d0e40d5-8ee6-4b0d-8c54-b831017c4c5e": {"__data__": {"id_": "0d0e40d5-8ee6-4b0d-8c54-b831017c4c5e", "embedding": null, "metadata": {"window": "Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n Thank you for your time. ", "original_text": "The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab40e5b7-312a-44de-bf09-bcec33df48d0", "node_type": "1", "metadata": {"window": "And we recently recruited Dr.  Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n", "original_text": "In the end, it all comes back to our people. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1f2b3152b3adbc229939be547ca34aad98c73bf3fd9e36f417d8aee20208b2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09fb4811-03b4-41e9-92bc-ecac9bb19224", "node_type": "1", "metadata": {"window": "We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n Thank you for your time.  And with that, I'll turn it over to Britt.  \n ", "original_text": "And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible. "}, "hash": "2ce41d1149eb6ed961cf99f6228d41271613990ff09959656ba0456acdb31fbb", "class_name": "RelatedNodeInfo"}}, "text": "The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special. ", "start_char_idx": 3405, "end_char_idx": 3495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09fb4811-03b4-41e9-92bc-ecac9bb19224": {"__data__": {"id_": "09fb4811-03b4-41e9-92bc-ecac9bb19224", "embedding": null, "metadata": {"window": "We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n Thank you for your time.  And with that, I'll turn it over to Britt.  \n ", "original_text": "And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d0e40d5-8ee6-4b0d-8c54-b831017c4c5e", "node_type": "1", "metadata": {"window": "Kelvin Baggett to the newly created role of Chief Impact Officer reporting to me \nwhere he will be responsible for  advancing our strategy and execution related to diversity, equity and inclusion, \nESG and McKesson's overall social impact.  We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n Thank you for your time. ", "original_text": "The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d77de939c55a19ff4d0a4b7414a1b27ef996f70f90e3d14d7cf0f1562cc13055", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc46cdc1-0f68-4ffa-97fc-53abf040d50e", "node_type": "1", "metadata": {"window": "In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n Thank you for your time.  And with that, I'll turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "My greatest thanks to them all.  \n \n"}, "hash": "cfe4020abcf15cb32c3eba41ef84f0d381eae1cdafa45eaa245160b4689e1868", "class_name": "RelatedNodeInfo"}}, "text": "And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible. ", "start_char_idx": 3495, "end_char_idx": 3592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc46cdc1-0f68-4ffa-97fc-53abf040d50e": {"__data__": {"id_": "bc46cdc1-0f68-4ffa-97fc-53abf040d50e", "embedding": null, "metadata": {"window": "In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n Thank you for your time.  And with that, I'll turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "My greatest thanks to them all.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09fb4811-03b4-41e9-92bc-ecac9bb19224", "node_type": "1", "metadata": {"window": "We're excited to have Kelvin on the team.  \n \n In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n Thank you for your time.  And with that, I'll turn it over to Britt.  \n ", "original_text": "And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c0692d5779ffe888984e619df90662d539fbd4470e66907ada628fdf1a83f58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04163cd6-c145-4c3e-953a-59f8d95ece74", "node_type": "1", "metadata": {"window": "The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n Thank you for your time.  And with that, I'll turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Thank you for your time. "}, "hash": "5c7403105fdb3b21985cace71a87cd2629b5a07112cf904593dac3107fc91a1e", "class_name": "RelatedNodeInfo"}}, "text": "My greatest thanks to them all.  \n \n", "start_char_idx": 3592, "end_char_idx": 3628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04163cd6-c145-4c3e-953a-59f8d95ece74": {"__data__": {"id_": "04163cd6-c145-4c3e-953a-59f8d95ece74", "embedding": null, "metadata": {"window": "The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n Thank you for your time.  And with that, I'll turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Thank you for your time. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc46cdc1-0f68-4ffa-97fc-53abf040d50e", "node_type": "1", "metadata": {"window": "In the end, it all comes back to our people.  The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n Thank you for your time.  And with that, I'll turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "My greatest thanks to them all.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64fe19225df24655349b648183330f2b9bbfec106cf0993d9efc80053f36fd2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b97d3d02-3f9a-4c53-917d-b15c7c909e48", "node_type": "1", "metadata": {"window": "And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n Thank you for your time.  And with that, I'll turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And with that, I'll turn it over to Britt.  \n "}, "hash": "a97cf41b24128501eef15be7b04e20a49da53315c246138232b7328de7fdc972", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for your time. ", "start_char_idx": 3628, "end_char_idx": 3653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b97d3d02-3f9a-4c53-917d-b15c7c909e48": {"__data__": {"id_": "b97d3d02-3f9a-4c53-917d-b15c7c909e48", "embedding": null, "metadata": {"window": "And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n Thank you for your time.  And with that, I'll turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And with that, I'll turn it over to Britt.  \n ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04163cd6-c145-4c3e-953a-59f8d95ece74", "node_type": "1", "metadata": {"window": "The passion and the focus of our 80,000 plus  employees are what \nmakes McKesson special.  And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n Thank you for your time.  And with that, I'll turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Thank you for your time. ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ad0c5a475daddf78747d291251dff70b93332e8ba59ee0b40d8fcc5e42e25eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e183617-f898-4d28-aeb8-9dfd1046bac1", "node_type": "1", "metadata": {"window": "My greatest thanks to them all.  \n \n Thank you for your time.  And with that, I'll turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "d10b7f2de7baa8731ac618b788ebbb03a9647c1f84bacfea819615b90b9e01b0", "class_name": "RelatedNodeInfo"}}, "text": "And with that, I'll turn it over to Britt.  \n ", "start_char_idx": 3653, "end_char_idx": 3699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e183617-f898-4d28-aeb8-9dfd1046bac1": {"__data__": {"id_": "4e183617-f898-4d28-aeb8-9dfd1046bac1", "embedding": null, "metadata": {"window": "My greatest thanks to them all.  \n \n Thank you for your time.  And with that, I'll turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "87efe71c-a497-4ce2-bcc7-296e354ade52", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f856f66c3988a4c3a91c16b96e1bfbe20464bfee7811d2079d0df4109acf18da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b97d3d02-3f9a-4c53-917d-b15c7c909e48", "node_type": "1", "metadata": {"window": "And without them, the work we are doing to combat the COVID -19 pandemic would not \nbe possible.  My greatest thanks to them all.  \n \n Thank you for your time.  And with that, I'll turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And with that, I'll turn it over to Britt.  \n ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97397973beb74b2bd15b6fd411ab4795ad7fee4ae1158935245e3f383b275978", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "625159f2-612c-46ca-910e-81b48bef8563", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone.  I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "298cffc678531cf19a1437e9f69dc8f35508a23711e96c69b94d7c2f27ca3110", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 3699, "end_char_idx": 4044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "625159f2-612c-46ca-910e-81b48bef8563": {"__data__": {"id_": "625159f2-612c-46ca-910e-81b48bef8563", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone.  I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e183617-f898-4d28-aeb8-9dfd1046bac1", "node_type": "1", "metadata": {"window": "My greatest thanks to them all.  \n \n Thank you for your time.  And with that, I'll turn it over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67b8be84c25933900e29712949d4c1113b19d1b2c510df3e79a1d64aee2fb045", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5a9120a-bf19-4160-ae9e-65f0081ed130", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone.  I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone. "}, "hash": "4fa78a1422e736ada8ed3db4090d0b4eb3c5d76f22a95897663ce63d327380a2", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5a9120a-bf19-4160-ae9e-65f0081ed130": {"__data__": {"id_": "e5a9120a-bf19-4160-ae9e-65f0081ed130", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone.  I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "625159f2-612c-46ca-910e-81b48bef8563", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone.  I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7f0f87e8b032c780bc0a98a42ad42d798aecebd82190f55477abeb15a56e294e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87ea6fc1-15b8-4604-b069-05cd7a95730a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone.  I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter. ", "original_text": "I'm pleased to speak to you about another solid quarter for \nMcKesson. "}, "hash": "0be6c85c8e9b040fffe69a831a3b085e6b9a745547c0ba738275d63cd87218c8", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone. ", "start_char_idx": 16, "end_char_idx": 232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87ea6fc1-15b8-4604-b069-05cd7a95730a": {"__data__": {"id_": "87ea6fc1-15b8-4604-b069-05cd7a95730a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone.  I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter. ", "original_text": "I'm pleased to speak to you about another solid quarter for \nMcKesson. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5a9120a-bf19-4160-ae9e-65f0081ed130", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone.  I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61cce72c64287b7e1826b62a67b68fe17e00d2b6445bef25774cbd29a2d5bcc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fddd58d7-dc85-44e0-b61a-f967708d1bab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone.  I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n", "original_text": "Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n"}, "hash": "765e69b974220da456cfffdeb8653be5105b56cf196bbeb9fd481fec6df4220c", "class_name": "RelatedNodeInfo"}}, "text": "I'm pleased to speak to you about another solid quarter for \nMcKesson. ", "start_char_idx": 232, "end_char_idx": 303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fddd58d7-dc85-44e0-b61a-f967708d1bab": {"__data__": {"id_": "fddd58d7-dc85-44e0-b61a-f967708d1bab", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone.  I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n", "original_text": "Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87ea6fc1-15b8-4604-b069-05cd7a95730a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone.  I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter. ", "original_text": "I'm pleased to speak to you about another solid quarter for \nMcKesson. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e74e3d34274ecc43ecc67453beae3b967d78291d52844d592655241308ee019", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a49e850a-4bc5-4ece-836d-774b4bf69c02", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone.  I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance. ", "original_text": "The underlying core business continues to be fundamentally sound. "}, "hash": "a52b96326295dabf3909a15e4b389ca27576c22dba34285309b7f4fa5c8f84af", "class_name": "RelatedNodeInfo"}}, "text": "Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n", "start_char_idx": 303, "end_char_idx": 523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a49e850a-4bc5-4ece-836d-774b4bf69c02": {"__data__": {"id_": "a49e850a-4bc5-4ece-836d-774b4bf69c02", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone.  I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance. ", "original_text": "The underlying core business continues to be fundamentally sound. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fddd58d7-dc85-44e0-b61a-f967708d1bab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone.  I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n", "original_text": "Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d75c03e79e7aecc222e86b9fa01ec72ed48c8d31d2a16c61d9146950723deed1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3ced4d1-2673-400c-944e-ff9023211217", "node_type": "1", "metadata": {"window": "I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022. ", "original_text": "And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter. "}, "hash": "9116b2102f8ac5a1e0d828a55b9dce2f49b3c94778176663800196ffe6b8920c", "class_name": "RelatedNodeInfo"}}, "text": "The underlying core business continues to be fundamentally sound. ", "start_char_idx": 523, "end_char_idx": 589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3ced4d1-2673-400c-944e-ff9023211217": {"__data__": {"id_": "e3ced4d1-2673-400c-944e-ff9023211217", "embedding": null, "metadata": {"window": "I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022. ", "original_text": "And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a49e850a-4bc5-4ece-836d-774b4bf69c02", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone.  I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance. ", "original_text": "The underlying core business continues to be fundamentally sound. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34b0b4c9fc6c3ec6a7d144bbc76c4c0408f11549f56f6347364e2abb8954307d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0346339d-d452-4376-ba61-5187b272f758", "node_type": "1", "metadata": {"window": "Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n", "original_text": "Our solid \nbroad -based third quarter results reflect this momentum.  \n \n"}, "hash": "724952cc9ccdc9b7c6b8dd8172bfd0b9538f318f1154240fefae566cd285d17a", "class_name": "RelatedNodeInfo"}}, "text": "And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter. ", "start_char_idx": 589, "end_char_idx": 735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0346339d-d452-4376-ba61-5187b272f758": {"__data__": {"id_": "0346339d-d452-4376-ba61-5187b272f758", "embedding": null, "metadata": {"window": "Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n", "original_text": "Our solid \nbroad -based third quarter results reflect this momentum.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3ced4d1-2673-400c-944e-ff9023211217", "node_type": "1", "metadata": {"window": "I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022. ", "original_text": "And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c99bb5985e6988fe8daa8f2f0706710c90d1ae7fac1745d238fef1fc3b734179", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da757c88-f6e3-485e-b88d-e7bfc58be2ea", "node_type": "1", "metadata": {"window": "The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels. ", "original_text": "Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance. "}, "hash": "c2989f700b4372e402e49fef9fdcbee12d6144596f2098aa2a974337546847d9", "class_name": "RelatedNodeInfo"}}, "text": "Our solid \nbroad -based third quarter results reflect this momentum.  \n \n", "start_char_idx": 735, "end_char_idx": 808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da757c88-f6e3-485e-b88d-e7bfc58be2ea": {"__data__": {"id_": "da757c88-f6e3-485e-b88d-e7bfc58be2ea", "embedding": null, "metadata": {"window": "The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels. ", "original_text": "Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0346339d-d452-4376-ba61-5187b272f758", "node_type": "1", "metadata": {"window": "Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n", "original_text": "Our solid \nbroad -based third quarter results reflect this momentum.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce7f8a055ce4a25bf29d056ef3cc9d5fe2ec21032e63a12cf278b8d3a83f7bd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2949101d-26f7-491a-be70-b17d8e14ab5b", "node_type": "1", "metadata": {"window": "And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter. ", "original_text": "As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022. "}, "hash": "c950147cf36b346fc06e347b82e90a87469569e8b1d7f0562d08849ba2cc18e2", "class_name": "RelatedNodeInfo"}}, "text": "Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance. ", "start_char_idx": 808, "end_char_idx": 1028, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2949101d-26f7-491a-be70-b17d8e14ab5b": {"__data__": {"id_": "2949101d-26f7-491a-be70-b17d8e14ab5b", "embedding": null, "metadata": {"window": "And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter. ", "original_text": "As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da757c88-f6e3-485e-b88d-e7bfc58be2ea", "node_type": "1", "metadata": {"window": "The underlying core business continues to be fundamentally sound.  And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels. ", "original_text": "Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b89cd6770a12a3ba514d20fde4de157e452bf17b1e1f03479790d546c7a3e273", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06bd555d-939c-42fc-97c3-4c6ff56f2244", "node_type": "1", "metadata": {"window": "Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter. ", "original_text": "We saw this \nuneven recovery play out in Q3.  \n \n"}, "hash": "d50e62edc4fb45aab4681ebdf2a309d793070f015da991ad072611f1da7a3c35", "class_name": "RelatedNodeInfo"}}, "text": "As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022. ", "start_char_idx": 1028, "end_char_idx": 1249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06bd555d-939c-42fc-97c3-4c6ff56f2244": {"__data__": {"id_": "06bd555d-939c-42fc-97c3-4c6ff56f2244", "embedding": null, "metadata": {"window": "Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter. ", "original_text": "We saw this \nuneven recovery play out in Q3.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2949101d-26f7-491a-be70-b17d8e14ab5b", "node_type": "1", "metadata": {"window": "And we've built solid revenue, op erating profit \nand cash flow momentum over the past several quarters, which continued in the December quarter.  Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter. ", "original_text": "As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e75cd729bd123ef9c5e7861fad8af960c702bd976ed4cc9bb071d1fb182ecda7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2f49db5-c503-403f-b27e-4f4c88a1b084", "node_type": "1", "metadata": {"window": "Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels. ", "original_text": "COVID -19 cases and hospitalizations reached their highest levels. "}, "hash": "ee0f681aa27e7fc61b4bbb3c4d28238ca84128ae5ce9af04cecf1e96cecef300", "class_name": "RelatedNodeInfo"}}, "text": "We saw this \nuneven recovery play out in Q3.  \n \n", "start_char_idx": 1249, "end_char_idx": 1298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2f49db5-c503-403f-b27e-4f4c88a1b084": {"__data__": {"id_": "c2f49db5-c503-403f-b27e-4f4c88a1b084", "embedding": null, "metadata": {"window": "Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels. ", "original_text": "COVID -19 cases and hospitalizations reached their highest levels. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06bd555d-939c-42fc-97c3-4c6ff56f2244", "node_type": "1", "metadata": {"window": "Our solid \nbroad -based third quarter results reflect this momentum.  \n \n Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter. ", "original_text": "We saw this \nuneven recovery play out in Q3.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "69fdb10315b7d683e9a1c3da1f7ebeacc383629c44b32aa2ea138e788d2c90fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fba1c902-eabd-4727-ad38-6edd637f3c71", "node_type": "1", "metadata": {"window": "As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth. ", "original_text": "This led to some softening in recovery tre nds \nduring the quarter. "}, "hash": "24f9b05871eecfcd6bc3388c18590d2d52fce61534e4038f3d6d011a28419c33", "class_name": "RelatedNodeInfo"}}, "text": "COVID -19 cases and hospitalizations reached their highest levels. ", "start_char_idx": 1298, "end_char_idx": 1365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fba1c902-eabd-4727-ad38-6edd637f3c71": {"__data__": {"id_": "fba1c902-eabd-4727-ad38-6edd637f3c71", "embedding": null, "metadata": {"window": "As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth. ", "original_text": "This led to some softening in recovery tre nds \nduring the quarter. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2f49db5-c503-403f-b27e-4f4c88a1b084", "node_type": "1", "metadata": {"window": "Our demonstrated delivery of consistent and stable organic growth, combined w ith the execution of the vaccine \nand kitting programs with the US Government, are enabling us to further increase fiscal year 2021 guidance.  As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels. ", "original_text": "COVID -19 cases and hospitalizations reached their highest levels. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb3eaa0706c6c1495595271ae4021027e2ff53dd7457d7cef62713f3da1cdfe9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57c3aa20-12e3-490e-bd67-9a8f938a7fb5", "node_type": "1", "metadata": {"window": "We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n", "original_text": "Prescription volumes were softer than the prior quarter. "}, "hash": "e93fafe107096834bc7d867d2f5303fc7f03dea515d8e0575753658a09917da9", "class_name": "RelatedNodeInfo"}}, "text": "This led to some softening in recovery tre nds \nduring the quarter. ", "start_char_idx": 1365, "end_char_idx": 1433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57c3aa20-12e3-490e-bd67-9a8f938a7fb5": {"__data__": {"id_": "57c3aa20-12e3-490e-bd67-9a8f938a7fb5", "embedding": null, "metadata": {"window": "We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n", "original_text": "Prescription volumes were softer than the prior quarter. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fba1c902-eabd-4727-ad38-6edd637f3c71", "node_type": "1", "metadata": {"window": "As \nwe mentioned during our first and second quarter earnings calls, we expected the non -linear recovery from the \neffects of the pandemic to persist for the remainder of our fiscal year and likely into our fiscal 2022.  We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth. ", "original_text": "This led to some softening in recovery tre nds \nduring the quarter. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875fafc5ac506b1d33f1108f417c43e63a37b0772db8d20163b228cfad8b04ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3da361fe-ca60-4e23-8e46-d8f6fa7c0e58", "node_type": "1", "metadata": {"window": "COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine. ", "original_text": "And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels. "}, "hash": "cff93bda3b3baff24308f5563256ec27a06af8bfc2e1d6aece665e46465d40bd", "class_name": "RelatedNodeInfo"}}, "text": "Prescription volumes were softer than the prior quarter. ", "start_char_idx": 1433, "end_char_idx": 1490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3da361fe-ca60-4e23-8e46-d8f6fa7c0e58": {"__data__": {"id_": "3da361fe-ca60-4e23-8e46-d8f6fa7c0e58", "embedding": null, "metadata": {"window": "COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine. ", "original_text": "And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57c3aa20-12e3-490e-bd67-9a8f938a7fb5", "node_type": "1", "metadata": {"window": "We saw this \nuneven recovery play out in Q3.  \n \n COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n", "original_text": "Prescription volumes were softer than the prior quarter. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "128fd4e844c80ff57c3ace1794d59b5803af0916724239ce69a3fb92b75167a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5dbbea56-cb4c-4113-9d57-b24bc83e8df5", "node_type": "1", "metadata": {"window": "This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n", "original_text": "Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth. "}, "hash": "aa6b520850c4e35a26d0a7171d20dfe72974d0536c731aa787759d19e196dbd3", "class_name": "RelatedNodeInfo"}}, "text": "And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels. ", "start_char_idx": 1490, "end_char_idx": 1592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5dbbea56-cb4c-4113-9d57-b24bc83e8df5": {"__data__": {"id_": "5dbbea56-cb4c-4113-9d57-b24bc83e8df5", "embedding": null, "metadata": {"window": "This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n", "original_text": "Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3da361fe-ca60-4e23-8e46-d8f6fa7c0e58", "node_type": "1", "metadata": {"window": "COVID -19 cases and hospitalizations reached their highest levels.  This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine. ", "original_text": "And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26c920396fb91ace479d13a512d046a92732b6f2906f41ac35169e0e39677f48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fb79b84-d94d-4d93-ab80-dbf49768794e", "node_type": "1", "metadata": {"window": "Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n", "original_text": "And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n"}, "hash": "1c29f50d4f26cb02f78775ad029d0dfac1bce23f608863870dbdab8dfa4b10ef", "class_name": "RelatedNodeInfo"}}, "text": "Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth. ", "start_char_idx": 1592, "end_char_idx": 1700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fb79b84-d94d-4d93-ab80-dbf49768794e": {"__data__": {"id_": "9fb79b84-d94d-4d93-ab80-dbf49768794e", "embedding": null, "metadata": {"window": "Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n", "original_text": "And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5dbbea56-cb4c-4113-9d57-b24bc83e8df5", "node_type": "1", "metadata": {"window": "This led to some softening in recovery tre nds \nduring the quarter.  Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n", "original_text": "Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "731fb05442bb36dab1602b784932d6dc6321ea83a12c070204bfe621f10768f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d68fcda4-ef6f-4f7a-a84c-4236928d4ca7", "node_type": "1", "metadata": {"window": "And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts. ", "original_text": "In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine. "}, "hash": "c83decf2e41bb5b68d714135711c6c6d7695c782f9dc7f1539f12f1469c6ab5f", "class_name": "RelatedNodeInfo"}}, "text": "And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n", "start_char_idx": 1700, "end_char_idx": 1797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d68fcda4-ef6f-4f7a-a84c-4236928d4ca7": {"__data__": {"id_": "d68fcda4-ef6f-4f7a-a84c-4236928d4ca7", "embedding": null, "metadata": {"window": "And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts. ", "original_text": "In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fb79b84-d94d-4d93-ab80-dbf49768794e", "node_type": "1", "metadata": {"window": "Prescription volumes were softer than the prior quarter.  And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n", "original_text": "And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0eb272867ded4e9f033a21fe1fe89b0346d1d9b20d1d6b2748dea571766c9498", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe6c1024-0450-4cb6-b119-f3f67733da28", "node_type": "1", "metadata": {"window": "Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n", "original_text": "And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n"}, "hash": "c17cb923156b33bb654f796971d713a0f84f363feea995a47306c60429478a6d", "class_name": "RelatedNodeInfo"}}, "text": "In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine. ", "start_char_idx": 1797, "end_char_idx": 1976, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe6c1024-0450-4cb6-b119-f3f67733da28": {"__data__": {"id_": "fe6c1024-0450-4cb6-b119-f3f67733da28", "embedding": null, "metadata": {"window": "Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n", "original_text": "And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d68fcda4-ef6f-4f7a-a84c-4236928d4ca7", "node_type": "1", "metadata": {"window": "And primary care patient visits and \nelective procedures continued to remain below pre -COVID levels.  Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts. ", "original_text": "In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "638d07bd1c7da5bd946914c0768a0b54a98409a9ba28e751091543b0ce2a3880", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39affadf-f571-4324-b3d2-1b760d740e89", "node_type": "1", "metadata": {"window": "And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website. ", "original_text": "Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n"}, "hash": "3d3175d8f411334dbebf15086f3cfe2e9753074ac6d810910d0bb8b2a0db3449", "class_name": "RelatedNodeInfo"}}, "text": "And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n", "start_char_idx": 1976, "end_char_idx": 2095, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39affadf-f571-4324-b3d2-1b760d740e89": {"__data__": {"id_": "39affadf-f571-4324-b3d2-1b760d740e89", "embedding": null, "metadata": {"window": "And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website. ", "original_text": "Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe6c1024-0450-4cb6-b119-f3f67733da28", "node_type": "1", "metadata": {"window": "Despite these challenges, in Q3, all segments \ndelivered year -over-year adju sted operating profit growth.  And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n", "original_text": "And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "340bfb58195ab012380b7d3205544063d70318b4292050aaebcc1414db4d7e62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2742a2ca-4702-4508-9ace-10586714db58", "node_type": "1", "metadata": {"window": "In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter. ", "original_text": "According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts. "}, "hash": "57839f09310618dc3715f6f60b52a5fe643232df463edb8588b70e802d51f9df", "class_name": "RelatedNodeInfo"}}, "text": "Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n", "start_char_idx": 2095, "end_char_idx": 2317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2742a2ca-4702-4508-9ace-10586714db58": {"__data__": {"id_": "2742a2ca-4702-4508-9ace-10586714db58", "embedding": null, "metadata": {"window": "In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter. ", "original_text": "According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39affadf-f571-4324-b3d2-1b760d740e89", "node_type": "1", "metadata": {"window": "And year -to-date, adjusted earnings per diluted share \ngrew 14% compared to the prior year.  \n \n In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website. ", "original_text": "Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c36c513fa57745efdabf2d9635843f0f5ef2baec74ac60179fd3d8bcb4c814f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34c67f6b-5cd8-43b7-a75b-b006a0268926", "node_type": "1", "metadata": {"window": "And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable. ", "original_text": "And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n"}, "hash": "ee9710594404eb787da3b2103102111f5d55d34d0149028e01390d3a6de76646", "class_name": "RelatedNodeInfo"}}, "text": "According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts. ", "start_char_idx": 2317, "end_char_idx": 2467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34c67f6b-5cd8-43b7-a75b-b006a0268926": {"__data__": {"id_": "34c67f6b-5cd8-43b7-a75b-b006a0268926", "embedding": null, "metadata": {"window": "And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable. ", "original_text": "And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2742a2ca-4702-4508-9ace-10586714db58", "node_type": "1", "metadata": {"window": "In the third quarter, we recognized a benefit from our work with the US Government for assembling and \ndistributing ancillary supply ki ts needed to administer COVID -19 vaccine.  And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter. ", "original_text": "According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "119ce1fee315ab02375d42564835b0a1d8a93848ecd81b0bf46e6facac204e1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ead0f5d4-cd28-4bc7-9200-a3ef10154920", "node_type": "1", "metadata": {"window": "Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated. ", "original_text": "Now on to our third quarter results which can be found in the Investors section of our website. "}, "hash": "8b3e1d59e4dbe8d509e4803ea9b65f6b5bbee00d4eaf454624346f2b3bcd1155", "class_name": "RelatedNodeInfo"}}, "text": "And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n", "start_char_idx": 2467, "end_char_idx": 2615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ead0f5d4-cd28-4bc7-9200-a3ef10154920": {"__data__": {"id_": "ead0f5d4-cd28-4bc7-9200-a3ef10154920", "embedding": null, "metadata": {"window": "Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated. ", "original_text": "Now on to our third quarter results which can be found in the Investors section of our website. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34c67f6b-5cd8-43b7-a75b-b006a0268926", "node_type": "1", "metadata": {"window": "And while not material to the quarter, we \nalso began distributing the Moderna COVID -19 vaccine in late December.  \n \n Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable. ", "original_text": "And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08b013bdb22aef66fd348cabfcd2933e254d8c26ec483b9a9e260807a651b4c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "884a15a3-6a2c-4b9e-92fe-e7e48f8885af", "node_type": "1", "metadata": {"window": "According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax. ", "original_text": "And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter. "}, "hash": "467fbb076d02fcf3a312cf031ccbcfe8560dfe578d014e718ccda43b665777b7", "class_name": "RelatedNodeInfo"}}, "text": "Now on to our third quarter results which can be found in the Investors section of our website. ", "start_char_idx": 2615, "end_char_idx": 2711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "884a15a3-6a2c-4b9e-92fe-e7e48f8885af": {"__data__": {"id_": "884a15a3-6a2c-4b9e-92fe-e7e48f8885af", "embedding": null, "metadata": {"window": "According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax. ", "original_text": "And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ead0f5d4-cd28-4bc7-9200-a3ef10154920", "node_type": "1", "metadata": {"window": "Volumes for COVID -related testing and personal protective equipment, or PPE, continued to remain hig h in our \nMedical segment while the impacts of social distancing measures have resulted in a soft cold and flu season. \n According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated. ", "original_text": "Now on to our third quarter results which can be found in the Investors section of our website. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a04086ec2e77c7b037236a4f38041ddacdecd3db1f58fcdef8a28c46f749f957", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "493c94ca-731b-46ed-b8f8-1a8d84a78986", "node_type": "1", "metadata": {"window": "And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n", "original_text": "Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable. "}, "hash": "b4462ecb0efacfbb7be57acaf3f18e0ad438cbbeb6cc7b1890d87aad8290ab68", "class_name": "RelatedNodeInfo"}}, "text": "And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter. ", "start_char_idx": 2711, "end_char_idx": 2809, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "493c94ca-731b-46ed-b8f8-1a8d84a78986": {"__data__": {"id_": "493c94ca-731b-46ed-b8f8-1a8d84a78986", "embedding": null, "metadata": {"window": "And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n", "original_text": "Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "884a15a3-6a2c-4b9e-92fe-e7e48f8885af", "node_type": "1", "metadata": {"window": "According to IQVIA, the US adult flu diagnoses were down approximately 10% compared to the prior year, which \nresulted in lower generic flu  scripts.  And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax. ", "original_text": "And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "490b4c2311f0bff96f487ec3c930fe4207c5d6e87ced982e8250030e27dbb74f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1ad7bfb-cb48-400b-841f-d3fa54023667", "node_type": "1", "metadata": {"window": "Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4. ", "original_text": "It can be reasonably estimated. "}, "hash": "1fcb183e02e376bd038e3405a6f44f1c56cfd934ec944b4a8ad4e43d6771b6f9", "class_name": "RelatedNodeInfo"}}, "text": "Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable. ", "start_char_idx": 2809, "end_char_idx": 3004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1ad7bfb-cb48-400b-841f-d3fa54023667": {"__data__": {"id_": "d1ad7bfb-cb48-400b-841f-d3fa54023667", "embedding": null, "metadata": {"window": "Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4. ", "original_text": "It can be reasonably estimated. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "493c94ca-731b-46ed-b8f8-1a8d84a78986", "node_type": "1", "metadata": {"window": "And similar to last quarter, in the third quarter, we recognized unplanned \ngains on equity investments within our McKesson Ventures portfolio.  \n \n Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n", "original_text": "Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49aa57d9e752be0107fc96b106b151f2b6a14f91ba705b5ac39efc2fcd06bc73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "821c90a3-1fb0-4181-a203-02e0f091b7ab", "node_type": "1", "metadata": {"window": "And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S. ", "original_text": "And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax. "}, "hash": "afbd6c3b4e8cf22a178f977829302fef7d01848ea47d95704cf914574c1c4947", "class_name": "RelatedNodeInfo"}}, "text": "It can be reasonably estimated. ", "start_char_idx": 3004, "end_char_idx": 3036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "821c90a3-1fb0-4181-a203-02e0f091b7ab": {"__data__": {"id_": "821c90a3-1fb0-4181-a203-02e0f091b7ab", "embedding": null, "metadata": {"window": "And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S. ", "original_text": "And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1ad7bfb-cb48-400b-841f-d3fa54023667", "node_type": "1", "metadata": {"window": "Now on to our third quarter results which can be found in the Investors section of our website.  And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4. ", "original_text": "It can be reasonably estimated. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "474b182224946798a1157a944afe0412ec42d12df4169d3db52b5a143f329425", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8e9cd68-6724-498f-b281-4c03be7ec71c", "node_type": "1", "metadata": {"window": "Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE. ", "original_text": "Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n"}, "hash": "0523e7caca3106dc33297a4c3694df83828b1304c25ba6f2efe45628e3541ba2", "class_name": "RelatedNodeInfo"}}, "text": "And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax. ", "start_char_idx": 3036, "end_char_idx": 3126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8e9cd68-6724-498f-b281-4c03be7ec71c": {"__data__": {"id_": "d8e9cd68-6724-498f-b281-4c03be7ec71c", "embedding": null, "metadata": {"window": "Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE. ", "original_text": "Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "821c90a3-1fb0-4181-a203-02e0f091b7ab", "node_type": "1", "metadata": {"window": "And le t me start by \npointing out two items that impacted our GAAP -only results in the quarter.  Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S. ", "original_text": "And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c99d3bc589de623eaf2f7f2dd5961c33121e1af97850c29a58065659b9462c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dce430b7-7f71-4bcd-82a0-a450810d2e83", "node_type": "1", "metadata": {"window": "It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE.  This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n", "original_text": "Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4. "}, "hash": "a0e2e5192ab4b56b644df254e77e213638836e44aff69a4f45371ba95feb323f", "class_name": "RelatedNodeInfo"}}, "text": "Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n", "start_char_idx": 3126, "end_char_idx": 3298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dce430b7-7f71-4bcd-82a0-a450810d2e83": {"__data__": {"id_": "dce430b7-7f71-4bcd-82a0-a450810d2e83", "embedding": null, "metadata": {"window": "It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE.  This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n", "original_text": "Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8e9cd68-6724-498f-b281-4c03be7ec71c", "node_type": "1", "metadata": {"window": "Based on the substantial progress \ntoward a settlement of our ongoing opioid -related claims, it is concluded that a broad settlement of opioid claims \nby governmental en tities is now probable.  It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE. ", "original_text": "Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ff3bb54903a5eedcdd5d942557e58e17701e70fde4304a567f286ea33766235", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb8c7993-65e1-4157-92c9-21a25c443f09", "node_type": "1", "metadata": {"window": "And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE.  This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit increased 7% year -over-year driven by growth in the Medical -Surgical segment, which once \nagain benefited from the contribution of near -term opportunities, including distribution of COVID -19 tests and our \nwork assembling ancillary supply kit for COVID -19 vaccine.  \n ", "original_text": "Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S. "}, "hash": "ea8f13873b06e0d790300cd980342553edaf1eea68d9e97e8329d83e69bddbc0", "class_name": "RelatedNodeInfo"}}, "text": "Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4. ", "start_char_idx": 3298, "end_char_idx": 3437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb8c7993-65e1-4157-92c9-21a25c443f09": {"__data__": {"id_": "eb8c7993-65e1-4157-92c9-21a25c443f09", "embedding": null, "metadata": {"window": "And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE.  This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit increased 7% year -over-year driven by growth in the Medical -Surgical segment, which once \nagain benefited from the contribution of near -term opportunities, including distribution of COVID -19 tests and our \nwork assembling ancillary supply kit for COVID -19 vaccine.  \n ", "original_text": "Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dce430b7-7f71-4bcd-82a0-a450810d2e83", "node_type": "1", "metadata": {"window": "It can be reasonably estimated.  And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE.  This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n", "original_text": "Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8291744c880fa024de5f0a93bd8a79392e3043f228a7e9af9768c6427a0f7c0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f787808-d5b5-43de-9d08-adf59c6a0321", "node_type": "1", "metadata": {"window": "Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE.  This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit increased 7% year -over-year driven by growth in the Medical -Surgical segment, which once \nagain benefited from the contribution of near -term opportunities, including distribution of COVID -19 tests and our \nwork assembling ancillary supply kit for COVID -19 vaccine.  \n ", "original_text": "Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE. "}, "hash": "789e9cdb7e84589f2db7affbab92b33d2eb4df0200466c05a21a1442adb043bc", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S. ", "start_char_idx": 3437, "end_char_idx": 3585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f787808-d5b5-43de-9d08-adf59c6a0321": {"__data__": {"id_": "7f787808-d5b5-43de-9d08-adf59c6a0321", "embedding": null, "metadata": {"window": "Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE.  This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit increased 7% year -over-year driven by growth in the Medical -Surgical segment, which once \nagain benefited from the contribution of near -term opportunities, including distribution of COVID -19 tests and our \nwork assembling ancillary supply kit for COVID -19 vaccine.  \n ", "original_text": "Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb8c7993-65e1-4157-92c9-21a25c443f09", "node_type": "1", "metadata": {"window": "And as a result, we reported a pre -tax \ncharge of $8.1 billion, $6.7 billion after -tax.  Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE.  This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit increased 7% year -over-year driven by growth in the Medical -Surgical segment, which once \nagain benefited from the contribution of near -term opportunities, including distribution of COVID -19 tests and our \nwork assembling ancillary supply kit for COVID -19 vaccine.  \n ", "original_text": "Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d436347f42a24e84d5d113b071e1fbe4284c7785fd48d394bb20b613bb0f4547", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cff03c1-d518-4911-b006-6b60aa089cea", "node_type": "1", "metadata": {"window": "Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE.  This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit increased 7% year -over-year driven by growth in the Medical -Surgical segment, which once \nagain benefited from the contribution of near -term opportunities, including distribution of COVID -19 tests and our \nwork assembling ancillary supply kit for COVID -19 vaccine.  \n ", "original_text": "This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n"}, "hash": "182785704b7d33bde721c85849f037fbea54624277b890d1d238fbc663270d33", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE. ", "start_char_idx": 3585, "end_char_idx": 3692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cff03c1-d518-4911-b006-6b60aa089cea": {"__data__": {"id_": "5cff03c1-d518-4911-b006-6b60aa089cea", "embedding": null, "metadata": {"window": "Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE.  This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit increased 7% year -over-year driven by growth in the Medical -Surgical segment, which once \nagain benefited from the contribution of near -term opportunities, including distribution of COVID -19 tests and our \nwork assembling ancillary supply kit for COVID -19 vaccine.  \n ", "original_text": "This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f787808-d5b5-43de-9d08-adf59c6a0321", "node_type": "1", "metadata": {"window": "Secondly, we recorded a pre -tax long -lived asset impairment charge of \n$115 million primarily related to McKesson' s retail pharmacy businesses in Canada and Europe.  \n \n Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE.  This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit increased 7% year -over-year driven by growth in the Medical -Surgical segment, which once \nagain benefited from the contribution of near -term opportunities, including distribution of COVID -19 tests and our \nwork assembling ancillary supply kit for COVID -19 vaccine.  \n ", "original_text": "Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE. ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "948aaf1d31d46b8355c375e77d2affe471b9ff635186a801329d57eb5d16947f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6214e694-d1b2-4bb3-96a0-d7e834fe774e", "node_type": "1", "metadata": {"window": "Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE.  This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit increased 7% year -over-year driven by growth in the Medical -Surgical segment, which once \nagain benefited from the contribution of near -term opportunities, including distribution of COVID -19 tests and our \nwork assembling ancillary supply kit for COVID -19 vaccine.  \n ", "original_text": "Adjusted gross profit increased 7% year -over-year driven by growth in the Medical -Surgical segment, which once \nagain benefited from the contribution of near -term opportunities, including distribution of COVID -19 tests and our \nwork assembling ancillary supply kit for COVID -19 vaccine.  \n "}, "hash": "b6eac5df428b8a2c6284ffc0bb72c3f3f81920e7293af92dee9fe95796e7bec3", "class_name": "RelatedNodeInfo"}}, "text": "This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n", "start_char_idx": 3692, "end_char_idx": 3862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6214e694-d1b2-4bb3-96a0-d7e834fe774e": {"__data__": {"id_": "6214e694-d1b2-4bb3-96a0-d7e834fe774e", "embedding": null, "metadata": {"window": "Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE.  This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit increased 7% year -over-year driven by growth in the Medical -Surgical segment, which once \nagain benefited from the contribution of near -term opportunities, including distribution of COVID -19 tests and our \nwork assembling ancillary supply kit for COVID -19 vaccine.  \n ", "original_text": "Adjusted gross profit increased 7% year -over-year driven by growth in the Medical -Surgical segment, which once \nagain benefited from the contribution of near -term opportunities, including distribution of COVID -19 tests and our \nwork assembling ancillary supply kit for COVID -19 vaccine.  \n ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "875a28f04fd36c3159235e16f6ce964a36ad5a1722db213a65b0bcfbdbf36403", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cff03c1-d518-4911-b006-6b60aa089cea", "node_type": "1", "metadata": {"window": "Let's move now to a discussion of our adjusted earnings results for the third quarter, starting with our consolidated \nresults on slide 4.  Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE.  This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit increased 7% year -over-year driven by growth in the Medical -Surgical segment, which once \nagain benefited from the contribution of near -term opportunities, including distribution of COVID -19 tests and our \nwork assembling ancillary supply kit for COVID -19 vaccine.  \n ", "original_text": "This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb612172fda828f5ecddfdc12d0b455bfc6a72ce0975d1b8ab786c2a421fa75e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3abc02ae-cb43-4cdc-b11d-9619eb01b762", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "dc4ad185be92637d897055bb35c80cc818a6d5d652990f7179f42cfcc7cebb11", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit increased 7% year -over-year driven by growth in the Medical -Surgical segment, which once \nagain benefited from the contribution of near -term opportunities, including distribution of COVID -19 tests and our \nwork assembling ancillary supply kit for COVID -19 vaccine.  \n ", "start_char_idx": 3862, "end_char_idx": 4157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3abc02ae-cb43-4cdc-b11d-9619eb01b762": {"__data__": {"id_": "3abc02ae-cb43-4cdc-b11d-9619eb01b762", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6214e694-d1b2-4bb3-96a0-d7e834fe774e", "node_type": "1", "metadata": {"window": "Consolidated revenues of $62.6 billion were up 6% compared to the prior year, primarily due to \nmarket growth, higher specialty volumes in our U.S.  Pharmaceutical segment and COVID -related volumes in our \nMedical business, including COVID tests and PPE.  This was partially offset by branded to generic conversions \nand the co ntribution of our German wholesale business to a joint venture with Walgreens Boots Alliance.  \n \n Adjusted gross profit increased 7% year -over-year driven by growth in the Medical -Surgical segment, which once \nagain benefited from the contribution of near -term opportunities, including distribution of COVID -19 tests and our \nwork assembling ancillary supply kit for COVID -19 vaccine.  \n ", "original_text": "Adjusted gross profit increased 7% year -over-year driven by growth in the Medical -Surgical segment, which once \nagain benefited from the contribution of near -term opportunities, including distribution of COVID -19 tests and our \nwork assembling ancillary supply kit for COVID -19 vaccine.  \n ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a6dc9cbcbbaa359d560e3547a5a525492ce72172f7083907fd7860c865c30f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7125747-1f13-4759-94a2-1a993149472e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n"}, "hash": "31d594f835ccdf87d58c1b5100ae13e241ed22b517d2d7cbe8070bb77335d766", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7125747-1f13-4759-94a2-1a993149472e": {"__data__": {"id_": "a7125747-1f13-4759-94a2-1a993149472e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3abc02ae-cb43-4cdc-b11d-9619eb01b762", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4be161c2ae1ce0b478ab5c5c54a4e483621a16b42ea22ca412b364130409ae7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "feed1182-05b5-49a2-b5c8-fea823e9e625", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million. ", "original_text": "Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year. "}, "hash": "63a20298a09e69f034363fdbfe6172de0ac506219e6516ffdd01061245b1a04c", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n", "start_char_idx": 16, "end_char_idx": 533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "feed1182-05b5-49a2-b5c8-fea823e9e625": {"__data__": {"id_": "feed1182-05b5-49a2-b5c8-fea823e9e625", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million. ", "original_text": "Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7125747-1f13-4759-94a2-1a993149472e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60a0e9b643a91d6fabf41df14962e0caff38f73ea8b657732dbaa2c635ef2f29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ea17033-66e0-4316-acce-4d5020a5c07a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n", "original_text": "When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n"}, "hash": "5fd935f54ab1578051be270285fb5e84bbdc50007e6eb333268aa33edff00a63", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year. ", "start_char_idx": 533, "end_char_idx": 641, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ea17033-66e0-4316-acce-4d5020a5c07a": {"__data__": {"id_": "6ea17033-66e0-4316-acce-4d5020a5c07a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n", "original_text": "When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "feed1182-05b5-49a2-b5c8-fea823e9e625", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million. ", "original_text": "Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d55e8bd42e9258ea391bac26fe483f504c88cecc6784400a43bcff3b5e15401", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b6ac80c-a2d9-459f-96d0-a1d8e140a66a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment. ", "original_text": "Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt. "}, "hash": "5b3f8ee3729ddca78f975a62b47efea797c175853939aeff5b20b45a77e709c3", "class_name": "RelatedNodeInfo"}}, "text": "When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n", "start_char_idx": 641, "end_char_idx": 834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b6ac80c-a2d9-459f-96d0-a1d8e140a66a": {"__data__": {"id_": "9b6ac80c-a2d9-459f-96d0-a1d8e140a66a", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment. ", "original_text": "Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ea17033-66e0-4316-acce-4d5020a5c07a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n", "original_text": "When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c61c5e9694445403ca1112ad8e7beb5a6e53f363eaa58c0340b81f5c736f0184", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d97afb29-fb70-4b3a-9a18-9ee4d4fe23fb", "node_type": "1", "metadata": {"window": "Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare. ", "original_text": "We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million. "}, "hash": "7c1d3027fb9ea49a40d08ab94fa410509f567e3dcfa146ee473e5e4d8fd0925b", "class_name": "RelatedNodeInfo"}}, "text": "Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt. ", "start_char_idx": 834, "end_char_idx": 1037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d97afb29-fb70-4b3a-9a18-9ee4d4fe23fb": {"__data__": {"id_": "d97afb29-fb70-4b3a-9a18-9ee4d4fe23fb", "embedding": null, "metadata": {"window": "Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare. ", "original_text": "We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b6ac80c-a2d9-459f-96d0-a1d8e140a66a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment. ", "original_text": "Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d98d33aad398a0474344d52f5e3d17e9d9dc2c8f45cab5d38c3f429a9877169", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a25e308-2007-4955-91e6-6f08b8622ed9", "node_type": "1", "metadata": {"window": "When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n", "original_text": "Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n"}, "hash": "7c135327c75bae4d0331aadbdd39394e93022783ac01d1e3f52b36052aa0e779", "class_name": "RelatedNodeInfo"}}, "text": "We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million. ", "start_char_idx": 1037, "end_char_idx": 1128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a25e308-2007-4955-91e6-6f08b8622ed9": {"__data__": {"id_": "5a25e308-2007-4955-91e6-6f08b8622ed9", "embedding": null, "metadata": {"window": "When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n", "original_text": "Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d97afb29-fb70-4b3a-9a18-9ee4d4fe23fb", "node_type": "1", "metadata": {"window": "Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare. ", "original_text": "We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbe923e61eb4c72224400383bccf311738eedf1cbe255db001cbbae350ac268b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e6c6d20-f175-4b08-bfb5-f589a63be6eb", "node_type": "1", "metadata": {"window": "Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year. ", "original_text": "Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment. "}, "hash": "432ccd5806dd207ef0129bacf4090a8b95faf6704dc722a0ff4cb0c32c927d06", "class_name": "RelatedNodeInfo"}}, "text": "Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n", "start_char_idx": 1128, "end_char_idx": 1266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e6c6d20-f175-4b08-bfb5-f589a63be6eb": {"__data__": {"id_": "4e6c6d20-f175-4b08-bfb5-f589a63be6eb", "embedding": null, "metadata": {"window": "Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year. ", "original_text": "Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a25e308-2007-4955-91e6-6f08b8622ed9", "node_type": "1", "metadata": {"window": "When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n", "original_text": "Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24564f63ae9a3fccd064d3b3a5f760d2a72ed4281f15ef43dab548288db430b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76859463-347e-4b41-853e-0c964c0528e8", "node_type": "1", "metadata": {"window": "We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n", "original_text": "These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare. "}, "hash": "2f1c0bfee74ae1f635740721705e11532a7c1890b937ed84fa421e383d5f9c01", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment. ", "start_char_idx": 1266, "end_char_idx": 1474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76859463-347e-4b41-853e-0c964c0528e8": {"__data__": {"id_": "76859463-347e-4b41-853e-0c964c0528e8", "embedding": null, "metadata": {"window": "We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n", "original_text": "These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e6c6d20-f175-4b08-bfb5-f589a63be6eb", "node_type": "1", "metadata": {"window": "Interest expense was $55 million in the quarter, a decline of 14% compared to the prior year, which was driven by \nlower commercial paper balances and the retirement of approximately $1 billion of debt.  We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year. ", "original_text": "Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a63f52b290b7d6f85df41eccd2c014b9c5a08b0bbbcdf75fce9819d84d86e202", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3dff1ea8-8c1c-4639-9b6a-ab2dc7b8fba0", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n", "original_text": "Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n"}, "hash": "1db4a329bf3ba93f14e8f8a7a414da4c0a60b4cc4030ef07a73cac8057657281", "class_name": "RelatedNodeInfo"}}, "text": "These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare. ", "start_char_idx": 1474, "end_char_idx": 1631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3dff1ea8-8c1c-4639-9b6a-ab2dc7b8fba0": {"__data__": {"id_": "3dff1ea8-8c1c-4639-9b6a-ab2dc7b8fba0", "embedding": null, "metadata": {"window": "Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n", "original_text": "Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76859463-347e-4b41-853e-0c964c0528e8", "node_type": "1", "metadata": {"window": "We now expect fiscal \n2021 interest expense in the range o f $210 million to $230 million.  Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n", "original_text": "These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c27191cd639a6df87f9d95eda7bdb298d89dd2c30bf25e4176b8d04143e92200", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93e4bd42-c8b2-440f-ae0b-b577b84a5bdc", "node_type": "1", "metadata": {"window": "Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions. ", "original_text": "Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year. "}, "hash": "1845ea907afc3d586598e16f248f4e8e1a7f77813f0797228c32b4a68c0f0b53", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n", "start_char_idx": 1631, "end_char_idx": 1840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93e4bd42-c8b2-440f-ae0b-b577b84a5bdc": {"__data__": {"id_": "93e4bd42-c8b2-440f-ae0b-b577b84a5bdc", "embedding": null, "metadata": {"window": "Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions. ", "original_text": "Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3dff1ea8-8c1c-4639-9b6a-ab2dc7b8fba0", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 21.6% for the \nquarter and we continue to assume a full year adjusted tax rate of approximately 18% to 20%.  \n \n Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n", "original_text": "Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a54cb806f4d7080b2fc4c5d803f4489637d076420ecb0523a9a7b0b7777fa31c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb896f3d-b867-4f33-b385-5a48099057b6", "node_type": "1", "metadata": {"window": "These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada. ", "original_text": "We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n"}, "hash": "0052e3ff2cc637433e614cff5640c74294684951a9f9f5f3b377bdc734f3f61a", "class_name": "RelatedNodeInfo"}}, "text": "Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year. ", "start_char_idx": 1840, "end_char_idx": 2259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb896f3d-b867-4f33-b385-5a48099057b6": {"__data__": {"id_": "eb896f3d-b867-4f33-b385-5a48099057b6", "embedding": null, "metadata": {"window": "These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada. ", "original_text": "We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93e4bd42-c8b2-440f-ae0b-b577b84a5bdc", "node_type": "1", "metadata": {"window": "Third quarter adjusted earnings per diluted share was $4.60, which was up 21% in the quart er compared to the \nprior year, driven by a lower share count and growth in the Medical -Surgical Solutions segment.  These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions. ", "original_text": "Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b9781d7ae2ea7f78749e81a4ab2df7923da17bb90a22fd55c567ab5d5befe4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8eefe91e-4b88-4ae5-b194-c6c8e6145f1a", "node_type": "1", "metadata": {"window": "Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth. ", "original_text": "And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n"}, "hash": "8866b7ec3580c81a0d5366b72134836fc7673553bbae07b6fbc433992a2359a1", "class_name": "RelatedNodeInfo"}}, "text": "We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n", "start_char_idx": 2259, "end_char_idx": 2363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8eefe91e-4b88-4ae5-b194-c6c8e6145f1a": {"__data__": {"id_": "8eefe91e-4b88-4ae5-b194-c6c8e6145f1a", "embedding": null, "metadata": {"window": "Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth. ", "original_text": "And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb896f3d-b867-4f33-b385-5a48099057b6", "node_type": "1", "metadata": {"window": "These items \nwere partially offset by a higher tax rate and the lapping of the prior year contribution from the company's \ninvestment in Change  Healthcare.  Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada. ", "original_text": "We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c40eb402aee560451d8b4ab0267525679496bf9ae19b4530aa442444ae4f770c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "484ac9d6-a22e-4a0b-b80c-8b05d95d032b", "node_type": "1", "metadata": {"window": "Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n", "original_text": "Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions. "}, "hash": "674bff0c047a3a49ae7b4ecc951e3458f368276d9c66e4fb2032f95aefed3ce4", "class_name": "RelatedNodeInfo"}}, "text": "And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n", "start_char_idx": 2363, "end_char_idx": 2482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "484ac9d6-a22e-4a0b-b80c-8b05d95d032b": {"__data__": {"id_": "484ac9d6-a22e-4a0b-b80c-8b05d95d032b", "embedding": null, "metadata": {"window": "Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n", "original_text": "Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8eefe91e-4b88-4ae5-b194-c6c8e6145f1a", "node_type": "1", "metadata": {"window": "Third quarter adjusted earnings per diluted share also includes net pre -tax \ngains of approximately $30 million or $0.14 per diluted share, which is associated with McKesson Ventures' equity \ninvestment.  \n \n Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth. ", "original_text": "And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f17daaa4a1b65ae7dbc5a6cda0429006bdbcc3fa30c59afa6ac5f7cedd14f80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1e70d42-8466-4cd0-b98e-75deb184d26b", "node_type": "1", "metadata": {"window": "We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter. ", "original_text": "Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada. "}, "hash": "f87f2f84b262dfd06aeccdc180781a357b9ca4417ccb31359813db457a1e4198", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions. ", "start_char_idx": 2482, "end_char_idx": 2647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1e70d42-8466-4cd0-b98e-75deb184d26b": {"__data__": {"id_": "a1e70d42-8466-4cd0-b98e-75deb184d26b", "embedding": null, "metadata": {"window": "We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter. ", "original_text": "Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "484ac9d6-a22e-4a0b-b80c-8b05d95d032b", "node_type": "1", "metadata": {"window": "Wrapping up our consolidated results, th ird quarter diluted weighted average shares were 161 million, a decrease \nof 10% year -over-year, driven by the successful tax -free exit of our investment in Change Healthcare at the end of \nfiscal 2020, which lowered our shares outstanding by approximately [ ph] 15 -point million (00:25:33) shares and in \naddition to share repurchase activity in the current and prior year.  We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n", "original_text": "Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6924ead11acda8736a04c56be2375f095d1ae5857a8de26950da51540df0605e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c05f315-183f-4c95-a180-83a9a8378c03", "node_type": "1", "metadata": {"window": "And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n", "original_text": "These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth. "}, "hash": "34752f2a65751bded39e4f94de829c16d4809374579411353b2a067e2ad3edbd", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada. ", "start_char_idx": 2647, "end_char_idx": 2849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c05f315-183f-4c95-a180-83a9a8378c03": {"__data__": {"id_": "9c05f315-183f-4c95-a180-83a9a8378c03", "embedding": null, "metadata": {"window": "And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n", "original_text": "These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1e70d42-8466-4cd0-b98e-75deb184d26b", "node_type": "1", "metadata": {"window": "We now expect diluted weighted shares \noutstanding for fiscal 2021 to be approximately 162 million.  \n \n And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter. ", "original_text": "Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "988a34442cfe1f38a531f86b72545215f81791465f9f99897b075dea8c118cd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33d49ac4-2de3-4df5-8fc4-dd7e58f15c4c", "node_type": "1", "metadata": {"window": "Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations. ", "original_text": "Our segment results were also negatively impacted by the light cold and flu season.  \n \n"}, "hash": "541ebced51570dc3f9a6e51638a9c745bb0fb8d2c19a06cfa6f8895caed4d16d", "class_name": "RelatedNodeInfo"}}, "text": "These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth. ", "start_char_idx": 2849, "end_char_idx": 2944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33d49ac4-2de3-4df5-8fc4-dd7e58f15c4c": {"__data__": {"id_": "33d49ac4-2de3-4df5-8fc4-dd7e58f15c4c", "embedding": null, "metadata": {"window": "Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations. ", "original_text": "Our segment results were also negatively impacted by the light cold and flu season.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c05f315-183f-4c95-a180-83a9a8378c03", "node_type": "1", "metadata": {"window": "And next I'll review our third quarter se gment results, which can be found on slides 5 through 9, starting with U.S. \n Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n", "original_text": "These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e04fba3725435582a3377d2254bac9837d460373702e5f382d1843fa6db0a61f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f194c86-af9b-4d24-8be6-96b3b5b140e6", "node_type": "1", "metadata": {"window": "Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n", "original_text": "Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter. "}, "hash": "6c822947455dec78fcc0980586be584e2a67752039cab1703a556e7533ccba29", "class_name": "RelatedNodeInfo"}}, "text": "Our segment results were also negatively impacted by the light cold and flu season.  \n \n", "start_char_idx": 2944, "end_char_idx": 3032, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f194c86-af9b-4d24-8be6-96b3b5b140e6": {"__data__": {"id_": "5f194c86-af9b-4d24-8be6-96b3b5b140e6", "embedding": null, "metadata": {"window": "Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n", "original_text": "Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33d49ac4-2de3-4df5-8fc4-dd7e58f15c4c", "node_type": "1", "metadata": {"window": "Pharmaceutical, where revenues were $49.5 billion, up 7%, driven by market growth and higher specialty \nvolumes, partially offset by branded to generic conversions.  Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations. ", "original_text": "Our segment results were also negatively impacted by the light cold and flu season.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "652e18e499124c2f2da97926b67af8654bd0e0bbe1a28c50ceb98af05b261114", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4229859b-965c-4dfc-bf6f-dfba50008773", "node_type": "1", "metadata": {"window": "These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International. ", "original_text": "I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n"}, "hash": "01b084863090ec00c0282720d2984932a1a0be70fb217f502f76303ee9114f8e", "class_name": "RelatedNodeInfo"}}, "text": "Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter. ", "start_char_idx": 3032, "end_char_idx": 3194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4229859b-965c-4dfc-bf6f-dfba50008773": {"__data__": {"id_": "4229859b-965c-4dfc-bf6f-dfba50008773", "embedding": null, "metadata": {"window": "These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International. ", "original_text": "I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f194c86-af9b-4d24-8be6-96b3b5b140e6", "node_type": "1", "metadata": {"window": "Adjusted operati ng profit increased 2% to $656 \nmillion, driven by growth in specialty, partially offset by higher operating expenses in support of our strategic \ngrowth initiatives, including Ontada.  These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n", "original_text": "Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "308f3d86b87d8330bfa78b367679d3ad6e2450719dfa95e40d8149f3ec098c91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b819602e-af52-4235-9db4-670d50d4f1f8", "node_type": "1", "metadata": {"window": "Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year. ", "original_text": "And for the third quarter, branded price activity trended in line with our expectations. "}, "hash": "1574beaa73dd26a7b8fd94eba8e1f4a09cff7e678bb6d2916a33b6f74cda1587", "class_name": "RelatedNodeInfo"}}, "text": "I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n", "start_char_idx": 3194, "end_char_idx": 3302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b819602e-af52-4235-9db4-670d50d4f1f8": {"__data__": {"id_": "b819602e-af52-4235-9db4-670d50d4f1f8", "embedding": null, "metadata": {"window": "Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year. ", "original_text": "And for the third quarter, branded price activity trended in line with our expectations. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4229859b-965c-4dfc-bf6f-dfba50008773", "node_type": "1", "metadata": {"window": "These investments accounted for an approximate 2% headwind to year -over-\nyear segment growth.  Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International. ", "original_text": "I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ceada53a13800bcd2b6da4cf516cd8ecaf742f2a6358ffb3eeaf2514a1a3dd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcd90753-b0af-4d2a-a8ae-4b8dfa614b3e", "node_type": "1", "metadata": {"window": "Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n", "original_text": "Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n"}, "hash": "c978c53a0837628566a1f0f56cde9f5e4ac01654b4cbbd92525de59c23b28351", "class_name": "RelatedNodeInfo"}}, "text": "And for the third quarter, branded price activity trended in line with our expectations. ", "start_char_idx": 3302, "end_char_idx": 3391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcd90753-b0af-4d2a-a8ae-4b8dfa614b3e": {"__data__": {"id_": "fcd90753-b0af-4d2a-a8ae-4b8dfa614b3e", "embedding": null, "metadata": {"window": "Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n", "original_text": "Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b819602e-af52-4235-9db4-670d50d4f1f8", "node_type": "1", "metadata": {"window": "Our segment results were also negatively impacted by the light cold and flu season.  \n \n Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year. ", "original_text": "And for the third quarter, branded price activity trended in line with our expectations. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610f762c776dfa12261b56e488afae9ed2f14e830c50ce578637b6ee593b7e94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fccbd99b-9584-46cc-a5c2-4c1c29fa3981", "node_type": "1", "metadata": {"window": "I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year. ", "original_text": "Next, International. "}, "hash": "1f8c398c5c22b46324937a0b335e6ec3fcb7806d896902f8e7c17a80cebd91b5", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n", "start_char_idx": 3391, "end_char_idx": 3596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fccbd99b-9584-46cc-a5c2-4c1c29fa3981": {"__data__": {"id_": "fccbd99b-9584-46cc-a5c2-4c1c29fa3981", "embedding": null, "metadata": {"window": "I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year. ", "original_text": "Next, International. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcd90753-b0af-4d2a-a8ae-4b8dfa614b3e", "node_type": "1", "metadata": {"window": "Given the timing of FDA approval of Moderna's COVID -19 vaccine in December, earnings related to the vaccines \ndistribution were immaterial in the third quarter.  I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n", "original_text": "Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d71ece2e27050c5c231a88fdb3e4f35d24337696c435569156b1553e791b4306", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cdf0472-da77-4050-9a33-d129d44d5ce3", "node_type": "1", "metadata": {"window": "And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year.  Excluding the impact from the divestiture of our ", "original_text": "Revenues were $9.3 billion, a decrease of 6% year -over-year. "}, "hash": "619e770307a1b8a585a94dd23921ed80ed23c45c475c2461b0fc38e116bb5ed8", "class_name": "RelatedNodeInfo"}}, "text": "Next, International. ", "start_char_idx": 3596, "end_char_idx": 3617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cdf0472-da77-4050-9a33-d129d44d5ce3": {"__data__": {"id_": "0cdf0472-da77-4050-9a33-d129d44d5ce3", "embedding": null, "metadata": {"window": "And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year.  Excluding the impact from the divestiture of our ", "original_text": "Revenues were $9.3 billion, a decrease of 6% year -over-year. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fccbd99b-9584-46cc-a5c2-4c1c29fa3981", "node_type": "1", "metadata": {"window": "I'll provide more detail on our outlook related to COVID -19 \nvaccine distribution later in my remarks.  \n \n And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year. ", "original_text": "Next, International. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff87d10119663914c6ef7dccc882e44465f224492373f89babbc7ab10dad99c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bed89a27-1d92-4790-b1c9-1dfbd8edb0a9", "node_type": "1", "metadata": {"window": "Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year.  Excluding the impact from the divestiture of our ", "original_text": "On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n"}, "hash": "8e92016986fba420887f514b822e30fa7efcb0483ea42eeebd2da57bd98cc690", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $9.3 billion, a decrease of 6% year -over-year. ", "start_char_idx": 3617, "end_char_idx": 3679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bed89a27-1d92-4790-b1c9-1dfbd8edb0a9": {"__data__": {"id_": "bed89a27-1d92-4790-b1c9-1dfbd8edb0a9", "embedding": null, "metadata": {"window": "Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year.  Excluding the impact from the divestiture of our ", "original_text": "On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cdf0472-da77-4050-9a33-d129d44d5ce3", "node_type": "1", "metadata": {"window": "And for the third quarter, branded price activity trended in line with our expectations.  Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year.  Excluding the impact from the divestiture of our ", "original_text": "Revenues were $9.3 billion, a decrease of 6% year -over-year. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50350e9d5359296de2baaeefb1148a12bc54ffd4c0525957c5dcefacc59d1c2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad051438-5e2b-49e0-b3d2-0e7ba457c0cf", "node_type": "1", "metadata": {"window": "Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year.  Excluding the impact from the divestiture of our ", "original_text": "The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year. "}, "hash": "1a8041a2f4f698d3b509f31174352822c44be4f2e10b4ea09f40a0c1d504e806", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n", "start_char_idx": 3679, "end_char_idx": 3915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad051438-5e2b-49e0-b3d2-0e7ba457c0cf": {"__data__": {"id_": "ad051438-5e2b-49e0-b3d2-0e7ba457c0cf", "embedding": null, "metadata": {"window": "Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year.  Excluding the impact from the divestiture of our ", "original_text": "The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bed89a27-1d92-4790-b1c9-1dfbd8edb0a9", "node_type": "1", "metadata": {"window": "Additionally, based on \nmanufacturer price actions taken  in January, we are maintaining our full year fiscal 2021 assumption of branded \nprice increases to be in the mid -single -digit percent range.  \n \n Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year.  Excluding the impact from the divestiture of our ", "original_text": "On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d66d5a9dec7f5747f23cb6e7a363f8aecb52dfe5e7c4b10a855d17ea7292864", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2383e33e-604d-459b-b551-07353e8ad9d5", "node_type": "1", "metadata": {"window": "Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year.  Excluding the impact from the divestiture of our ", "original_text": "Excluding the impact from the divestiture of our "}, "hash": "1ad6c7975c544a3497bc75b2deeee142dc9bf74774266a96cdc4c5776d0e52cd", "class_name": "RelatedNodeInfo"}}, "text": "The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year. ", "start_char_idx": 3915, "end_char_idx": 4095, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2383e33e-604d-459b-b551-07353e8ad9d5": {"__data__": {"id_": "2383e33e-604d-459b-b551-07353e8ad9d5", "embedding": null, "metadata": {"window": "Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year.  Excluding the impact from the divestiture of our ", "original_text": "Excluding the impact from the divestiture of our ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6a26bc02bbe9725762e5131e3a64eabf9c28df48abbcebc5e72d959051c7c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad051438-5e2b-49e0-b3d2-0e7ba457c0cf", "node_type": "1", "metadata": {"window": "Next, International.  Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year.  Excluding the impact from the divestiture of our ", "original_text": "The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year. ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8348c3947a1379716cb78d3479d3bfe50f65a11120b184994199d756f7958bba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "518ac18f-81be-40d3-8bf1-c1018e4a9d3a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "e3ec919c0be64f1f0fad2f20c7551eafd37db291985652f30d676b41df0ec271", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact from the divestiture of our ", "start_char_idx": 4095, "end_char_idx": 4144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "518ac18f-81be-40d3-8bf1-c1018e4a9d3a": {"__data__": {"id_": "518ac18f-81be-40d3-8bf1-c1018e4a9d3a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2383e33e-604d-459b-b551-07353e8ad9d5", "node_type": "1", "metadata": {"window": "Revenues were $9.3 billion, a decrease of 6% year -over-year.  On an FX -adjusted basis, \nrevenue s decreased 10%, primarily driven by the contribution of our German wholesale business to the newly \nformed joint venture with Walgreens Boots Alliance, which was effective as of November 1, 2020.  \n \n The segment also had lower volumes in the Canadian pharmace utical distribution business, largely due to the exit \nof an unprofitable customer at the beginning of the fiscal year.  Excluding the impact from the divestiture of our ", "original_text": "Excluding the impact from the divestiture of our ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcbabc5ebd8a841bcbc286a72821af9e8c10a36064ceeb9c2a8d70d17ad4610e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "672085d7-3704-4881-a57c-e5f557d2ef46", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n"}, "hash": "3adbc0377618954e193f4fd658353eecefd7e2c0e1a02a88f4a4f0d9cb51b4fd", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "672085d7-3704-4881-a57c-e5f557d2ef46": {"__data__": {"id_": "672085d7-3704-4881-a57c-e5f557d2ef46", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "518ac18f-81be-40d3-8bf1-c1018e4a9d3a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e732c66136066915b7c1c22d581f67ed1d6caf972fdbe2b1d46a89804f0c4aa4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "296cbf9d-dc10-4f3b-a267-25cec7ec158b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic. ", "original_text": "Adjusted operating profit increased 9% year -over-year to $158 million. "}, "hash": "cb52352ad0eb1745549d05b6e741d44df59b98be7b6785616bb7a0bb9afcc826", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n", "start_char_idx": 16, "end_char_idx": 298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "296cbf9d-dc10-4f3b-a267-25cec7ec158b": {"__data__": {"id_": "296cbf9d-dc10-4f3b-a267-25cec7ec158b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic. ", "original_text": "Adjusted operating profit increased 9% year -over-year to $158 million. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "672085d7-3704-4881-a57c-e5f557d2ef46", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90474ea99cfe485c340d2fdc117f08d97d76858370fe2c61ff54155f3246b18d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6dd8aa47-43cb-43c4-9ca2-2c8e6b8f3e98", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE. ", "original_text": "On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n"}, "hash": "23df5671baed460828d1ed7d9d653131fe5e92e24e2a35f4b94f3be50674b784", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit increased 9% year -over-year to $158 million. ", "start_char_idx": 298, "end_char_idx": 370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6dd8aa47-43cb-43c4-9ca2-2c8e6b8f3e98": {"__data__": {"id_": "6dd8aa47-43cb-43c4-9ca2-2c8e6b8f3e98", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE. ", "original_text": "On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "296cbf9d-dc10-4f3b-a267-25cec7ec158b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic. ", "original_text": "Adjusted operating profit increased 9% year -over-year to $158 million. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3fec9547bff6d08e33de82b3e1516081f67e1b9b57aa6a6ca5a75971012ea3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c6c93a1-f84f-45e0-b38f-ebb2ba4ae8e8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels. ", "original_text": "Now moving on to Medical -Surgical Solutions. "}, "hash": "13750c21aa23bcbe9bb78aac198918f9d26492a10524529112ac255aa15ad607", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n", "start_char_idx": 370, "end_char_idx": 556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c6c93a1-f84f-45e0-b38f-ebb2ba4ae8e8": {"__data__": {"id_": "1c6c93a1-f84f-45e0-b38f-ebb2ba4ae8e8", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels. ", "original_text": "Now moving on to Medical -Surgical Solutions. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6dd8aa47-43cb-43c4-9ca2-2c8e6b8f3e98", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE. ", "original_text": "On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "263dfcf2d3940e94d5534ea0dcf58bcecf8bb7f2a9b588e7c0b04452ce241c76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36ec6937-7b93-4c9c-999a-2c8c41b2d700", "node_type": "1", "metadata": {"window": "Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic. ", "original_text": "Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic. "}, "hash": "e8fb54fada096c22801961a709402c2bc6bdfc9fef36fbae225fbb812a8d9520", "class_name": "RelatedNodeInfo"}}, "text": "Now moving on to Medical -Surgical Solutions. ", "start_char_idx": 556, "end_char_idx": 602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36ec6937-7b93-4c9c-999a-2c8c41b2d700": {"__data__": {"id_": "36ec6937-7b93-4c9c-999a-2c8c41b2d700", "embedding": null, "metadata": {"window": "Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic. ", "original_text": "Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c6c93a1-f84f-45e0-b38f-ebb2ba4ae8e8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels. ", "original_text": "Now moving on to Medical -Surgical Solutions. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80d308409c67f928578998c917829a6e4a9f99cbbd077100b2ce8535774de951", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8243e97f-ea35-423c-9670-c3c601e2fc39", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n", "original_text": "We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE. "}, "hash": "d9bff42957cd1639b83436fa8fd88c252ddf2d7478c31dc49a61f32204f7b002", "class_name": "RelatedNodeInfo"}}, "text": "Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic. ", "start_char_idx": 602, "end_char_idx": 685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8243e97f-ea35-423c-9670-c3c601e2fc39": {"__data__": {"id_": "8243e97f-ea35-423c-9670-c3c601e2fc39", "embedding": null, "metadata": {"window": "On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n", "original_text": "We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36ec6937-7b93-4c9c-999a-2c8c41b2d700", "node_type": "1", "metadata": {"window": "Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic. ", "original_text": "Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0cf7745e45f1137e621b93a3fb587316138e98a56732b085d43be637be2f99a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43481d98-90c7-42aa-b3c3-afa00df38dc6", "node_type": "1", "metadata": {"window": "Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S. ", "original_text": "We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels. "}, "hash": "60e55df2f09cec2527648f5d654ebf7d1f93109478b25d837bc51a0c9b4e71ce", "class_name": "RelatedNodeInfo"}}, "text": "We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE. ", "start_char_idx": 685, "end_char_idx": 827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43481d98-90c7-42aa-b3c3-afa00df38dc6": {"__data__": {"id_": "43481d98-90c7-42aa-b3c3-afa00df38dc6", "embedding": null, "metadata": {"window": "Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S. ", "original_text": "We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8243e97f-ea35-423c-9670-c3c601e2fc39", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n", "original_text": "We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "089c8e7609f7f6e26176c9e6f25f344495d6002dca45af7fe58d92bedcc85455", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc28ae99-bbab-4f2d-862a-1f35a2640b9c", "node_type": "1", "metadata": {"window": "Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year. ", "original_text": "Our customers have been resilient \nthroughout the pandemic. "}, "hash": "9e03cd8d052fee57d4e23140a9f07d77293c0b66e160d1177b70decfdb0aa1eb", "class_name": "RelatedNodeInfo"}}, "text": "We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels. ", "start_char_idx": 827, "end_char_idx": 953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc28ae99-bbab-4f2d-862a-1f35a2640b9c": {"__data__": {"id_": "fc28ae99-bbab-4f2d-862a-1f35a2640b9c", "embedding": null, "metadata": {"window": "Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year. ", "original_text": "Our customers have been resilient \nthroughout the pandemic. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43481d98-90c7-42aa-b3c3-afa00df38dc6", "node_type": "1", "metadata": {"window": "Now moving on to Medical -Surgical Solutions.  Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S. ", "original_text": "We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03261014549f9fe47e105937e96e4e8b33c115f62e8d23ada9106c0a72175119", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f01045c6-86d3-4c0b-8c24-10831cd9d62a", "node_type": "1", "metadata": {"window": "We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n", "original_text": "And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n"}, "hash": "0aacce3a15d6b2ef90bcaf4a1af1bb1537f4078b9267a6571ad35d79e9f4c169", "class_name": "RelatedNodeInfo"}}, "text": "Our customers have been resilient \nthroughout the pandemic. ", "start_char_idx": 953, "end_char_idx": 1013, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f01045c6-86d3-4c0b-8c24-10831cd9d62a": {"__data__": {"id_": "f01045c6-86d3-4c0b-8c24-10831cd9d62a", "embedding": null, "metadata": {"window": "We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n", "original_text": "And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc28ae99-bbab-4f2d-862a-1f35a2640b9c", "node_type": "1", "metadata": {"window": "Our Medical -Surgical segment continues to be impacted by the \nCOVID -19 pandemic.  We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year. ", "original_text": "Our customers have been resilient \nthroughout the pandemic. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e8d928f425f83f976873ab857c07712087147c5f416e6d51f1f791f666d9992", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e02f751a-9e50-44bb-92af-ebc5348bd5b6", "node_type": "1", "metadata": {"window": "We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE. ", "original_text": "Similar to the U.S. "}, "hash": "99d5c24dfd7b7aac6ae0c9bc53743a675ee7dd81b9082c59df534654ed271850", "class_name": "RelatedNodeInfo"}}, "text": "And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n", "start_char_idx": 1013, "end_char_idx": 1198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e02f751a-9e50-44bb-92af-ebc5348bd5b6": {"__data__": {"id_": "e02f751a-9e50-44bb-92af-ebc5348bd5b6", "embedding": null, "metadata": {"window": "We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE. ", "original_text": "Similar to the U.S. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f01045c6-86d3-4c0b-8c24-10831cd9d62a", "node_type": "1", "metadata": {"window": "We experienced strong demand for COVID -19 tests throughout the quarter and often \nunpredictable and uneven levels o f demand related to PPE.  We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n", "original_text": "And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "109b293f14dfcfbde0a7a4920a84878b8366591b32f628bed2814b4310a693f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52ce847a-7030-49bc-8093-7c6875714ffc", "node_type": "1", "metadata": {"window": "Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n", "original_text": "Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year. "}, "hash": "acc56b20c70efd12cf993cc1aa7ac7f51e533e2ec21267211901a9ad929e9513", "class_name": "RelatedNodeInfo"}}, "text": "Similar to the U.S. ", "start_char_idx": 1198, "end_char_idx": 1218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52ce847a-7030-49bc-8093-7c6875714ffc": {"__data__": {"id_": "52ce847a-7030-49bc-8093-7c6875714ffc", "embedding": null, "metadata": {"window": "Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n", "original_text": "Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e02f751a-9e50-44bb-92af-ebc5348bd5b6", "node_type": "1", "metadata": {"window": "We're also pleased to have delivered solid growth in \nthe core business, despite patient mobility trailing pre -COVID levels.  Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE. ", "original_text": "Similar to the U.S. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd29e0ab7b25937d87d9e9bf6982cab4ebc4abb9b7bda322293a676c1be527a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "527e934f-1928-458a-bc8c-f152e8240234", "node_type": "1", "metadata": {"window": "And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients. ", "original_text": "Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n"}, "hash": "4a5f16c834fc39c6700b99db098e7335226223607f42cfd46cec043c0a3e6477", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year. ", "start_char_idx": 1218, "end_char_idx": 1383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "527e934f-1928-458a-bc8c-f152e8240234": {"__data__": {"id_": "527e934f-1928-458a-bc8c-f152e8240234", "embedding": null, "metadata": {"window": "And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients. ", "original_text": "Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52ce847a-7030-49bc-8093-7c6875714ffc", "node_type": "1", "metadata": {"window": "Our customers have been resilient \nthroughout the pandemic.  And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n", "original_text": "Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72afa9a0f3102608054b3ac4711b0afb1d73f371a90a9a85aee778955d074379", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c2d8e8a-b525-4ab0-bf24-e52b597387de", "node_type": "1", "metadata": {"window": "Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic. ", "original_text": "As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE. "}, "hash": "25efff07f6e754d6d1a64de8dd963ba4cdf3b0ca946d22b989057aed1f03ca88", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n", "start_char_idx": 1383, "end_char_idx": 1531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c2d8e8a-b525-4ab0-bf24-e52b597387de": {"__data__": {"id_": "9c2d8e8a-b525-4ab0-bf24-e52b597387de", "embedding": null, "metadata": {"window": "Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic. ", "original_text": "As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "527e934f-1928-458a-bc8c-f152e8240234", "node_type": "1", "metadata": {"window": "And we're supporting providers and their patient s with the breadth of our primary and \nextended care capabilities, such as lab solutions, private brands and patient home delivery.  \n \n Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients. ", "original_text": "Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "372e6f902bb2f3fa17f5d174a55839610273219817d62999e617236b2d5bb72c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e4da415-04ec-4fc2-bdf6-c9d75fc60246", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges. ", "original_text": "This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n"}, "hash": "61a4f3136fd37c867a20729346f378bceb20f830f92672d540a05865b97a08ad", "class_name": "RelatedNodeInfo"}}, "text": "As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE. ", "start_char_idx": 1531, "end_char_idx": 1722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e4da415-04ec-4fc2-bdf6-c9d75fc60246": {"__data__": {"id_": "2e4da415-04ec-4fc2-bdf6-c9d75fc60246", "embedding": null, "metadata": {"window": "Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges. ", "original_text": "This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c2d8e8a-b525-4ab0-bf24-e52b597387de", "node_type": "1", "metadata": {"window": "Similar to the U.S.  Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic. ", "original_text": "As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c760e353ca0548a8d1581b1087949b77834f2b9faaf1b039fc604217db81a969", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92addbb9-a3ea-439c-a001-8b93d5493690", "node_type": "1", "metadata": {"window": "Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n", "original_text": "Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients. "}, "hash": "8d7daf48c1cbcd87dcba88f8097ff3a62932c76de4327a4e7776691658e57701", "class_name": "RelatedNodeInfo"}}, "text": "This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n", "start_char_idx": 1722, "end_char_idx": 2004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92addbb9-a3ea-439c-a001-8b93d5493690": {"__data__": {"id_": "92addbb9-a3ea-439c-a001-8b93d5493690", "embedding": null, "metadata": {"window": "Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n", "original_text": "Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e4da415-04ec-4fc2-bdf6-c9d75fc60246", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, Q3 results were also impacted by the light cold and flu season, and \nwe expect this to continue throughout the remainder of our fiscal year.  Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges. ", "original_text": "This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99e14d5bdf53a906ff11f07c73942887c01ff00f6d6c793707a458df58a6cd37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32cc18c7-26ca-4906-8907-d4630997c146", "node_type": "1", "metadata": {"window": "As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products. ", "original_text": "Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic. "}, "hash": "395f4bc0767fccc9ce6a318dbc3aed7d1e2a186ce40ccc0082aefa27a0fca5cb", "class_name": "RelatedNodeInfo"}}, "text": "Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients. ", "start_char_idx": 2004, "end_char_idx": 2213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32cc18c7-26ca-4906-8907-d4630997c146": {"__data__": {"id_": "32cc18c7-26ca-4906-8907-d4630997c146", "embedding": null, "metadata": {"window": "As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products. ", "original_text": "Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92addbb9-a3ea-439c-a001-8b93d5493690", "node_type": "1", "metadata": {"window": "Revenues were $3.1 billion in the quarter, \nup 43%, primarily driven by demand for COVID -19 tests in the primary and extended care businesses.  \n \n As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n", "original_text": "Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "652ef3dd8041437a6b866ed1e21075d9942d031a56c29821788110d4dfa3e5c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd540dba-1f81-4bb7-8f10-37aedc3992f1", "node_type": "1", "metadata": {"window": "This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n", "original_text": "Due to these dynamics, some PPE and related items experienced inventory charges. "}, "hash": "0834bd596367186daa098c5bccfbbd4db5fdbcee63a57ac5c4b413efe0316776", "class_name": "RelatedNodeInfo"}}, "text": "Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic. ", "start_char_idx": 2213, "end_char_idx": 2361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd540dba-1f81-4bb7-8f10-37aedc3992f1": {"__data__": {"id_": "bd540dba-1f81-4bb7-8f10-37aedc3992f1", "embedding": null, "metadata": {"window": "This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n", "original_text": "Due to these dynamics, some PPE and related items experienced inventory charges. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32cc18c7-26ca-4906-8907-d4630997c146", "node_type": "1", "metadata": {"window": "As we discussed on the second quarter call, our Med ical-Surgical business built supply quickly to meet demands \nfrom our customers for COVID -19 tests and elevated levels of demand for PPE.  This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products. ", "original_text": "Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53cd9ce0d1ecdc22472ab341b4de0e1cc032e51557dc69aa8ea5417e6423f286", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a8ca926-f5da-4cfb-976c-d50ba6402241", "node_type": "1", "metadata": {"window": "Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions. ", "original_text": "In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n"}, "hash": "f9ef2bf39ecf6a5ba36c37bcbd92ee28b2c523f19b27ab9c0fdad804ffd73935", "class_name": "RelatedNodeInfo"}}, "text": "Due to these dynamics, some PPE and related items experienced inventory charges. ", "start_char_idx": 2361, "end_char_idx": 2442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a8ca926-f5da-4cfb-976c-d50ba6402241": {"__data__": {"id_": "8a8ca926-f5da-4cfb-976c-d50ba6402241", "embedding": null, "metadata": {"window": "Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions. ", "original_text": "In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd540dba-1f81-4bb7-8f10-37aedc3992f1", "node_type": "1", "metadata": {"window": "This elevated and uneven \ndemand is reflected again in our third quarter results, as COVID -19 cases and hospitalizations  reached their \nhighest levels, impacting patient mobility and elective procedures, which were down 15% to 20% at times in the \nquarter according to IQVIA.  \n \n Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n", "original_text": "Due to these dynamics, some PPE and related items experienced inventory charges. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9544f2f603b1a66fa8948547d22938fef40f6cc1440a6ff55c586c0aed4e4847", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2733f0ca-937e-44f3-801f-45910d9f0bf3", "node_type": "1", "metadata": {"window": "Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs. ", "original_text": "For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products. "}, "hash": "cadf2e8f803493752e1a2a961dd86df6632055d7f77b42078e2b2aaf43845332", "class_name": "RelatedNodeInfo"}}, "text": "In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n", "start_char_idx": 2442, "end_char_idx": 2531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2733f0ca-937e-44f3-801f-45910d9f0bf3": {"__data__": {"id_": "2733f0ca-937e-44f3-801f-45910d9f0bf3", "embedding": null, "metadata": {"window": "Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs. ", "original_text": "For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a8ca926-f5da-4cfb-976c-d50ba6402241", "node_type": "1", "metadata": {"window": "Throughout the pandemic, and as always, our focus has been meeting the needs of our customers and the ir \npatients, providing access to the supplies including PPE that they need to continue to treat patients.  Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions. ", "original_text": "In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "caa87b95929b19cfb9a349adaca8555ec66e76823e677b6929d2651c7d6282ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3448f426-bc04-4d31-b9d4-76b91f5ccaa4", "node_type": "1", "metadata": {"window": "Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business. ", "original_text": "Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n"}, "hash": "e5ec14e3c34f2e0d5d0603c937c8379ff2ba2ae67f2c9b044c5eaaf3f72600ac", "class_name": "RelatedNodeInfo"}}, "text": "For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products. ", "start_char_idx": 2531, "end_char_idx": 2822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3448f426-bc04-4d31-b9d4-76b91f5ccaa4": {"__data__": {"id_": "3448f426-bc04-4d31-b9d4-76b91f5ccaa4", "embedding": null, "metadata": {"window": "Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business. ", "original_text": "Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2733f0ca-937e-44f3-801f-45910d9f0bf3", "node_type": "1", "metadata": {"window": "Early on, we \nprocured these products in a highly volatile market, with unpredictable supply and demand levels due to the \nimpacts of the pandemic.  Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs. ", "original_text": "For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ecfc7dc5f5602e994cac7fc2c561ba598daba26ddb6042d386baeae90a77a51b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6abeb063-26d9-4198-8e31-0a11e42fd253", "node_type": "1", "metadata": {"window": "In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n", "original_text": "Next, Prescription Technology Solutions. "}, "hash": "337064638ce4ae94a3fc45b72ab5d5c442446210a7f3914c53b60670880383b3", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n", "start_char_idx": 2822, "end_char_idx": 2978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6abeb063-26d9-4198-8e31-0a11e42fd253": {"__data__": {"id_": "6abeb063-26d9-4198-8e31-0a11e42fd253", "embedding": null, "metadata": {"window": "In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n", "original_text": "Next, Prescription Technology Solutions. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3448f426-bc04-4d31-b9d4-76b91f5ccaa4", "node_type": "1", "metadata": {"window": "Due to these dynamics, some PPE and related items experienced inventory charges.  In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business. ", "original_text": "Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be6a88aa10314621c7b58cbe8a0e4eab330a17237b924d91248d414eb95cae80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9d6d7eb-6a48-42a2-a1d8-7a68886d732a", "node_type": "1", "metadata": {"window": "For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio. ", "original_text": "Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs. "}, "hash": "78c68dda83b38f081b382bcebd98bc04b5cfcc52484fb5a84881bbbfd1d53d12", "class_name": "RelatedNodeInfo"}}, "text": "Next, Prescription Technology Solutions. ", "start_char_idx": 2978, "end_char_idx": 3019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9d6d7eb-6a48-42a2-a1d8-7a68886d732a": {"__data__": {"id_": "f9d6d7eb-6a48-42a2-a1d8-7a68886d732a", "embedding": null, "metadata": {"window": "For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio. ", "original_text": "Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6abeb063-26d9-4198-8e31-0a11e42fd253", "node_type": "1", "metadata": {"window": "In \nour third quarter, we recorded $35 million of charges related to these products.  \n \n For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n", "original_text": "Next, Prescription Technology Solutions. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "942de5ae47c20c0a5293faa6ad82027481ea6631170dd7d334a17eeffb050b7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a9238db-6f89-4a03-951b-4f3853c244b3", "node_type": "1", "metadata": {"window": "Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio.  This was partially offset by an increase in employee expenses as well as lower \ninterest income. ", "original_text": "Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business. "}, "hash": "c481eadfa812229ad1a66992bcc13ce50a8a2fe40c22f1bd0868f0af8bbc5022", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs. ", "start_char_idx": 3019, "end_char_idx": 3136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a9238db-6f89-4a03-951b-4f3853c244b3": {"__data__": {"id_": "5a9238db-6f89-4a03-951b-4f3853c244b3", "embedding": null, "metadata": {"window": "Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio.  This was partially offset by an increase in employee expenses as well as lower \ninterest income. ", "original_text": "Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9d6d7eb-6a48-42a2-a1d8-7a68886d732a", "node_type": "1", "metadata": {"window": "For the quarter, adjusted operating profit increased 52% to $279 million, driven by demand for  COVID -19 tests \nand the contribution from the kitting and distribution of ancillary supplies for COVID -19 vaccines, partially offset by \nthe inventory charges on certain PPE -related products.  Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio. ", "original_text": "Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcbd5cf4842d32e0d4f2dae037c19e90019862a06fb21d9831d00c7385080c55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c264609-71f3-4602-95fb-dceef3f8d8c8", "node_type": "1", "metadata": {"window": "Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio.  This was partially offset by an increase in employee expenses as well as lower \ninterest income.  This quarter, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  \n ", "original_text": "While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n"}, "hash": "f24fe745c5ab5eece5b67dc2e10f16f66d6fc5fd586522f1f94816fe0b3a3bf6", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business. ", "start_char_idx": 3136, "end_char_idx": 3237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c264609-71f3-4602-95fb-dceef3f8d8c8": {"__data__": {"id_": "5c264609-71f3-4602-95fb-dceef3f8d8c8", "embedding": null, "metadata": {"window": "Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio.  This was partially offset by an increase in employee expenses as well as lower \ninterest income.  This quarter, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  \n ", "original_text": "While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a9238db-6f89-4a03-951b-4f3853c244b3", "node_type": "1", "metadata": {"window": "Excluding the impact of incremental PPE and COVID -19 \ntests, adjus ted operating profit in the segment is up 29% year -over-year in the third quarter.  \n \n Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio.  This was partially offset by an increase in employee expenses as well as lower \ninterest income. ", "original_text": "Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "004165699b8444ebfd050e602034fc736d368fb84811feccf378f277f494edb2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30d8ba1f-ca52-4448-8407-cf8984eac727", "node_type": "1", "metadata": {"window": "Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio.  This was partially offset by an increase in employee expenses as well as lower \ninterest income.  This quarter, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  \n ", "original_text": "Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio. "}, "hash": "e789ccb6deb355d0b43121cb5c9e5a3f700e576c60eb4f1b46d3e80371297f8d", "class_name": "RelatedNodeInfo"}}, "text": "While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n", "start_char_idx": 3237, "end_char_idx": 3472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30d8ba1f-ca52-4448-8407-cf8984eac727": {"__data__": {"id_": "30d8ba1f-ca52-4448-8407-cf8984eac727", "embedding": null, "metadata": {"window": "Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio.  This was partially offset by an increase in employee expenses as well as lower \ninterest income.  This quarter, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  \n ", "original_text": "Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c264609-71f3-4602-95fb-dceef3f8d8c8", "node_type": "1", "metadata": {"window": "Next, Prescription Technology Solutions.  Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio.  This was partially offset by an increase in employee expenses as well as lower \ninterest income.  This quarter, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  \n ", "original_text": "While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dadf39478a550a943a99551c1a397718fa8b3bdf43870209ecb180df454fdc8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "148e2572-e7c3-4b0c-bfb9-560cdfcea2d4", "node_type": "1", "metadata": {"window": "Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio.  This was partially offset by an increase in employee expenses as well as lower \ninterest income.  This quarter, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  \n ", "original_text": "This was partially offset by an increase in employee expenses as well as lower \ninterest income. "}, "hash": "cce228e0db4b1208292a39b864c86dae166a3c70675f969af176808bb377da03", "class_name": "RelatedNodeInfo"}}, "text": "Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio. ", "start_char_idx": 3472, "end_char_idx": 3718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "148e2572-e7c3-4b0c-bfb9-560cdfcea2d4": {"__data__": {"id_": "148e2572-e7c3-4b0c-bfb9-560cdfcea2d4", "embedding": null, "metadata": {"window": "Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio.  This was partially offset by an increase in employee expenses as well as lower \ninterest income.  This quarter, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  \n ", "original_text": "This was partially offset by an increase in employee expenses as well as lower \ninterest income. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30d8ba1f-ca52-4448-8407-cf8984eac727", "node_type": "1", "metadata": {"window": "Revenues were $777 million, an increase of 9%, driven by new and \nhigher volumes of existing brand support programs.  Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio.  This was partially offset by an increase in employee expenses as well as lower \ninterest income.  This quarter, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  \n ", "original_text": "Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "13832023e9c940670d1425a386362159781b11952d70f4732cf89d2629239b8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9899304-4164-47de-849b-81eacef93fbc", "node_type": "1", "metadata": {"window": "While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio.  This was partially offset by an increase in employee expenses as well as lower \ninterest income.  This quarter, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  \n ", "original_text": "This quarter, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  \n "}, "hash": "7ea6980a40d7ad5967af31abf4c04caee31fefb1938db61d69b5bec20bb6b0ef", "class_name": "RelatedNodeInfo"}}, "text": "This was partially offset by an increase in employee expenses as well as lower \ninterest income. ", "start_char_idx": 3718, "end_char_idx": 3815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9899304-4164-47de-849b-81eacef93fbc": {"__data__": {"id_": "b9899304-4164-47de-849b-81eacef93fbc", "embedding": null, "metadata": {"window": "While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio.  This was partially offset by an increase in employee expenses as well as lower \ninterest income.  This quarter, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  \n ", "original_text": "This quarter, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  \n ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c533f2dd9349cb20842ea805cc9b1d7d541394ee8ac368c5850c2116b414426", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "148e2572-e7c3-4b0c-bfb9-560cdfcea2d4", "node_type": "1", "metadata": {"window": "Adjusted operat ing profit increased 27% to $131 million, \ndriven by organic growth in the business.  While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio.  This was partially offset by an increase in employee expenses as well as lower \ninterest income.  This quarter, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  \n ", "original_text": "This was partially offset by an increase in employee expenses as well as lower \ninterest income. ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a95c84dcf09b8e3a8c5f6f7679e08f4c85080f1e062ecf448bb1c2265ff6baf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cee55e0-4c35-4e29-9503-92831409e035", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance.  And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11. ", "original_text": "McKesson Corp.  "}, "hash": "99e0201e72a84527752899a291cfc3316be0a0a01e8c8a1241a2afe6e2bbe771", "class_name": "RelatedNodeInfo"}}, "text": "This quarter, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  \n ", "start_char_idx": 3815, "end_char_idx": 3935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cee55e0-4c35-4e29-9503-92831409e035": {"__data__": {"id_": "8cee55e0-4c35-4e29-9503-92831409e035", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance.  And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9899304-4164-47de-849b-81eacef93fbc", "node_type": "1", "metadata": {"window": "While we continue to invest in the expansion of our technology offerings \nfor our biopharma customers, we are starting to recognize the benefits of these investments, such a s our \ninvestment in AMP, which Brian discussed earlier.  \n \n Moving on to corporate, McKesson recorded $158 million in adjusted corporate expenses in the quarter, a \ndecrease of 6% year -over-year, driven by gains of approximately $30 million on equity investmen ts within our \nMcKesson Ventures portfolio.  This was partially offset by an increase in employee expenses as well as lower \ninterest income.  This quarter, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  \n ", "original_text": "This quarter, we had fair value adjustments related to several of our portfolio companies within \nMcKesson Ventures.  \n ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3997a79414b0aaef30b0c05834e90697e5b111d159a9c4258273bfdbc10d819", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9cc98ed-14be-44cf-a3ec-28b494cb1de4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance.  And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance. "}, "hash": "716f37451028bfa54250f141a7e7f95cda297e84aa5a15e6bbb3ffc79c84bf2e", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9cc98ed-14be-44cf-a3ec-28b494cb1de4": {"__data__": {"id_": "d9cc98ed-14be-44cf-a3ec-28b494cb1de4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance.  And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cee55e0-4c35-4e29-9503-92831409e035", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance.  And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c4a7a34f6467c5837deba5949bfb1472bcb16d6362e3b3f2a5bf4513a1cc651", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9a75af7-87e4-4c11-976d-1f7391c513b1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance.  And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million. ", "original_text": "And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n"}, "hash": "203eb0835c81ab264efcc53dd796aa18444d6895fbd9894a9269f1fcf586117f", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance. ", "start_char_idx": 16, "end_char_idx": 436, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9a75af7-87e4-4c11-976d-1f7391c513b1": {"__data__": {"id_": "e9a75af7-87e4-4c11-976d-1f7391c513b1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance.  And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million. ", "original_text": "And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9cc98ed-14be-44cf-a3ec-28b494cb1de4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance.  And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b631892b0daf6f92b4250b52856dcfa9aef8b9b15961747066676d8e11a40656", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b0e9fa8-38f2-415f-adde-c198aa53261e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance.  And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n", "original_text": "Turning now to cash which can be found on slide 11. "}, "hash": "91759b7449a48fbf48c7155994a36473ded4bc131b56912150234a71e30b5cc7", "class_name": "RelatedNodeInfo"}}, "text": "And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n", "start_char_idx": 436, "end_char_idx": 630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b0e9fa8-38f2-415f-adde-c198aa53261e": {"__data__": {"id_": "2b0e9fa8-38f2-415f-adde-c198aa53261e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance.  And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n", "original_text": "Turning now to cash which can be found on slide 11. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9a75af7-87e4-4c11-976d-1f7391c513b1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance.  And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million. ", "original_text": "And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af2f7eb2e9bb93f45e4a5114210b9cf3aa118a078ebdad110d990da76f060aa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a244f89-d860-4249-959a-dd8aacd28965", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance.  And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand. ", "original_text": "We ended the quarter  with a cash balance of $3.6 billion. \n"}, "hash": "eb03ef047d5ad14af0610f19db2454100b5dd8f7baab5d42e84731368498f1d8", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to cash which can be found on slide 11. ", "start_char_idx": 630, "end_char_idx": 682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a244f89-d860-4249-959a-dd8aacd28965": {"__data__": {"id_": "7a244f89-d860-4249-959a-dd8aacd28965", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance.  And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand. ", "original_text": "We ended the quarter  with a cash balance of $3.6 billion. \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b0e9fa8-38f2-415f-adde-c198aa53261e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance.  And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n", "original_text": "Turning now to cash which can be found on slide 11. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a8fda0fcd0f3799308190362bd1bc584e2c755bb5f3de3704c9d94e32311df5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab19a41c-da3c-4c63-a78f-21ecdd816e5d", "node_type": "1", "metadata": {"window": "And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE. ", "original_text": "And for the first nine months of the fiscal year, we generated free cash flow of $745 million. "}, "hash": "ab4c2c068329ec8850a1469ab95a403921e900afcc570bf72402f42a27b61698", "class_name": "RelatedNodeInfo"}}, "text": "We ended the quarter  with a cash balance of $3.6 billion. \n", "start_char_idx": 682, "end_char_idx": 742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab19a41c-da3c-4c63-a78f-21ecdd816e5d": {"__data__": {"id_": "ab19a41c-da3c-4c63-a78f-21ecdd816e5d", "embedding": null, "metadata": {"window": "And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE. ", "original_text": "And for the first nine months of the fiscal year, we generated free cash flow of $745 million. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a244f89-d860-4249-959a-dd8aacd28965", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance.  And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand. ", "original_text": "We ended the quarter  with a cash balance of $3.6 billion. \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3cc1a5c0d64342a3e3c31bb89cfab771ed972ae1b4bdae632a9c868a001d366", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b432f1c-eb11-44ab-ab8a-13303f7430d7", "node_type": "1", "metadata": {"window": "Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S. ", "original_text": "Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n"}, "hash": "7df8b104fab90d4059c8f8fe57909db0d50b46a9da2669ecbe5a1326759cc17c", "class_name": "RelatedNodeInfo"}}, "text": "And for the first nine months of the fiscal year, we generated free cash flow of $745 million. ", "start_char_idx": 742, "end_char_idx": 837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b432f1c-eb11-44ab-ab8a-13303f7430d7": {"__data__": {"id_": "3b432f1c-eb11-44ab-ab8a-13303f7430d7", "embedding": null, "metadata": {"window": "Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S. ", "original_text": "Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab19a41c-da3c-4c63-a78f-21ecdd816e5d", "node_type": "1", "metadata": {"window": "And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE. ", "original_text": "And for the first nine months of the fiscal year, we generated free cash flow of $745 million. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49effcfea63a7d246e95e45889c0827132fcb226cdc4a91a87fe63a61f75483a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c684f2ae-fc94-415b-8643-5839bd3e97a8", "node_type": "1", "metadata": {"window": "We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n", "original_text": "In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand. "}, "hash": "5e06798175dac10bcf6b885bf9d0bd925832ad7874f37ba2192aec9318022a44", "class_name": "RelatedNodeInfo"}}, "text": "Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n", "start_char_idx": 837, "end_char_idx": 1017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c684f2ae-fc94-415b-8643-5839bd3e97a8": {"__data__": {"id_": "c684f2ae-fc94-415b-8643-5839bd3e97a8", "embedding": null, "metadata": {"window": "We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n", "original_text": "In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b432f1c-eb11-44ab-ab8a-13303f7430d7", "node_type": "1", "metadata": {"window": "Turning now to cash which can be found on slide 11.  We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S. ", "original_text": "Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f141d461420f366e0a31c4fb981e1f71af1a7d2ec84c0cbff2fa7b2c9ad52d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "089a3874-e49a-4e77-a26f-35b9b15fd984", "node_type": "1", "metadata": {"window": "And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services. ", "original_text": "In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE. "}, "hash": "4d23b00a53cad2cc2637498a2e0a69a3531b3bae5e1286696fc8221bcb5c87e4", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand. ", "start_char_idx": 1017, "end_char_idx": 1119, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "089a3874-e49a-4e77-a26f-35b9b15fd984": {"__data__": {"id_": "089a3874-e49a-4e77-a26f-35b9b15fd984", "embedding": null, "metadata": {"window": "And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services. ", "original_text": "In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c684f2ae-fc94-415b-8643-5839bd3e97a8", "node_type": "1", "metadata": {"window": "We ended the quarter  with a cash balance of $3.6 billion. \n And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n", "original_text": "In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19749de46e6f5f38d72a26c81e0b550362144f30ff4b137d45294a6198e50f75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e03d1643-8a00-46f5-91e4-1144c5f0d6a1", "node_type": "1", "metadata": {"window": "Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n", "original_text": "As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S. "}, "hash": "295c49be2d306b589e583f809e40171991bdb8633fda4b55dcedb6918f708d03", "class_name": "RelatedNodeInfo"}}, "text": "In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE. ", "start_char_idx": 1119, "end_char_idx": 1239, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e03d1643-8a00-46f5-91e4-1144c5f0d6a1": {"__data__": {"id_": "e03d1643-8a00-46f5-91e4-1144c5f0d6a1", "embedding": null, "metadata": {"window": "Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n", "original_text": "As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "089a3874-e49a-4e77-a26f-35b9b15fd984", "node_type": "1", "metadata": {"window": "And for the first nine months of the fiscal year, we generated free cash flow of $745 million.  Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services. ", "original_text": "In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54c417eb6f1dd82804455a56acacf0046dd02c56d5457fae5ebd70b434919f24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d75eade-63b6-4030-91ba-60801e38550f", "node_type": "1", "metadata": {"window": "In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021. ", "original_text": "Government, we may \nexperience additional working capital volatility.  \n \n"}, "hash": "d13ee7fd747795cd66948d5cc71714b6fdfbbb62aaac02ca32242ae65902ba23", "class_name": "RelatedNodeInfo"}}, "text": "As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S. ", "start_char_idx": 1239, "end_char_idx": 1330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d75eade-63b6-4030-91ba-60801e38550f": {"__data__": {"id_": "4d75eade-63b6-4030-91ba-60801e38550f", "embedding": null, "metadata": {"window": "In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021. ", "original_text": "Government, we may \nexperience additional working capital volatility.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e03d1643-8a00-46f5-91e4-1144c5f0d6a1", "node_type": "1", "metadata": {"window": "Our working capital \nmetrics and resulting free cash flow vary from quarter -to-quarter, impacted by timing, including the da y of the \nweek that marks the close of a quarter.  \n \n In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n", "original_text": "As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d08449ef7296d8cd715864fb6da1d9967f745feb28c4e93001c217116d1a6fee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e001030-53b4-4e9e-9268-d761a7dabdb7", "node_type": "1", "metadata": {"window": "In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways. ", "original_text": "Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services. "}, "hash": "61775e989accb9bbc5619d2a896b1de98e96fe30dbe859215b2c736757030bea", "class_name": "RelatedNodeInfo"}}, "text": "Government, we may \nexperience additional working capital volatility.  \n \n", "start_char_idx": 1330, "end_char_idx": 1404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e001030-53b4-4e9e-9268-d761a7dabdb7": {"__data__": {"id_": "6e001030-53b4-4e9e-9268-d761a7dabdb7", "embedding": null, "metadata": {"window": "In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways. ", "original_text": "Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d75eade-63b6-4030-91ba-60801e38550f", "node_type": "1", "metadata": {"window": "In fiscal 2021, our cash flow dynamics have also been impacted by changing levels of customer demand.  In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021. ", "original_text": "Government, we may \nexperience additional working capital volatility.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "013ee6e2d235775b1c513bb2dfc5c6be99d753b3f06900276ef7cbff17d2d6ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25aecd66-0ed5-49ab-9227-183bfec04319", "node_type": "1", "metadata": {"window": "As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n", "original_text": "For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n"}, "hash": "e9c47d0b46c4f74e2b1d548aaf704b7aff3ef3a500762aeb42b90402f155aa07", "class_name": "RelatedNodeInfo"}}, "text": "Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services. ", "start_char_idx": 1404, "end_char_idx": 1671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25aecd66-0ed5-49ab-9227-183bfec04319": {"__data__": {"id_": "25aecd66-0ed5-49ab-9227-183bfec04319", "embedding": null, "metadata": {"window": "As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n", "original_text": "For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e001030-53b4-4e9e-9268-d761a7dabdb7", "node_type": "1", "metadata": {"window": "In Q3, \nwe again saw higher levels of inventory, resulting primarily from increased quantities of COVID t ests and PPE.  As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways. ", "original_text": "Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5df14ca1ecf2acba52056116168f80699b73ab54537360c19d3ae0f8f7c10094", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96036f9e-78e4-4dcf-8d58-7677212d81a8", "node_type": "1", "metadata": {"window": "Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n", "original_text": "Let me now turn to our outlook for the balance of fiscal 2021. "}, "hash": "9e2ebe2dcbf13d44dd72091238536967acbb018844eeda0ff6ce85db009f56cf", "class_name": "RelatedNodeInfo"}}, "text": "For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n", "start_char_idx": 1671, "end_char_idx": 1864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96036f9e-78e4-4dcf-8d58-7677212d81a8": {"__data__": {"id_": "96036f9e-78e4-4dcf-8d58-7677212d81a8", "embedding": null, "metadata": {"window": "Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n", "original_text": "Let me now turn to our outlook for the balance of fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25aecd66-0ed5-49ab-9227-183bfec04319", "node_type": "1", "metadata": {"window": "As \nwe work to meet the evolving needs of our customers and ramp up our work with the U.S.  Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n", "original_text": "For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad320a928e2888afdb0b4ff120a6dfbad09a68d35c83c7c1f0bafe298c5c17bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b0b0ca8-187e-49df-b525-2559b6248f2b", "node_type": "1", "metadata": {"window": "Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday. ", "original_text": "The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways. "}, "hash": "7ee6e87136e8c0f78c86b11664f840488e63b944690e5d8034c2027d74b334ab", "class_name": "RelatedNodeInfo"}}, "text": "Let me now turn to our outlook for the balance of fiscal 2021. ", "start_char_idx": 1864, "end_char_idx": 1927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b0b0ca8-187e-49df-b525-2559b6248f2b": {"__data__": {"id_": "3b0b0ca8-187e-49df-b525-2559b6248f2b", "embedding": null, "metadata": {"window": "Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday. ", "original_text": "The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96036f9e-78e4-4dcf-8d58-7677212d81a8", "node_type": "1", "metadata": {"window": "Government, we may \nexperience additional working capital volatility.  \n \n Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n", "original_text": "Let me now turn to our outlook for the balance of fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d19456756cfe7c94c06075165a07ed93333cfb35e7bc2a740cb62e4a81e3fce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "367c4f56-1143-4533-a7ff-93d74a92622c", "node_type": "1", "metadata": {"window": "For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services. ", "original_text": "The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n"}, "hash": "1146485865a9f85225e9fc172f79c99498d4d4c6747a8c3adc4210cd26e36e21", "class_name": "RelatedNodeInfo"}}, "text": "The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways. ", "start_char_idx": 1927, "end_char_idx": 2031, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "367c4f56-1143-4533-a7ff-93d74a92622c": {"__data__": {"id_": "367c4f56-1143-4533-a7ff-93d74a92622c", "embedding": null, "metadata": {"window": "For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services. ", "original_text": "The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b0b0ca8-187e-49df-b525-2559b6248f2b", "node_type": "1", "metadata": {"window": "Year -to-date, we made $427 million of capital expenditures, includes internal inve stments to support our COVID -\n19 vaccine and kitting efforts and technology, data and analytics investments to support our strategic initiatives of \noncology and biopharma services.  For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday. ", "original_text": "The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f00d6d3cb5e3292c4c9e466ec31f04c5ad8d1447b126861017277e276224a5d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad46d9cd-7441-48e1-bc2e-7c822bd1a713", "node_type": "1", "metadata": {"window": "Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n", "original_text": "However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n"}, "hash": "0a405ce7461b27993958354757ca463feb9769efc6262295b92e58c7ea9c4e53", "class_name": "RelatedNodeInfo"}}, "text": "The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n", "start_char_idx": 2031, "end_char_idx": 2196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad46d9cd-7441-48e1-bc2e-7c822bd1a713": {"__data__": {"id_": "ad46d9cd-7441-48e1-bc2e-7c822bd1a713", "embedding": null, "metadata": {"window": "Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n", "original_text": "However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "367c4f56-1143-4533-a7ff-93d74a92622c", "node_type": "1", "metadata": {"window": "For the first nine months of the fiscal year, we returned $709 million of ca sh to \nour shareholders through $500 million of share repurchases and the payment of $209 million in dividends.  \n \n Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services. ", "original_text": "The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9ee48805abe0375b079195cd918601d51e3959aa56518e88595309f8c5d7b7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cdbe0ae-6ecc-4f77-a19d-8cfa0edb8b66", "node_type": "1", "metadata": {"window": "The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022. ", "original_text": "Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday. "}, "hash": "9ab0bd63924e85074de117299c86f30b0a33395b35c3ddd2a76cdf920c9b2ed9", "class_name": "RelatedNodeInfo"}}, "text": "However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n", "start_char_idx": 2196, "end_char_idx": 2437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cdbe0ae-6ecc-4f77-a19d-8cfa0edb8b66": {"__data__": {"id_": "9cdbe0ae-6ecc-4f77-a19d-8cfa0edb8b66", "embedding": null, "metadata": {"window": "The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022. ", "original_text": "Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad46d9cd-7441-48e1-bc2e-7c822bd1a713", "node_type": "1", "metadata": {"window": "Let me now turn to our outlook for the balance of fiscal 2021.  The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n", "original_text": "However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5f31ed257aa4e231cb4063fbc5ae82c62aa176570cf472c48c3be4830cc8f31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e28eb4fa-bbb1-4055-9982-e72ad71db54a", "node_type": "1", "metadata": {"window": "The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n", "original_text": "First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services. "}, "hash": "15c7558fe08147895c7a534c1667be52e9501de2daea0a30bfa77622c6b74635", "class_name": "RelatedNodeInfo"}}, "text": "Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday. ", "start_char_idx": 2437, "end_char_idx": 2553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e28eb4fa-bbb1-4055-9982-e72ad71db54a": {"__data__": {"id_": "e28eb4fa-bbb1-4055-9982-e72ad71db54a", "embedding": null, "metadata": {"window": "The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n", "original_text": "First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cdbe0ae-6ecc-4f77-a19d-8cfa0edb8b66", "node_type": "1", "metadata": {"window": "The COVID -19 virus and effects of the pandemic \ncontinue to impact our communities  in different ways.  The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022. ", "original_text": "Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d27b8c421e3f7e5b119aa3791d2f0f61839014b27f91dee99b7cfc920324004", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c07252c-0dfb-4652-b4ce-0a95d850ce9a", "node_type": "1", "metadata": {"window": "However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories. ", "original_text": "And second, we do not \nassume any systemic customer i nsolvency event.  \n \n"}, "hash": "6b5441e362979c07f542940a30a98f8cf1299d8e10b20576cd31ee6b30adb9c7", "class_name": "RelatedNodeInfo"}}, "text": "First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services. ", "start_char_idx": 2553, "end_char_idx": 2741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c07252c-0dfb-4652-b4ce-0a95d850ce9a": {"__data__": {"id_": "0c07252c-0dfb-4652-b4ce-0a95d850ce9a", "embedding": null, "metadata": {"window": "However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories. ", "original_text": "And second, we do not \nassume any systemic customer i nsolvency event.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e28eb4fa-bbb1-4055-9982-e72ad71db54a", "node_type": "1", "metadata": {"window": "The sharp declines across our businesses in the first \nquarter, followed by a more positive trajectory through our second quarter indicated signs of stabilization. \n However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n", "original_text": "First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f3ce98e3b2808511d3477ccfb32d4e829f72947a3bc3c9bfe574e0613f64fe6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4fd9bdc-2ec3-4fd0-9f48-75afe01c96de", "node_type": "1", "metadata": {"window": "Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n", "original_text": "I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022. "}, "hash": "358a183471679f7bc049ad12fe7557a4f8ada161efce04b1ee02a068e9ef87d8", "class_name": "RelatedNodeInfo"}}, "text": "And second, we do not \nassume any systemic customer i nsolvency event.  \n \n", "start_char_idx": 2741, "end_char_idx": 2816, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4fd9bdc-2ec3-4fd0-9f48-75afe01c96de": {"__data__": {"id_": "c4fd9bdc-2ec3-4fd0-9f48-75afe01c96de", "embedding": null, "metadata": {"window": "Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n", "original_text": "I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c07252c-0dfb-4652-b4ce-0a95d850ce9a", "node_type": "1", "metadata": {"window": "However, the third quarter was another good example of the non -linear sha pe of the recovery that we've been \ntalking about all year, as increased case counts and hospitalizations led to a softening of the trends in the third \nquarter.  \n \n Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories. ", "original_text": "And second, we do not \nassume any systemic customer i nsolvency event.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27f1df2579927562843ed1e70904f6900a1083dab839c76b02182c97c27eaf40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6baa69fa-618e-497c-832f-bd0c88197fb4", "node_type": "1", "metadata": {"window": "First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50. ", "original_text": "Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n"}, "hash": "c1e6d629554a9d6ec78e9f540bbdc1781226e90410ec2fb81a2b44f7280a5d15", "class_name": "RelatedNodeInfo"}}, "text": "I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022. ", "start_char_idx": 2816, "end_char_idx": 3023, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6baa69fa-618e-497c-832f-bd0c88197fb4": {"__data__": {"id_": "6baa69fa-618e-497c-832f-bd0c88197fb4", "embedding": null, "metadata": {"window": "First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50. ", "original_text": "Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4fd9bdc-2ec3-4fd0-9f48-75afe01c96de", "node_type": "1", "metadata": {"window": "Two important assumptions have underpinned our guidance throughout fiscal 2021 and we're reiter ating those \ntoday.  First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n", "original_text": "I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d00379c80fa194d55736cac5bf08334310b88f86c3325c9f98116ec66ff761b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2499827-b829-433a-9a95-b74462551e3d", "node_type": "1", "metadata": {"window": "And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50.  We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021. ", "original_text": "Through our third quarter, we've seen elevated levels of these product categories. "}, "hash": "3ef04ca94352577c36118228bdadfca9fc8b35da6937ee8b48fad03819e46451", "class_name": "RelatedNodeInfo"}}, "text": "Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n", "start_char_idx": 3023, "end_char_idx": 3176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2499827-b829-433a-9a95-b74462551e3d": {"__data__": {"id_": "c2499827-b829-433a-9a95-b74462551e3d", "embedding": null, "metadata": {"window": "And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50.  We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021. ", "original_text": "Through our third quarter, we've seen elevated levels of these product categories. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6baa69fa-618e-497c-832f-bd0c88197fb4", "node_type": "1", "metadata": {"window": "First, we do not assume a new wave of COVID -19 which would lead to shelter -at-home and economic \nlockdown, which would preclude patient mobility and consumption of health care services.  And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50. ", "original_text": "Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "989662a91144f3ffeb9624658c2e6ce6d83598bd8f9f6032cfd5b9a1a297c280", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2da6de91-be19-49a2-bfa5-c441fbc5e715", "node_type": "1", "metadata": {"window": "I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50.  We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021.  And we now expect the consolidated \nadjusted operating profit will grow 7% to 9% for the ful l year, excluding the results of Change Healthcare from the \nprior year, which is up from our prior guidance of an increase between 2% and 6%.  ", "original_text": "However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n"}, "hash": "6b3d723a8b2452b5427df7f81a98baa0fd0a464043617f873e0ebabb0533db6e", "class_name": "RelatedNodeInfo"}}, "text": "Through our third quarter, we've seen elevated levels of these product categories. ", "start_char_idx": 3176, "end_char_idx": 3259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2da6de91-be19-49a2-bfa5-c441fbc5e715": {"__data__": {"id_": "2da6de91-be19-49a2-bfa5-c441fbc5e715", "embedding": null, "metadata": {"window": "I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50.  We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021.  And we now expect the consolidated \nadjusted operating profit will grow 7% to 9% for the ful l year, excluding the results of Change Healthcare from the \nprior year, which is up from our prior guidance of an increase between 2% and 6%.  ", "original_text": "However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2499827-b829-433a-9a95-b74462551e3d", "node_type": "1", "metadata": {"window": "And second, we do not \nassume any systemic customer i nsolvency event.  \n \n I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50.  We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021. ", "original_text": "Through our third quarter, we've seen elevated levels of these product categories. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a47cf13638f554e2ad366f0570182adb5b4e0b61ca0686242f9d24f6032cc49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7950d5f3-63be-47a9-9fa8-53c6dbccbf66", "node_type": "1", "metadata": {"window": "Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50.  We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021.  And we now expect the consolidated \nadjusted operating profit will grow 7% to 9% for the ful l year, excluding the results of Change Healthcare from the \nprior year, which is up from our prior guidance of an increase between 2% and 6%.  ", "original_text": "As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50. "}, "hash": "962928321b39e2d0dc7f7bcb62330e861e78ce0312556a26dd9ca7288b54172b", "class_name": "RelatedNodeInfo"}}, "text": "However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n", "start_char_idx": 3259, "end_char_idx": 3600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7950d5f3-63be-47a9-9fa8-53c6dbccbf66": {"__data__": {"id_": "7950d5f3-63be-47a9-9fa8-53c6dbccbf66", "embedding": null, "metadata": {"window": "Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50.  We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021.  And we now expect the consolidated \nadjusted operating profit will grow 7% to 9% for the ful l year, excluding the results of Change Healthcare from the \nprior year, which is up from our prior guidance of an increase between 2% and 6%.  ", "original_text": "As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2da6de91-be19-49a2-bfa5-c441fbc5e715", "node_type": "1", "metadata": {"window": "I'd also like to reiterate that we believe that the recovery will take longer than initially anticipated and will not be in \na straight line as the impacts of the pandemic will persist into our fiscal 2022.  Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50.  We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021.  And we now expect the consolidated \nadjusted operating profit will grow 7% to 9% for the ful l year, excluding the results of Change Healthcare from the \nprior year, which is up from our prior guidance of an increase between 2% and 6%.  ", "original_text": "However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "640ecb0ccb5a16284aeba97ada1f34a8910f1cc30fa6cd7c571af54147de3d99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a78d001-71cc-4644-8cbe-db4f16edd65e", "node_type": "1", "metadata": {"window": "Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50.  We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021.  And we now expect the consolidated \nadjusted operating profit will grow 7% to 9% for the ful l year, excluding the results of Change Healthcare from the \nprior year, which is up from our prior guidance of an increase between 2% and 6%.  ", "original_text": "We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021. "}, "hash": "566deac433340f69781b23c20a056339a806e14f990b95d5599b23f41917876a", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50. ", "start_char_idx": 3600, "end_char_idx": 3914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a78d001-71cc-4644-8cbe-db4f16edd65e": {"__data__": {"id_": "0a78d001-71cc-4644-8cbe-db4f16edd65e", "embedding": null, "metadata": {"window": "Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50.  We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021.  And we now expect the consolidated \nadjusted operating profit will grow 7% to 9% for the ful l year, excluding the results of Change Healthcare from the \nprior year, which is up from our prior guidance of an increase between 2% and 6%.  ", "original_text": "We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7950d5f3-63be-47a9-9fa8-53c6dbccbf66", "node_type": "1", "metadata": {"window": "Further, we do expect that there  will \ncontinue to be significant volatility in the demand and ultimate volume levels for COVID -19 test kits and PPE. \n Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50.  We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021.  And we now expect the consolidated \nadjusted operating profit will grow 7% to 9% for the ful l year, excluding the results of Change Healthcare from the \nprior year, which is up from our prior guidance of an increase between 2% and 6%.  ", "original_text": "As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48ec88b61f425cff15b8ee0538a0af2a696ecdbe7a2bc06eb9be566da731a397", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36828cf7-f5d0-491d-983e-cfc063641b1c", "node_type": "1", "metadata": {"window": "However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50.  We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021.  And we now expect the consolidated \nadjusted operating profit will grow 7% to 9% for the ful l year, excluding the results of Change Healthcare from the \nprior year, which is up from our prior guidance of an increase between 2% and 6%.  ", "original_text": "And we now expect the consolidated \nadjusted operating profit will grow 7% to 9% for the ful l year, excluding the results of Change Healthcare from the \nprior year, which is up from our prior guidance of an increase between 2% and 6%.  "}, "hash": "3f3e39b4540ae5c69c86e80a01713a95c03c3322f790647d79e6eb7c500be4b7", "class_name": "RelatedNodeInfo"}}, "text": "We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021. ", "start_char_idx": 3914, "end_char_idx": 4009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36828cf7-f5d0-491d-983e-cfc063641b1c": {"__data__": {"id_": "36828cf7-f5d0-491d-983e-cfc063641b1c", "embedding": null, "metadata": {"window": "However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50.  We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021.  And we now expect the consolidated \nadjusted operating profit will grow 7% to 9% for the ful l year, excluding the results of Change Healthcare from the \nprior year, which is up from our prior guidance of an increase between 2% and 6%.  ", "original_text": "And we now expect the consolidated \nadjusted operating profit will grow 7% to 9% for the ful l year, excluding the results of Change Healthcare from the \nprior year, which is up from our prior guidance of an increase between 2% and 6%.  ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3b0a29539e8717909bc7d95f45dd9d9bee6d6029d652c056ff7edbcc0f7decc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a78d001-71cc-4644-8cbe-db4f16edd65e", "node_type": "1", "metadata": {"window": "Through our third quarter, we've seen elevated levels of these product categories.  However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50.  We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021.  And we now expect the consolidated \nadjusted operating profit will grow 7% to 9% for the ful l year, excluding the results of Change Healthcare from the \nprior year, which is up from our prior guidance of an increase between 2% and 6%.  ", "original_text": "We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98b6128f1ab856b0dff71bc7bd2cf7e2728775ba49fa53f5963718185003fbbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5936876-768b-4e61-847e-2d2f69ee6889", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments.  In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year. ", "original_text": "McKesson Corp.  "}, "hash": "98110ab62e464007270c531d8e704de3dda796af62239cfffe5d9abfba4ab427", "class_name": "RelatedNodeInfo"}}, "text": "And we now expect the consolidated \nadjusted operating profit will grow 7% to 9% for the ful l year, excluding the results of Change Healthcare from the \nprior year, which is up from our prior guidance of an increase between 2% and 6%.  ", "start_char_idx": 4009, "end_char_idx": 4246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5936876-768b-4e61-847e-2d2f69ee6889": {"__data__": {"id_": "e5936876-768b-4e61-847e-2d2f69ee6889", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments.  In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36828cf7-f5d0-491d-983e-cfc063641b1c", "node_type": "1", "metadata": {"window": "However, we do expect these \ndynamic volumes will moderat e. \n \nAlso, given there is now an approved COVID -19 vaccine that is within the scope of McKesson's contract, our \nguidance now takes into account earnings related to COVID -19 vaccine distribution, in accordance with the \ndistribution schedule provided to McKes son by the CDC.  \n \n As a result of our solid third quarter performance and outlook for the remainder of the year, which now includes \nestimated earnings tied to the distribution of COVID -19 vaccines, we are increasing and narrowing our adjusted \nearnings guidan ce range to $16.95 to $17.25 from our previous range of $16 to $16.50.  We continue to anticipate \nconsolidated revenues to increase between 2% to 4% for fiscal 2021.  And we now expect the consolidated \nadjusted operating profit will grow 7% to 9% for the ful l year, excluding the results of Change Healthcare from the \nprior year, which is up from our prior guidance of an increase between 2% and 6%.  ", "original_text": "And we now expect the consolidated \nadjusted operating profit will grow 7% to 9% for the ful l year, excluding the results of Change Healthcare from the \nprior year, which is up from our prior guidance of an increase between 2% and 6%.  ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae2bd2a97424783c79f70c86b0a6be2a2a40c855ff8c4b4721a2b12abe978f41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d254eb80-2781-4818-81b9-a10b5e2a3a2a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments.  In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments. "}, "hash": "66ee64f1509faa7f4ed7680f8564859fbd0d61df19ea3a3c462afdc384798dee", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d254eb80-2781-4818-81b9-a10b5e2a3a2a": {"__data__": {"id_": "d254eb80-2781-4818-81b9-a10b5e2a3a2a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments.  In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5936876-768b-4e61-847e-2d2f69ee6889", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments.  In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8609ca07a9cd55892869e4aeec8e6ca13bbf21615bfd20b4d8d5e601b087dc20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1ff1ca3-9496-4aee-835b-2c2c118eef0a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments.  In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n", "original_text": "In our U.S. "}, "hash": "4cb1620d1a4e7229a2f2508a9351665baf148fbb8849ebf8669ac9a6f223cd74", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments. ", "start_char_idx": 16, "end_char_idx": 211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1ff1ca3-9496-4aee-835b-2c2c118eef0a": {"__data__": {"id_": "b1ff1ca3-9496-4aee-835b-2c2c118eef0a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments.  In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n", "original_text": "In our U.S. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d254eb80-2781-4818-81b9-a10b5e2a3a2a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments.  In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c41dd286f6dfe9d0d236e907dcac6688b06106c4f256a2d3342ca0885ee19f14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8fb2ab3-5c91-408e-b077-f5dcb129da6b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments.  In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021. ", "original_text": "Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year. "}, "hash": "32dd0ef5665335eb918c981ee535468b0809acbdbcafd9aff714d2780a97e4a6", "class_name": "RelatedNodeInfo"}}, "text": "In our U.S. ", "start_char_idx": 211, "end_char_idx": 223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8fb2ab3-5c91-408e-b077-f5dcb129da6b": {"__data__": {"id_": "d8fb2ab3-5c91-408e-b077-f5dcb129da6b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments.  In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021. ", "original_text": "Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1ff1ca3-9496-4aee-835b-2c2c118eef0a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments.  In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n", "original_text": "In our U.S. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97bdb514b15c9aecdc776ff1c6bfb9c6c7c1d8d37c7baea078a4d3931cd98a3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18dab790-0e68-4d4f-80f1-c04b6ce4df90", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments.  In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n", "original_text": "We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine. "}, "hash": "ba295e4cf78f2a8cb7269f99605895584384159528922ccb9155afd40bb16d07", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year. ", "start_char_idx": 223, "end_char_idx": 383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18dab790-0e68-4d4f-80f1-c04b6ce4df90": {"__data__": {"id_": "18dab790-0e68-4d4f-80f1-c04b6ce4df90", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments.  In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n", "original_text": "We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8fb2ab3-5c91-408e-b077-f5dcb129da6b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments.  In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021. ", "original_text": "Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fb7bdfe25f494e5eaacffb65daea739b4acc5131d0fa1bbb811b18d5442dc4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56ab5f76-6a01-4705-b1f1-5fc535078b9c", "node_type": "1", "metadata": {"window": "In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical. ", "original_text": "This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n"}, "hash": "70869cf08256fb20b70656cece589a41dd7f54536c6d5af3c32438c1903e1643", "class_name": "RelatedNodeInfo"}}, "text": "We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine. ", "start_char_idx": 383, "end_char_idx": 588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56ab5f76-6a01-4705-b1f1-5fc535078b9c": {"__data__": {"id_": "56ab5f76-6a01-4705-b1f1-5fc535078b9c", "embedding": null, "metadata": {"window": "In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical. ", "original_text": "This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18dab790-0e68-4d4f-80f1-c04b6ce4df90", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments.  In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n", "original_text": "We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85fa223e7e5117d278279364755633f016bd48ffd24b8c21b6bb7cff22213a8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab08f443-2bc5-4a34-86cc-d7efd4739b2c", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market. ", "original_text": "I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021. "}, "hash": "e711d8301d4d70ce2b0e23ca2a93a30d428259cb5c1748f37c6e5e2c7429993a", "class_name": "RelatedNodeInfo"}}, "text": "This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n", "start_char_idx": 588, "end_char_idx": 731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab08f443-2bc5-4a34-86cc-d7efd4739b2c": {"__data__": {"id_": "ab08f443-2bc5-4a34-86cc-d7efd4739b2c", "embedding": null, "metadata": {"window": "Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market. ", "original_text": "I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56ab5f76-6a01-4705-b1f1-5fc535078b9c", "node_type": "1", "metadata": {"window": "In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical. ", "original_text": "This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a96738d3ff1d94e03aebd9158cb385bb8b581f2fa5aee85f48a05e0ef6951d63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc21e756-1d0e-483a-9f81-33ae387d0cdc", "node_type": "1", "metadata": {"window": "We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE. ", "original_text": "In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n"}, "hash": "e847cd024ee187a8ad20343c10206131ad19a5866c059193edf8ecfbc17c05bf", "class_name": "RelatedNodeInfo"}}, "text": "I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021. ", "start_char_idx": 731, "end_char_idx": 1016, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc21e756-1d0e-483a-9f81-33ae387d0cdc": {"__data__": {"id_": "fc21e756-1d0e-483a-9f81-33ae387d0cdc", "embedding": null, "metadata": {"window": "We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE. ", "original_text": "In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab08f443-2bc5-4a34-86cc-d7efd4739b2c", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year.  We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market. ", "original_text": "I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a557c392b38201e3dd55e1753edba2455fb388348683278d36b287470aa6a7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec6b21ba-a7f0-4c5d-af68-0698fb90b9c6", "node_type": "1", "metadata": {"window": "This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate. ", "original_text": "Let me now turn to Medical -Surgical. "}, "hash": "0e7c9d0f63c75956ec475faf2f62b1d50967af81b0510682f2f780899c384241", "class_name": "RelatedNodeInfo"}}, "text": "In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n", "start_char_idx": 1016, "end_char_idx": 1173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec6b21ba-a7f0-4c5d-af68-0698fb90b9c6": {"__data__": {"id_": "ec6b21ba-a7f0-4c5d-af68-0698fb90b9c6", "embedding": null, "metadata": {"window": "This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate. ", "original_text": "Let me now turn to Medical -Surgical. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc21e756-1d0e-483a-9f81-33ae387d0cdc", "node_type": "1", "metadata": {"window": "We've included in \nour guidance a net benefit to fiscal 2021 adjusted earnings per diluted share of approximately $0.25 to $0.35 \nrelated to our role as the centralized dis tributor for COVID -19 vaccine.  This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE. ", "original_text": "In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cad3fef938727908be4d5aade6c7a5d31c3faa52e61376bdb0798700b6733c51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ebdc7fd-2f8a-4e88-9fa2-f747fd133732", "node_type": "1", "metadata": {"window": "I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n", "original_text": "The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market. "}, "hash": "048e4b5c39c0899910da0f4b3a0e4c385445431f67b49edb5e910cb266200fb8", "class_name": "RelatedNodeInfo"}}, "text": "Let me now turn to Medical -Surgical. ", "start_char_idx": 1173, "end_char_idx": 1211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ebdc7fd-2f8a-4e88-9fa2-f747fd133732": {"__data__": {"id_": "0ebdc7fd-2f8a-4e88-9fa2-f747fd133732", "embedding": null, "metadata": {"window": "I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n", "original_text": "The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec6b21ba-a7f0-4c5d-af68-0698fb90b9c6", "node_type": "1", "metadata": {"window": "This range is dependent on a number of \nfactors, which includes final vaccine distribution volumes and product mix as directed by the CDC.  \n \n I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate. ", "original_text": "Let me now turn to Medical -Surgical. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa0fb7f41fa80fa1e9d236b61ea303dfaa71889b50f17c109d2eda20e48f38cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09ac6bb2-16db-41cd-b1ac-cbb32a032bb9", "node_type": "1", "metadata": {"window": "In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n", "original_text": "As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE. "}, "hash": "edb6f94eabfe91058f6595c2acd26d2b449fd7d22763a52a4d1ae10e962eadf4", "class_name": "RelatedNodeInfo"}}, "text": "The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market. ", "start_char_idx": 1211, "end_char_idx": 1337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09ac6bb2-16db-41cd-b1ac-cbb32a032bb9": {"__data__": {"id_": "09ac6bb2-16db-41cd-b1ac-cbb32a032bb9", "embedding": null, "metadata": {"window": "In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n", "original_text": "As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ebdc7fd-2f8a-4e88-9fa2-f747fd133732", "node_type": "1", "metadata": {"window": "I would also remind you of our continued commitment to invest in and extend our leadin g position in oncology, \nwhere we are making incremental investments in the second half of fiscal 2021, which equates to a headwind of \napproximately $0.05 to $0.10 of adjusted EPS for fiscal 2021.  In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n", "original_text": "The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50e9ae21823023d7daae0e1ae64b954725126216f56f4dd18a71bee58ef50263", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "718b230a-aeef-49ae-a2b6-77244d579c85", "node_type": "1", "metadata": {"window": "Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine. ", "original_text": "We expect to see shift in volumes, \nwhich we anticipate will moderate. "}, "hash": "6ceff31e8893fb427f22eed9b28469ddc65499c07c333fe79c36375233a32c61", "class_name": "RelatedNodeInfo"}}, "text": "As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE. ", "start_char_idx": 1337, "end_char_idx": 1472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "718b230a-aeef-49ae-a2b6-77244d579c85": {"__data__": {"id_": "718b230a-aeef-49ae-a2b6-77244d579c85", "embedding": null, "metadata": {"window": "Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine. ", "original_text": "We expect to see shift in volumes, \nwhich we anticipate will moderate. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09ac6bb2-16db-41cd-b1ac-cbb32a032bb9", "node_type": "1", "metadata": {"window": "In our International segment, we now expect a \nrevenue declin e of 5% to 9% year -over-year and segment adjusted operating profit to be 1% to 3% growth.  \n \n Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n", "original_text": "As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "048fcb48ea41c286162b6b15397b19365c2747325ab00462a7a37dab96329180", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8208c04-0e27-46ff-90a4-5b1caf9a6313", "node_type": "1", "metadata": {"window": "The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%. ", "original_text": "We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n"}, "hash": "9c4abc3dfad9035da276100792431de237d9426408a5bde67ea43a6535fe76d8", "class_name": "RelatedNodeInfo"}}, "text": "We expect to see shift in volumes, \nwhich we anticipate will moderate. ", "start_char_idx": 1472, "end_char_idx": 1543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8208c04-0e27-46ff-90a4-5b1caf9a6313": {"__data__": {"id_": "d8208c04-0e27-46ff-90a4-5b1caf9a6313", "embedding": null, "metadata": {"window": "The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%. ", "original_text": "We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "718b230a-aeef-49ae-a2b6-77244d579c85", "node_type": "1", "metadata": {"window": "Let me now turn to Medical -Surgical.  The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine. ", "original_text": "We expect to see shift in volumes, \nwhich we anticipate will moderate. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbde2f140628133f7601b6f6b3c1d6d096f83896aedf11a4829952137a926525", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fbe613b-9c45-4e88-8195-dc43c017467f", "node_type": "1", "metadata": {"window": "As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n", "original_text": "During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n"}, "hash": "a6652db4973b45de0be72b649182afaea6a3a7b96c7b203276ce626e50dcee80", "class_name": "RelatedNodeInfo"}}, "text": "We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n", "start_char_idx": 1543, "end_char_idx": 1717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fbe613b-9c45-4e88-8195-dc43c017467f": {"__data__": {"id_": "4fbe613b-9c45-4e88-8195-dc43c017467f", "embedding": null, "metadata": {"window": "As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n", "original_text": "During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8208c04-0e27-46ff-90a4-5b1caf9a6313", "node_type": "1", "metadata": {"window": "The shifting pattern and recovery path of COVID -19 remains a pivotable \nvariable within the Medical -Surgical supply market.  As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%. ", "original_text": "We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b6364d8f66daf5b4854b108fd64a050c240bfa114d0aaec959dae1dc1e0d55d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fac9ecaf-cde6-4114-8aa8-27b052876f74", "node_type": "1", "metadata": {"window": "We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year. ", "original_text": "Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine. "}, "hash": "f4dbaf567d1c37a350bb2e33fa8edb27223adfd5b63f25a06135f9d5c72677b7", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n", "start_char_idx": 1717, "end_char_idx": 1948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fac9ecaf-cde6-4114-8aa8-27b052876f74": {"__data__": {"id_": "fac9ecaf-cde6-4114-8aa8-27b052876f74", "embedding": null, "metadata": {"window": "We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year. ", "original_text": "Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fbe613b-9c45-4e88-8195-dc43c017467f", "node_type": "1", "metadata": {"window": "As I referenced earlier, throughout the third quarter, we \ncontinued to see elevated levels of demand for COVID -19 test kits and PPE.  We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n", "original_text": "During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5cc36bd3ad48c12b678f8925dcca333412e2d8e016620e765f93288d908aa67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93213fdd-9f12-43d8-a375-313ca2868edb", "node_type": "1", "metadata": {"window": "We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n", "original_text": "Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%. "}, "hash": "e2e87553f4c5e273ae8078ac36e2959f42eec89552b74e4295e58ce4e9adb1f6", "class_name": "RelatedNodeInfo"}}, "text": "Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine. ", "start_char_idx": 1948, "end_char_idx": 2133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93213fdd-9f12-43d8-a375-313ca2868edb": {"__data__": {"id_": "93213fdd-9f12-43d8-a375-313ca2868edb", "embedding": null, "metadata": {"window": "We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n", "original_text": "Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fac9ecaf-cde6-4114-8aa8-27b052876f74", "node_type": "1", "metadata": {"window": "We expect to see shift in volumes, \nwhich we anticipate will moderate.  We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year. ", "original_text": "Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96a28b25c8c775b0c24a3c85f36e35c0b4955f1b937e40a499e87b1b43c1deec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "935678a8-88d8-4056-8b91-d9c16c35dcbd", "node_type": "1", "metadata": {"window": "During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment. ", "original_text": "And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n"}, "hash": "afe58493d12488b4007a2c9f97f8f0159e742cdb159353178cef1e641aa3528c", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%. ", "start_char_idx": 2133, "end_char_idx": 2238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "935678a8-88d8-4056-8b91-d9c16c35dcbd": {"__data__": {"id_": "935678a8-88d8-4056-8b91-d9c16c35dcbd", "embedding": null, "metadata": {"window": "During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment. ", "original_text": "And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93213fdd-9f12-43d8-a375-313ca2868edb", "node_type": "1", "metadata": {"window": "We expect these sales to be a near -term opportunity in the  segment, and \nelevated levels of demand are factored into our guidance for the remainder of our fiscal year.  \n \n During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n", "original_text": "Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f13dcce1e1eeb8d38e21d555af60cc6853930f4a48bb85155fca1e7e299b4b7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb766495-fdfa-4a66-be9d-afec306a30f5", "node_type": "1", "metadata": {"window": "Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion. ", "original_text": "In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year. "}, "hash": "755318d7d741d616961676e1b54d8cd148e47a5419b13b9c054b0817606adfd8", "class_name": "RelatedNodeInfo"}}, "text": "And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n", "start_char_idx": 2238, "end_char_idx": 2509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb766495-fdfa-4a66-be9d-afec306a30f5": {"__data__": {"id_": "cb766495-fdfa-4a66-be9d-afec306a30f5", "embedding": null, "metadata": {"window": "Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion. ", "original_text": "In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "935678a8-88d8-4056-8b91-d9c16c35dcbd", "node_type": "1", "metadata": {"window": "During the quarter, we expanded our contract with HHS for the assembly and storage of COVID -19 ancillary \nsupply kit and also contracted with Pfize r to distribute ancillary kits directed to administration sites on their behalf. \n Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment. ", "original_text": "And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5bf1bc88d470b6e53492222d8105684f1efb65a75ee178d271381b44af03b6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adb3dae9-d685-42fe-b238-9dbc984b8cae", "node_type": "1", "metadata": {"window": "Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year. ", "original_text": "And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n"}, "hash": "952342a600e477e6656df4513b2701c46f4c1a09271bda3bb9ae2e5c8b3d363b", "class_name": "RelatedNodeInfo"}}, "text": "In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year. ", "start_char_idx": 2509, "end_char_idx": 2681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adb3dae9-d685-42fe-b238-9dbc984b8cae": {"__data__": {"id_": "adb3dae9-d685-42fe-b238-9dbc984b8cae", "embedding": null, "metadata": {"window": "Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year. ", "original_text": "And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb766495-fdfa-4a66-be9d-afec306a30f5", "node_type": "1", "metadata": {"window": "Due to this expanded scope, we now expect a benefit of approximately $0.20 to $0.30 in FY 2021 related to the \nkitting and distribution of ancillary supplies for the COVID -19 vaccine.  Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion. ", "original_text": "In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e5fc587d02d7909fc4569c0ce7c385656625b3bbe4ac731aa2cea2150b170c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b197093-1f03-41ef-a52e-420c83a259ea", "node_type": "1", "metadata": {"window": "And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases. ", "original_text": "Let me wrap up our outlook with capital deployment. "}, "hash": "caf365de780bae1933bd404f727625103a3e0bd616a31d1a885ffbc8ace367c6", "class_name": "RelatedNodeInfo"}}, "text": "And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n", "start_char_idx": 2681, "end_char_idx": 2778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b197093-1f03-41ef-a52e-420c83a259ea": {"__data__": {"id_": "3b197093-1f03-41ef-a52e-420c83a259ea", "embedding": null, "metadata": {"window": "And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases. ", "original_text": "Let me wrap up our outlook with capital deployment. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adb3dae9-d685-42fe-b238-9dbc984b8cae", "node_type": "1", "metadata": {"window": "Therefore, we now expect fiscal 2021 \nMedical -Surgical segment revenue to increase between 27% and 32%.  And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year. ", "original_text": "And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ecd491d698b770a16aac72bd5c023253c28d67809984225d713b7ecf9f1b77d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b806e4cc-79b7-430c-b4f2-8c83fd7bb36e", "node_type": "1", "metadata": {"window": "In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n", "original_text": "We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion. "}, "hash": "987dc21ba679cdf620f328bef9b924e46d6685ef2d5c25d528d15c916d0af9b3", "class_name": "RelatedNodeInfo"}}, "text": "Let me wrap up our outlook with capital deployment. ", "start_char_idx": 2778, "end_char_idx": 2830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b806e4cc-79b7-430c-b4f2-8c83fd7bb36e": {"__data__": {"id_": "b806e4cc-79b7-430c-b4f2-8c83fd7bb36e", "embedding": null, "metadata": {"window": "In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n", "original_text": "We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b197093-1f03-41ef-a52e-420c83a259ea", "node_type": "1", "metadata": {"window": "And as a result of our improved third \nquarter performance and outlook, including the increase in our expected contribution from the kitting and \ndistribution of ancillary vaccine supply, we now expect adjusted operating profit will grow in the range of 29% to \n37%.  \n \n In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases. ", "original_text": "Let me wrap up our outlook with capital deployment. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10af19da751f85a2766b76107c22bd7641492fa52454f048c8d6f859561c733c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1076b4c-5d26-44a5-9d12-b988536e544b", "node_type": "1", "metadata": {"window": "And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate. ", "original_text": "As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year. "}, "hash": "e1a7fd15f3f482a1985681be620c8fbe22cb1ded1837944cd95c5dd46fdc4857", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion. ", "start_char_idx": 2830, "end_char_idx": 2916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1076b4c-5d26-44a5-9d12-b988536e544b": {"__data__": {"id_": "f1076b4c-5d26-44a5-9d12-b988536e544b", "embedding": null, "metadata": {"window": "And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate. ", "original_text": "As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b806e4cc-79b7-430c-b4f2-8c83fd7bb36e", "node_type": "1", "metadata": {"window": "In our Prescription Technology Solutions segment, we expect revenue to grow 5% to 8% and now expect \nadjusted operating profit to be appr oximately flat to the prior year.  And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n", "original_text": "We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d23f8f123a19e186e81f7e5c9661411bec8e4e8e0cf16abbba238454032d6d59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95f1a12f-6931-4a3e-8138-8f01b9c813ad", "node_type": "1", "metadata": {"window": "Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n", "original_text": "This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases. "}, "hash": "5113fd9b5e2a175c2b157b3198cf7338e521a136223116c0b1006e4fdb00da00", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year. ", "start_char_idx": 2916, "end_char_idx": 3030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95f1a12f-6931-4a3e-8138-8f01b9c813ad": {"__data__": {"id_": "95f1a12f-6931-4a3e-8138-8f01b9c813ad", "embedding": null, "metadata": {"window": "Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n", "original_text": "This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1076b4c-5d26-44a5-9d12-b988536e544b", "node_type": "1", "metadata": {"window": "And finally, we now expect corporate expenses \nin the range of $645 million to $685 million.  \n \n Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate. ", "original_text": "As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "825fee15d62e936fb21964710510c5f6e5000a31ed916ff82c91fcd0a2f7ed0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b555871-fb62-4f8e-bb8b-9b9db9d5ea50", "node_type": "1", "metadata": {"window": "We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year. ", "original_text": "Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n"}, "hash": "2763ef5f8efe3ec8f183cd5f19d3f64f118a5fd19fb2fe7b80225c9a5bd1745e", "class_name": "RelatedNodeInfo"}}, "text": "This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases. ", "start_char_idx": 3030, "end_char_idx": 3367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b555871-fb62-4f8e-bb8b-9b9db9d5ea50": {"__data__": {"id_": "2b555871-fb62-4f8e-bb8b-9b9db9d5ea50", "embedding": null, "metadata": {"window": "We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year. ", "original_text": "Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95f1a12f-6931-4a3e-8138-8f01b9c813ad", "node_type": "1", "metadata": {"window": "Let me wrap up our outlook with capital deployment.  We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n", "original_text": "This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ac6109bcb1eef88e54f2dac83e2a60197cd277021f5a0da8b1015d4d7119953", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59211d96-3276-49a2-840b-5e0b097ecbb2", "node_type": "1", "metadata": {"window": "As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop. ", "original_text": "In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate. "}, "hash": "7fe6211a5fed4d60401b80da81ba366b074877fb1563875ca07d3d149f14b9a8", "class_name": "RelatedNodeInfo"}}, "text": "Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n", "start_char_idx": 3367, "end_char_idx": 3467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59211d96-3276-49a2-840b-5e0b097ecbb2": {"__data__": {"id_": "59211d96-3276-49a2-840b-5e0b097ecbb2", "embedding": null, "metadata": {"window": "As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop. ", "original_text": "In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b555871-fb62-4f8e-bb8b-9b9db9d5ea50", "node_type": "1", "metadata": {"window": "We continue to expect free cash flow of approximately $2.3 \nbillion to $2.7 bi llion.  As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year. ", "original_text": "Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7f9382f1577dc7afffad9d82f8cf3ca31297fe9f3da008ef7aa10b2332d047b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08165203-81e7-4c98-8f7a-cc783db97bce", "node_type": "1", "metadata": {"window": "This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop.  Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada. ", "original_text": "These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n"}, "hash": "733b4e4b2193b973c3f33b61bdc50a55dd1b0946cdce05e219cebc9292f3d2df", "class_name": "RelatedNodeInfo"}}, "text": "In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate. ", "start_char_idx": 3467, "end_char_idx": 3624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08165203-81e7-4c98-8f7a-cc783db97bce": {"__data__": {"id_": "08165203-81e7-4c98-8f7a-cc783db97bce", "embedding": null, "metadata": {"window": "This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop.  Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada. ", "original_text": "These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59211d96-3276-49a2-840b-5e0b097ecbb2", "node_type": "1", "metadata": {"window": "As a reminder, we historically have generated the majority of our cash in the fourth quarter of \nour fiscal year.  This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop. ", "original_text": "In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78ec705fbcdc25c9fc0feb22b0db3b8aec42bc330f0e8ec7a14904f71130f697", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f9b33c4-304c-4a9a-ad16-42e1ca389ae4", "node_type": "1", "metadata": {"window": "Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop.  Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada.  As a proud partner of the US Government in the COVID -19 vaccine effort, we look forward to continuing ", "original_text": "In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year. "}, "hash": "4ac4b2033c9f2e9547e9646a5dbf6ac79e446bfa1d3bb70d02a43b71d681f680", "class_name": "RelatedNodeInfo"}}, "text": "These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n", "start_char_idx": 3624, "end_char_idx": 3775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f9b33c4-304c-4a9a-ad16-42e1ca389ae4": {"__data__": {"id_": "4f9b33c4-304c-4a9a-ad16-42e1ca389ae4", "embedding": null, "metadata": {"window": "Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop.  Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada.  As a proud partner of the US Government in the COVID -19 vaccine effort, we look forward to continuing ", "original_text": "In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08165203-81e7-4c98-8f7a-cc783db97bce", "node_type": "1", "metadata": {"window": "This strong cash flow generation provides the financial flexibility to execute a balanced capital \nallocation approach, investing in our strategies of oncology and biopharma services, positioning our business for \nlong-term growth, while remaining committed to return capital to shareholders through our dividend and share \nrepurchases.  Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop.  Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada. ", "original_text": "These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59bcb8cc7f4d083ac0abb6ea4e7195664a09840c55f5f6dddb3fab2374583b46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd73d913-59df-46a7-b97e-298dcdffd70e", "node_type": "1", "metadata": {"window": "In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop.  Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada.  As a proud partner of the US Government in the COVID -19 vaccine effort, we look forward to continuing ", "original_text": "I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop. "}, "hash": "4c1b40392a3b9f761a4d28bceae190f03169d5bc09694549b6d7ebc6dcf35cf8", "class_name": "RelatedNodeInfo"}}, "text": "In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year. ", "start_char_idx": 3775, "end_char_idx": 3930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd73d913-59df-46a7-b97e-298dcdffd70e": {"__data__": {"id_": "cd73d913-59df-46a7-b97e-298dcdffd70e", "embedding": null, "metadata": {"window": "In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop.  Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada.  As a proud partner of the US Government in the COVID -19 vaccine effort, we look forward to continuing ", "original_text": "I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f9b33c4-304c-4a9a-ad16-42e1ca389ae4", "node_type": "1", "metadata": {"window": "Our investment -grade credit rating remains a priority and underpins our financial flexibility.  \n \n In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop.  Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada.  As a proud partner of the US Government in the COVID -19 vaccine effort, we look forward to continuing ", "original_text": "In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "058a837b067fdc69dc819bed9fd6bf67950c1b328f721d435f68a3baf361b4b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e92e504-a8e6-436b-8b39-a3b480ec14ad", "node_type": "1", "metadata": {"window": "These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop.  Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada.  As a proud partner of the US Government in the COVID -19 vaccine effort, we look forward to continuing ", "original_text": "Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada. "}, "hash": "e2c70ee26bd4f9486995fde0fc2b6447be7b13e7694dbfa116ac361ab7d6754f", "class_name": "RelatedNodeInfo"}}, "text": "I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop. ", "start_char_idx": 3930, "end_char_idx": 4035, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e92e504-a8e6-436b-8b39-a3b480ec14ad": {"__data__": {"id_": "5e92e504-a8e6-436b-8b39-a3b480ec14ad", "embedding": null, "metadata": {"window": "These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop.  Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada.  As a proud partner of the US Government in the COVID -19 vaccine effort, we look forward to continuing ", "original_text": "Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd73d913-59df-46a7-b97e-298dcdffd70e", "node_type": "1", "metadata": {"window": "In Q3, we utilized a portion of our free cash flow to retire approximately $1 billion of debt, and we issued a $500 \nmillion bond at attractive market rate.  These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop.  Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada.  As a proud partner of the US Government in the COVID -19 vaccine effort, we look forward to continuing ", "original_text": "I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a41cb320445d18820e7f7cf4cba57827a9addf37a7d1dedac6d7721324026df1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28c8c488-587e-433f-bd00-409058ae7212", "node_type": "1", "metadata": {"window": "In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop.  Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada.  As a proud partner of the US Government in the COVID -19 vaccine effort, we look forward to continuing ", "original_text": "As a proud partner of the US Government in the COVID -19 vaccine effort, we look forward to continuing "}, "hash": "9e8261de854e9383314fd02c6ab29a465f9ace8918fa4e0b3ecae212ed3ac77a", "class_name": "RelatedNodeInfo"}}, "text": "Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada. ", "start_char_idx": 4035, "end_char_idx": 4242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28c8c488-587e-433f-bd00-409058ae7212": {"__data__": {"id_": "28c8c488-587e-433f-bd00-409058ae7212", "embedding": null, "metadata": {"window": "In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop.  Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada.  As a proud partner of the US Government in the COVID -19 vaccine effort, we look forward to continuing ", "original_text": "As a proud partner of the US Government in the COVID -19 vaccine effort, we look forward to continuing ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e8d0b106d5bfe2a9ad58aa60350fad0e2bdaaa87b43905d36d89c636bde6b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e92e504-a8e6-436b-8b39-a3b480ec14ad", "node_type": "1", "metadata": {"window": "These actions, which were in line with our stated intent to mo destly delever, \nfurther strengthened our balance sheet and our financial position.  \n \n In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop.  Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada.  As a proud partner of the US Government in the COVID -19 vaccine effort, we look forward to continuing ", "original_text": "Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada. ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c90630ee2e19dae4ecb1ace03fed32957969f0c1cccb78db6590e9cd4fde879", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9afb920f-0838-4d74-8b85-2e30c41b577d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "original_text": "McKesson Corp.  "}, "hash": "a31a00b6a6deeb0eb9dab160f85619c725b1188f8afe0f3949f216ded9741251", "class_name": "RelatedNodeInfo"}}, "text": "As a proud partner of the US Government in the COVID -19 vaccine effort, we look forward to continuing ", "start_char_idx": 4242, "end_char_idx": 4345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9afb920f-0838-4d74-8b85-2e30c41b577d": {"__data__": {"id_": "9afb920f-0838-4d74-8b85-2e30c41b577d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28c8c488-587e-433f-bd00-409058ae7212", "node_type": "1", "metadata": {"window": "In closing, we're pleased with the results of our fiscal third quarter and we feel confident in our updated outlook for \nthe remainder of the fiscal year.  I'm proud of our f ocus and execution across the business despite a challenging \nmacroeconomic backdrop.  Investing in the strategies we've outlined remains a priority, as we drive further \ndifferentiation in our positions in oncology and biopharma services, as evidenced by our  continued investment in \nOntada.  As a proud partner of the US Government in the COVID -19 vaccine effort, we look forward to continuing ", "original_text": "As a proud partner of the US Government in the COVID -19 vaccine effort, we look forward to continuing ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0ab04675efea64558a62994a485b015a7915c8aa95670b95535264db338d64d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27371df5-75a0-468b-909f-842e5d0e397d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n"}, "hash": "bc35b25c94dfa2f374c355904c40830866b34bedac3b4b6dc8274d9e39ee02e8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27371df5-75a0-468b-909f-842e5d0e397d": {"__data__": {"id_": "27371df5-75a0-468b-909f-842e5d0e397d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9afb920f-0838-4d74-8b85-2e30c41b577d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b291bd47f831770d41ef6a115ed73268f808324174369621c78ede5948a03d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb333738-60bd-4e45-8bad-9ce7c3588af6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt.  We will now take questions. ", "original_text": "And with that, Holly, let me turn the call back over to you for Q&A.  \n "}, "hash": "82680ae39f9b1cd9ff19f1b24ef3be0c64e607af9b24a8c5fdf3e44285c04505", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n", "start_char_idx": 16, "end_char_idx": 305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb333738-60bd-4e45-8bad-9ce7c3588af6": {"__data__": {"id_": "eb333738-60bd-4e45-8bad-9ce7c3588af6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt.  We will now take questions. ", "original_text": "And with that, Holly, let me turn the call back over to you for Q&A.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27371df5-75a0-468b-909f-842e5d0e397d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d2b065ef746d79930f6cb75f808e1f5121a986f3b7fa9358e0f9f5b8998815c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0fb9584-a411-4e4c-8294-7a90fc0b28f7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt.  We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n"}, "hash": "fad8494ec89f724d436ea77b4ea00d1eff516c714d985cc177f9de2db07600fc", "class_name": "RelatedNodeInfo"}}, "text": "And with that, Holly, let me turn the call back over to you for Q&A.  \n ", "start_char_idx": 305, "end_char_idx": 377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0fb9584-a411-4e4c-8294-7a90fc0b28f7": {"__data__": {"id_": "b0fb9584-a411-4e4c-8294-7a90fc0b28f7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt.  We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb333738-60bd-4e45-8bad-9ce7c3588af6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt.  We will now take questions. ", "original_text": "And with that, Holly, let me turn the call back over to you for Q&A.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd65b418eed53f50893bab135d1a71aa1dd134df518fe639d505ac23d2ef6d7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c701210c-14e4-45af-b0db-76a0de73fe5e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt.  We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n ", "original_text": "Thanks, Britt. "}, "hash": "1c34d28266427890b1306b7770fdbec7c503814469f954d0d2a9eff0e33c2221", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "start_char_idx": 377, "end_char_idx": 737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c701210c-14e4-45af-b0db-76a0de73fe5e": {"__data__": {"id_": "c701210c-14e4-45af-b0db-76a0de73fe5e", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt.  We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n ", "original_text": "Thanks, Britt. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0fb9584-a411-4e4c-8294-7a90fc0b28f7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt.  We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "38e4b02aba4983e4b05cd459fe4f98fbbf7db21c8512a0a9d5a81858f481bc36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de4c30c6-07ec-42ae-9583-8af050b78834", "node_type": "1", "metadata": {"window": "And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt.  We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "We will now take questions. "}, "hash": "7f4ca5920a1681b004c5624d46de8d6f9e99f0b677b8966f9f6786713b0d227a", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Britt. ", "start_char_idx": 737, "end_char_idx": 752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de4c30c6-07ec-42ae-9583-8af050b78834": {"__data__": {"id_": "de4c30c6-07ec-42ae-9583-8af050b78834", "embedding": null, "metadata": {"window": "And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt.  We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "We will now take questions. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c701210c-14e4-45af-b0db-76a0de73fe5e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt.  We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n ", "original_text": "Thanks, Britt. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "273977d36e3d14231245541ff371d43bdb81c99223f86f55378d3c7cd0ec9c8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "314c0f68-87e3-4f90-a338-d95f278d5c6d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt.  We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America. ", "original_text": "In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate. "}, "hash": "daece2b929b065b3a07df86e25cd815c31db5db2b86ef948420c867ec30b37ba", "class_name": "RelatedNodeInfo"}}, "text": "We will now take questions. ", "start_char_idx": 752, "end_char_idx": 780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "314c0f68-87e3-4f90-a338-d95f278d5c6d": {"__data__": {"id_": "314c0f68-87e3-4f90-a338-d95f278d5c6d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt.  We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America. ", "original_text": "In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de4c30c6-07ec-42ae-9583-8af050b78834", "node_type": "1", "metadata": {"window": "And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt.  We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "We will now take questions. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0de24373e4377ef4c8fe5aabcab193a30af8a2ec0258849551304782658425d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52926c40-f213-4065-83bf-77704259f81d", "node_type": "1", "metadata": {"window": "Thanks, Britt.  We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n ", "original_text": "Operator, please go ahead.  \n "}, "hash": "fe040f8238ad844cb197456562249b03e1a19adb23bc60cf880124eb93145db2", "class_name": "RelatedNodeInfo"}}, "text": "In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate. ", "start_char_idx": 780, "end_char_idx": 904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52926c40-f213-4065-83bf-77704259f81d": {"__data__": {"id_": "52926c40-f213-4065-83bf-77704259f81d", "embedding": null, "metadata": {"window": "Thanks, Britt.  We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n ", "original_text": "Operator, please go ahead.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "314c0f68-87e3-4f90-a338-d95f278d5c6d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thanks, Britt.  We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America. ", "original_text": "In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b70a4724f5542fc161251475b6e9814db2c9ab694cb28a9b32bca86802d83e1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aadc36b2-e8a6-4eee-9157-41cf1b9538cb", "node_type": "1", "metadata": {"window": "We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. "}, "hash": "a2d351f8c30a52263ba0247329946d6bd3d753499e8790f2d42d2d2e4befb94c", "class_name": "RelatedNodeInfo"}}, "text": "Operator, please go ahead.  \n ", "start_char_idx": 904, "end_char_idx": 934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aadc36b2-e8a6-4eee-9157-41cf1b9538cb": {"__data__": {"id_": "aadc36b2-e8a6-4eee-9157-41cf1b9538cb", "embedding": null, "metadata": {"window": "We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52926c40-f213-4065-83bf-77704259f81d", "node_type": "1", "metadata": {"window": "Thanks, Britt.  We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n ", "original_text": "Operator, please go ahead.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56f8e33b66cc70049abe466e59e163dc4a45bfe57d724fd0b97002b77100f6d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69b5e25f-c243-4b61-ba9e-4251491995a2", "node_type": "1", "metadata": {"window": "In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning. ", "original_text": "[Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America. "}, "hash": "87f682d67453fc6f0d366aa64e104965bf253fcdd063c7e62e4d4f420711dbc0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "start_char_idx": 934, "end_char_idx": 1247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69b5e25f-c243-4b61-ba9e-4251491995a2": {"__data__": {"id_": "69b5e25f-c243-4b61-ba9e-4251491995a2", "embedding": null, "metadata": {"window": "In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning. ", "original_text": "[Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aadc36b2-e8a6-4eee-9157-41cf1b9538cb", "node_type": "1", "metadata": {"window": "We will now take questions.  In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc17fc8a2d64937af4e6d87fb23948450f0a13cff37015322bbb5afccaf37d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d235b88-c9cf-4a80-852b-6ff65d1c9bde", "node_type": "1", "metadata": {"window": "Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning.  Thanks for all the color and congratulations on the strong results. ", "original_text": "Your line is open.  \n "}, "hash": "e849ccf6775f5f1b89ff897591beb9f6456925df0a4a872e7733a01089402b6b", "class_name": "RelatedNodeInfo"}}, "text": "[Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America. ", "start_char_idx": 1247, "end_char_idx": 1359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d235b88-c9cf-4a80-852b-6ff65d1c9bde": {"__data__": {"id_": "3d235b88-c9cf-4a80-852b-6ff65d1c9bde", "embedding": null, "metadata": {"window": "Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning.  Thanks for all the color and congratulations on the strong results. ", "original_text": "Your line is open.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69b5e25f-c243-4b61-ba9e-4251491995a2", "node_type": "1", "metadata": {"window": "In the interest of time, I ask that you limit yourself to just one question \nto allow others an opportunity to participate.  Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning. ", "original_text": "[Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0df656e12181e01e0a8738e1a269c8164ff40ebd701ff16999fea85067f875f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93a9f7d6-c223-4b27-9ea8-e2b2b7a3c664", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning.  Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  "}, "hash": "386a4db6a7c0f47cad1e06931e15c296e8005786718e158871b9fa12e2504e6b", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n ", "start_char_idx": 1359, "end_char_idx": 1381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93a9f7d6-c223-4b27-9ea8-e2b2b7a3c664": {"__data__": {"id_": "93a9f7d6-c223-4b27-9ea8-e2b2b7a3c664", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning.  Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d235b88-c9cf-4a80-852b-6ff65d1c9bde", "node_type": "1", "metadata": {"window": "Operator, please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning.  Thanks for all the color and congratulations on the strong results. ", "original_text": "Your line is open.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82efcc3d5af00ac5616f5312a9b2a5538e9ac789ae499c184b21a12b10cf1b87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cefdb178-fb58-49c2-8aef-6a225c5f0484", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning.  Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n ", "original_text": "Q \nGood morning. "}, "hash": "8c2270a1bbcb3caaf27dbaf61bcc58965f4716099d7ab817b28d6389c19bad45", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "start_char_idx": 1381, "end_char_idx": 1687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cefdb178-fb58-49c2-8aef-6a225c5f0484": {"__data__": {"id_": "cefdb178-fb58-49c2-8aef-6a225c5f0484", "embedding": null, "metadata": {"window": "[Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning.  Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n ", "original_text": "Q \nGood morning. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93a9f7d6-c223-4b27-9ea8-e2b2b7a3c664", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning.  Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "475ef10e5bd7b21dcdd52df6ce56cae5234b1ab762e091eec08c5453c41f8c8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83b3640b-cde9-4e5c-abec-8d63ea7e738e", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning.  Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Thanks for all the color and congratulations on the strong results. "}, "hash": "3c526dff20280abb1a2b3b21a11eaa42d364ad00cc8ca0e83e31622a6e66cdf9", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGood morning. ", "start_char_idx": 1687, "end_char_idx": 1704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83b3640b-cde9-4e5c-abec-8d63ea7e738e": {"__data__": {"id_": "83b3640b-cde9-4e5c-abec-8d63ea7e738e", "embedding": null, "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning.  Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Thanks for all the color and congratulations on the strong results. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cefdb178-fb58-49c2-8aef-6a225c5f0484", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question will come from the line of Michael Cherny \nwith Bank of America.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning.  Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n ", "original_text": "Q \nGood morning. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "812cd84d908d7c841ad3601b7c371fddfb87c1cce2d867fc7047f1d336f70f3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59593de9-88c3-46e0-99e1-beac873081f1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning.  Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure. ", "original_text": "I want to dive in a little, if I can, \nto the pharma segment profit. "}, "hash": "576a6143ea07b72414e131e16ce0127fa23f868d9a352db8c73ca642db182a39", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for all the color and congratulations on the strong results. ", "start_char_idx": 1704, "end_char_idx": 1772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59593de9-88c3-46e0-99e1-beac873081f1": {"__data__": {"id_": "59593de9-88c3-46e0-99e1-beac873081f1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning.  Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure. ", "original_text": "I want to dive in a little, if I can, \nto the pharma segment profit. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83b3640b-cde9-4e5c-abec-8d63ea7e738e", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning.  Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Thanks for all the color and congratulations on the strong results. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2bba917c1ef64d97a255ecbc3c305fd564142c60acb9d58ec25d8a74f3c3abf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a228f731-1d24-4210-b2d6-631581311675", "node_type": "1", "metadata": {"window": "Q \nGood morning.  Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Let me start and Britt can add any color. ", "original_text": "Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n "}, "hash": "a651cdd5bc6871951f856fbfcdd664899687ac2b4c236780b48ddfbc6d56eb8c", "class_name": "RelatedNodeInfo"}}, "text": "I want to dive in a little, if I can, \nto the pharma segment profit. ", "start_char_idx": 1772, "end_char_idx": 1841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a228f731-1d24-4210-b2d6-631581311675": {"__data__": {"id_": "a228f731-1d24-4210-b2d6-631581311675", "embedding": null, "metadata": {"window": "Q \nGood morning.  Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Let me start and Britt can add any color. ", "original_text": "Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59593de9-88c3-46e0-99e1-beac873081f1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood morning.  Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure. ", "original_text": "I want to dive in a little, if I can, \nto the pharma segment profit. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ca350ac352406774678ec5409f21ae6bc3cc0939cabe939c99053c82553ff34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1ba0c46-5568-4194-a032-16b118879150", "node_type": "1", "metadata": {"window": "Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "6ecc8f2c4cb9503a7befff0a83d42edab31f15239f832ff8b2f068d39d61a25e", "class_name": "RelatedNodeInfo"}}, "text": "Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n ", "start_char_idx": 1841, "end_char_idx": 2363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1ba0c46-5568-4194-a032-16b118879150": {"__data__": {"id_": "b1ba0c46-5568-4194-a032-16b118879150", "embedding": null, "metadata": {"window": "Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a228f731-1d24-4210-b2d6-631581311675", "node_type": "1", "metadata": {"window": "Q \nGood morning.  Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Let me start and Britt can add any color. ", "original_text": "Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9eea2bfdcff6747741332f0a79d5b19b1134848727c201c07866d5704ef98fb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9170ca6b-c831-4fa1-a555-a7687adde2e0", "node_type": "1", "metadata": {"window": "I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n", "original_text": "A \nSure. "}, "hash": "531a3062fc86b04d45db23f25ecbb5b12d3452108490ef68dbb387ff2003fe75", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2363, "end_char_idx": 2692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9170ca6b-c831-4fa1-a555-a7687adde2e0": {"__data__": {"id_": "9170ca6b-c831-4fa1-a555-a7687adde2e0", "embedding": null, "metadata": {"window": "I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n", "original_text": "A \nSure. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1ba0c46-5568-4194-a032-16b118879150", "node_type": "1", "metadata": {"window": "Thanks for all the color and congratulations on the strong results.  I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7bd6ae9bb67626835afe37ba277b9bebf52c8b275c1a2c4cbf583ccd07199", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "081e83c4-0ef5-4ca3-91eb-c1df33260efb", "node_type": "1", "metadata": {"window": "Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment. ", "original_text": "Let me start and Britt can add any color. "}, "hash": "1c62a66f763e6a06093ffd8b3040d15ee6cd0fd2f40687705dc23b866342b81b", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure. ", "start_char_idx": 2692, "end_char_idx": 2701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "081e83c4-0ef5-4ca3-91eb-c1df33260efb": {"__data__": {"id_": "081e83c4-0ef5-4ca3-91eb-c1df33260efb", "embedding": null, "metadata": {"window": "Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment. ", "original_text": "Let me start and Britt can add any color. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9170ca6b-c831-4fa1-a555-a7687adde2e0", "node_type": "1", "metadata": {"window": "I want to dive in a little, if I can, \nto the pharma segment profit.  Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n", "original_text": "A \nSure. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97c5b2019f4f2d42cbb54989788e7765bf34fe75aaeff458f7341add98516460", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a72874d-3f00-4ec2-87b7-59e5221cba70", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment. ", "original_text": "I mean, we're very pleased with the results from our core \nPharmaceutical business. "}, "hash": "51eba934fc8f3860fbe0abbe97770a565ac546bc6ee9f81bd97f1091c12a2694", "class_name": "RelatedNodeInfo"}}, "text": "Let me start and Britt can add any color. ", "start_char_idx": 2701, "end_char_idx": 2743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a72874d-3f00-4ec2-87b7-59e5221cba70": {"__data__": {"id_": "2a72874d-3f00-4ec2-87b7-59e5221cba70", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment. ", "original_text": "I mean, we're very pleased with the results from our core \nPharmaceutical business. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "081e83c4-0ef5-4ca3-91eb-c1df33260efb", "node_type": "1", "metadata": {"window": "Given the moving pieces you had in the investments in that segments, also with \nobviously the offset of the COVID vaccine, can you just give us in terms of how you think about the implications \nfor 4Q growth and also with all the market dynamics in place, how the trajectory should progress on the core \npharma side and packing out the puts and takes in terms of directionally or conceptually on the volume side \nversus some of the strategic investments versus the COVID benefits that you'll be seeing in that segment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment. ", "original_text": "Let me start and Britt can add any color. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8be4e351c387bf71684a2797c4f5e3fdd07262a054cdeebe9d07d798f0593548", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db9c89f0-9275-4d37-94b4-ae6ee2e65e48", "node_type": "1", "metadata": {"window": "A \nSure.  Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures. ", "original_text": "I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n"}, "hash": "7fa438a6d969bcbf9d69b406c80271206a85abf29e134f08f8d12d6f70c65c2b", "class_name": "RelatedNodeInfo"}}, "text": "I mean, we're very pleased with the results from our core \nPharmaceutical business. ", "start_char_idx": 2743, "end_char_idx": 2827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db9c89f0-9275-4d37-94b4-ae6ee2e65e48": {"__data__": {"id_": "db9c89f0-9275-4d37-94b4-ae6ee2e65e48", "embedding": null, "metadata": {"window": "A \nSure.  Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures. ", "original_text": "I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a72874d-3f00-4ec2-87b7-59e5221cba70", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure.  Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment. ", "original_text": "I mean, we're very pleased with the results from our core \nPharmaceutical business. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c0c35f9e691714df728dc5b065cdf8c9596c4c2f566becd3a105fcacae11fa5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9470000-7397-471f-a8d1-d9c404f65f38", "node_type": "1", "metadata": {"window": "Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n ", "original_text": "I mean, we're continuing to invest in this segment. "}, "hash": "e4b54474359ccccde579fb02618edf1b951f353510da3ba80886e08a64125c7e", "class_name": "RelatedNodeInfo"}}, "text": "I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n", "start_char_idx": 2827, "end_char_idx": 3209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9470000-7397-471f-a8d1-d9c404f65f38": {"__data__": {"id_": "c9470000-7397-471f-a8d1-d9c404f65f38", "embedding": null, "metadata": {"window": "Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n ", "original_text": "I mean, we're continuing to invest in this segment. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db9c89f0-9275-4d37-94b4-ae6ee2e65e48", "node_type": "1", "metadata": {"window": "A \nSure.  Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures. ", "original_text": "I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "892e808d1cb312274e2c008c9625e9fe950723c16d756f0284a51fb6008d0be0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc3c0d4c-267a-4846-9a3f-8780dd2e6f30", "node_type": "1", "metadata": {"window": "I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment. "}, "hash": "7514a33ab2612be07044a2787054fec3c926f3dcfb8885be7ea69525d7dc5f6b", "class_name": "RelatedNodeInfo"}}, "text": "I mean, we're continuing to invest in this segment. ", "start_char_idx": 3209, "end_char_idx": 3261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc3c0d4c-267a-4846-9a3f-8780dd2e6f30": {"__data__": {"id_": "dc3c0d4c-267a-4846-9a3f-8780dd2e6f30", "embedding": null, "metadata": {"window": "I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9470000-7397-471f-a8d1-d9c404f65f38", "node_type": "1", "metadata": {"window": "Let me start and Britt can add any color.  I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n ", "original_text": "I mean, we're continuing to invest in this segment. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e21954ed5ea3bbc3fcda79009af31d4c10911a39034dc93258b0bc66b72b32d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "abe2ae4a-91e4-496e-8615-04fc0ade0fdc", "node_type": "1", "metadata": {"window": "I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures. "}, "hash": "6387f89d06d239bcfa0702102a7c5a6d9a7f246d80ef2e92c1e625faebdd6bcb", "class_name": "RelatedNodeInfo"}}, "text": "And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment. ", "start_char_idx": 3261, "end_char_idx": 3532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "abe2ae4a-91e4-496e-8615-04fc0ade0fdc": {"__data__": {"id_": "abe2ae4a-91e4-496e-8615-04fc0ade0fdc", "embedding": null, "metadata": {"window": "I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc3c0d4c-267a-4846-9a3f-8780dd2e6f30", "node_type": "1", "metadata": {"window": "I mean, we're very pleased with the results from our core \nPharmaceutical business.  I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b682da631f458371b8daa7f4c2d5df7072de055ab7618d1bf7e889dd0d6a608", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7730d5ba-a801-4c40-a53c-3a3b6f2f2fc7", "node_type": "1", "metadata": {"window": "I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter. ", "original_text": "But overall, \nwe're very pleased with the progress of this segment.  \n "}, "hash": "91fd2fc6bac459dbd98bfe7fefca5c0b902e9acc0b9a59949f840f6d08a6c860", "class_name": "RelatedNodeInfo"}}, "text": "So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures. ", "start_char_idx": 3532, "end_char_idx": 3774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7730d5ba-a801-4c40-a53c-3a3b6f2f2fc7": {"__data__": {"id_": "7730d5ba-a801-4c40-a53c-3a3b6f2f2fc7", "embedding": null, "metadata": {"window": "I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter. ", "original_text": "But overall, \nwe're very pleased with the progress of this segment.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "abe2ae4a-91e4-496e-8615-04fc0ade0fdc", "node_type": "1", "metadata": {"window": "I think we see that kind of step back from COVID impacts, we'd sa y market \nfundamentals are consistent with where we thought they would be in the beginning of the year, brand price \ninflation in line with the dynamics that we see in the generics marketplace, both in terms of our go -to-market \nstrategies and our sourcing ca pabilities, we're pleased to see where they're at.  \n \n I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c077768ac281c21969f81dd7184fdf9eb6ae70ddb1c19239634d8f55ef45ef47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "631ae70a-2e90-4f79-8a80-529ceac6aa77", "node_type": "1", "metadata": {"window": "And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter.  So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "0b2e22f238a40f094f6c6c06ce5d769b334b8fe9a69c3c0fca7186f848c64014", "class_name": "RelatedNodeInfo"}}, "text": "But overall, \nwe're very pleased with the progress of this segment.  \n ", "start_char_idx": 3774, "end_char_idx": 3845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "631ae70a-2e90-4f79-8a80-529ceac6aa77": {"__data__": {"id_": "631ae70a-2e90-4f79-8a80-529ceac6aa77", "embedding": null, "metadata": {"window": "And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter.  So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7730d5ba-a801-4c40-a53c-3a3b6f2f2fc7", "node_type": "1", "metadata": {"window": "I mean, we're continuing to invest in this segment.  And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter. ", "original_text": "But overall, \nwe're very pleased with the progress of this segment.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89d12f3f252758dca1b7e6c06ce406701f359ab0fc4ea74d8f44bb06cfe5b9a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a841b3d6-81b1-4434-935c-01c523d6ff72", "node_type": "1", "metadata": {"window": "So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter.  So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth.  As Brian mentioned, we continue to invest. ", "original_text": "A \nYeah. "}, "hash": "285008079012f9ea1f489c462117ed64177207c8ad8591bcaeee94180f856b53", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 3845, "end_char_idx": 4190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a841b3d6-81b1-4434-935c-01c523d6ff72": {"__data__": {"id_": "a841b3d6-81b1-4434-935c-01c523d6ff72", "embedding": null, "metadata": {"window": "So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter.  So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth.  As Brian mentioned, we continue to invest. ", "original_text": "A \nYeah. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "631ae70a-2e90-4f79-8a80-529ceac6aa77", "node_type": "1", "metadata": {"window": "And that investment particularly in the area of oncology comes \nat the expense of a little bit of what could be operating profit growth, but we think tha t that's very important \ninvestment to make for the long -term positioning and the long -term growth of the segment.  So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter.  So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "828ed47abfa611524f6d8c6f4c91488d6939138fe167a498a4ea061293ea67f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34d7b68e-a660-41cc-bbb0-d4d8f4091754", "node_type": "1", "metadata": {"window": "But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter.  So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth.  As Brian mentioned, we continue to invest. ", "original_text": "Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter. "}, "hash": "ce234da8dd112660b01a93dd6ce95f0f94a0e7cc383dcd7b26286b999c03a374", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 4190, "end_char_idx": 4199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34d7b68e-a660-41cc-bbb0-d4d8f4091754": {"__data__": {"id_": "34d7b68e-a660-41cc-bbb0-d4d8f4091754", "embedding": null, "metadata": {"window": "But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter.  So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth.  As Brian mentioned, we continue to invest. ", "original_text": "Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a841b3d6-81b1-4434-935c-01c523d6ff72", "node_type": "1", "metadata": {"window": "So I think, in general, \neverybody recognizes that cold and cough and flu season was a little bit lighter than what we would historically \nhave seen, probably the result of the social responsibility, social distancing, mask wearing measures.  But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter.  So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth.  As Brian mentioned, we continue to invest. ", "original_text": "A \nYeah. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ac8179d8d8117e2ad9f7f9b81e34f9d72ba12c6d7e0a0bfbd84078fe513859f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8b818ff-65fe-4349-b7e5-0680aaefb3f7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter.  So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth.  As Brian mentioned, we continue to invest. ", "original_text": "So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth. "}, "hash": "03d97573311108fd7f0afae9ed931e9b524bdd63ab39c4ddf88f6cc9def61cd8", "class_name": "RelatedNodeInfo"}}, "text": "Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter. ", "start_char_idx": 4199, "end_char_idx": 4468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8b818ff-65fe-4349-b7e5-0680aaefb3f7": {"__data__": {"id_": "d8b818ff-65fe-4349-b7e5-0680aaefb3f7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter.  So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth.  As Brian mentioned, we continue to invest. ", "original_text": "So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34d7b68e-a660-41cc-bbb0-d4d8f4091754", "node_type": "1", "metadata": {"window": "But overall, \nwe're very pleased with the progress of this segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter.  So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth.  As Brian mentioned, we continue to invest. ", "original_text": "Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d1616e92f254d414652438fe4f6f4e10697e040232c12b453ed69f19793461d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29182047-0b72-42f4-a9ce-5f22f7c374b5", "node_type": "1", "metadata": {"window": "A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter.  So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth.  As Brian mentioned, we continue to invest. ", "original_text": "As Brian mentioned, we continue to invest. "}, "hash": "ea6d3782ff904409e4feadb6b0d01abb228a2b119bbe0ae34b3830f77063b62c", "class_name": "RelatedNodeInfo"}}, "text": "So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth. ", "start_char_idx": 4468, "end_char_idx": 4601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29182047-0b72-42f4-a9ce-5f22f7c374b5": {"__data__": {"id_": "29182047-0b72-42f4-a9ce-5f22f7c374b5", "embedding": null, "metadata": {"window": "A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter.  So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth.  As Brian mentioned, we continue to invest. ", "original_text": "As Brian mentioned, we continue to invest. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87d438ae22ffa755276ace9801d1e65e230ba37afac64991106704b5fb28df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8b818ff-65fe-4349-b7e5-0680aaefb3f7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter.  So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth.  As Brian mentioned, we continue to invest. ", "original_text": "So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06ed097521a94a65f3853a79d6d19f451bfafc3af7c2d69fe2417d38ba507672", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "458e00ca-0ad7-4468-9437-c4f31b16b0ad", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada.  So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n ", "original_text": "McKesson Corp.  "}, "hash": "2c8225a72d2fa5d3b951452e6d85e1f0dbb55168626f07ac3c833de77baad0ef", "class_name": "RelatedNodeInfo"}}, "text": "As Brian mentioned, we continue to invest. ", "start_char_idx": 4601, "end_char_idx": 4644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "458e00ca-0ad7-4468-9437-c4f31b16b0ad": {"__data__": {"id_": "458e00ca-0ad7-4468-9437-c4f31b16b0ad", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada.  So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29182047-0b72-42f4-a9ce-5f22f7c374b5", "node_type": "1", "metadata": {"window": "A \nYeah.  Mike, maybe what I would just add is I think part of the trends that we talked about the softening trends in \nQ3 really I think as we go into Q4, a lot of that will depend on how the pandemic continue to persist, but despite \nthat, we continue to grow i n the quarter.  So, our business, despite the kind of lumpiness in the overall \nenvironment, continues to grow and we feel confident in that growth.  As Brian mentioned, we continue to invest. ", "original_text": "As Brian mentioned, we continue to invest. ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33e762abf2e9ccd7ea7b33763010fc415578e23c2a3d5e6780cb1685782a9827", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37197734-21ad-4427-8f67-21b3b00939c1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada.  So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada. "}, "hash": "516b80530d356855a317fe31fd33aec5426b7a7d943393564845c82b32400fcb", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37197734-21ad-4427-8f67-21b3b00939c1": {"__data__": {"id_": "37197734-21ad-4427-8f67-21b3b00939c1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada.  So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "458e00ca-0ad7-4468-9437-c4f31b16b0ad", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada.  So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2cd886bef09b61306c826113f610370c637a3a9783acb389ff2c2db43f517f9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db0476b2-40f4-4bab-9865-9a8c3c4affca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada.  So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n ", "original_text": "So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there. "}, "hash": "d51bc127768e159115825707ffbe03cc23716a7b316838f9389dddfde1c75d82", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada. ", "start_char_idx": 16, "end_char_idx": 264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db0476b2-40f4-4bab-9865-9a8c3c4affca": {"__data__": {"id_": "db0476b2-40f4-4bab-9865-9a8c3c4affca", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada.  So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n ", "original_text": "So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37197734-21ad-4427-8f67-21b3b00939c1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada.  So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6129a7314a09077fdc6d480bcb9d1a1b1046146b2064401eb40256925891a57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8faf4072-c3c9-480a-9de9-af476c63d9f5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada.  So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n ", "original_text": "And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n "}, "hash": "82942b809cd618217c1e01ce505ff0ea72a32f8c1e1f39eac9d58ba7dc413039", "class_name": "RelatedNodeInfo"}}, "text": "So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there. ", "start_char_idx": 264, "end_char_idx": 491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8faf4072-c3c9-480a-9de9-af476c63d9f5": {"__data__": {"id_": "8faf4072-c3c9-480a-9de9-af476c63d9f5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada.  So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n ", "original_text": "And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db0476b2-40f4-4bab-9865-9a8c3c4affca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada.  So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n ", "original_text": "So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "369ba520ae1792d41416ae957111d442b169d7bcebf714b0985ee907e0a968a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d00a49c-15a4-4e47-be26-c8f32de6e7ea", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada.  So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  "}, "hash": "cdee133b0744c71656308f4c1f6d1be7b87af1c307798b5f581c55548e0bb653", "class_name": "RelatedNodeInfo"}}, "text": "And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n ", "start_char_idx": 491, "end_char_idx": 588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d00a49c-15a4-4e47-be26-c8f32de6e7ea": {"__data__": {"id_": "2d00a49c-15a4-4e47-be26-c8f32de6e7ea", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada.  So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8faf4072-c3c9-480a-9de9-af476c63d9f5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada.  So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n ", "original_text": "And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "981c57bce8b18059f5663b8d4e1ec6045a6aebb650902e73defff4915c24a6d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7294f7da-0858-4ff8-9345-f88b7578938d", "node_type": "1", "metadata": {"window": "So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning. ", "original_text": "A \nOperator, next question, please?  \n "}, "hash": "ca209c9e556b552caa9e9bf523695d677dfd3760454f9bf41265e77ad5f90774", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "start_char_idx": 588, "end_char_idx": 947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7294f7da-0858-4ff8-9345-f88b7578938d": {"__data__": {"id_": "7294f7da-0858-4ff8-9345-f88b7578938d", "embedding": null, "metadata": {"window": "So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning. ", "original_text": "A \nOperator, next question, please?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d00a49c-15a4-4e47-be26-c8f32de6e7ea", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada.  So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ed553624d9ee8a4a827ce11eb83ff786332a533ac3b3b4eff512f1171de91a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1beea350-b2f6-4a48-baf1-79f8c0863cf9", "node_type": "1", "metadata": {"window": "And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n "}, "hash": "e099854a01082ccab309d391b7a8e443bb45b7cd17191773ce3799c55b4491ef", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator, next question, please?  \n ", "start_char_idx": 947, "end_char_idx": 986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1beea350-b2f6-4a48-baf1-79f8c0863cf9": {"__data__": {"id_": "1beea350-b2f6-4a48-baf1-79f8c0863cf9", "embedding": null, "metadata": {"window": "And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7294f7da-0858-4ff8-9345-f88b7578938d", "node_type": "1", "metadata": {"window": "So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning. ", "original_text": "A \nOperator, next question, please?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0bab68962000fffc0c613f5c3c1eb125ec119e3911a25b7424c2bfb01076fa5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46884386-6a01-4c93-a661-4110af3ee4b1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. "}, "hash": "8b4591d2d3bdb8cd7b53a721971d2657a9e2d4f7897d1c7e8a509aba52e3fd85", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n ", "start_char_idx": 986, "end_char_idx": 1306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46884386-6a01-4c93-a661-4110af3ee4b1": {"__data__": {"id_": "46884386-6a01-4c93-a661-4110af3ee4b1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1beea350-b2f6-4a48-baf1-79f8c0863cf9", "node_type": "1", "metadata": {"window": "And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79fa89e27bc7395524c7d7f5d5218763b5df318db28947386dcd6a66e9a94fc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb24db04-6d3b-4e7c-b374-a4261f3c7c55", "node_type": "1", "metadata": {"window": "A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35. ", "original_text": "Good morning. "}, "hash": "ed3e91ff213cef3c920e63a2ee128b1b664356197e2fe4a8d699bf48c23c685a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "start_char_idx": 1306, "end_char_idx": 1633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb24db04-6d3b-4e7c-b374-a4261f3c7c55": {"__data__": {"id_": "cb24db04-6d3b-4e7c-b374-a4261f3c7c55", "embedding": null, "metadata": {"window": "A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35. ", "original_text": "Good morning. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46884386-6a01-4c93-a661-4110af3ee4b1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4a67115a63ed31fa0aeae9ad0f505004a04aa7eb55c97c5d2af231439ddd12a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "261143c1-57fe-43c5-b975-91e1a3061ebe", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis? ", "original_text": "So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine. "}, "hash": "aaf7983fa2fbb77e5eaeca1a8a688ace9498874c6080df533a4067a686cd282f", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 1633, "end_char_idx": 1647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "261143c1-57fe-43c5-b975-91e1a3061ebe": {"__data__": {"id_": "261143c1-57fe-43c5-b975-91e1a3061ebe", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis? ", "original_text": "So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb24db04-6d3b-4e7c-b374-a4261f3c7c55", "node_type": "1", "metadata": {"window": "A \nOperator, next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35. ", "original_text": "Good morning. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f74ae4a782d9fcc6b5de5f6e81b2eb9722a7350fb3fa96542d101457cfd7900", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b99929d5-82fe-4de8-91b3-f3446a01312e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis?  Number one.  \n \n", "original_text": "So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter. "}, "hash": "b08215a13d7b2ab4086caf3c969d796a250b16a90144e63fedfb330860b5714a", "class_name": "RelatedNodeInfo"}}, "text": "So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine. ", "start_char_idx": 1647, "end_char_idx": 1787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b99929d5-82fe-4de8-91b3-f3446a01312e": {"__data__": {"id_": "b99929d5-82fe-4de8-91b3-f3446a01312e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis?  Number one.  \n \n", "original_text": "So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "261143c1-57fe-43c5-b975-91e1a3061ebe", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And the next will be Lisa Gill  with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis? ", "original_text": "So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5fff875c29a92b82a3ac156c533695a770ebcca4a8f001986e28adc6736bdb7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b21231a9-411d-4058-acae-7b1969863f22", "node_type": "1", "metadata": {"window": "Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis?  Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well. ", "original_text": "You talked about the $0.25 to \n$0.35. "}, "hash": "d0cc076457301c8e42b8a31ec198b80f6e873ce2d0453d8b2363eceb441baed0", "class_name": "RelatedNodeInfo"}}, "text": "So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter. ", "start_char_idx": 1787, "end_char_idx": 1929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b21231a9-411d-4058-acae-7b1969863f22": {"__data__": {"id_": "b21231a9-411d-4058-acae-7b1969863f22", "embedding": null, "metadata": {"window": "Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis?  Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well. ", "original_text": "You talked about the $0.25 to \n$0.35. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b99929d5-82fe-4de8-91b3-f3446a01312e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis?  Number one.  \n \n", "original_text": "So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8176b24c31da4d32f87e2d336ed966aac6221233f5c946a1dc74ab4fe0e94d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf1f4b2e-4ed0-4ad3-bba9-5246ecc24211", "node_type": "1", "metadata": {"window": "So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis?  Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n ", "original_text": "How do I think about that on a per dose basis? "}, "hash": "350370b8b8e0af7b0138bfe1ba51b9d0b0567fb47b0a19b9c8d1c6fedbdcbe68", "class_name": "RelatedNodeInfo"}}, "text": "You talked about the $0.25 to \n$0.35. ", "start_char_idx": 1929, "end_char_idx": 1967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf1f4b2e-4ed0-4ad3-bba9-5246ecc24211": {"__data__": {"id_": "cf1f4b2e-4ed0-4ad3-bba9-5246ecc24211", "embedding": null, "metadata": {"window": "So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis?  Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n ", "original_text": "How do I think about that on a per dose basis? ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b21231a9-411d-4058-acae-7b1969863f22", "node_type": "1", "metadata": {"window": "Good morning.  So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis?  Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well. ", "original_text": "You talked about the $0.25 to \n$0.35. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ade08cf2dd6fc3a2a26d7ae814a87880bf7cfe91f0af43b4d7191b9286e11931", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "826d38ec-4a0b-4610-b4da-c725b90020fc", "node_type": "1", "metadata": {"window": "So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis?  Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Number one.  \n \n"}, "hash": "50cf8710c41acaa1cce0e6e685f27d3a7ec8f9570634c5202cbf949f35667945", "class_name": "RelatedNodeInfo"}}, "text": "How do I think about that on a per dose basis? ", "start_char_idx": 1967, "end_char_idx": 2014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "826d38ec-4a0b-4610-b4da-c725b90020fc": {"__data__": {"id_": "826d38ec-4a0b-4610-b4da-c725b90020fc", "embedding": null, "metadata": {"window": "So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis?  Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Number one.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf1f4b2e-4ed0-4ad3-bba9-5246ecc24211", "node_type": "1", "metadata": {"window": "So, Britt, I know I asked this a couple of weeks ago at my conference, and \nthat's around the actual profitability per dose on the vaccine.  So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis?  Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n ", "original_text": "How do I think about that on a per dose basis? ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "712f09c550ba92aa788840cfdd96ffd1ab2579f1a6f2578646854eea01011556", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d099745e-4647-4e6a-ac3e-344fa9c028df", "node_type": "1", "metadata": {"window": "You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis?  Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa. ", "original_text": "And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well. "}, "hash": "beeb80779e671d8bd886cfab5efb749977c975f20dbe90e56be04adb253a9283", "class_name": "RelatedNodeInfo"}}, "text": "Number one.  \n \n", "start_char_idx": 2014, "end_char_idx": 2030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d099745e-4647-4e6a-ac3e-344fa9c028df": {"__data__": {"id_": "d099745e-4647-4e6a-ac3e-344fa9c028df", "embedding": null, "metadata": {"window": "You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis?  Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa. ", "original_text": "And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "826d38ec-4a0b-4610-b4da-c725b90020fc", "node_type": "1", "metadata": {"window": "So now that that y ou've given us some numbers, you \ntalked about 25 million doses being on target, not a lot of impact in the third quarter.  You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis?  Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Number one.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d9cc245cf7542a2aaaa3472c713743e38381c307bac8e8eedb3f385109458d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccb860d8-37fc-41ae-b213-535847395450", "node_type": "1", "metadata": {"window": "How do I think about that on a per dose basis?  Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa.  Thank you for that question. ", "original_text": "What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n "}, "hash": "7a867a5e7ce277205a020f8933f82fa11f9682c123d8444adaec16535146dff4", "class_name": "RelatedNodeInfo"}}, "text": "And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well. ", "start_char_idx": 2030, "end_char_idx": 2193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccb860d8-37fc-41ae-b213-535847395450": {"__data__": {"id_": "ccb860d8-37fc-41ae-b213-535847395450", "embedding": null, "metadata": {"window": "How do I think about that on a per dose basis?  Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa.  Thank you for that question. ", "original_text": "What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d099745e-4647-4e6a-ac3e-344fa9c028df", "node_type": "1", "metadata": {"window": "You talked about the $0.25 to \n$0.35.  How do I think about that on a per dose basis?  Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa. ", "original_text": "And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "514aec4c226d0758cd4c6171456730d961bc3c1fcfa1f3d1116b871b9082f800", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53ec5dd8-0629-4470-959b-e7e6e896a4df", "node_type": "1", "metadata": {"window": "Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa.  Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "cac56c16facfd5fc056c8c4d47e1b7246d47eb2849826ee66d741b0f0ea923b5", "class_name": "RelatedNodeInfo"}}, "text": "What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n ", "start_char_idx": 2193, "end_char_idx": 2324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53ec5dd8-0629-4470-959b-e7e6e896a4df": {"__data__": {"id_": "53ec5dd8-0629-4470-959b-e7e6e896a4df", "embedding": null, "metadata": {"window": "Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa.  Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccb860d8-37fc-41ae-b213-535847395450", "node_type": "1", "metadata": {"window": "How do I think about that on a per dose basis?  Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa.  Thank you for that question. ", "original_text": "What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4709eeeb5275970c5fc8f76ad0a7b2100b3e56c39f5a052af61448b07ecd1206", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1bad39a-148c-4dca-a778-20a2e6dfe58f", "node_type": "1", "metadata": {"window": "And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa.  Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify. ", "original_text": "A \nGood morning, Lisa. "}, "hash": "e78cab1097ccd3742a49a07135679826dbe802440285cb8e085c4001c92d35e2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2324, "end_char_idx": 2669, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1bad39a-148c-4dca-a778-20a2e6dfe58f": {"__data__": {"id_": "d1bad39a-148c-4dca-a778-20a2e6dfe58f", "embedding": null, "metadata": {"window": "And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa.  Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify. ", "original_text": "A \nGood morning, Lisa. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53ec5dd8-0629-4470-959b-e7e6e896a4df", "node_type": "1", "metadata": {"window": "Number one.  \n \n And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa.  Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba198a743c4109abef11068a0a148f618c0c9d5762a724895ff62babc5322e24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f043f4b-a524-46da-8075-0e37b1fffa36", "node_type": "1", "metadata": {"window": "What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa.  Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary. ", "original_text": "Thank you for that question. "}, "hash": "95f3f677e650f84cec96b1f3657fc8cf0a49a37b809404da365cd5b40ab9d3fd", "class_name": "RelatedNodeInfo"}}, "text": "A \nGood morning, Lisa. ", "start_char_idx": 2669, "end_char_idx": 2692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f043f4b-a524-46da-8075-0e37b1fffa36": {"__data__": {"id_": "6f043f4b-a524-46da-8075-0e37b1fffa36", "embedding": null, "metadata": {"window": "What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa.  Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary. ", "original_text": "Thank you for that question. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1bad39a-148c-4dca-a778-20a2e6dfe58f", "node_type": "1", "metadata": {"window": "And then number two, there's been som e news articles talking about your two chief competitors saying, hey, we'll \nhelp out with the vaccine distribution as well.  What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa.  Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify. ", "original_text": "A \nGood morning, Lisa. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18a59747d58d7b3cc9ffa161bcc830aeed6904dd017396fc8e610e30d3fdcd9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd200555-38d5-474e-9994-aec798e47a12", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa.  Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results. ", "original_text": "Let me start and I think Brian will probably want to tackle on \nsome of your later questions. "}, "hash": "564b23d90d7241a0c40f6a7cddc15c6d22cea1f1631a812c6f6ac279631fe125", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for that question. ", "start_char_idx": 2692, "end_char_idx": 2721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd200555-38d5-474e-9994-aec798e47a12": {"__data__": {"id_": "dd200555-38d5-474e-9994-aec798e47a12", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa.  Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results. ", "original_text": "Let me start and I think Brian will probably want to tackle on \nsome of your later questions. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f043f4b-a524-46da-8075-0e37b1fffa36", "node_type": "1", "metadata": {"window": "What would that potentially do as far as the amount of volume that \nMcKesson would potentially get given your current contract?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa.  Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary. ", "original_text": "Thank you for that question. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e72c713371d0efdaaab2e6f48d2da539550c6f2fc73c53b8f889646e232c573", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83e2e364-91bd-49d2-9f14-4f81508662bb", "node_type": "1", "metadata": {"window": "A \nGood morning, Lisa.  Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation. ", "original_text": "Just to clarify. "}, "hash": "e34708d16863dd6b8d96356a620edddd38bd313b910e4010ea684caf8d906268", "class_name": "RelatedNodeInfo"}}, "text": "Let me start and I think Brian will probably want to tackle on \nsome of your later questions. ", "start_char_idx": 2721, "end_char_idx": 2815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83e2e364-91bd-49d2-9f14-4f81508662bb": {"__data__": {"id_": "83e2e364-91bd-49d2-9f14-4f81508662bb", "embedding": null, "metadata": {"window": "A \nGood morning, Lisa.  Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation. ", "original_text": "Just to clarify. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd200555-38d5-474e-9994-aec798e47a12", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Lisa.  Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results. ", "original_text": "Let me start and I think Brian will probably want to tackle on \nsome of your later questions. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2f00487445dda57e25bd72e98d973d9f5da28459c0a002b250a0268e8edbc69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b05999c6-c251-4cfb-9d88-1c77a52b1f66", "node_type": "1", "metadata": {"window": "Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n ", "original_text": "What Bria n talked about in his remarks was 25 million doses through \nJanuary. "}, "hash": "04c2ce81bcae38d21126a4621a9a9180a17efa78026031aa6cff8424d1b655dd", "class_name": "RelatedNodeInfo"}}, "text": "Just to clarify. ", "start_char_idx": 2815, "end_char_idx": 2832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b05999c6-c251-4cfb-9d88-1c77a52b1f66": {"__data__": {"id_": "b05999c6-c251-4cfb-9d88-1c77a52b1f66", "embedding": null, "metadata": {"window": "Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n ", "original_text": "What Bria n talked about in his remarks was 25 million doses through \nJanuary. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83e2e364-91bd-49d2-9f14-4f81508662bb", "node_type": "1", "metadata": {"window": "A \nGood morning, Lisa.  Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation. ", "original_text": "Just to clarify. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "efa4f1a9b090c4eb68bbf80897ab1fe6ec065f61a030cea688fb8db9dc47578f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78c1dff8-b51b-4cfd-a439-546d8ff595a6", "node_type": "1", "metadata": {"window": "Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And as I talked about, the amount that was in our quarter was immaterial to our results. "}, "hash": "f30e972a4ba1a9892d470582d92d4c849ab98fa94c48b69620f0e8831ee0d083", "class_name": "RelatedNodeInfo"}}, "text": "What Bria n talked about in his remarks was 25 million doses through \nJanuary. ", "start_char_idx": 2832, "end_char_idx": 2911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78c1dff8-b51b-4cfd-a439-546d8ff595a6": {"__data__": {"id_": "78c1dff8-b51b-4cfd-a439-546d8ff595a6", "embedding": null, "metadata": {"window": "Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And as I talked about, the amount that was in our quarter was immaterial to our results. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b05999c6-c251-4cfb-9d88-1c77a52b1f66", "node_type": "1", "metadata": {"window": "Thank you for that question.  Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n ", "original_text": "What Bria n talked about in his remarks was 25 million doses through \nJanuary. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a386e23a7eb715ec5da36f525ba2dfa69447e29da2a08dcc9e275b4fa18cc0c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de5fcaf0-0dee-4ea6-a848-cf31e1ef425c", "node_type": "1", "metadata": {"window": "Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated. ", "original_text": "We don't get into \na per dose conversation. "}, "hash": "daf3646a46dccbfa5015cbd9d0349b91f98e04dc914f1d1d0f56547b541aaeb7", "class_name": "RelatedNodeInfo"}}, "text": "And as I talked about, the amount that was in our quarter was immaterial to our results. ", "start_char_idx": 2911, "end_char_idx": 3000, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de5fcaf0-0dee-4ea6-a848-cf31e1ef425c": {"__data__": {"id_": "de5fcaf0-0dee-4ea6-a848-cf31e1ef425c", "embedding": null, "metadata": {"window": "Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated. ", "original_text": "We don't get into \na per dose conversation. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78c1dff8-b51b-4cfd-a439-546d8ff595a6", "node_type": "1", "metadata": {"window": "Let me start and I think Brian will probably want to tackle on \nsome of your later questions.  Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And as I talked about, the amount that was in our quarter was immaterial to our results. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "899a3aff053972ad8b0b637c5d2b412e20db75f021df75f28d211e1ef6a3e588", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e39bbe81-f6c7-4640-91dd-dfbea35ffbac", "node_type": "1", "metadata": {"window": "What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people. ", "original_text": "What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n "}, "hash": "7316d54d099c0f45236e0ad1d8deffe9b288ae9f6a10f42ab9c1e48de58a1546", "class_name": "RelatedNodeInfo"}}, "text": "We don't get into \na per dose conversation. ", "start_char_idx": 3000, "end_char_idx": 3044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e39bbe81-f6c7-4640-91dd-dfbea35ffbac": {"__data__": {"id_": "e39bbe81-f6c7-4640-91dd-dfbea35ffbac", "embedding": null, "metadata": {"window": "What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people. ", "original_text": "What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de5fcaf0-0dee-4ea6-a848-cf31e1ef425c", "node_type": "1", "metadata": {"window": "Just to clarify.  What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated. ", "original_text": "We don't get into \na per dose conversation. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7961d2ef71aac2b12d861708e4de96550d7639e4fa79326af2b8d9269f0d55ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f1f4b81-4aba-4c68-9ccd-7fb10f7a4ee9", "node_type": "1", "metadata": {"window": "And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "8b19087e2959b1a747ee1b8066de0e39f95c17d2e72395e7eed3bb6e9dec56f1", "class_name": "RelatedNodeInfo"}}, "text": "What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n ", "start_char_idx": 3044, "end_char_idx": 3238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f1f4b81-4aba-4c68-9ccd-7fb10f7a4ee9": {"__data__": {"id_": "0f1f4b81-4aba-4c68-9ccd-7fb10f7a4ee9", "embedding": null, "metadata": {"window": "And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e39bbe81-f6c7-4640-91dd-dfbea35ffbac", "node_type": "1", "metadata": {"window": "What Bria n talked about in his remarks was 25 million doses through \nJanuary.  And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people. ", "original_text": "What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27ebf3439764c079f0b60c6db48025fafa1d59ba4edf11439a933af1f9e454af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10c0924e-aa0b-4df2-a36e-47d7809ada5d", "node_type": "1", "metadata": {"window": "We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way. ", "original_text": "A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated. "}, "hash": "ada126a649f85ca9f978f5cef32f4ff8865dd5fd024e91bb03e83fe72a771e9b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3238, "end_char_idx": 3567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10c0924e-aa0b-4df2-a36e-47d7809ada5d": {"__data__": {"id_": "10c0924e-aa0b-4df2-a36e-47d7809ada5d", "embedding": null, "metadata": {"window": "We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way. ", "original_text": "A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f1f4b81-4aba-4c68-9ccd-7fb10f7a4ee9", "node_type": "1", "metadata": {"window": "And as I talked about, the amount that was in our quarter was immaterial to our results.  We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce2e1cfb3d3dea913af590ea95bab7ab7a410137ebed3f81901eff3c8fc6c6c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01e82e06-82c8-4492-bde4-f39589738bf4", "node_type": "1", "metadata": {"window": "What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site. ", "original_text": "In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people. "}, "hash": "e904deecfe4db899b8d7a5f087f8a35315196e7e00e5f7fe70d011487515abf2", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated. ", "start_char_idx": 3567, "end_char_idx": 3810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01e82e06-82c8-4492-bde4-f39589738bf4": {"__data__": {"id_": "01e82e06-82c8-4492-bde4-f39589738bf4", "embedding": null, "metadata": {"window": "What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site. ", "original_text": "In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10c0924e-aa0b-4df2-a36e-47d7809ada5d", "node_type": "1", "metadata": {"window": "We don't get into \na per dose conversation.  What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way. ", "original_text": "A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b78e50439fc1af0adc89ac261adaccb9a8849aff2226821264e1b4b62c4910c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19a00b6f-c844-4bd8-8387-35bf8a2468a8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product. ", "original_text": "We have built capacity to ramp up to provide hundreds of \nmillions of doses. "}, "hash": "62e3598e1e889a472b3dc70f5373854d5266dbc4dd5411a83c5e8c58a2277683", "class_name": "RelatedNodeInfo"}}, "text": "In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people. ", "start_char_idx": 3810, "end_char_idx": 3969, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19a00b6f-c844-4bd8-8387-35bf8a2468a8": {"__data__": {"id_": "19a00b6f-c844-4bd8-8387-35bf8a2468a8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product. ", "original_text": "We have built capacity to ramp up to provide hundreds of \nmillions of doses. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01e82e06-82c8-4492-bde4-f39589738bf4", "node_type": "1", "metadata": {"window": "What we have guided here is based on the distribution vo lumes that we've been \nprovided by the CDC and we expect that that will deliver $0.25 to $0.35 of contribution in our fourth quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site. ", "original_text": "In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e12559a6cd1a2538323c7be1d755d17232dc2080c4e8c71854c2f41802975847", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46d5af73-9a78-4cfd-925d-718691676b52", "node_type": "1", "metadata": {"window": "A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n", "original_text": "And we think it's the fastest, safest way. "}, "hash": "a0193a64ba8607079f540b245f2d439fb490ed951ab5ee603152870497253b56", "class_name": "RelatedNodeInfo"}}, "text": "We have built capacity to ramp up to provide hundreds of \nmillions of doses. ", "start_char_idx": 3969, "end_char_idx": 4046, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46d5af73-9a78-4cfd-925d-718691676b52": {"__data__": {"id_": "46d5af73-9a78-4cfd-925d-718691676b52", "embedding": null, "metadata": {"window": "A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n", "original_text": "And we think it's the fastest, safest way. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19a00b6f-c844-4bd8-8387-35bf8a2468a8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product. ", "original_text": "We have built capacity to ramp up to provide hundreds of \nmillions of doses. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1541924b657d135a3340ad3f01455369f70cc80a8e649c451f2f4050bef5a8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84d7edc8-008a-4c0e-9ced-bef95cda4016", "node_type": "1", "metadata": {"window": "In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea. ", "original_text": "And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site. "}, "hash": "50f79b4bf789439d3a0e80f88f40336ab0fb5dfcf6dd85916e0286d55d60a75d", "class_name": "RelatedNodeInfo"}}, "text": "And we think it's the fastest, safest way. ", "start_char_idx": 4046, "end_char_idx": 4089, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84d7edc8-008a-4c0e-9ced-bef95cda4016": {"__data__": {"id_": "84d7edc8-008a-4c0e-9ced-bef95cda4016", "embedding": null, "metadata": {"window": "In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea. ", "original_text": "And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46d5af73-9a78-4cfd-925d-718691676b52", "node_type": "1", "metadata": {"window": "A \nYeah, let me \u2013 and to the second point, Lisa, it' s like a lot of people have offered their help and support of the \nvaccine distribution program and we appreciate everyone's desire to help facilitate the nation getting itself \nvaccinated.  In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n", "original_text": "And we think it's the fastest, safest way. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2826db027e1224e04961979930ae0c712b34ef7426d196d409088443382d4af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0470aa4c-1bd0-4076-8f68-cdbb45cb192f", "node_type": "1", "metadata": {"window": "We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake. ", "original_text": "It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product. "}, "hash": "8a0be8ef810337247055a10d4d10e28357733d740b3b8dd97a54971f4d796deb", "class_name": "RelatedNodeInfo"}}, "text": "And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site. ", "start_char_idx": 4089, "end_char_idx": 4212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0470aa4c-1bd0-4076-8f68-cdbb45cb192f": {"__data__": {"id_": "0470aa4c-1bd0-4076-8f68-cdbb45cb192f", "embedding": null, "metadata": {"window": "We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake. ", "original_text": "It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84d7edc8-008a-4c0e-9ced-bef95cda4016", "node_type": "1", "metadata": {"window": "In our view, we think the centralized distribution model that we hav e is the safest and the fastest way \nto get these COVID vaccines into the arms of people.  We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea. ", "original_text": "And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26d067fcadd2a2841cf9315b31f8eb6e124fc80df1acab4200a88fd5eb79e9a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ba8d025-cbb4-4d20-9cde-0f6d54bead5e", "node_type": "1", "metadata": {"window": "And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake.  Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n ", "original_text": "So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n"}, "hash": "7a1202bcfc1675eb7cd303147e4c3f78d6ed26d795ba5189ea697df1cde6559f", "class_name": "RelatedNodeInfo"}}, "text": "It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product. ", "start_char_idx": 4212, "end_char_idx": 4325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ba8d025-cbb4-4d20-9cde-0f6d54bead5e": {"__data__": {"id_": "9ba8d025-cbb4-4d20-9cde-0f6d54bead5e", "embedding": null, "metadata": {"window": "And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake.  Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n ", "original_text": "So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0470aa4c-1bd0-4076-8f68-cdbb45cb192f", "node_type": "1", "metadata": {"window": "We have built capacity to ramp up to provide hundreds of \nmillions of doses.  And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake. ", "original_text": "It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89d149f6c2b2122e66a540b9ff6e300c622118757619797ce444865c2c6d5ff9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77d07391-a6b6-4cc8-836f-ca9165d75a86", "node_type": "1", "metadata": {"window": "And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake.  Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Now, to the extent we can find ways to be faster, we're open for any idea. "}, "hash": "8cee97bb43831778780a1e9311868833e90ae7e313d1fe9a337fe9b25e46099b", "class_name": "RelatedNodeInfo"}}, "text": "So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n", "start_char_idx": 4325, "end_char_idx": 4487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77d07391-a6b6-4cc8-836f-ca9165d75a86": {"__data__": {"id_": "77d07391-a6b6-4cc8-836f-ca9165d75a86", "embedding": null, "metadata": {"window": "And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake.  Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Now, to the extent we can find ways to be faster, we're open for any idea. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ba8d025-cbb4-4d20-9cde-0f6d54bead5e", "node_type": "1", "metadata": {"window": "And we think it's the fastest, safest way.  And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake.  Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n ", "original_text": "So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23b536e1624c2e539d66e75d8e59ffc02cd9bec4f85d3a7d7f0e6463a16e38c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c37362aa-966c-4618-ac72-7a4b8d8c93b4", "node_type": "1", "metadata": {"window": "It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake.  Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Make no mistake. "}, "hash": "567d282412f93fd4cc0773e68a52ab94dab474e951b06184ef0a8215a7a05a40", "class_name": "RelatedNodeInfo"}}, "text": "Now, to the extent we can find ways to be faster, we're open for any idea. ", "start_char_idx": 4487, "end_char_idx": 4562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c37362aa-966c-4618-ac72-7a4b8d8c93b4": {"__data__": {"id_": "c37362aa-966c-4618-ac72-7a4b8d8c93b4", "embedding": null, "metadata": {"window": "It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake.  Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Make no mistake. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77d07391-a6b6-4cc8-836f-ca9165d75a86", "node_type": "1", "metadata": {"window": "And by that, I mean it's the least time from the  time an \norder is delivered to that vaccine arriving at a provider site.  It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake.  Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Now, to the extent we can find ways to be faster, we're open for any idea. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab71a4c5362078faf1a406fa7c651c9da33e1252b83f2e30d6e7e14984022796", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce6bc3a7-e9f2-4f8a-9111-5f8c11bbb71c", "node_type": "1", "metadata": {"window": "So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake.  Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n "}, "hash": "681437dfcc2de70420f58fee814b7b09472c5921e717acefc0f5529c1630920b", "class_name": "RelatedNodeInfo"}}, "text": "Make no mistake. ", "start_char_idx": 4562, "end_char_idx": 4579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce6bc3a7-e9f2-4f8a-9111-5f8c11bbb71c": {"__data__": {"id_": "ce6bc3a7-e9f2-4f8a-9111-5f8c11bbb71c", "embedding": null, "metadata": {"window": "So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake.  Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c37362aa-966c-4618-ac72-7a4b8d8c93b4", "node_type": "1", "metadata": {"window": "It's the least handoffs and handling and chances for \ntemperature excursions or lost product or damaged product.  So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake.  Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Make no mistake. ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "13c3e17993a608b112dcb7bc02e8a3deb4b2df9495b2d08a099588933b7084a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce59d728-7ef6-4b22-b7ba-160e02f069b1", "node_type": "1", "metadata": {"window": "Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake.  Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   "}, "hash": "bda04b0326f4f599cc2759397fdeb9b88f08e8fbff17d5b87f677b274da42e49", "class_name": "RelatedNodeInfo"}}, "text": "Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n ", "start_char_idx": 4579, "end_char_idx": 4743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce59d728-7ef6-4b22-b7ba-160e02f069b1": {"__data__": {"id_": "ce59d728-7ef6-4b22-b7ba-160e02f069b1", "embedding": null, "metadata": {"window": "Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake.  Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbf98f51d74d5798f46c9ea5e1e4e539fa176ef6dfaf853eddca84f9df473122", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce6bc3a7-e9f2-4f8a-9111-5f8c11bbb71c", "node_type": "1", "metadata": {"window": "So, in essence, it's going to allow us to get the \nmaximum amount of dos es out of what is produced and available from the manufacturers in the fastest time.  \n \n Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake.  Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f74b576e4ee5da388f96f94f4c379dedf09930db630814fb44f64393f2832771", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c56dec4c-d24a-4acd-889c-1ebc8fabca29", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n ", "original_text": "McKesson Corp.  "}, "hash": "a122ee7d2e3b41b221b7eeb7eeb9a91f2a8c95767fbcffc0ed89009c8b223a69", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "start_char_idx": 588, "end_char_idx": 844, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c56dec4c-d24a-4acd-889c-1ebc8fabca29": {"__data__": {"id_": "c56dec4c-d24a-4acd-889c-1ebc8fabca29", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce59d728-7ef6-4b22-b7ba-160e02f069b1", "node_type": "1", "metadata": {"window": "Now, to the extent we can find ways to be faster, we're open for any idea.  Make no mistake.  Our goal is to get this \nproduct to into patients' arms as quickly as we can so  that we can get this country vaccinated and back to a more \nnormal environment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f71c05ebfab26563cdf075a497b9a2718d0d3d2dd72a67bb43ce28a5cbf3c06d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4516986c-1f8f-45b0-904c-d086db47e723", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  "}, "hash": "f39b4738c8b05d81290cfbc4aa79c7b9758f31982444392c1eb9732bf17783d7", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4516986c-1f8f-45b0-904c-d086db47e723": {"__data__": {"id_": "4516986c-1f8f-45b0-904c-d086db47e723", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c56dec4c-d24a-4acd-889c-1ebc8fabca29", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "993ea4f4e25c72cc6ed3834aa6fa4dd3e928a3b3fe4204adf24186ef5965e8a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ff75f50-6aa3-416e-8d66-9efc3dc3852e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning. ", "original_text": "A \nOperator, next question?  \n "}, "hash": "9a4c2d586c495ab0bdd5b9e7b67ff1b128e7e895849f43c6ff9c50c44de46456", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ff75f50-6aa3-416e-8d66-9efc3dc3852e": {"__data__": {"id_": "2ff75f50-6aa3-416e-8d66-9efc3dc3852e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning. ", "original_text": "A \nOperator, next question?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4516986c-1f8f-45b0-904c-d086db47e723", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fd1df2afa945e14de65f2e96c7bc99ab9c344aa3bb628c9175cdfb5e701832b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9329efc5-08db-46a2-af91-5eab6274918a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning.  And sorry, toggling several calls this morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n "}, "hash": "4da7617b569ebbe86b64a4e6b5ab4b3eff8c6cd4c93f8ac50b16cdf31de7776e", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator, next question?  \n ", "start_char_idx": 283, "end_char_idx": 314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9329efc5-08db-46a2-af91-5eab6274918a": {"__data__": {"id_": "9329efc5-08db-46a2-af91-5eab6274918a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning.  And sorry, toggling several calls this morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ff75f50-6aa3-416e-8d66-9efc3dc3852e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning. ", "original_text": "A \nOperator, next question?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef58e43abce292cd592f83b21f5cd5d0dd459e2d38d5ad37d3cf723ae16105ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "879eb2da-a5db-463d-bed5-aee8879e3caa", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning.  And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  "}, "hash": "b9b7bac6dc136b0a21d9d19e5db29e3f056abb9581c88812125a1b4203a58c65", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n ", "start_char_idx": 314, "end_char_idx": 631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "879eb2da-a5db-463d-bed5-aee8879e3caa": {"__data__": {"id_": "879eb2da-a5db-463d-bed5-aee8879e3caa", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning.  And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9329efc5-08db-46a2-af91-5eab6274918a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning.  And sorry, toggling several calls this morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c384c326b6c56a46c7e9d218f1153a9780699618d790c97361a833876a9de22a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba0816f6-fefc-4181-ace5-8332bd802334", "node_type": "1", "metadata": {"window": "A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning.  And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly.  If you addressed it, I apologize. ", "original_text": "Q \nThanks very much and good morning. "}, "hash": "7ad9f691af6f2167209e14d78b14eb9bba8177391c56301eb8cae48ddaab2c6d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "start_char_idx": 631, "end_char_idx": 948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba0816f6-fefc-4181-ace5-8332bd802334": {"__data__": {"id_": "ba0816f6-fefc-4181-ace5-8332bd802334", "embedding": null, "metadata": {"window": "A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning.  And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly.  If you addressed it, I apologize. ", "original_text": "Q \nThanks very much and good morning. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "879eb2da-a5db-463d-bed5-aee8879e3caa", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning.  And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "349b844897c1551e1e46598e7a66e553eb2321a6a88f4956e9a39594acb9fa75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32780749-e88f-4b0e-aede-98ba411c93c1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning.  And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly.  If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far. ", "original_text": "And sorry, toggling several calls this morning. "}, "hash": "ad2f071dd3b1dd7fa416c6e485f8fdc98d084404b5efa37a6c65a4509f723dcf", "class_name": "RelatedNodeInfo"}}, "text": "Q \nThanks very much and good morning. ", "start_char_idx": 948, "end_char_idx": 986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32780749-e88f-4b0e-aede-98ba411c93c1": {"__data__": {"id_": "32780749-e88f-4b0e-aede-98ba411c93c1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning.  And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly.  If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far. ", "original_text": "And sorry, toggling several calls this morning. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba0816f6-fefc-4181-ace5-8332bd802334", "node_type": "1", "metadata": {"window": "A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning.  And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly.  If you addressed it, I apologize. ", "original_text": "Q \nThanks very much and good morning. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3d785d86e32c92a8e2fe556f2c5a66aee2166a41fd8b6e2b6ba765d0c4ac188", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56ad9cac-5d95-4b1a-9b7d-6fe57cd60c4b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning.  And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly.  If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that. ", "original_text": "I want to just follow up on \none thing here quickly. "}, "hash": "90346199bf525216582b7832576c3ca8395db6da60692c9e1626c569c65e3a6c", "class_name": "RelatedNodeInfo"}}, "text": "And sorry, toggling several calls this morning. ", "start_char_idx": 986, "end_char_idx": 1034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56ad9cac-5d95-4b1a-9b7d-6fe57cd60c4b": {"__data__": {"id_": "56ad9cac-5d95-4b1a-9b7d-6fe57cd60c4b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning.  And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly.  If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that. ", "original_text": "I want to just follow up on \none thing here quickly. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32780749-e88f-4b0e-aede-98ba411c93c1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning.  And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly.  If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far. ", "original_text": "And sorry, toggling several calls this morning. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42b200f11b39e87a8a434fa208d961e0d40895bd94ec05cd9e61dd59a331d371", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b9414c7-025f-404d-a1d0-5e2c206ecfa3", "node_type": "1", "metadata": {"window": "Q \nThanks very much and good morning.  And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly.  If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n ", "original_text": "If you addressed it, I apologize. "}, "hash": "69a741d5c297ced89d317b1fc5be472a61c13dbbeff65146c4aea7b25aeeed80", "class_name": "RelatedNodeInfo"}}, "text": "I want to just follow up on \none thing here quickly. ", "start_char_idx": 1034, "end_char_idx": 1087, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b9414c7-025f-404d-a1d0-5e2c206ecfa3": {"__data__": {"id_": "5b9414c7-025f-404d-a1d0-5e2c206ecfa3", "embedding": null, "metadata": {"window": "Q \nThanks very much and good morning.  And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly.  If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n ", "original_text": "If you addressed it, I apologize. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56ad9cac-5d95-4b1a-9b7d-6fe57cd60c4b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks very much and good morning.  And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly.  If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that. ", "original_text": "I want to just follow up on \none thing here quickly. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66e44c35dad76997554d527147adbe4f5c40b94b90b0ee1a0d91a65d9ec248b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56407c3a-99b8-471e-a575-a4ae019aed8d", "node_type": "1", "metadata": {"window": "And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly.  If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I know you've tal ked about the 25 million doses mostly in \nthe month of January so far. "}, "hash": "99bf6ab895ae8d337e4d481af452c526515ac82d80e07bb3ea6db0433018f953", "class_name": "RelatedNodeInfo"}}, "text": "If you addressed it, I apologize. ", "start_char_idx": 1087, "end_char_idx": 1121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56407c3a-99b8-471e-a575-a4ae019aed8d": {"__data__": {"id_": "56407c3a-99b8-471e-a575-a4ae019aed8d", "embedding": null, "metadata": {"window": "And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly.  If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I know you've tal ked about the 25 million doses mostly in \nthe month of January so far. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b9414c7-025f-404d-a1d0-5e2c206ecfa3", "node_type": "1", "metadata": {"window": "Q \nThanks very much and good morning.  And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly.  If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n ", "original_text": "If you addressed it, I apologize. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dffa26cb6b12725dd90d4bc0d1d4e40737346bef1e55c0b5b1803f4eaf07eb60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83447fdd-d579-4831-bd96-738b39d7878e", "node_type": "1", "metadata": {"window": "I want to just follow up on \none thing here quickly.  If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC. ", "original_text": "I guess, a couple of questions around that. "}, "hash": "9b9c13033980e2174d597e7dfadd2a9bd42b2627a724df600e90a2da128a2d4d", "class_name": "RelatedNodeInfo"}}, "text": "I know you've tal ked about the 25 million doses mostly in \nthe month of January so far. ", "start_char_idx": 1121, "end_char_idx": 1210, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83447fdd-d579-4831-bd96-738b39d7878e": {"__data__": {"id_": "83447fdd-d579-4831-bd96-738b39d7878e", "embedding": null, "metadata": {"window": "I want to just follow up on \none thing here quickly.  If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC. ", "original_text": "I guess, a couple of questions around that. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56407c3a-99b8-471e-a575-a4ae019aed8d", "node_type": "1", "metadata": {"window": "And sorry, toggling several calls this morning.  I want to just follow up on \none thing here quickly.  If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I know you've tal ked about the 25 million doses mostly in \nthe month of January so far. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f14310815a07ecf277127890ed552e56b90c5c7268ac4acd8165409afc42c9e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0021258f-8def-499a-9e95-785cb0d38bd7", "node_type": "1", "metadata": {"window": "If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies. ", "original_text": "First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n "}, "hash": "1acdf493f9bd611cdbda1e403a6bf42d2e202cbb9bf1051afb137f1615d53ed2", "class_name": "RelatedNodeInfo"}}, "text": "I guess, a couple of questions around that. ", "start_char_idx": 1210, "end_char_idx": 1254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0021258f-8def-499a-9e95-785cb0d38bd7": {"__data__": {"id_": "0021258f-8def-499a-9e95-785cb0d38bd7", "embedding": null, "metadata": {"window": "If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies. ", "original_text": "First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83447fdd-d579-4831-bd96-738b39d7878e", "node_type": "1", "metadata": {"window": "I want to just follow up on \none thing here quickly.  If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC. ", "original_text": "I guess, a couple of questions around that. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15c0d19485d29722c486782980e0636cdf4da9be24a5cf837f121b66e9cc9b7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6071aad9-0ecf-4919-89cc-fed50e7f3a75", "node_type": "1", "metadata": {"window": "I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "6c10cb7e6eade22e31742ab60c5df797cfa65ef28faf95da17a15364afca09f6", "class_name": "RelatedNodeInfo"}}, "text": "First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n ", "start_char_idx": 1254, "end_char_idx": 1404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6071aad9-0ecf-4919-89cc-fed50e7f3a75": {"__data__": {"id_": "6071aad9-0ecf-4919-89cc-fed50e7f3a75", "embedding": null, "metadata": {"window": "I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0021258f-8def-499a-9e95-785cb0d38bd7", "node_type": "1", "metadata": {"window": "If you addressed it, I apologize.  I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies. ", "original_text": "First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d12aedf7be8e12f216f152cecf98e260659ca809687da78b7904747776c48e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bc4c945-45d3-415f-ace9-827a987e4713", "node_type": "1", "metadata": {"window": "I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "A \nThe guidance we provided ties to the schedule we have been provided by the CDC. "}, "hash": "d651887cc3bb525e5875ac082ed23f73fb6bcc13d428207512f9a126c84d0bce", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1404, "end_char_idx": 1733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bc4c945-45d3-415f-ace9-827a987e4713": {"__data__": {"id_": "8bc4c945-45d3-415f-ace9-827a987e4713", "embedding": null, "metadata": {"window": "I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "A \nThe guidance we provided ties to the schedule we have been provided by the CDC. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6071aad9-0ecf-4919-89cc-fed50e7f3a75", "node_type": "1", "metadata": {"window": "I know you've tal ked about the 25 million doses mostly in \nthe month of January so far.  I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "736b4f53bec6bd4ccb3111ba3bb36f474c3fb186a4ade13e64bdf85876a2d2db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3df7df9-22af-489e-bcca-fbd6d11fff3b", "node_type": "1", "metadata": {"window": "First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay. ", "original_text": "And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies. "}, "hash": "78c72942c7779edd1487f0b39a5be09a8a7cffcdbb6ff5589e4e96540292a991", "class_name": "RelatedNodeInfo"}}, "text": "A \nThe guidance we provided ties to the schedule we have been provided by the CDC. ", "start_char_idx": 1733, "end_char_idx": 1816, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3df7df9-22af-489e-bcca-fbd6d11fff3b": {"__data__": {"id_": "c3df7df9-22af-489e-bcca-fbd6d11fff3b", "embedding": null, "metadata": {"window": "First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay. ", "original_text": "And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bc4c945-45d3-415f-ace9-827a987e4713", "node_type": "1", "metadata": {"window": "I guess, a couple of questions around that.  First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "A \nThe guidance we provided ties to the schedule we have been provided by the CDC. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3215e81afd6ec8ad07898f70c9061ba1bf2d6bf3e6be688d3530e5ceba69c71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "011dc32f-4626-4212-a9f9-0711a89f28c4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Fair enough. ", "original_text": "So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n "}, "hash": "f648ca8b95c183d684980e8686e6ea211dc747ac5a90bda5fd5a1453ed6cfe55", "class_name": "RelatedNodeInfo"}}, "text": "And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies. ", "start_char_idx": 1816, "end_char_idx": 1925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "011dc32f-4626-4212-a9f9-0711a89f28c4": {"__data__": {"id_": "011dc32f-4626-4212-a9f9-0711a89f28c4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Fair enough. ", "original_text": "So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3df7df9-22af-489e-bcca-fbd6d11fff3b", "node_type": "1", "metadata": {"window": "First off, are you able to provide your \nexpectations for total doses in fiscal 4Q specifically, so the next two months, how much that might ra mp. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay. ", "original_text": "And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b85ab34eb91624d2b5155e14ed09d39e5f7465c3112e500fa85d2922e3c9d533", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6c57703-4d3b-4612-8079-d299ab2304d6", "node_type": "1", "metadata": {"window": "A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Fair enough.  And then just my follow -up on that was the kitting opportunity. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  "}, "hash": "1cdb3dd3c84a65549fe40f27e40067520a2bf36c6ebba14294c4c55e8f22f810", "class_name": "RelatedNodeInfo"}}, "text": "So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n ", "start_char_idx": 1925, "end_char_idx": 2050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6c57703-4d3b-4612-8079-d299ab2304d6": {"__data__": {"id_": "f6c57703-4d3b-4612-8079-d299ab2304d6", "embedding": null, "metadata": {"window": "A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Fair enough.  And then just my follow -up on that was the kitting opportunity. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "011dc32f-4626-4212-a9f9-0711a89f28c4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Fair enough. ", "original_text": "So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "864f7c2164f1de2c9f394e5ae28d2791544ba22c783ccc56dbd1fa68868dbd66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96867894-7617-475d-b58b-90ddba56a198", "node_type": "1", "metadata": {"window": "And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Fair enough.  And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date. ", "original_text": "Q \nOkay. "}, "hash": "8f4e79d6b974a0690923d8e84659e5696b498f8198a1a07e5913eee3a921bf36", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "start_char_idx": 631, "end_char_idx": 948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96867894-7617-475d-b58b-90ddba56a198": {"__data__": {"id_": "96867894-7617-475d-b58b-90ddba56a198", "embedding": null, "metadata": {"window": "And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Fair enough.  And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date. ", "original_text": "Q \nOkay. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6c57703-4d3b-4612-8079-d299ab2304d6", "node_type": "1", "metadata": {"window": "A \nThe guidance we provided ties to the schedule we have been provided by the CDC.  And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Fair enough.  And then just my follow -up on that was the kitting opportunity. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c124a2936503ea1aa1df4369f0f2159fc9a01f481d6014401f1d18a4e57860d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e869dc4-3410-4d64-9d27-2bdc2a33b41d", "node_type": "1", "metadata": {"window": "So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Fair enough.  And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week. ", "original_text": "Fair enough. "}, "hash": "b4662040dcbb000d27191cac2e8240f7ed96ea82ce2ee9cc872211e389f425ab", "class_name": "RelatedNodeInfo"}}, "text": "Q \nOkay. ", "start_char_idx": 2367, "end_char_idx": 2376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e869dc4-3410-4d64-9d27-2bdc2a33b41d": {"__data__": {"id_": "3e869dc4-3410-4d64-9d27-2bdc2a33b41d", "embedding": null, "metadata": {"window": "So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Fair enough.  And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week. ", "original_text": "Fair enough. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96867894-7617-475d-b58b-90ddba56a198", "node_type": "1", "metadata": {"window": "And just like every other \nmajor customer we have, we don't comment on their plans and business str ategies.  So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Fair enough.  And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date. ", "original_text": "Q \nOkay. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "774b75d1f9ca98b5ced0694b725787ba02f8791f86b78379b57203a7b50179ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c32d2f15-ada6-4b6c-8d51-6785310cd077", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Fair enough.  And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022. ", "original_text": "And then just my follow -up on that was the kitting opportunity. "}, "hash": "77cbf0426d88a45e419bde80f7915c9e791e71bb2f0cf5b116f13e18a5dfea5f", "class_name": "RelatedNodeInfo"}}, "text": "Fair enough. ", "start_char_idx": 2376, "end_char_idx": 2389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c32d2f15-ada6-4b6c-8d51-6785310cd077": {"__data__": {"id_": "c32d2f15-ada6-4b6c-8d51-6785310cd077", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Fair enough.  And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022. ", "original_text": "And then just my follow -up on that was the kitting opportunity. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e869dc4-3410-4d64-9d27-2bdc2a33b41d", "node_type": "1", "metadata": {"window": "So, we're not able to talk \nabout that, but the guidance we provided ties to the schedule we've been provided by the CDC.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Fair enough.  And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week. ", "original_text": "Fair enough. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f172c363c5d407c21131801c49b51c22d641466a0b01f12b33775776fda13f22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13273932-7196-4122-a499-5d990bef731a", "node_type": "1", "metadata": {"window": "Q \nOkay.  Fair enough.  And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n ", "original_text": "Obviously, you've assembled a \ntremendous number of kits to -date. "}, "hash": "724f73befe7eab1adf3fa457821116cc2a6f7f112102b3cd2961a5e0f64a2c6a", "class_name": "RelatedNodeInfo"}}, "text": "And then just my follow -up on that was the kitting opportunity. ", "start_char_idx": 2389, "end_char_idx": 2454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13273932-7196-4122-a499-5d990bef731a": {"__data__": {"id_": "13273932-7196-4122-a499-5d990bef731a", "embedding": null, "metadata": {"window": "Q \nOkay.  Fair enough.  And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n ", "original_text": "Obviously, you've assembled a \ntremendous number of kits to -date. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c32d2f15-ada6-4b6c-8d51-6785310cd077", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Fair enough.  And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022. ", "original_text": "And then just my follow -up on that was the kitting opportunity. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e11c8830ed89d64da7f4d2b20ee21c03d26c9b357dbc5e6592c934111679cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "261941de-fd15-42fb-ab1d-21c0273798f2", "node_type": "1", "metadata": {"window": "Fair enough.  And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "You're making 10 to 15 million a month or a week. "}, "hash": "9cd5c3c9450d331e0d5a883949d714f7114db2a6415b53b789451d9efe7bbdb4", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, you've assembled a \ntremendous number of kits to -date. ", "start_char_idx": 2454, "end_char_idx": 2521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "261941de-fd15-42fb-ab1d-21c0273798f2": {"__data__": {"id_": "261941de-fd15-42fb-ab1d-21c0273798f2", "embedding": null, "metadata": {"window": "Fair enough.  And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "You're making 10 to 15 million a month or a week. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13273932-7196-4122-a499-5d990bef731a", "node_type": "1", "metadata": {"window": "Q \nOkay.  Fair enough.  And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n ", "original_text": "Obviously, you've assembled a \ntremendous number of kits to -date. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "748a77d86ec2177171ff10ae34c48d397e3ae5b2ee8753b57691e729a8f95dd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b8071eb-425e-443c-9dc9-2802d36f85ea", "node_type": "1", "metadata": {"window": "And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "I'm just curious, does the \nkitting opportunity extend into fiscal 2022. "}, "hash": "827a041a5d1399a3eab09f1d2b61d49fd49769b0784987b007f50b5f69042114", "class_name": "RelatedNodeInfo"}}, "text": "You're making 10 to 15 million a month or a week. ", "start_char_idx": 2521, "end_char_idx": 2571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b8071eb-425e-443c-9dc9-2802d36f85ea": {"__data__": {"id_": "6b8071eb-425e-443c-9dc9-2802d36f85ea", "embedding": null, "metadata": {"window": "And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "I'm just curious, does the \nkitting opportunity extend into fiscal 2022. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "261941de-fd15-42fb-ab1d-21c0273798f2", "node_type": "1", "metadata": {"window": "Fair enough.  And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "You're making 10 to 15 million a month or a week. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "199eefe47daffeda5a6549223e896c0ca166f505bb2bc2e47b4338910418cc95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "741b3698-ef39-4455-af4c-8fd1a1c5f202", "node_type": "1", "metadata": {"window": "Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Eric, thank you for the question. ", "original_text": "Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n "}, "hash": "1baa7a8d5277e546fde20f757b5c57906593bef1e4cee00f9603eb7d3dfbc69e", "class_name": "RelatedNodeInfo"}}, "text": "I'm just curious, does the \nkitting opportunity extend into fiscal 2022. ", "start_char_idx": 2571, "end_char_idx": 2644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "741b3698-ef39-4455-af4c-8fd1a1c5f202": {"__data__": {"id_": "741b3698-ef39-4455-af4c-8fd1a1c5f202", "embedding": null, "metadata": {"window": "Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Eric, thank you for the question. ", "original_text": "Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b8071eb-425e-443c-9dc9-2802d36f85ea", "node_type": "1", "metadata": {"window": "And then just my follow -up on that was the kitting opportunity.  Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "I'm just curious, does the \nkitting opportunity extend into fiscal 2022. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1331fb675d36dcb4c6ceeed61f661b58702f39eb669c9cdf580785d37d52ffca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cb15c2c-f898-4d91-97d4-ec3c2a6f9675", "node_type": "1", "metadata": {"window": "You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "108af66c1d5571f0626786406567898350efd9817532bf5e637d2f8608b3f23e", "class_name": "RelatedNodeInfo"}}, "text": "Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n ", "start_char_idx": 2644, "end_char_idx": 2807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cb15c2c-f898-4d91-97d4-ec3c2a6f9675": {"__data__": {"id_": "6cb15c2c-f898-4d91-97d4-ec3c2a6f9675", "embedding": null, "metadata": {"window": "You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "741b3698-ef39-4455-af4c-8fd1a1c5f202", "node_type": "1", "metadata": {"window": "Obviously, you've assembled a \ntremendous number of kits to -date.  You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Eric, thank you for the question. ", "original_text": "Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d823899002ee2afbef8993b951663ca64dd69358fce2123c5bb38c5542c4561f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d92d8ef8-c72e-4ccf-9ed7-2d17edaa2328", "node_type": "1", "metadata": {"window": "I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call. ", "original_text": "A \nYeah. "}, "hash": "758c67c1cc84d175c8c51fc3fb60025437eee4cac9362ea5ec89cd706d24043b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2807, "end_char_idx": 3152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d92d8ef8-c72e-4ccf-9ed7-2d17edaa2328": {"__data__": {"id_": "d92d8ef8-c72e-4ccf-9ed7-2d17edaa2328", "embedding": null, "metadata": {"window": "I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cb15c2c-f898-4d91-97d4-ec3c2a6f9675", "node_type": "1", "metadata": {"window": "You're making 10 to 15 million a month or a week.  I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c649e15502f9614411cd88d7352ce9974bbdfb619cb0a35b0010da1de392ffa4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6291e14-7d6e-4636-b8fb-b3deaacae94f", "node_type": "1", "metadata": {"window": "Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out. ", "original_text": "Eric, thank you for the question. "}, "hash": "cbce6e296b8ded931998d8cb973e5bf043da4713ef0bc90ba640e9cb9eacc4bc", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 3152, "end_char_idx": 3161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6291e14-7d6e-4636-b8fb-b3deaacae94f": {"__data__": {"id_": "b6291e14-7d6e-4636-b8fb-b3deaacae94f", "embedding": null, "metadata": {"window": "Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out. ", "original_text": "Eric, thank you for the question. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d92d8ef8-c72e-4ccf-9ed7-2d17edaa2328", "node_type": "1", "metadata": {"window": "I'm just curious, does the \nkitting opportunity extend into fiscal 2022.  Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "641e9a96213c0c5c67bd2efdf9ca4d0ef3cc1beac49f2d0aa3d802e806c411d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a18a7f70-8c89-46d4-8dfb-287355e232fe", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year. ", "original_text": "Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine. "}, "hash": "e1cedfb159d28a1830bf5cc19ba754c87b208998372a85dfb3a16d942ff20022", "class_name": "RelatedNodeInfo"}}, "text": "Eric, thank you for the question. ", "start_char_idx": 3161, "end_char_idx": 3195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a18a7f70-8c89-46d4-8dfb-287355e232fe": {"__data__": {"id_": "a18a7f70-8c89-46d4-8dfb-287355e232fe", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year. ", "original_text": "Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6291e14-7d6e-4636-b8fb-b3deaacae94f", "node_type": "1", "metadata": {"window": "Are you so advanced on what you've assembled to -date that that \nopportunity really ends in fiscal 2021 even if the vaccines obviously extend into fiscal 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out. ", "original_text": "Eric, thank you for the question. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e675dc9fbd6524817a77bc8d353fee39739dd651c20d232bc6b3b23a05ee3a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ac629a4-a971-4ef4-b882-c3f838db1353", "node_type": "1", "metadata": {"window": "A \nYeah.  Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that. ", "original_text": "So, we talked about that on our Q2 call. "}, "hash": "b784586ba3302030e510fb0dd03f399b6d6fb6d8ebc09991c6f46e878f3ff550", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine. ", "start_char_idx": 3195, "end_char_idx": 3295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ac629a4-a971-4ef4-b882-c3f838db1353": {"__data__": {"id_": "6ac629a4-a971-4ef4-b882-c3f838db1353", "embedding": null, "metadata": {"window": "A \nYeah.  Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that. ", "original_text": "So, we talked about that on our Q2 call. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a18a7f70-8c89-46d4-8dfb-287355e232fe", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year. ", "original_text": "Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5c226209dbedbbb0857b8d792008bba4395318b7614693156bac6fc93a87fcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94a92063-a42d-4b34-a9c3-13d9f47c4883", "node_type": "1", "metadata": {"window": "Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year. ", "original_text": "I think it's a little early to tell how far this will \nactually play out. "}, "hash": "8caa035d2032469b78cc086bc50f814df97d35e488cf0c604ca042fd483c7fa3", "class_name": "RelatedNodeInfo"}}, "text": "So, we talked about that on our Q2 call. ", "start_char_idx": 3295, "end_char_idx": 3336, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94a92063-a42d-4b34-a9c3-13d9f47c4883": {"__data__": {"id_": "94a92063-a42d-4b34-a9c3-13d9f47c4883", "embedding": null, "metadata": {"window": "Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year. ", "original_text": "I think it's a little early to tell how far this will \nactually play out. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ac629a4-a971-4ef4-b882-c3f838db1353", "node_type": "1", "metadata": {"window": "A \nYeah.  Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that. ", "original_text": "So, we talked about that on our Q2 call. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e9f09167d8ef9217ad2e9b8f95d576f3610171c14081e0db78826afe68dd3a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d2457c9-bf9f-4957-b59f-89ed8c6b929a", "node_type": "1", "metadata": {"window": "Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year. ", "original_text": "We would expect that some kitting would continue on beyond o ur fiscal year. "}, "hash": "7b9009919b56cc502ddc0e7a90b9ae70fd16db31505db91a73a01d2a0e0de06c", "class_name": "RelatedNodeInfo"}}, "text": "I think it's a little early to tell how far this will \nactually play out. ", "start_char_idx": 3336, "end_char_idx": 3410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d2457c9-bf9f-4957-b59f-89ed8c6b929a": {"__data__": {"id_": "7d2457c9-bf9f-4957-b59f-89ed8c6b929a", "embedding": null, "metadata": {"window": "Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year. ", "original_text": "We would expect that some kitting would continue on beyond o ur fiscal year. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94a92063-a42d-4b34-a9c3-13d9f47c4883", "node_type": "1", "metadata": {"window": "Eric, thank you for the question.  Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year. ", "original_text": "I think it's a little early to tell how far this will \nactually play out. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05facb67d5ecd2fa323619dfe378e6a2390bebfa281cef18d4b8c29c49e5a8a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be5db252-9361-4cac-b370-4336ba5b0d3a", "node_type": "1", "metadata": {"window": "So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n ", "original_text": "But it's hard to say \nat this point how to value that. "}, "hash": "3767b3a6d962150a0c3e6309ddcc17778580276b1bd71a990ea0a2fa28eb6fa6", "class_name": "RelatedNodeInfo"}}, "text": "We would expect that some kitting would continue on beyond o ur fiscal year. ", "start_char_idx": 3410, "end_char_idx": 3487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be5db252-9361-4cac-b370-4336ba5b0d3a": {"__data__": {"id_": "be5db252-9361-4cac-b370-4336ba5b0d3a", "embedding": null, "metadata": {"window": "So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n ", "original_text": "But it's hard to say \nat this point how to value that. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d2457c9-bf9f-4957-b59f-89ed8c6b929a", "node_type": "1", "metadata": {"window": "Obviously, as we  think about the kitting opportunity, we produced kits in \nadvance of the vaccine.  So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year. ", "original_text": "We would expect that some kitting would continue on beyond o ur fiscal year. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b4dc1a6d0178be16d96acb1805d170e27c37381afc49c4dc6a3d44d5d28851a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac276198-992a-4d4c-bbbd-c0a8e624ebd0", "node_type": "1", "metadata": {"window": "I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year. "}, "hash": "44aa851e4cbdf0cbae0d7b448d81f1cabf48acab670070314300fdd113e0bd3f", "class_name": "RelatedNodeInfo"}}, "text": "But it's hard to say \nat this point how to value that. ", "start_char_idx": 3487, "end_char_idx": 3542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac276198-992a-4d4c-bbbd-c0a8e624ebd0": {"__data__": {"id_": "ac276198-992a-4d4c-bbbd-c0a8e624ebd0", "embedding": null, "metadata": {"window": "I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be5db252-9361-4cac-b370-4336ba5b0d3a", "node_type": "1", "metadata": {"window": "So, we talked about that on our Q2 call.  I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n ", "original_text": "But it's hard to say \nat this point how to value that. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f19967b2ab17202f4cf7237b902e33f97f4eaf83dc45aefb138c5080e36be42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9893cd72-1870-4ad7-be96-31a4c976f33b", "node_type": "1", "metadata": {"window": "We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n ", "original_text": "I think that you could expect to see some kitting into next year. "}, "hash": "55ca83a4db9f9f780e62e6c01f7bfeb9154622c908456defe2194a2c6d0c65a1", "class_name": "RelatedNodeInfo"}}, "text": "So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year. ", "start_char_idx": 3542, "end_char_idx": 3646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9893cd72-1870-4ad7-be96-31a4c976f33b": {"__data__": {"id_": "9893cd72-1870-4ad7-be96-31a4c976f33b", "embedding": null, "metadata": {"window": "We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n ", "original_text": "I think that you could expect to see some kitting into next year. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac276198-992a-4d4c-bbbd-c0a8e624ebd0", "node_type": "1", "metadata": {"window": "I think it's a little early to tell how far this will \nactually play out.  We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5f90fdbc6758e8bd0729156e064afb7065462557328c9dffd300ce60be67a68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea6cca50-1d19-47ac-a17e-9199d40a176e", "node_type": "1", "metadata": {"window": "But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n ", "original_text": "I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n "}, "hash": "000486171a81c2234b0f8d77808804d74bec83c705fcd56b9e82352972908b50", "class_name": "RelatedNodeInfo"}}, "text": "I think that you could expect to see some kitting into next year. ", "start_char_idx": 3646, "end_char_idx": 3712, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea6cca50-1d19-47ac-a17e-9199d40a176e": {"__data__": {"id_": "ea6cca50-1d19-47ac-a17e-9199d40a176e", "embedding": null, "metadata": {"window": "But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n ", "original_text": "I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9893cd72-1870-4ad7-be96-31a4c976f33b", "node_type": "1", "metadata": {"window": "We would expect that some kitting would continue on beyond o ur fiscal year.  But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n ", "original_text": "I think that you could expect to see some kitting into next year. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff59a65f0c74a20015706006bfcca41424880ba12a7870374ad487c9bac35f59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3de608f0-57da-4463-b143-7370b7d4d0bc", "node_type": "1", "metadata": {"window": "So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  "}, "hash": "d10377e8e8f4570041f713e6e0d96b418484fe756a045bef01971bd24afd728f", "class_name": "RelatedNodeInfo"}}, "text": "I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n ", "start_char_idx": 3712, "end_char_idx": 3841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3de608f0-57da-4463-b143-7370b7d4d0bc": {"__data__": {"id_": "3de608f0-57da-4463-b143-7370b7d4d0bc", "embedding": null, "metadata": {"window": "So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea6cca50-1d19-47ac-a17e-9199d40a176e", "node_type": "1", "metadata": {"window": "But it's hard to say \nat this point how to value that.  So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n ", "original_text": "I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c062296db720a25b9f2b1c23b7c5ec8f00ac6c5819c22c87c576d3ce668af788", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d49cc609-73d6-4657-a3d3-43a03d0afa23", "node_type": "1", "metadata": {"window": "I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "A \nOperator, next question?  \n "}, "hash": "58c92dcde9b7dee492ff540312c92d823fa53919a67be7253e7d6d4e7a83904a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "start_char_idx": 3841, "end_char_idx": 4200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d49cc609-73d6-4657-a3d3-43a03d0afa23": {"__data__": {"id_": "d49cc609-73d6-4657-a3d3-43a03d0afa23", "embedding": null, "metadata": {"window": "I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "A \nOperator, next question?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3de608f0-57da-4463-b143-7370b7d4d0bc", "node_type": "1", "metadata": {"window": "So, we feel good about increasing the guidance range for the kits that we expect to \nproduce this year.  I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "787d5ffdb17aeb5ca5a459edf729a297632a00748cbaa9430c001507c0fbf437", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7205682d-975f-4feb-b3bf-ae8f1c717f9e", "node_type": "1", "metadata": {"window": "I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n "}, "hash": "066646ad0290787e02f82c8b81c516df81d6022977235f3203955b05c91ac5e7", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator, next question?  \n ", "start_char_idx": 283, "end_char_idx": 314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7205682d-975f-4feb-b3bf-ae8f1c717f9e": {"__data__": {"id_": "7205682d-975f-4feb-b3bf-ae8f1c717f9e", "embedding": null, "metadata": {"window": "I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d49cc609-73d6-4657-a3d3-43a03d0afa23", "node_type": "1", "metadata": {"window": "I think that you could expect to see some kitting into next year.  I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "A \nOperator, next question?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7bc90388053cc719d384d03b663501e38955bdd05639f5867635840f784a7ec7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83e7a6df-0b33-408c-ba48-a1de9e15dae8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. "}, "hash": "a5e8247d1fad950da65fea812fc9ae42b1ce635c699c19ebaf86a80ebc697731", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n ", "start_char_idx": 4231, "end_char_idx": 4554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83e7a6df-0b33-408c-ba48-a1de9e15dae8": {"__data__": {"id_": "83e7a6df-0b33-408c-ba48-a1de9e15dae8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7205682d-975f-4feb-b3bf-ae8f1c717f9e", "node_type": "1", "metadata": {"window": "I guess, it will all really depend \non the distribution schedule that we get from the CDC and what the volumes are this year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6c2c3796dc26ea2316cbc054bfb5d470ff49accce58f4040fd5ff8bdc51ebc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f609b18-f23b-4590-a1c7-1f9a7aec5640", "node_type": "1", "metadata": {"window": "A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter.  And, Britt, I know y ou shared what the increased contribution you're viewing from kitting and ", "original_text": "LLC  Q \nGreat. "}, "hash": "1942e5aa09a966f63a3394203f3cc86edd0b975083d98c4be08c9e7c49ca110f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 4554, "end_char_idx": 4858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f609b18-f23b-4590-a1c7-1f9a7aec5640": {"__data__": {"id_": "8f609b18-f23b-4590-a1c7-1f9a7aec5640", "embedding": null, "metadata": {"window": "A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter.  And, Britt, I know y ou shared what the increased contribution you're viewing from kitting and ", "original_text": "LLC  Q \nGreat. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83e7a6df-0b33-408c-ba48-a1de9e15dae8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1cd03ee52485b9fd303ed558b65c89d53e4f717d3e807df4f6c774af94e16439", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d38d3531-2acd-4979-9193-ab4a664c993a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter.  And, Britt, I know y ou shared what the increased contribution you're viewing from kitting and ", "original_text": "Thanks for the question. "}, "hash": "32b43d47148317d8acc6417dd15fbfc65ae05d3e69b9b6f6d3e9f362fe4f7395", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nGreat. ", "start_char_idx": 4858, "end_char_idx": 4873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d38d3531-2acd-4979-9193-ab4a664c993a": {"__data__": {"id_": "d38d3531-2acd-4979-9193-ab4a664c993a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter.  And, Britt, I know y ou shared what the increased contribution you're viewing from kitting and ", "original_text": "Thanks for the question. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f609b18-f23b-4590-a1c7-1f9a7aec5640", "node_type": "1", "metadata": {"window": "A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter.  And, Britt, I know y ou shared what the increased contribution you're viewing from kitting and ", "original_text": "LLC  Q \nGreat. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e10dbe0f1c0c73279ffce852358ea789b6666ea26642427dd4472a15984748c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "038e0c0d-96e1-4c5f-9dfd-448425f5a222", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter.  And, Britt, I know y ou shared what the increased contribution you're viewing from kitting and ", "original_text": "I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter. "}, "hash": "e7d6f4b570e8da1814968c8d8fccbdd433ab8aa5175f9b463494e4b693bc18ab", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 4873, "end_char_idx": 4898, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "038e0c0d-96e1-4c5f-9dfd-448425f5a222": {"__data__": {"id_": "038e0c0d-96e1-4c5f-9dfd-448425f5a222", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter.  And, Britt, I know y ou shared what the increased contribution you're viewing from kitting and ", "original_text": "I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d38d3531-2acd-4979-9193-ab4a664c993a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter.  And, Britt, I know y ou shared what the increased contribution you're viewing from kitting and ", "original_text": "Thanks for the question. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87fe38c2e276d0896bc0cb9e53b1bb9c4f7e271760752c626061be03f9491462", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4240ed4-5d3e-4796-849c-04bd994b746f", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thanks for the question.  I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter.  And, Britt, I know y ou shared what the increased contribution you're viewing from kitting and ", "original_text": "And, Britt, I know y ou shared what the increased contribution you're viewing from kitting and "}, "hash": "27204df4230bdb12fb100ec24d01ff6fdd758eb980b8a3e2464db40fdfe1155a", "class_name": "RelatedNodeInfo"}}, "text": "I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter. ", "start_char_idx": 4898, "end_char_idx": 5004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4240ed4-5d3e-4796-849c-04bd994b746f": {"__data__": {"id_": "f4240ed4-5d3e-4796-849c-04bd994b746f", "embedding": null, "metadata": {"window": "LLC  Q \nGreat.  Thanks for the question.  I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter.  And, Britt, I know y ou shared what the increased contribution you're viewing from kitting and ", "original_text": "And, Britt, I know y ou shared what the increased contribution you're viewing from kitting and ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "10c17b1f-1297-4b9b-b906-6a61e058c790", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfce269822288d14855aa50e6c1539627ee40bf793f414479eb1aaad1bd875d7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "038e0c0d-96e1-4c5f-9dfd-448425f5a222", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the question.  I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter.  And, Britt, I know y ou shared what the increased contribution you're viewing from kitting and ", "original_text": "I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter. ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5f2fa4ca2e3c749c7aa69fca1d751279f4eaacbc2cfddcc873c1d3282594220", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63faace0-b5fb-4efc-83ad-c54db56cb696", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies.  But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n ", "original_text": "McKesson Corp.  "}, "hash": "4576f5a81d8a899d05093fa7dfd949cfcb52186bb9d6f6b62506e7049ba04d4a", "class_name": "RelatedNodeInfo"}}, "text": "And, Britt, I know y ou shared what the increased contribution you're viewing from kitting and ", "start_char_idx": 5004, "end_char_idx": 5099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63faace0-b5fb-4efc-83ad-c54db56cb696": {"__data__": {"id_": "63faace0-b5fb-4efc-83ad-c54db56cb696", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies.  But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4240ed4-5d3e-4796-849c-04bd994b746f", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thanks for the question.  I guess, maybe just to shift gears over to Med -Surg, EBIT there was particularly \nstrong in the quarter.  And, Britt, I know y ou shared what the increased contribution you're viewing from kitting and ", "original_text": "And, Britt, I know y ou shared what the increased contribution you're viewing from kitting and ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86fd99dbb946639cae587bfc18148d48275fed1a76bef7d068f462e3fa80fa67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7a57b37-57f3-4307-8f80-3cc0836d7482", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies.  But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.  ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies. "}, "hash": "9e5b1493a6cf1ecaadb649a12ac9cf7e83214b4409322be8586c6726f5bc1941", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7a57b37-57f3-4307-8f80-3cc0836d7482": {"__data__": {"id_": "a7a57b37-57f3-4307-8f80-3cc0836d7482", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies.  But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.  ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63faace0-b5fb-4efc-83ad-c54db56cb696", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies.  But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6596e148c7a009788e2b9fa91c766e6bb6ec550251dba597e44adfd937daf40c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b83b0ea8-e6ee-4cad-acc1-13961964e231", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies.  But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment. "}, "hash": "8dbcf057266529a15c50e8043811debc95df8b6c8655b775995c991c5351c8ea", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies. ", "start_char_idx": 16, "end_char_idx": 222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b83b0ea8-e6ee-4cad-acc1-13961964e231": {"__data__": {"id_": "b83b0ea8-e6ee-4cad-acc1-13961964e231", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies.  But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7a57b37-57f3-4307-8f80-3cc0836d7482", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies.  But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.  ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2923ab7274f9db76d565613310dc895a464350855b546aee4c0c4e4b22cca5b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0eba3e75-d4d6-4da5-8e3d-78eec5a7f589", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies.  But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning. ", "original_text": "So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n "}, "hash": "30a20e762c00e6571b636843470660a8cb6391c63de640328f0344460b369ad8", "class_name": "RelatedNodeInfo"}}, "text": "But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment. ", "start_char_idx": 222, "end_char_idx": 427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0eba3e75-d4d6-4da5-8e3d-78eec5a7f589": {"__data__": {"id_": "0eba3e75-d4d6-4da5-8e3d-78eec5a7f589", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies.  But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning. ", "original_text": "So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b83b0ea8-e6ee-4cad-acc1-13961964e231", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies.  But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ebdfa5e98beb3c38030c8c8e9e86677068f3eb9db7064b38047df7167259db1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d60cbbba-4c11-4903-b7e1-91fe568df2ea", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies.  But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thank you for that question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.  "}, "hash": "3cb79f41dc2d7687ba5a737bc014b074022fa563ed47866ecbb1a9b953bee206", "class_name": "RelatedNodeInfo"}}, "text": "So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n ", "start_char_idx": 427, "end_char_idx": 584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d60cbbba-4c11-4903-b7e1-91fe568df2ea": {"__data__": {"id_": "d60cbbba-4c11-4903-b7e1-91fe568df2ea", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies.  But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thank you for that question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0eba3e75-d4d6-4da5-8e3d-78eec5a7f589", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies.  But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning. ", "original_text": "So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b39ae47280c66831960e446762914fe6a8e97ffa51875531efefe7fbc77d1eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eec78512-3fa9-4d11-86a3-c680d6e88ddf", "node_type": "1", "metadata": {"window": "But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter. ", "original_text": "A \nYeah. "}, "hash": "20fb693bdd028d56a81417a2921e1b010cff3c8d899290ecb3c3a59f3949d17e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 584, "end_char_idx": 930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eec78512-3fa9-4d11-86a3-c680d6e88ddf": {"__data__": {"id_": "eec78512-3fa9-4d11-86a3-c680d6e88ddf", "embedding": null, "metadata": {"window": "But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d60cbbba-4c11-4903-b7e1-91fe568df2ea", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies.  But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thank you for that question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5573e33ada428a59b12ce8680632c2069a3b0ef4306e50887cb8cbb1a952602", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d752a15b-a0b3-408c-8dae-cdf18fb9aee6", "node_type": "1", "metadata": {"window": "So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE. ", "original_text": "Good morning. "}, "hash": "80a0c0170659053bae5b9ec6d86ff67fa42705d5abfa4db1f32b2c3bb21487e6", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 930, "end_char_idx": 939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d752a15b-a0b3-408c-8dae-cdf18fb9aee6": {"__data__": {"id_": "d752a15b-a0b3-408c-8dae-cdf18fb9aee6", "embedding": null, "metadata": {"window": "So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE. ", "original_text": "Good morning. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eec78512-3fa9-4d11-86a3-c680d6e88ddf", "node_type": "1", "metadata": {"window": "But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1c8265ca02b311db60f784c1e14b031e056d377fd0671666034f8c92d633b0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "458b2302-05f0-46ef-8ec4-afc858b6b4c9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n", "original_text": "Thank you for that question. "}, "hash": "e3b745bd146eb201f3afa740c6321f62ee479b22bc7f6cbc480dc4e7263a8ae4", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 939, "end_char_idx": 953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "458b2302-05f0-46ef-8ec4-afc858b6b4c9": {"__data__": {"id_": "458b2302-05f0-46ef-8ec4-afc858b6b4c9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n", "original_text": "Thank you for that question. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d752a15b-a0b3-408c-8dae-cdf18fb9aee6", "node_type": "1", "metadata": {"window": "So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE. ", "original_text": "Good morning. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52ba9168dbd99d41c30389e54c0eca81e05ffa4c4797281402a30fe73593f051", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "945a7464-5bb6-4568-8f15-a057043de8c7", "node_type": "1", "metadata": {"window": "A \nYeah.  Good morning.  Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site. ", "original_text": "You're right, our core business did continue to be very solid \ninto the quarter. "}, "hash": "4b688e9ff137e1ed181aa600537f513680bddbf847048d1de48de8d28ebdfe18", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for that question. ", "start_char_idx": 953, "end_char_idx": 982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "945a7464-5bb6-4568-8f15-a057043de8c7": {"__data__": {"id_": "945a7464-5bb6-4568-8f15-a057043de8c7", "embedding": null, "metadata": {"window": "A \nYeah.  Good morning.  Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site. ", "original_text": "You're right, our core business did continue to be very solid \ninto the quarter. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "458b2302-05f0-46ef-8ec4-afc858b6b4c9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice Presiden t & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n", "original_text": "Thank you for that question. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6fc06163f1018a285bfae0aca66f17334a8a3ad379f48de6a1af499fe9676dfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a86bd9d0-934b-4136-8514-1e151a2017f7", "node_type": "1", "metadata": {"window": "Good morning.  Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery. ", "original_text": "And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE. "}, "hash": "634b6644ad2bbcbd4ac7ac46925135d0ab4e8d0c1facaae177bece132d89e023", "class_name": "RelatedNodeInfo"}}, "text": "You're right, our core business did continue to be very solid \ninto the quarter. ", "start_char_idx": 982, "end_char_idx": 1063, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a86bd9d0-934b-4136-8514-1e151a2017f7": {"__data__": {"id_": "a86bd9d0-934b-4136-8514-1e151a2017f7", "embedding": null, "metadata": {"window": "Good morning.  Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery. ", "original_text": "And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "945a7464-5bb6-4568-8f15-a057043de8c7", "node_type": "1", "metadata": {"window": "A \nYeah.  Good morning.  Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site. ", "original_text": "You're right, our core business did continue to be very solid \ninto the quarter. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb6432d53b7235d6283969ce28676df624e6f7a9ea83c684108ce0ffcb827eee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40779665-dd3f-4f8e-a765-0abb8906ebae", "node_type": "1", "metadata": {"window": "Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n ", "original_text": "So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n"}, "hash": "006b3a0137535d65c91ff7288a0c3486fa9827127cf9be2cd48ef513dd673eae", "class_name": "RelatedNodeInfo"}}, "text": "And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE. ", "start_char_idx": 1063, "end_char_idx": 1175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40779665-dd3f-4f8e-a765-0abb8906ebae": {"__data__": {"id_": "40779665-dd3f-4f8e-a765-0abb8906ebae", "embedding": null, "metadata": {"window": "Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n ", "original_text": "So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a86bd9d0-934b-4136-8514-1e151a2017f7", "node_type": "1", "metadata": {"window": "Good morning.  Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery. ", "original_text": "And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3fdebbca18aa9ff6321c973d56feb39db2e42805cece99536895c4f57b7159f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8bced18-5ec8-4f19-9d77-2a4ca5ea8298", "node_type": "1", "metadata": {"window": "You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site. "}, "hash": "0487d07fe44f8a8e85dcd8836738a8981a69b071d8dd3b03c94d07b9c203fe53", "class_name": "RelatedNodeInfo"}}, "text": "So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n", "start_char_idx": 1175, "end_char_idx": 1269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8bced18-5ec8-4f19-9d77-2a4ca5ea8298": {"__data__": {"id_": "f8bced18-5ec8-4f19-9d77-2a4ca5ea8298", "embedding": null, "metadata": {"window": "You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40779665-dd3f-4f8e-a765-0abb8906ebae", "node_type": "1", "metadata": {"window": "Thank you for that question.  You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n ", "original_text": "So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd6577e78db6fc16e9e10c8ffd860340977e7567f27f1c399804022252311d1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdf44eb0-a0b4-4bb8-bac6-f2634aa5d529", "node_type": "1", "metadata": {"window": "And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n ", "original_text": "As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery. "}, "hash": "3152574264779bde4536b5e4ca3cd11533ce32e29cfe70737a718b94ff06c1d9", "class_name": "RelatedNodeInfo"}}, "text": "I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site. ", "start_char_idx": 1269, "end_char_idx": 1432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdf44eb0-a0b4-4bb8-bac6-f2634aa5d529": {"__data__": {"id_": "bdf44eb0-a0b4-4bb8-bac6-f2634aa5d529", "embedding": null, "metadata": {"window": "And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n ", "original_text": "As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8bced18-5ec8-4f19-9d77-2a4ca5ea8298", "node_type": "1", "metadata": {"window": "You're right, our core business did continue to be very solid \ninto the quarter.  And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ce9dd850ad73ae2590b43d951e14db0bbb5adb98f7e0a7a46e2219374764997", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5ee7bad-e252-4c3d-bd64-cf672a9a0d6d", "node_type": "1", "metadata": {"window": "So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n ", "original_text": "It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n "}, "hash": "b0141927b07e53acf58e731bb06a0cdc361769a89b56f180ba222368633d485e", "class_name": "RelatedNodeInfo"}}, "text": "As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery. ", "start_char_idx": 1432, "end_char_idx": 1626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5ee7bad-e252-4c3d-bd64-cf672a9a0d6d": {"__data__": {"id_": "f5ee7bad-e252-4c3d-bd64-cf672a9a0d6d", "embedding": null, "metadata": {"window": "So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n ", "original_text": "It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdf44eb0-a0b4-4bb8-bac6-f2634aa5d529", "node_type": "1", "metadata": {"window": "And I tried to call out a little bit for you in my remarks what our growth was e xcluding COVID tests \nand PPE.  So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n ", "original_text": "As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3180ed4a8aae7c797e310f59dcd051d27fb9c1fc1ea0114730c78464afa0b65f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "738bd9c6-6013-4971-ba69-5f625e4a2331", "node_type": "1", "metadata": {"window": "I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  "}, "hash": "abadc68d2604a6296e51f09bf2f9cad8ba73acd9d7d54ff1d729bad1c23f1d75", "class_name": "RelatedNodeInfo"}}, "text": "It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n ", "start_char_idx": 1626, "end_char_idx": 1814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "738bd9c6-6013-4971-ba69-5f625e4a2331": {"__data__": {"id_": "738bd9c6-6013-4971-ba69-5f625e4a2331", "embedding": null, "metadata": {"window": "I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5ee7bad-e252-4c3d-bd64-cf672a9a0d6d", "node_type": "1", "metadata": {"window": "So that gives you some sense that we did continue to see solid momentum into our quarter.  \n \n I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n ", "original_text": "It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4201add44ac40de53a80ca91fe9c58bc6eeda1262a2d0eeb3142559fc106443e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfdc5cfc-1836-4429-b7a9-08bf9ac58f8a", "node_type": "1", "metadata": {"window": "As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "A \nOpera tor, next question?  \n "}, "hash": "222b5a60ac6f079d607b9b0c6caa22e1e9873c97ef8d5d4aabf6f21de7908540", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "start_char_idx": 1814, "end_char_idx": 2173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfdc5cfc-1836-4429-b7a9-08bf9ac58f8a": {"__data__": {"id_": "dfdc5cfc-1836-4429-b7a9-08bf9ac58f8a", "embedding": null, "metadata": {"window": "As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "A \nOpera tor, next question?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "738bd9c6-6013-4971-ba69-5f625e4a2331", "node_type": "1", "metadata": {"window": "I talked about a few of the items and certainly Brian can elaborate on as well, but if you think about our business, \nit is across all settings of alternate site.  As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d346bbe0da949b37d9aabbfbb8949304ecb55f626a9af2cb42d87f8dc84ca0a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa2bb967-b253-4621-8045-62f09cb99943", "node_type": "1", "metadata": {"window": "It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n "}, "hash": "18d5d4021804ff49c5e36c21fcb5a8670f36e57c961a3fb0bd5bfcd53f007233", "class_name": "RelatedNodeInfo"}}, "text": "A \nOpera tor, next question?  \n ", "start_char_idx": 2173, "end_char_idx": 2205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa2bb967-b253-4621-8045-62f09cb99943": {"__data__": {"id_": "fa2bb967-b253-4621-8045-62f09cb99943", "embedding": null, "metadata": {"window": "It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfdc5cfc-1836-4429-b7a9-08bf9ac58f8a", "node_type": "1", "metadata": {"window": "As we've talked about in prior calls, our product breath is very large, \nprivate brand, lab solutions, certainly the depth of capabilities that we have in extended care, patient home \ndelivery.  It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "A \nOpera tor, next question?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "072bec082291bd9bcb8859bb6238c4479859d1125e05b5e673c99b33a53b3cd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf82442a-3740-4c6c-9733-bde2817d8a18", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Good morning.  Thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "2654de71ae9acb78cc08fb2d7a874eb8ae8b249eba2b56cc4ddba77a41114860", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n ", "start_char_idx": 2205, "end_char_idx": 2521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf82442a-3740-4c6c-9733-bde2817d8a18": {"__data__": {"id_": "cf82442a-3740-4c6c-9733-bde2817d8a18", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Good morning.  Thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa2bb967-b253-4621-8045-62f09cb99943", "node_type": "1", "metadata": {"window": "It's a very broad set of solutions, capabilities and customer set that we address, and we've seen that \nreally continue to grow in a very stable way over the last several quarters now.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2597cc034de438f54f8b24dfd5054d1d7974fbc4adffd7017d39c64b03cf1ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "879093b7-7d0e-40c6-8a6e-eaac7daeb74a", "node_type": "1", "metadata": {"window": "A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Good morning.  Thanks for taking the question.  Just two quick ones. ", "original_text": "LLC  Q \nYeah. "}, "hash": "df304701c2a1fd2ec3e6e664c9c8e5179aa038d1235b67d8e9fe2747a5aa2978", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 2521, "end_char_idx": 2815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "879093b7-7d0e-40c6-8a6e-eaac7daeb74a": {"__data__": {"id_": "879093b7-7d0e-40c6-8a6e-eaac7daeb74a", "embedding": null, "metadata": {"window": "A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Good morning.  Thanks for taking the question.  Just two quick ones. ", "original_text": "LLC  Q \nYeah. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf82442a-3740-4c6c-9733-bde2817d8a18", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Good morning.  Thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "532e430b30b9cca5504ee9a0c9d3f1a61faf7cba4d70290594def53b3dc0f45e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e56bb5d-5b09-4b6a-948b-fd34c6569359", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Good morning.  Thanks for taking the question.  Just two quick ones.  Britt, maybe just to clarify. ", "original_text": "Good morning. "}, "hash": "886082eb504eb8c3d9fbf1c766ba27bd4e750490cb3e49bc5f640321b693c804", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah. ", "start_char_idx": 2815, "end_char_idx": 2829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e56bb5d-5b09-4b6a-948b-fd34c6569359": {"__data__": {"id_": "6e56bb5d-5b09-4b6a-948b-fd34c6569359", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Good morning.  Thanks for taking the question.  Just two quick ones.  Britt, maybe just to clarify. ", "original_text": "Good morning. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "879093b7-7d0e-40c6-8a6e-eaac7daeb74a", "node_type": "1", "metadata": {"window": "A \nOpera tor, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Good morning.  Thanks for taking the question.  Just two quick ones. ", "original_text": "LLC  Q \nYeah. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1670029e6395ee2f4cb7568b69e0f8f100b9f4445f85a6fe937254d1e196274", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bd000e7-0600-4222-a271-d6f23b212f8e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Good morning.  Thanks for taking the question.  Just two quick ones.  Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0. ", "original_text": "Thanks for taking the question. "}, "hash": "f8da522dcdcd41aaa7329bd3e5e89d126398c43c7525cb96d0a37bce2f3cbff6", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 939, "end_char_idx": 953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bd000e7-0600-4222-a271-d6f23b212f8e": {"__data__": {"id_": "1bd000e7-0600-4222-a271-d6f23b212f8e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Good morning.  Thanks for taking the question.  Just two quick ones.  Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0. ", "original_text": "Thanks for taking the question. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e56bb5d-5b09-4b6a-948b-fd34c6569359", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Charles Rhyee with Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Good morning.  Thanks for taking the question.  Just two quick ones.  Britt, maybe just to clarify. ", "original_text": "Good morning. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5e7c235e6b4896546a39eea3d5c577cad867634d7b6e3ad13117b58f889bdc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da0f03e8-560f-490b-a83d-1d0a9ba5d3c3", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Good morning.  Thanks for taking the question.  Just two quick ones.  Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0.  30 from kitting. ", "original_text": "Just two quick ones. "}, "hash": "ab927447c88331a431842f5c6afe11f72e32a94bd2ce59b2edfb144747be94bf", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 2843, "end_char_idx": 2875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da0f03e8-560f-490b-a83d-1d0a9ba5d3c3": {"__data__": {"id_": "da0f03e8-560f-490b-a83d-1d0a9ba5d3c3", "embedding": null, "metadata": {"window": "LLC  Q \nYeah.  Good morning.  Thanks for taking the question.  Just two quick ones.  Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0.  30 from kitting. ", "original_text": "Just two quick ones. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bd000e7-0600-4222-a271-d6f23b212f8e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Good morning.  Thanks for taking the question.  Just two quick ones.  Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0. ", "original_text": "Thanks for taking the question. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "13574e5efa9dc59507131b777369a496c87b81272f01932e0940b6265c1cfdb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb82764c-e55d-4833-a434-8b8c5e26f5a6", "node_type": "1", "metadata": {"window": "Good morning.  Thanks for taking the question.  Just two quick ones.  Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0.  30 from kitting.  I think last call you talked about $0.15 to $0.20. ", "original_text": "Britt, maybe just to clarify. "}, "hash": "738b230743029cd676cd8595457b6abfe7fc3636e9ed6da5892c7034934d54cd", "class_name": "RelatedNodeInfo"}}, "text": "Just two quick ones. ", "start_char_idx": 2875, "end_char_idx": 2896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb82764c-e55d-4833-a434-8b8c5e26f5a6": {"__data__": {"id_": "cb82764c-e55d-4833-a434-8b8c5e26f5a6", "embedding": null, "metadata": {"window": "Good morning.  Thanks for taking the question.  Just two quick ones.  Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0.  30 from kitting.  I think last call you talked about $0.15 to $0.20. ", "original_text": "Britt, maybe just to clarify. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da0f03e8-560f-490b-a83d-1d0a9ba5d3c3", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Good morning.  Thanks for taking the question.  Just two quick ones.  Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0.  30 from kitting. ", "original_text": "Just two quick ones. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "515fd9a77e7ed7cf57854f496e808976fd9c8229bb4dc9c24e30faea66bb05dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13489f26-1014-480d-badd-9918d31d010e", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Just two quick ones.  Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0.  30 from kitting.  I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10? ", "original_text": "You talked \nabout the $0.20 to $0. "}, "hash": "34984fa2c66ceef78d781564d8ebfd9e914767fc1891b8645cca1d35d1fa0ae0", "class_name": "RelatedNodeInfo"}}, "text": "Britt, maybe just to clarify. ", "start_char_idx": 2896, "end_char_idx": 2926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13489f26-1014-480d-badd-9918d31d010e": {"__data__": {"id_": "13489f26-1014-480d-badd-9918d31d010e", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Just two quick ones.  Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0.  30 from kitting.  I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10? ", "original_text": "You talked \nabout the $0.20 to $0. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb82764c-e55d-4833-a434-8b8c5e26f5a6", "node_type": "1", "metadata": {"window": "Good morning.  Thanks for taking the question.  Just two quick ones.  Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0.  30 from kitting.  I think last call you talked about $0.15 to $0.20. ", "original_text": "Britt, maybe just to clarify. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a8e061ace89e1e6537df148b328214c8207958bf243de43024a60fff8b3eef1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0968ce33-e5de-4cf8-98a5-fa6a38231bae", "node_type": "1", "metadata": {"window": "Just two quick ones.  Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0.  30 from kitting.  I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here. ", "original_text": "30 from kitting. "}, "hash": "3867b02503892de176ea93182242ecd84ea4ac5279e8f4aba806fec8adea1b83", "class_name": "RelatedNodeInfo"}}, "text": "You talked \nabout the $0.20 to $0. ", "start_char_idx": 2926, "end_char_idx": 2961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0968ce33-e5de-4cf8-98a5-fa6a38231bae": {"__data__": {"id_": "0968ce33-e5de-4cf8-98a5-fa6a38231bae", "embedding": null, "metadata": {"window": "Just two quick ones.  Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0.  30 from kitting.  I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here. ", "original_text": "30 from kitting. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13489f26-1014-480d-badd-9918d31d010e", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Just two quick ones.  Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0.  30 from kitting.  I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10? ", "original_text": "You talked \nabout the $0.20 to $0. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "321bc2e9c57fd06d7a231c4a75ed492fcb2758ed5f5b70947c5ba0d7145645f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18835154-a547-4a46-b56b-4f0ce8b8b9c7", "node_type": "1", "metadata": {"window": "Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0.  30 from kitting.  I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit? ", "original_text": "I think last call you talked about $0.15 to $0.20. "}, "hash": "40b023d45b74f9540374cdc899422c86d4d8232a4512a93030211a336d5b9357", "class_name": "RelatedNodeInfo"}}, "text": "30 from kitting. ", "start_char_idx": 2961, "end_char_idx": 2978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18835154-a547-4a46-b56b-4f0ce8b8b9c7": {"__data__": {"id_": "18835154-a547-4a46-b56b-4f0ce8b8b9c7", "embedding": null, "metadata": {"window": "Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0.  30 from kitting.  I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit? ", "original_text": "I think last call you talked about $0.15 to $0.20. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0968ce33-e5de-4cf8-98a5-fa6a38231bae", "node_type": "1", "metadata": {"window": "Just two quick ones.  Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0.  30 from kitting.  I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here. ", "original_text": "30 from kitting. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5492c48a11e661a286bb6c0d522afbf5e5f2924a256a0cf0841110c22238ef4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b3e6ad0-875b-4b39-9870-51d907578a08", "node_type": "1", "metadata": {"window": "You talked \nabout the $0.20 to $0.  30 from kitting.  I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS. ", "original_text": "So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10? "}, "hash": "11b58fe6dc7b721e3f31319077827b9b6c96e4c0e6785bcf7934e0d82f94d358", "class_name": "RelatedNodeInfo"}}, "text": "I think last call you talked about $0.15 to $0.20. ", "start_char_idx": 2978, "end_char_idx": 3029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b3e6ad0-875b-4b39-9870-51d907578a08": {"__data__": {"id_": "5b3e6ad0-875b-4b39-9870-51d907578a08", "embedding": null, "metadata": {"window": "You talked \nabout the $0.20 to $0.  30 from kitting.  I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS. ", "original_text": "So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10? ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18835154-a547-4a46-b56b-4f0ce8b8b9c7", "node_type": "1", "metadata": {"window": "Britt, maybe just to clarify.  You talked \nabout the $0.20 to $0.  30 from kitting.  I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit? ", "original_text": "I think last call you talked about $0.15 to $0.20. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "69d90453d10307d1276572c1b51ad2efc4d0051a6633a5f1a9b9f83fe8bbdbdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bf00cb5-9c25-4536-aa97-0cf9ee27ace8", "node_type": "1", "metadata": {"window": "30 from kitting.  I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from. ", "original_text": "And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here. "}, "hash": "6344649ef65031868f6dc0c1c4f7a231e9a71fd6a43b4c2e4aa528d7aa67730b", "class_name": "RelatedNodeInfo"}}, "text": "So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10? ", "start_char_idx": 3029, "end_char_idx": 3150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bf00cb5-9c25-4536-aa97-0cf9ee27ace8": {"__data__": {"id_": "6bf00cb5-9c25-4536-aa97-0cf9ee27ace8", "embedding": null, "metadata": {"window": "30 from kitting.  I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from. ", "original_text": "And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b3e6ad0-875b-4b39-9870-51d907578a08", "node_type": "1", "metadata": {"window": "You talked \nabout the $0.20 to $0.  30 from kitting.  I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS. ", "original_text": "So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10? ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "950dfb96e68ae301e65a46e60d93ff1ed80b85bf1fbd581079a2b0d4b60ce832", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8ea22ad-faf6-40a0-a732-90e84ccfddef", "node_type": "1", "metadata": {"window": "I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n ", "original_text": "Was there any benefit? "}, "hash": "f69473abb500543f24270bedf7df463a522f8d7cfb5c1f4fe8fa0d0746f3243a", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here. ", "start_char_idx": 3150, "end_char_idx": 3260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8ea22ad-faf6-40a0-a732-90e84ccfddef": {"__data__": {"id_": "c8ea22ad-faf6-40a0-a732-90e84ccfddef", "embedding": null, "metadata": {"window": "I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n ", "original_text": "Was there any benefit? ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bf00cb5-9c25-4536-aa97-0cf9ee27ace8", "node_type": "1", "metadata": {"window": "30 from kitting.  I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from. ", "original_text": "And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45e955759ed7c68f97ed01cad5ad49966f8c295c0e3e82cf7786f2f91320613f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fc77c86-dd04-4533-a63d-c6125b4a61a1", "node_type": "1", "metadata": {"window": "So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I \nthink one of your peers talked about receiving some funding from NHS. "}, "hash": "05350348b73d84245b6ec761bd2bf4625620620f4e35f631e96550c66dabca90", "class_name": "RelatedNodeInfo"}}, "text": "Was there any benefit? ", "start_char_idx": 3260, "end_char_idx": 3283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fc77c86-dd04-4533-a63d-c6125b4a61a1": {"__data__": {"id_": "2fc77c86-dd04-4533-a63d-c6125b4a61a1", "embedding": null, "metadata": {"window": "So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I \nthink one of your peers talked about receiving some funding from NHS. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8ea22ad-faf6-40a0-a732-90e84ccfddef", "node_type": "1", "metadata": {"window": "I think last call you talked about $0.15 to $0.20.  So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n ", "original_text": "Was there any benefit? ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "faf5e7954feefe319351acd0a557ad05fdbc63af4125faf258ff6c6b4a088ff3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74581cdb-a03c-4156-b9cf-5612ccbaf73b", "node_type": "1", "metadata": {"window": "And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "Just wanted to see if that was something \nthat you guys were also benefiting from. "}, "hash": "30be1886a14026ed7a801395135165caa469a508de230bcf69cb0179acb70a91", "class_name": "RelatedNodeInfo"}}, "text": "I \nthink one of your peers talked about receiving some funding from NHS. ", "start_char_idx": 3283, "end_char_idx": 3356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74581cdb-a03c-4156-b9cf-5612ccbaf73b": {"__data__": {"id_": "74581cdb-a03c-4156-b9cf-5612ccbaf73b", "embedding": null, "metadata": {"window": "And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "Just wanted to see if that was something \nthat you guys were also benefiting from. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fc77c86-dd04-4533-a63d-c6125b4a61a1", "node_type": "1", "metadata": {"window": "So, is this an incremental \n$0.20 to $0.30 or is it really \u2013 are we talking about just kind of a bump of $0.05 to $0.10?  And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I \nthink one of your peers talked about receiving some funding from NHS. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49e43b98ee449170e7e298887cea580406c206025db36b1197d586e8a09558da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d8d9c82-304c-485a-8089-aa620348d209", "node_type": "1", "metadata": {"window": "Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning. ", "original_text": "Thanks.  \n "}, "hash": "f0a1e52539932366b2a06ee07270fcc75b548c57114711d416fc163381193dc7", "class_name": "RelatedNodeInfo"}}, "text": "Just wanted to see if that was something \nthat you guys were also benefiting from. ", "start_char_idx": 3356, "end_char_idx": 3439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d8d9c82-304c-485a-8089-aa620348d209": {"__data__": {"id_": "3d8d9c82-304c-485a-8089-aa620348d209", "embedding": null, "metadata": {"window": "Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning. ", "original_text": "Thanks.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74581cdb-a03c-4156-b9cf-5612ccbaf73b", "node_type": "1", "metadata": {"window": "And then secondly, in \nthe international drug retail business, you ob viously took an impairment charge here.  Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "Just wanted to see if that was something \nthat you guys were also benefiting from. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed27b84777866bd49a4965a2a0153a35e93a35160d0ea9d48de338c17159b197", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ce1c3cd-41bc-4d3b-9612-fddbcce2f561", "node_type": "1", "metadata": {"window": "I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "0e34587f923847bd34154463cedba8d84300c00ba1ebcfeaecf07f654c31e596", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 3439, "end_char_idx": 3450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ce1c3cd-41bc-4d3b-9612-fddbcce2f561": {"__data__": {"id_": "0ce1c3cd-41bc-4d3b-9612-fddbcce2f561", "embedding": null, "metadata": {"window": "I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d8d9c82-304c-485a-8089-aa620348d209", "node_type": "1", "metadata": {"window": "Was there any benefit?  I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning. ", "original_text": "Thanks.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9a251a45ac4ed53de3253c6bb0280744b7a1ccd4e10c6b39aa30ce098628f06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88b37a4c-a69e-478e-bd53-ca451d3e3427", "node_type": "1", "metadata": {"window": "Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thanks for the question.  Let me take the first one quickly. ", "original_text": "A \nYeah. "}, "hash": "7acfce69629a241f386850ca5cf2aa207685e6e48804b7f75f375e88b4d017ba", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 3450, "end_char_idx": 3795, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88b37a4c-a69e-478e-bd53-ca451d3e3427": {"__data__": {"id_": "88b37a4c-a69e-478e-bd53-ca451d3e3427", "embedding": null, "metadata": {"window": "Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thanks for the question.  Let me take the first one quickly. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ce1c3cd-41bc-4d3b-9612-fddbcce2f561", "node_type": "1", "metadata": {"window": "I \nthink one of your peers talked about receiving some funding from NHS.  Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de8fa212765836b4a88ace7e06761979cec38815339aaba7b98f44e23d2186cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3cd5a3f-3023-4ee3-8935-f8b5fe5cd27c", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thanks for the question.  Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20. ", "original_text": "Good morning. "}, "hash": "907696f5fe339d0bffbfd32514f990c8dc73de1d4ef4e33dff582ce850241919", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 930, "end_char_idx": 939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3cd5a3f-3023-4ee3-8935-f8b5fe5cd27c": {"__data__": {"id_": "c3cd5a3f-3023-4ee3-8935-f8b5fe5cd27c", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thanks for the question.  Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20. ", "original_text": "Good morning. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88b37a4c-a69e-478e-bd53-ca451d3e3427", "node_type": "1", "metadata": {"window": "Just wanted to see if that was something \nthat you guys were also benefiting from.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thanks for the question.  Let me take the first one quickly. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3afdcc7ec4426936cd1fe88c7e3efd2ac41371c755401050b91697bd5a3bdbb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d84385a1-09d0-4510-bac7-ae809864e98e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thanks for the question.  Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10. ", "original_text": "Thanks for the question. "}, "hash": "a5370f4f6c216e719821d3ef040eec55d40925e10b5ae6c58b488623f2908fc2", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 939, "end_char_idx": 953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d84385a1-09d0-4510-bac7-ae809864e98e": {"__data__": {"id_": "d84385a1-09d0-4510-bac7-ae809864e98e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thanks for the question.  Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10. ", "original_text": "Thanks for the question. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3cd5a3f-3023-4ee3-8935-f8b5fe5cd27c", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thanks for the question.  Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20. ", "original_text": "Good morning. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4ed615f4a8c5efdcab09c31da71c3d81643967d5b3b06300925f0db3b6fc9dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43a40742-a8ff-4377-bd31-3af3907e051b", "node_type": "1", "metadata": {"window": "A \nYeah.  Good morning.  Thanks for the question.  Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n ", "original_text": "Let me take the first one quickly. "}, "hash": "1b167b804f391e3c213e94ee08c813a06606dbffdfce8e2488d4ad3e984d8aca", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 3818, "end_char_idx": 3843, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43a40742-a8ff-4377-bd31-3af3907e051b": {"__data__": {"id_": "43a40742-a8ff-4377-bd31-3af3907e051b", "embedding": null, "metadata": {"window": "A \nYeah.  Good morning.  Thanks for the question.  Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n ", "original_text": "Let me take the first one quickly. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d84385a1-09d0-4510-bac7-ae809864e98e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Good morning.  Thanks for the question.  Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10. ", "original_text": "Thanks for the question. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c73f3bb6aa39fbfc43397362ba291ad45b129a1378db57da075bbe8649ef136b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "706c5a0d-c012-43dc-b15b-08d281babd14", "node_type": "1", "metadata": {"window": "Good morning.  Thanks for the question.  Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20. "}, "hash": "3fa02d12031a48913d5e0908668af16da51ddf82565ad6ed7e324dd9f359e5ab", "class_name": "RelatedNodeInfo"}}, "text": "Let me take the first one quickly. ", "start_char_idx": 3843, "end_char_idx": 3878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "706c5a0d-c012-43dc-b15b-08d281babd14": {"__data__": {"id_": "706c5a0d-c012-43dc-b15b-08d281babd14", "embedding": null, "metadata": {"window": "Good morning.  Thanks for the question.  Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43a40742-a8ff-4377-bd31-3af3907e051b", "node_type": "1", "metadata": {"window": "A \nYeah.  Good morning.  Thanks for the question.  Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n ", "original_text": "Let me take the first one quickly. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "325ebfdd5efe4808a9c358f99cd3503d5518e8d081da979f090a5cdad766a60f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83f9daf7-9d48-422e-9c53-001a775df315", "node_type": "1", "metadata": {"window": "Thanks for the question.  Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n ", "original_text": "So, we did increase it from the last  by that $0.05 to $0.10. "}, "hash": "4645743c93dfdb7a9f5fb0d600b3f7bccd676641e7cc9dca3bb03ad008fbe82a", "class_name": "RelatedNodeInfo"}}, "text": "The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20. ", "start_char_idx": 3878, "end_char_idx": 3959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83f9daf7-9d48-422e-9c53-001a775df315": {"__data__": {"id_": "83f9daf7-9d48-422e-9c53-001a775df315", "embedding": null, "metadata": {"window": "Thanks for the question.  Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n ", "original_text": "So, we did increase it from the last  by that $0.05 to $0.10. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "706c5a0d-c012-43dc-b15b-08d281babd14", "node_type": "1", "metadata": {"window": "Good morning.  Thanks for the question.  Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27c1e5dad0aec9502e6ad6f52eb4156e5ba25ea74a0a2c16cd0ffd320c27f4c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e99ec59-5e6d-4289-995e-1ed8d29b52ee", "node_type": "1", "metadata": {"window": "Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "original_text": "In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n "}, "hash": "67067403c56fad62709044e958b4403e9f659f7bd5669c9361d13f334454892a", "class_name": "RelatedNodeInfo"}}, "text": "So, we did increase it from the last  by that $0.05 to $0.10. ", "start_char_idx": 3959, "end_char_idx": 4021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e99ec59-5e6d-4289-995e-1ed8d29b52ee": {"__data__": {"id_": "9e99ec59-5e6d-4289-995e-1ed8d29b52ee", "embedding": null, "metadata": {"window": "Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "original_text": "In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83f9daf7-9d48-422e-9c53-001a775df315", "node_type": "1", "metadata": {"window": "Thanks for the question.  Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n ", "original_text": "So, we did increase it from the last  by that $0.05 to $0.10. ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64ac95a8009183b2bac9a966c061a2fbb136b814e911d7da8150da10a0255c45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "257fa90e-c0de-4af3-a32e-a73dc8ccb24c", "node_type": "1", "metadata": {"window": "The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  "}, "hash": "989d3fee592fa5860310b08ce74c216b8fb63e8771b0e67b4f7a4b80aa1e4a88", "class_name": "RelatedNodeInfo"}}, "text": "In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n ", "start_char_idx": 4021, "end_char_idx": 4144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "257fa90e-c0de-4af3-a32e-a73dc8ccb24c": {"__data__": {"id_": "257fa90e-c0de-4af3-a32e-a73dc8ccb24c", "embedding": null, "metadata": {"window": "The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e99ec59-5e6d-4289-995e-1ed8d29b52ee", "node_type": "1", "metadata": {"window": "Let me take the first one quickly.  The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "original_text": "In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf1d5406521f48aa5df1ff504a265dbe2ffce182c1631d6ffbf9ef762f119323", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "959965f5-05b1-4d73-853d-d6ace5c0bfb5", "node_type": "1", "metadata": {"window": "So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q ", "original_text": "A \nOperator,  next question?  \n "}, "hash": "31bb12b0b78792077d8567a527f11ce1704e06766bffed6d3ee7e9223bbcd48e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "start_char_idx": 1814, "end_char_idx": 2173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "959965f5-05b1-4d73-853d-d6ace5c0bfb5": {"__data__": {"id_": "959965f5-05b1-4d73-853d-d6ace5c0bfb5", "embedding": null, "metadata": {"window": "So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q ", "original_text": "A \nOperator,  next question?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "257fa90e-c0de-4af3-a32e-a73dc8ccb24c", "node_type": "1", "metadata": {"window": "The $0.20 to $0.30 is not \nincremental, it's $0.20 to $0.30 from $0.15 to $0.20.  So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8bce16159fe2ffbb31cc22779b2e79aa23c48bafb2f78ecc07c708ace4f8209", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b6b3d61-762a-4bc2-b1cc-ac00487e760e", "node_type": "1", "metadata": {"window": "In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n "}, "hash": "88ac80a0febe55c983613475fef58edbbac6a2e032cb3ee7652896843feb46ba", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator,  next question?  \n ", "start_char_idx": 4503, "end_char_idx": 4535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b6b3d61-762a-4bc2-b1cc-ac00487e760e": {"__data__": {"id_": "5b6b3d61-762a-4bc2-b1cc-ac00487e760e", "embedding": null, "metadata": {"window": "In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "959965f5-05b1-4d73-853d-d6ace5c0bfb5", "node_type": "1", "metadata": {"window": "So, we did increase it from the last  by that $0.05 to $0.10.  In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q ", "original_text": "A \nOperator,  next question?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "def577f2c886a174146bc52b26f689d66b2b165157aa97bf69ba9dcaee257758", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98d4bdb2-1997-4edf-bd89-ffa4bc0dbabc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q "}, "hash": "cadff0384313ef98271bb962fc6b7747872eedf59bb1220681d599a3485327b9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "start_char_idx": 4535, "end_char_idx": 4861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98d4bdb2-1997-4edf-bd89-ffa4bc0dbabc": {"__data__": {"id_": "98d4bdb2-1997-4edf-bd89-ffa4bc0dbabc", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "db8d5d3e-e808-457d-b744-7224d3302f44", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc10839280f29397d1a28d56f97d1e50671631455f00d3de904ade80bf3ef6ee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b6b3d61-762a-4bc2-b1cc-ac00487e760e", "node_type": "1", "metadata": {"window": "In \nterms of the International question, the NHS funding that you referenced here was fairly immaterial to our quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cdbe2c679fb3cfda8fc00c749840a855892fbfffd12db8c18a66ecbfaa2cafa8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "007f14c5-b700-4aed-ac00-8f491a8bb0bd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you.  So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength? ", "original_text": "McKesson Corp.  "}, "hash": "c6a70f9dbb4a8674413a085a5181e6d37dd53c9eb366109cb6b2d4920c1cc82f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q ", "start_char_idx": 4861, "end_char_idx": 5166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "007f14c5-b700-4aed-ac00-8f491a8bb0bd": {"__data__": {"id_": "007f14c5-b700-4aed-ac00-8f491a8bb0bd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you.  So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength? ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98d4bdb2-1997-4edf-bd89-ffa4bc0dbabc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator,  next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77e5d4ea5c9e87c26b82f429d45ecf7d64e7cb95aae5d7d5b5a40d08f10fbff9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01dcb3f5-1bf8-432d-93fc-6714bbc12adb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you.  So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you. "}, "hash": "13942ce6e49dfe10f517a0a6247e7b6b677eb6342c9888e1e1ccea842b79c5b6", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01dcb3f5-1bf8-432d-93fc-6714bbc12adb": {"__data__": {"id_": "01dcb3f5-1bf8-432d-93fc-6714bbc12adb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you.  So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "007f14c5-b700-4aed-ac00-8f491a8bb0bd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you.  So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength? ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40df69c4dfb0cd72c4e89b7f199cfc3021e91f2b40649ec9a530dfd03cb70010", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa19da2c-66c9-45b4-a8ad-37079f5dc49d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you.  So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver? ", "original_text": "So, in Medical, I think a lot of questions on kitting, vaccine. "}, "hash": "afc88f06c481430fbdc0f64fa155ecffa3ed4088b76d647e4a49fd965d40b2fd", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you. ", "start_char_idx": 16, "end_char_idx": 192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa19da2c-66c9-45b4-a8ad-37079f5dc49d": {"__data__": {"id_": "aa19da2c-66c9-45b4-a8ad-37079f5dc49d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you.  So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver? ", "original_text": "So, in Medical, I think a lot of questions on kitting, vaccine. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01dcb3f5-1bf8-432d-93fc-6714bbc12adb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you.  So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc99e4d3472a3c355fe66f5d57acbb5976f62955bbc8a04d6530d5b8329bcb46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "746b1be4-c714-402e-a860-80867612c7ab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you.  So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n ", "original_text": "Am I wrong to expect that this is really \ntesting -driven strength? "}, "hash": "07c2e7a7668af6ed79d68c6c5488df25d37062822d6ddc27d07f1dcc6bf7bb7d", "class_name": "RelatedNodeInfo"}}, "text": "So, in Medical, I think a lot of questions on kitting, vaccine. ", "start_char_idx": 192, "end_char_idx": 256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "746b1be4-c714-402e-a860-80867612c7ab": {"__data__": {"id_": "746b1be4-c714-402e-a860-80867612c7ab", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you.  So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n ", "original_text": "Am I wrong to expect that this is really \ntesting -driven strength? ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa19da2c-66c9-45b4-a8ad-37079f5dc49d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you.  So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver? ", "original_text": "So, in Medical, I think a lot of questions on kitting, vaccine. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "610cc9ef23c7308a8bcd128de380c7e0433c6b49378bcbcd2ca135ff1efd3ca7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7b78c38-4a6e-4aa8-a8f5-d8a7f2c4c439", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you.  So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter. "}, "hash": "18ed59f3bdebc848ebf9a8c234ccab7cd51feb49f0a2df82b87ed53faf6178cc", "class_name": "RelatedNodeInfo"}}, "text": "Am I wrong to expect that this is really \ntesting -driven strength? ", "start_char_idx": 256, "end_char_idx": 324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7b78c38-4a6e-4aa8-a8f5-d8a7f2c4c439": {"__data__": {"id_": "c7b78c38-4a6e-4aa8-a8f5-d8a7f2c4c439", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you.  So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "746b1be4-c714-402e-a860-80867612c7ab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you.  So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n ", "original_text": "Am I wrong to expect that this is really \ntesting -driven strength? ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a875f01ee9d19c9a59a85ce86d1d69923004b7acb5eb38d87d24a4dea0bfc846", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1167720-6c1e-4484-b12b-c63e7f371c9c", "node_type": "1", "metadata": {"window": "So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question. ", "original_text": "So, is that really the primary driver? "}, "hash": "5fee551b15fafddea1f1bbbb47b6a008f2cc5cebd6cb652b056d2c19fa52c8c5", "class_name": "RelatedNodeInfo"}}, "text": "And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter. ", "start_char_idx": 324, "end_char_idx": 434, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1167720-6c1e-4484-b12b-c63e7f371c9c": {"__data__": {"id_": "e1167720-6c1e-4484-b12b-c63e7f371c9c", "embedding": null, "metadata": {"window": "So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question. ", "original_text": "So, is that really the primary driver? ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7b78c38-4a6e-4aa8-a8f5-d8a7f2c4c439", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you.  So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6379e313fad8c5a4cf46112f4f9d35c166dca734f2277617ebe9f1c989e2fcd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "336868d9-1fe3-49b5-817d-4de1527ed823", "node_type": "1", "metadata": {"window": "Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question.  I would say it's really both things. ", "original_text": "And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n "}, "hash": "5fe79c5809499cd9a34e6df0557ad92a79fded4807327d085db6f78e6949d1fd", "class_name": "RelatedNodeInfo"}}, "text": "So, is that really the primary driver? ", "start_char_idx": 434, "end_char_idx": 473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "336868d9-1fe3-49b5-817d-4de1527ed823": {"__data__": {"id_": "336868d9-1fe3-49b5-817d-4de1527ed823", "embedding": null, "metadata": {"window": "Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question.  I would say it's really both things. ", "original_text": "And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1167720-6c1e-4484-b12b-c63e7f371c9c", "node_type": "1", "metadata": {"window": "So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question. ", "original_text": "So, is that really the primary driver? ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8eb4ddfab7e6592c0c9f1d0f6088e683478fb4621417523b7343712170687d3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab7b1257-f0fb-475e-b646-22d8df98c2e4", "node_type": "1", "metadata": {"window": "And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question.  I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "44b513c0c5c56e3d4eea56de34446f77614cbdb64a0a7b7956061a24d9bf0248", "class_name": "RelatedNodeInfo"}}, "text": "And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n ", "start_char_idx": 473, "end_char_idx": 583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab7b1257-f0fb-475e-b646-22d8df98c2e4": {"__data__": {"id_": "ab7b1257-f0fb-475e-b646-22d8df98c2e4", "embedding": null, "metadata": {"window": "And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question.  I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "336868d9-1fe3-49b5-817d-4de1527ed823", "node_type": "1", "metadata": {"window": "Am I wrong to expect that this is really \ntesting -driven strength?  And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question.  I would say it's really both things. ", "original_text": "And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c05d7baadda8d8223eee0ecb3a83ab98d84f9b075914c78aee4c6cfba2d477b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a99e7d9-1b22-4abc-a5bf-a969bc08f4fc", "node_type": "1", "metadata": {"window": "So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question.  I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting. ", "original_text": "A \nEric, thank you for the question. "}, "hash": "5615d45f24808007bc43fa04ce0a6ff855c225cfbde14059af88ee6e8977aaae", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 583, "end_char_idx": 912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a99e7d9-1b22-4abc-a5bf-a969bc08f4fc": {"__data__": {"id_": "2a99e7d9-1b22-4abc-a5bf-a969bc08f4fc", "embedding": null, "metadata": {"window": "So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question.  I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting. ", "original_text": "A \nEric, thank you for the question. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab7b1257-f0fb-475e-b646-22d8df98c2e4", "node_type": "1", "metadata": {"window": "And we look at the testing numbers, they seem to have doubled or tripled from quarter to \nquarter to quarter.  So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question.  I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ccf52d98d1db0bbd0c96ec15af357958c10d1ff8cf2e9dec17b756213274b1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d7f9c74-86e9-43c5-9665-8fc8c320610a", "node_type": "1", "metadata": {"window": "And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question.  I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n", "original_text": "I would say it's really both things. "}, "hash": "3cda4ab3526d6ab6555150d816536e1014a9254abcf38ac23b0b5c98a46b16bf", "class_name": "RelatedNodeInfo"}}, "text": "A \nEric, thank you for the question. ", "start_char_idx": 912, "end_char_idx": 949, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d7f9c74-86e9-43c5-9665-8fc8c320610a": {"__data__": {"id_": "1d7f9c74-86e9-43c5-9665-8fc8c320610a", "embedding": null, "metadata": {"window": "And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question.  I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n", "original_text": "I would say it's really both things. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a99e7d9-1b22-4abc-a5bf-a969bc08f4fc", "node_type": "1", "metadata": {"window": "So, is that really the primary driver?  And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question.  I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting. ", "original_text": "A \nEric, thank you for the question. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f622eb3ab1c785d9791d845fac5e87157242f669b14efe5b0c159e69d71721b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14937692-3fbf-416d-8ffb-254d0a5f11fc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question.  I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly. ", "original_text": "I mean, I think the PPE demand has remained \nelevated and strong. "}, "hash": "32f1e50f5ba48b178361001ddd2682775ea0bd04278f814aede0b61c47e03485", "class_name": "RelatedNodeInfo"}}, "text": "I would say it's really both things. ", "start_char_idx": 949, "end_char_idx": 986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14937692-3fbf-416d-8ffb-254d0a5f11fc": {"__data__": {"id_": "14937692-3fbf-416d-8ffb-254d0a5f11fc", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question.  I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly. ", "original_text": "I mean, I think the PPE demand has remained \nelevated and strong. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d7f9c74-86e9-43c5-9665-8fc8c320610a", "node_type": "1", "metadata": {"window": "And is the supply there continuing to expand in ways that \nwill enable you to contin ue facilitating that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question.  I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n", "original_text": "I would say it's really both things. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5944db7fc5bcf2e567143c245f038ae86a69e2f4fd24786ddb997cd983858002", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae5afb72-1e8c-4113-8cef-e110892ea113", "node_type": "1", "metadata": {"window": "A \nEric, thank you for the question.  I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n ", "original_text": "That's certainly contrib uting. "}, "hash": "8405f9f29cadf92785e2433d5d533cf60c92589785c48ea519d4b964389de3cd", "class_name": "RelatedNodeInfo"}}, "text": "I mean, I think the PPE demand has remained \nelevated and strong. ", "start_char_idx": 986, "end_char_idx": 1052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae5afb72-1e8c-4113-8cef-e110892ea113": {"__data__": {"id_": "ae5afb72-1e8c-4113-8cef-e110892ea113", "embedding": null, "metadata": {"window": "A \nEric, thank you for the question.  I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n ", "original_text": "That's certainly contrib uting. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14937692-3fbf-416d-8ffb-254d0a5f11fc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nEric, thank you for the question.  I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly. ", "original_text": "I mean, I think the PPE demand has remained \nelevated and strong. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "823d6bf0e776017957e708932da49d166174ebe075f878022319f3e78ba39203", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5b3294c-0265-4446-a13a-e15c9fd0819b", "node_type": "1", "metadata": {"window": "I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n"}, "hash": "333b7cebbad968bcd64410b61dadf9a5199efaa19ca8fb743ec26d4ab2afdb07", "class_name": "RelatedNodeInfo"}}, "text": "That's certainly contrib uting. ", "start_char_idx": 1052, "end_char_idx": 1084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5b3294c-0265-4446-a13a-e15c9fd0819b": {"__data__": {"id_": "f5b3294c-0265-4446-a13a-e15c9fd0819b", "embedding": null, "metadata": {"window": "I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae5afb72-1e8c-4113-8cef-e110892ea113", "node_type": "1", "metadata": {"window": "A \nEric, thank you for the question.  I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n ", "original_text": "That's certainly contrib uting. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ded4a3be831a3fe2bfd43855a77fc0146e627dd04471c87c9f9a18e6ea26460b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35f1e843-6b11-42f5-8745-9748746172e3", "node_type": "1", "metadata": {"window": "I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on. ", "original_text": "So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly. "}, "hash": "97a30ce6de21bf9399a18dacc2ded9c0bde15ffbaa83a70d94139f3e3dfa0205", "class_name": "RelatedNodeInfo"}}, "text": "And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n", "start_char_idx": 1084, "end_char_idx": 1272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35f1e843-6b11-42f5-8745-9748746172e3": {"__data__": {"id_": "35f1e843-6b11-42f5-8745-9748746172e3", "embedding": null, "metadata": {"window": "I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on. ", "original_text": "So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5b3294c-0265-4446-a13a-e15c9fd0819b", "node_type": "1", "metadata": {"window": "I would say it's really both things.  I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6c1f97cb360795daaebb008da0bbe3888cdafa945f54ef58723517f5ef38cc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87ff3ef5-72d4-4399-91ec-6e6c8965b2a1", "node_type": "1", "metadata": {"window": "That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n ", "original_text": "And we have certainly benefited from the strong demand for COVID test kits.  \n "}, "hash": "6a09b4c69b7cc56faa1e403ee124889c29ad0f638231b8696751152e00028650", "class_name": "RelatedNodeInfo"}}, "text": "So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly. ", "start_char_idx": 1272, "end_char_idx": 1520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87ff3ef5-72d4-4399-91ec-6e6c8965b2a1": {"__data__": {"id_": "87ff3ef5-72d4-4399-91ec-6e6c8965b2a1", "embedding": null, "metadata": {"window": "That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n ", "original_text": "And we have certainly benefited from the strong demand for COVID test kits.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35f1e843-6b11-42f5-8745-9748746172e3", "node_type": "1", "metadata": {"window": "I mean, I think the PPE demand has remained \nelevated and strong.  That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on. ", "original_text": "So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6da00fe3f38393f148d31eb30c14ba763519f018e6ea7fe1342bdfe4a5745ce4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f84ac324-769e-4f8f-ab0b-fc95929857f4", "node_type": "1", "metadata": {"window": "And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "530dce59b3e5f2e7f469e58467bb312b2cfbe02088115b07c2e83caf7da3066c", "class_name": "RelatedNodeInfo"}}, "text": "And we have certainly benefited from the strong demand for COVID test kits.  \n ", "start_char_idx": 1520, "end_char_idx": 1599, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f84ac324-769e-4f8f-ab0b-fc95929857f4": {"__data__": {"id_": "f84ac324-769e-4f8f-ab0b-fc95929857f4", "embedding": null, "metadata": {"window": "And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87ff3ef5-72d4-4399-91ec-6e6c8965b2a1", "node_type": "1", "metadata": {"window": "That's certainly contrib uting.  And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n ", "original_text": "And we have certainly benefited from the strong demand for COVID test kits.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54b70ce3ffc9e8becd9d2359fac68b6ee5caf9ca1676b999158acb62a8f68d86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8967fef5-a0b8-4566-bec8-b525901e3546", "node_type": "1", "metadata": {"window": "So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n ", "original_text": "A \nAnd Eric, maybe I'll just add on. "}, "hash": "675da90a0ad933ebfafbe9af12a2603ebaab84ca7d668cd1d57b661086d86ec0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 1599, "end_char_idx": 1944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8967fef5-a0b8-4566-bec8-b525901e3546": {"__data__": {"id_": "8967fef5-a0b8-4566-bec8-b525901e3546", "embedding": null, "metadata": {"window": "So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n ", "original_text": "A \nAnd Eric, maybe I'll just add on. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f84ac324-769e-4f8f-ab0b-fc95929857f4", "node_type": "1", "metadata": {"window": "And there's no question that as COVID test kits emerged on the \nscene \u2013 remember, when we provided our guide at the beginning of this year, there wasn't such a thing as a \nCOVID test.  \n \n So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "38b860151b0d1499ea1430f390db2f550e88bca3cbaf77b64e12bc971e212cce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07505390-43df-483e-a725-241d9728f5ed", "node_type": "1", "metadata": {"window": "And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n ", "original_text": "I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n "}, "hash": "3c6ea87332ca582ff5f4e5867d3ee189141279bf02753979a7315f80bdf7c95b", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd Eric, maybe I'll just add on. ", "start_char_idx": 1944, "end_char_idx": 1981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07505390-43df-483e-a725-241d9728f5ed": {"__data__": {"id_": "07505390-43df-483e-a725-241d9728f5ed", "embedding": null, "metadata": {"window": "And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n ", "original_text": "I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8967fef5-a0b8-4566-bec8-b525901e3546", "node_type": "1", "metadata": {"window": "So, as the scientific community, the lab community began to develo p these tests, whether molecular, antigen, \nantibody, because of our existing business in the lab, we were really well -positioned to help get those to market \nquickly and swiftly.  And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n ", "original_text": "A \nAnd Eric, maybe I'll just add on. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08b7453e77f06fddfecf3843b34a811cf0f9e66d0ac6d2341252eae9f360250f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e580d55-ae1c-4dfb-8959-211fcd59b729", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  "}, "hash": "ef9c63c07c6fd37db01bd53a88e3a23e052a5c0173bfbfbd15ef6b4202815c99", "class_name": "RelatedNodeInfo"}}, "text": "I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n ", "start_char_idx": 1981, "end_char_idx": 2338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e580d55-ae1c-4dfb-8959-211fcd59b729": {"__data__": {"id_": "5e580d55-ae1c-4dfb-8959-211fcd59b729", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07505390-43df-483e-a725-241d9728f5ed", "node_type": "1", "metadata": {"window": "And we have certainly benefited from the strong demand for COVID test kits.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n ", "original_text": "I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a2c36c7cdc29f57a7cf3977f23291ba956ab171ce2ed6ba58c7c26e8d0248d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3386d0ce-2af5-4161-b300-cdb7ea023af8", "node_type": "1", "metadata": {"window": "A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you. ", "original_text": "A \nOperator, next question?  \n "}, "hash": "b5974b9bdb35da34800ce70e3e09701effc89501381d6e93a85221850bee7eb8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "start_char_idx": 2338, "end_char_idx": 2697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3386d0ce-2af5-4161-b300-cdb7ea023af8": {"__data__": {"id_": "3386d0ce-2af5-4161-b300-cdb7ea023af8", "embedding": null, "metadata": {"window": "A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you. ", "original_text": "A \nOperator, next question?  \n ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e580d55-ae1c-4dfb-8959-211fcd59b729", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2918113795e3d4f495e896c1c9c2dba68604180614eefd18887e27f79a4ed9e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "012aa14c-e413-4dfb-9e87-737e0a079c78", "node_type": "1", "metadata": {"window": "I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you.  A quick  clarification on vaccine. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n "}, "hash": "edf2927ba246cf003a72812867a3e2900c2e3f744f50abf6cce09be2dfffaaaa", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator, next question?  \n ", "start_char_idx": 2697, "end_char_idx": 2728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "012aa14c-e413-4dfb-9e87-737e0a079c78": {"__data__": {"id_": "012aa14c-e413-4dfb-9e87-737e0a079c78", "embedding": null, "metadata": {"window": "I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you.  A quick  clarification on vaccine. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3386d0ce-2af5-4161-b300-cdb7ea023af8", "node_type": "1", "metadata": {"window": "A \nAnd Eric, maybe I'll just add on.  I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you. ", "original_text": "A \nOperator, next question?  \n ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f545ed25003232bb22738eed85554b5d68dfa1815bf9b36212d6fa9e14fbb36b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66ced4c7-c53b-4403-8881-f84d28003b71", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you.  A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes. "}, "hash": "bdd4bbc544a0311030960321f4e19c24281b553bdea965cb8dab93fd4bef7edc", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n ", "start_char_idx": 2728, "end_char_idx": 3054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66ced4c7-c53b-4403-8881-f84d28003b71": {"__data__": {"id_": "66ced4c7-c53b-4403-8881-f84d28003b71", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you.  A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "012aa14c-e413-4dfb-9e87-737e0a079c78", "node_type": "1", "metadata": {"window": "I did try to call out in my comments here that, while this has been elevated and \nwe've seen sort of an uneven supply and demand throug hout the year, we do expect that this will moderate and \nwe expect the elevated demands to remain through our fiscal year, but we do expect that at some point in FY \n2022 these elevated levels of demand will moderate.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you.  A quick  clarification on vaccine. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24b17a2b0a53c7d651458954195892ebf2a558c69f5be0d04bd5c803785e70cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77e418c5-a50a-4408-a9cc-78d452b50711", "node_type": "1", "metadata": {"window": "A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you.  A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance. ", "original_text": "Thank you. "}, "hash": "d4833e6925efe710600d86a0726f7721bff9b9780cb155995a3b379e74750eb6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes. ", "start_char_idx": 3054, "end_char_idx": 3382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77e418c5-a50a-4408-a9cc-78d452b50711": {"__data__": {"id_": "77e418c5-a50a-4408-a9cc-78d452b50711", "embedding": null, "metadata": {"window": "A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you.  A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance. ", "original_text": "Thank you. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66ced4c7-c53b-4403-8881-f84d28003b71", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you.  A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72fc99f893a6533fdcceec4d2e0d4cb615f2eb14fa6a96ae2dce3cc1d38d26b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9b771be-b39e-4bbb-b516-6a8976ce07b0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you.  A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021? ", "original_text": "A quick  clarification on vaccine. "}, "hash": "69f2a2b52ab26191c07aacf1c65f37c9e81fcfa2c286787896232eea9cb18367", "class_name": "RelatedNodeInfo"}}, "text": "Thank you. ", "start_char_idx": 181, "end_char_idx": 192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9b771be-b39e-4bbb-b516-6a8976ce07b0": {"__data__": {"id_": "b9b771be-b39e-4bbb-b516-6a8976ce07b0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you.  A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021? ", "original_text": "A quick  clarification on vaccine. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77e418c5-a50a-4408-a9cc-78d452b50711", "node_type": "1", "metadata": {"window": "A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you.  A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance. ", "original_text": "Thank you. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de49ced0bd7b4667cfc45e68255e636efa2781e0cbde99a668073bfc3eac7773", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6aafa541-8a5b-41e1-8a8b-ce23e053abc2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you.  A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n ", "original_text": "Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US? "}, "hash": "a412e91c2f6efc6ee59385a7f71c30f91d01f693ba947c06343e30a0b0d9ac66", "class_name": "RelatedNodeInfo"}}, "text": "A quick  clarification on vaccine. ", "start_char_idx": 3393, "end_char_idx": 3428, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6aafa541-8a5b-41e1-8a8b-ce23e053abc2": {"__data__": {"id_": "6aafa541-8a5b-41e1-8a8b-ce23e053abc2", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you.  A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n ", "original_text": "Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US? ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9b771be-b39e-4bbb-b516-6a8976ce07b0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Jailendra Singh with Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you.  A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021? ", "original_text": "A quick  clarification on vaccine. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "865090e77ebf81ce6f78046a2f09932d32b0102136c94ecf720967104985a17f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3aa3a2dc-4ae4-47ea-97ad-dcaca633c35c", "node_type": "1", "metadata": {"window": "Thank you.  A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance. "}, "hash": "50f424a8db23b0d7420f90fb2cdd8d73c3ed825545700dba18603f70f252ade5", "class_name": "RelatedNodeInfo"}}, "text": "Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US? ", "start_char_idx": 3428, "end_char_idx": 3539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3aa3a2dc-4ae4-47ea-97ad-dcaca633c35c": {"__data__": {"id_": "3aa3a2dc-4ae4-47ea-97ad-dcaca633c35c", "embedding": null, "metadata": {"window": "Thank you.  A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6aafa541-8a5b-41e1-8a8b-ce23e053abc2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nYes.  Thank you.  A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n ", "original_text": "Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US? ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b670bef25d423dd1bfa1ede0753071578c5c5d31678147eea6ebc27c1530b63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbce21b6-0302-4cef-bc4d-4a5414bd69b8", "node_type": "1", "metadata": {"window": "A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021? "}, "hash": "fbf87eeecccf9642821fc93bfca591494235e3ea8b40d4d5a483c7f5b14f536e", "class_name": "RelatedNodeInfo"}}, "text": "And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance. ", "start_char_idx": 3539, "end_char_idx": 3654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbce21b6-0302-4cef-bc4d-4a5414bd69b8": {"__data__": {"id_": "bbce21b6-0302-4cef-bc4d-4a5414bd69b8", "embedding": null, "metadata": {"window": "A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021? ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3aa3a2dc-4ae4-47ea-97ad-dcaca633c35c", "node_type": "1", "metadata": {"window": "Thank you.  A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05aeea3def9f36eb42134bbfe628093895a43c5913dd1185f8abdfa09a44ffc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c5c3ce4-1cdf-474d-a560-c2fc0940539f", "node_type": "1", "metadata": {"window": "Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I'll just start with the guide for the vaccine. ", "original_text": "Any color there will be helpful.  \n "}, "hash": "ed07394b6ff94486b6772c9daa69d6b3fff155d223801ec4fcfa6e372004ad2e", "class_name": "RelatedNodeInfo"}}, "text": "Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021? ", "start_char_idx": 3654, "end_char_idx": 3763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c5c3ce4-1cdf-474d-a560-c2fc0940539f": {"__data__": {"id_": "6c5c3ce4-1cdf-474d-a560-c2fc0940539f", "embedding": null, "metadata": {"window": "Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I'll just start with the guide for the vaccine. ", "original_text": "Any color there will be helpful.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbce21b6-0302-4cef-bc4d-4a5414bd69b8", "node_type": "1", "metadata": {"window": "A quick  clarification on vaccine.  Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021? ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1cbecc299d8df81348e8580dcb3db50d9b26cfe4554f008e5a5285e051ff66b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3efe36e7-2d83-40a7-bf43-8c170c240c32", "node_type": "1", "metadata": {"window": "And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "d4b0e8e36ba6361e45c4c95fe6b884ab366c39cb177b54849eb764bd40206f99", "class_name": "RelatedNodeInfo"}}, "text": "Any color there will be helpful.  \n ", "start_char_idx": 3763, "end_char_idx": 3799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3efe36e7-2d83-40a7-bf43-8c170c240c32": {"__data__": {"id_": "3efe36e7-2d83-40a7-bf43-8c170c240c32", "embedding": null, "metadata": {"window": "And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c5c3ce4-1cdf-474d-a560-c2fc0940539f", "node_type": "1", "metadata": {"window": "Does the vaccine EPS contribution take into account additional \nvaccines receiving approval for use in the US?  And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I'll just start with the guide for the vaccine. ", "original_text": "Any color there will be helpful.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e048955d4c220736445dac863f64feeff88afb4fce5410d2658df7d5df73e11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c238d40b-3ed5-4eb0-aeff-7bdd3d12d4b8", "node_type": "1", "metadata": {"window": "Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "A \nYeah. "}, "hash": "8254e8b8b86d4b67f26bd0127ebcd474f96cd9ac6bcc753d2e0608ff554da87a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 583, "end_char_idx": 912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c238d40b-3ed5-4eb0-aeff-7bdd3d12d4b8": {"__data__": {"id_": "c238d40b-3ed5-4eb0-aeff-7bdd3d12d4b8", "embedding": null, "metadata": {"window": "Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "A \nYeah. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3efe36e7-2d83-40a7-bf43-8c170c240c32", "node_type": "1", "metadata": {"window": "And then my main question, I want to better understand the $100 \nmillion increase to the company's CapEx guidance.  Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07382bf9d02841cc8dd1a564be62455500c1152858fd66916d529b538630f973", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "052a07c2-4934-4e1a-b382-14625813f28f", "node_type": "1", "metadata": {"window": "Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one. ", "original_text": "I'll just start with the guide for the vaccine. "}, "hash": "3e635b6a7954926ab00e4f172e7676b94e3facca1434467fe1fa6d4af0ef0496", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 4128, "end_char_idx": 4137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "052a07c2-4934-4e1a-b382-14625813f28f": {"__data__": {"id_": "052a07c2-4934-4e1a-b382-14625813f28f", "embedding": null, "metadata": {"window": "Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one. ", "original_text": "I'll just start with the guide for the vaccine. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c238d40b-3ed5-4eb0-aeff-7bdd3d12d4b8", "node_type": "1", "metadata": {"window": "Is th at all related to building out more infrastructure for COVID \nvaccine distribution beyond fiscal 2021?  Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "A \nYeah. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb0339592446569ffd1c928608e39095e6b7b076415fa1c20c415add34598d14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44e59188-6206-471e-8e35-773d911c9f41", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx. ", "original_text": "It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n "}, "hash": "7bbf37dc8f6272b65d97afaabd54d2483e13866e324f6029ecadba8314ea0e22", "class_name": "RelatedNodeInfo"}}, "text": "I'll just start with the guide for the vaccine. ", "start_char_idx": 4137, "end_char_idx": 4185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44e59188-6206-471e-8e35-773d911c9f41": {"__data__": {"id_": "44e59188-6206-471e-8e35-773d911c9f41", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx. ", "original_text": "It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "052a07c2-4934-4e1a-b382-14625813f28f", "node_type": "1", "metadata": {"window": "Any color there will be helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one. ", "original_text": "I'll just start with the guide for the vaccine. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0dbe54c60d93bf663d5a33b5d1dbaf9e979b1821ecbd34d7e8283b5e10f97afb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b388715-3c35-40d0-be46-4fb2efe5dd3a", "node_type": "1", "metadata": {"window": "A \nYeah.  I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx.  Part of that is to support the vaccine and kitting \nprograms. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "be3a5a64f911730d792d9ab893f5d23fc21acd1fa99754d5639abe7ee9e2397c", "class_name": "RelatedNodeInfo"}}, "text": "It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n ", "start_char_idx": 4185, "end_char_idx": 4325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b388715-3c35-40d0-be46-4fb2efe5dd3a": {"__data__": {"id_": "9b388715-3c35-40d0-be46-4fb2efe5dd3a", "embedding": null, "metadata": {"window": "A \nYeah.  I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx.  Part of that is to support the vaccine and kitting \nprograms. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44e59188-6206-471e-8e35-773d911c9f41", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx. ", "original_text": "It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee2f50e0426b17b2a428c242edb2415786792de1ff454606d1ee08c789844a72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ab76461-0ff0-47a9-8077-4797d7ffc09d", "node_type": "1", "metadata": {"window": "I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx.  Part of that is to support the vaccine and kitting \nprograms.  But a larger part of that is really continuing to invest in our strategies, technology, data and analytics to ", "original_text": "A \nAnd I'll take the Cap Ex one. "}, "hash": "26330ee12660b059207b656a72c8d69cb6b666d477065c14276b4a40eeea5917", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 1599, "end_char_idx": 1944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ab76461-0ff0-47a9-8077-4797d7ffc09d": {"__data__": {"id_": "4ab76461-0ff0-47a9-8077-4797d7ffc09d", "embedding": null, "metadata": {"window": "I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx.  Part of that is to support the vaccine and kitting \nprograms.  But a larger part of that is really continuing to invest in our strategies, technology, data and analytics to ", "original_text": "A \nAnd I'll take the Cap Ex one. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b388715-3c35-40d0-be46-4fb2efe5dd3a", "node_type": "1", "metadata": {"window": "A \nYeah.  I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx.  Part of that is to support the vaccine and kitting \nprograms. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "baaadb62b38543acd8eb1cb03f8f5b015b70b12eecc9522b92ac2230e23a5ee1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc1119d1-d8f0-4ef5-b9ee-196341296ee4", "node_type": "1", "metadata": {"window": "It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx.  Part of that is to support the vaccine and kitting \nprograms.  But a larger part of that is really continuing to invest in our strategies, technology, data and analytics to ", "original_text": "We did increase our guide on CapEx. "}, "hash": "d602d88515bff258a09bd6d3add9abf744d2aa39a411d2a815e75523e939b3d9", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd I'll take the Cap Ex one. ", "start_char_idx": 4670, "end_char_idx": 4703, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc1119d1-d8f0-4ef5-b9ee-196341296ee4": {"__data__": {"id_": "dc1119d1-d8f0-4ef5-b9ee-196341296ee4", "embedding": null, "metadata": {"window": "It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx.  Part of that is to support the vaccine and kitting \nprograms.  But a larger part of that is really continuing to invest in our strategies, technology, data and analytics to ", "original_text": "We did increase our guide on CapEx. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ab76461-0ff0-47a9-8077-4797d7ffc09d", "node_type": "1", "metadata": {"window": "I'll just start with the guide for the vaccine.  It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx.  Part of that is to support the vaccine and kitting \nprograms.  But a larger part of that is really continuing to invest in our strategies, technology, data and analytics to ", "original_text": "A \nAnd I'll take the Cap Ex one. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "241a98da2afafcf52c6a4782c73ca7df6c002f7ea5a7c518afc67eff219e3a47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62ba9b61-5f6a-4bdd-b13e-b1583599fbc2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx.  Part of that is to support the vaccine and kitting \nprograms.  But a larger part of that is really continuing to invest in our strategies, technology, data and analytics to ", "original_text": "Part of that is to support the vaccine and kitting \nprograms. "}, "hash": "50ddd76c4776d662aba2867f1a2185357aad12a8a443c5809382a99f089a4b90", "class_name": "RelatedNodeInfo"}}, "text": "We did increase our guide on CapEx. ", "start_char_idx": 4703, "end_char_idx": 4739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62ba9b61-5f6a-4bdd-b13e-b1583599fbc2": {"__data__": {"id_": "62ba9b61-5f6a-4bdd-b13e-b1583599fbc2", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx.  Part of that is to support the vaccine and kitting \nprograms.  But a larger part of that is really continuing to invest in our strategies, technology, data and analytics to ", "original_text": "Part of that is to support the vaccine and kitting \nprograms. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc1119d1-d8f0-4ef5-b9ee-196341296ee4", "node_type": "1", "metadata": {"window": "It is tied to the schedule that the CDC has provided us, which \nwould be largely consistent with what you read in the public statements.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx.  Part of that is to support the vaccine and kitting \nprograms.  But a larger part of that is really continuing to invest in our strategies, technology, data and analytics to ", "original_text": "We did increase our guide on CapEx. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ceace362a50af20f046472e0cd0f8bdf4531d1bd0d17629dc5d30f3d6f0a09f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90303622-fa9b-440f-b52e-1fdc4ac9bd14", "node_type": "1", "metadata": {"window": "A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx.  Part of that is to support the vaccine and kitting \nprograms.  But a larger part of that is really continuing to invest in our strategies, technology, data and analytics to ", "original_text": "But a larger part of that is really continuing to invest in our strategies, technology, data and analytics to "}, "hash": "f5aba40b7bab6bd6db5945a0f049fb154b959111cf4a5ba757c316be3a79495d", "class_name": "RelatedNodeInfo"}}, "text": "Part of that is to support the vaccine and kitting \nprograms. ", "start_char_idx": 4739, "end_char_idx": 4801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90303622-fa9b-440f-b52e-1fdc4ac9bd14": {"__data__": {"id_": "90303622-fa9b-440f-b52e-1fdc4ac9bd14", "embedding": null, "metadata": {"window": "A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx.  Part of that is to support the vaccine and kitting \nprograms.  But a larger part of that is really continuing to invest in our strategies, technology, data and analytics to ", "original_text": "But a larger part of that is really continuing to invest in our strategies, technology, data and analytics to ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6ac7948c-840a-4576-910f-d22be89beb77", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c8658ef820c1d74ab91f5b3650fcec51072d22c7b3a66f55fa2e6902f888712", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62ba9b61-5f6a-4bdd-b13e-b1583599fbc2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx.  Part of that is to support the vaccine and kitting \nprograms.  But a larger part of that is really continuing to invest in our strategies, technology, data and analytics to ", "original_text": "Part of that is to support the vaccine and kitting \nprograms. ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df8f239cba8880bd0985164dd679561feb9a692ed1ecbb2b1e1d2ecac886c0d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7385dc4b-bfc8-4367-9e7b-2a74901ff8b9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies.  So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "McKesson Corp.  "}, "hash": "483d8cfb62d4c4338b0c99ce879b3d8a4aece0644cb9ed3da3b30b721c51b2c6", "class_name": "RelatedNodeInfo"}}, "text": "But a larger part of that is really continuing to invest in our strategies, technology, data and analytics to ", "start_char_idx": 4801, "end_char_idx": 4911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7385dc4b-bfc8-4367-9e7b-2a74901ff8b9": {"__data__": {"id_": "7385dc4b-bfc8-4367-9e7b-2a74901ff8b9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies.  So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90303622-fa9b-440f-b52e-1fdc4ac9bd14", "node_type": "1", "metadata": {"window": "A \nAnd I'll take the Cap Ex one.  We did increase our guide on CapEx.  Part of that is to support the vaccine and kitting \nprograms.  But a larger part of that is really continuing to invest in our strategies, technology, data and analytics to ", "original_text": "But a larger part of that is really continuing to invest in our strategies, technology, data and analytics to ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b967cb430c407205d261f170055d522854bb3c40500f2ba6994c296ef8e9acc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "061d8647-7deb-4841-829f-be3c4817fbe1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies.  So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies. "}, "hash": "f615ab4cbd914128002c3e5745f990a2a9abcef9c7c5ebe9a0f3ae52b487c0a3", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "061d8647-7deb-4841-829f-be3c4817fbe1": {"__data__": {"id_": "061d8647-7deb-4841-829f-be3c4817fbe1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies.  So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7385dc4b-bfc8-4367-9e7b-2a74901ff8b9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies.  So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61c35de7490185467b69585d60a45fa7813dcf0d9bed331a418aeefa9865deaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7075bd82-20b2-44b1-9fe8-2d2c3d9f31d9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies.  So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n ", "original_text": "So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n "}, "hash": "42803e8a7f485155d6c50abe89e88836a54032ea2a1b3d07689c527e0d3a5b9a", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies. ", "start_char_idx": 16, "end_char_idx": 207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7075bd82-20b2-44b1-9fe8-2d2c3d9f31d9": {"__data__": {"id_": "7075bd82-20b2-44b1-9fe8-2d2c3d9f31d9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies.  So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n ", "original_text": "So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "061d8647-7deb-4841-829f-be3c4817fbe1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies.  So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2ad673dae4596a43741153038ac14b432975f7b1d6332879e335b066c345369", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f008790-2956-4f15-a24b-23ea3642fcd9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies.  So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  "}, "hash": "36e139dd8633ed7259009b5e6533e5e8287b55cef73d9011fc048fc9dea6db16", "class_name": "RelatedNodeInfo"}}, "text": "So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n ", "start_char_idx": 207, "end_char_idx": 361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f008790-2956-4f15-a24b-23ea3642fcd9": {"__data__": {"id_": "0f008790-2956-4f15-a24b-23ea3642fcd9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies.  So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7075bd82-20b2-44b1-9fe8-2d2c3d9f31d9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies.  So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n ", "original_text": "So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98cc7f959198a2799581a986a250306d71e36b20aac0b7e0f3e86c0be0c5a227", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d808a5f-61d7-461a-a2f8-e9e7c9561848", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies.  So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question. ", "original_text": "A \nOperator, next que stion?  \n "}, "hash": "83b74fef464c8a267a345507faf20bd32853569f4e19300162e7a6d50f6df77c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "start_char_idx": 361, "end_char_idx": 720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d808a5f-61d7-461a-a2f8-e9e7c9561848": {"__data__": {"id_": "6d808a5f-61d7-461a-a2f8-e9e7c9561848", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies.  So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question. ", "original_text": "A \nOperator, next que stion?  \n ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f008790-2956-4f15-a24b-23ea3642fcd9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies.  So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8266693ed16a79cb4c4de4abd637094cd3cc5e462eda2f6bde14c212b1d72ecd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8fbfa72-d7b7-430c-a0b2-3ad8aed3a9f6", "node_type": "1", "metadata": {"window": "So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n "}, "hash": "497e2868c74cc71e7c4d6cc7a70351e8017caa15d2f15fbbc350599e46b17a71", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator, next que stion?  \n ", "start_char_idx": 720, "end_char_idx": 752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8fbfa72-d7b7-430c-a0b2-3ad8aed3a9f6": {"__data__": {"id_": "f8fbfa72-d7b7-430c-a0b2-3ad8aed3a9f6", "embedding": null, "metadata": {"window": "So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d808a5f-61d7-461a-a2f8-e9e7c9561848", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies.  So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question. ", "original_text": "A \nOperator, next que stion?  \n ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f284c09fa2dcd42418575b51eda6e3b0a55312271a9fde3e7168c40e8787081", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98ff77b7-6305-422b-b23a-9b7a3e5410af", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes. "}, "hash": "0be27049e0fbc40be74d76184dbb457a27c3b535987e6d154db1b331681e1d47", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n ", "start_char_idx": 752, "end_char_idx": 1086, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98ff77b7-6305-422b-b23a-9b7a3e5410af": {"__data__": {"id_": "98ff77b7-6305-422b-b23a-9b7a3e5410af", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8fbfa72-d7b7-430c-a0b2-3ad8aed3a9f6", "node_type": "1", "metadata": {"window": "So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aeb6dcf5a71c2a6c158200a4d62068086009675e3c0c4bb5a87f3bdfde56f1b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c437555c-ae45-4464-b1fc-8c4a10c64589", "node_type": "1", "metadata": {"window": "A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow. ", "original_text": "Thanks for taking my question. "}, "hash": "348793d89533547e96fb43b431261190cda43afc63801d0d87f0e863b4e2b0f5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes. ", "start_char_idx": 1086, "end_char_idx": 1405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c437555c-ae45-4464-b1fc-8c4a10c64589": {"__data__": {"id_": "c437555c-ae45-4464-b1fc-8c4a10c64589", "embedding": null, "metadata": {"window": "A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow. ", "original_text": "Thanks for taking my question. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98ff77b7-6305-422b-b23a-9b7a3e5410af", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0c4c7cdfcbf45e0c518388a8b261323d4a8265b4a8a0287fe306006e16882bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28562d13-8f29-4fa6-a4e5-5dc1039d86e8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet. ", "original_text": "Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point. "}, "hash": "57451c9067e59c87bbe68d29d425417ee88d40798cc8451c083856da08f023bd", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my question. ", "start_char_idx": 1405, "end_char_idx": 1436, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28562d13-8f29-4fa6-a4e5-5dc1039d86e8": {"__data__": {"id_": "28562d13-8f29-4fa6-a4e5-5dc1039d86e8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet. ", "original_text": "Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c437555c-ae45-4464-b1fc-8c4a10c64589", "node_type": "1", "metadata": {"window": "A \nOperator, next que stion?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow. ", "original_text": "Thanks for taking my question. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "970161d5624148816997a360b0a9c0f342418c16767083156330e752d6ec13de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb1ad679-1325-4aba-9537-d0789c6db02f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n ", "original_text": "But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm. "}, "hash": "f97593d25dd15a9d0863fec1e021be964a5a882d4a63ceabad45820aa2e5417e", "class_name": "RelatedNodeInfo"}}, "text": "Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point. ", "start_char_idx": 1436, "end_char_idx": 1553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb1ad679-1325-4aba-9537-d0789c6db02f": {"__data__": {"id_": "eb1ad679-1325-4aba-9537-d0789c6db02f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n ", "original_text": "But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28562d13-8f29-4fa6-a4e5-5dc1039d86e8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Glen Santangelo with Guggenheim Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet. ", "original_text": "Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c4d75bce574377b1c5e210107d5e8c3bdf6b9dc325848b8e375bf1a01deaceb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bce4caf-96e2-4d4a-85f2-ed5903073431", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow. "}, "hash": "514fde4477c0733e3b01c07bdcdd3d06c22cfaf94658227ce3ab0ad4fda35785", "class_name": "RelatedNodeInfo"}}, "text": "But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm. ", "start_char_idx": 1553, "end_char_idx": 1719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bce4caf-96e2-4d4a-85f2-ed5903073431": {"__data__": {"id_": "3bce4caf-96e2-4d4a-85f2-ed5903073431", "embedding": null, "metadata": {"window": "Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb1ad679-1325-4aba-9537-d0789c6db02f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nGlen Santangelo  \nAnalyst, Guggenheim Securities LLC  Q \nYes.  Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n ", "original_text": "But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "251fea56355613101d239379141e2a0c36b897afe5da77d2a98086cee170a106", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0f3bb48-c5e1-4251-ab73-f7d3378f5e64", "node_type": "1", "metadata": {"window": "Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen. ", "original_text": "And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet. "}, "hash": "7f0c0bdbbe82840938f47bfb4211f3dd256939b2febd02cf6ef847c6aec8893e", "class_name": "RelatedNodeInfo"}}, "text": "And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow. ", "start_char_idx": 1719, "end_char_idx": 1928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0f3bb48-c5e1-4251-ab73-f7d3378f5e64": {"__data__": {"id_": "e0f3bb48-c5e1-4251-ab73-f7d3378f5e64", "embedding": null, "metadata": {"window": "Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen. ", "original_text": "And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bce4caf-96e2-4d4a-85f2-ed5903073431", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a9989945c3529931c0450d424c1cf2c8fd1cad1c791621569a6ba890dd82381e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c48e2f1-4589-4b05-8661-d9b18626aa61", "node_type": "1", "metadata": {"window": "But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer. ", "original_text": "Thanks.  \n "}, "hash": "a5a7e1d3d86aa941149d5d4bb589717cba41ece06129a9a70f38d8963a29ad6b", "class_name": "RelatedNodeInfo"}}, "text": "And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet. ", "start_char_idx": 1928, "end_char_idx": 2060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c48e2f1-4589-4b05-8661-d9b18626aa61": {"__data__": {"id_": "3c48e2f1-4589-4b05-8661-d9b18626aa61", "embedding": null, "metadata": {"window": "But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0f3bb48-c5e1-4251-ab73-f7d3378f5e64", "node_type": "1", "metadata": {"window": "Hey, Brian, I appreciate there's probably not much you can say with respect \nto the opioid settlement at this point.  But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen. ", "original_text": "And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53469acd513f8ebf46d373e172b9e094751122d000ff3b205a8b05dc175113f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91cb59b5-69f4-484f-8cd9-dcb239558665", "node_type": "1", "metadata": {"window": "And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "0e2aa6f5dc3b5260a0af262c0fcec7c71c66a12ecff43ad4124640c3d2eecaeb", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 2060, "end_char_idx": 2071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91cb59b5-69f4-484f-8cd9-dcb239558665": {"__data__": {"id_": "91cb59b5-69f4-484f-8cd9-dcb239558665", "embedding": null, "metadata": {"window": "And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c48e2f1-4589-4b05-8661-d9b18626aa61", "node_type": "1", "metadata": {"window": "But if we assume for a second that it does come to fruition, as you outlined, I \nwanted to ask about the potential impact on the future capital deployment algorithm.  And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49672a82fb8e023060e06a6eed98ad91c2fa25fc41a94c6693bee3c519ffaae3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9030b909-e0bc-402f-8845-2919423f31fa", "node_type": "1", "metadata": {"window": "And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow. ", "original_text": "A \nThanks, Glen. "}, "hash": "4e4adccac151708268598f9aefd2aadbdb90aed6557e6954aa4ca237e7cba6cf", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2071, "end_char_idx": 2400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9030b909-e0bc-402f-8845-2919423f31fa": {"__data__": {"id_": "9030b909-e0bc-402f-8845-2919423f31fa", "embedding": null, "metadata": {"window": "And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow. ", "original_text": "A \nThanks, Glen. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91cb59b5-69f4-484f-8cd9-dcb239558665", "node_type": "1", "metadata": {"window": "And to that, if we look at the \nafter-tax settlement over 1 8 years, maybe netting that against some of the legal costs that go away, it looks like it \ncould consume roughly 10% to 15% of your free cash flow.  And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45f5e8671be14d7dd5662cfb25a6bb42abfed173652f56b94bf857a3a62b2741", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f13086f-348a-4042-860e-eb5f7e99628e", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow.  We have a strong balance sheet. ", "original_text": "Well, you mentioned a couple of things that I'll come back to you in my answer. "}, "hash": "1a06a187626dde6596362cbd3924f207f4a4956067944fa09df5b65e70da33b8", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks, Glen. ", "start_char_idx": 2400, "end_char_idx": 2417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f13086f-348a-4042-860e-eb5f7e99628e": {"__data__": {"id_": "5f13086f-348a-4042-860e-eb5f7e99628e", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow.  We have a strong balance sheet. ", "original_text": "Well, you mentioned a couple of things that I'll come back to you in my answer. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9030b909-e0bc-402f-8845-2919423f31fa", "node_type": "1", "metadata": {"window": "And so I'm trying to reconcile the future capital \ndeployment versus maintaining the investment -grade rating on the balance sheet.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow. ", "original_text": "A \nThanks, Glen. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a96534c66dc048ce2467f978862ff26a499ed885e5008fb2437cf2056add04ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fca98014-73f4-4b8f-a3a2-62e0332665c1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow.  We have a strong balance sheet.  We've had time to contemplate this. ", "original_text": "One is we are very \nfocused on maintaining our investment -grade credit rating. "}, "hash": "d5e81f302b6c0f2aefda721cae1d3052f0ed642fe3b11207f332ec24b3339f81", "class_name": "RelatedNodeInfo"}}, "text": "Well, you mentioned a couple of things that I'll come back to you in my answer. ", "start_char_idx": 2417, "end_char_idx": 2497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fca98014-73f4-4b8f-a3a2-62e0332665c1": {"__data__": {"id_": "fca98014-73f4-4b8f-a3a2-62e0332665c1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow.  We have a strong balance sheet.  We've had time to contemplate this. ", "original_text": "One is we are very \nfocused on maintaining our investment -grade credit rating. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f13086f-348a-4042-860e-eb5f7e99628e", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow.  We have a strong balance sheet. ", "original_text": "Well, you mentioned a couple of things that I'll come back to you in my answer. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "12dd82808073aea13d62bdd4453a87a38d8bf3c61b5216963e0fa2f6d200193f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adfc0a97-d783-4f2b-a6c5-7d00829b9e31", "node_type": "1", "metadata": {"window": "A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow.  We have a strong balance sheet.  We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change. ", "original_text": "We think we have a business that generates good \ncash flow. "}, "hash": "560443a3a053b60fd42f3051233a36fa109ad0e92e34c085d6abdac1c2ca1a98", "class_name": "RelatedNodeInfo"}}, "text": "One is we are very \nfocused on maintaining our investment -grade credit rating. ", "start_char_idx": 2497, "end_char_idx": 2577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adfc0a97-d783-4f2b-a6c5-7d00829b9e31": {"__data__": {"id_": "adfc0a97-d783-4f2b-a6c5-7d00829b9e31", "embedding": null, "metadata": {"window": "A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow.  We have a strong balance sheet.  We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change. ", "original_text": "We think we have a business that generates good \ncash flow. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fca98014-73f4-4b8f-a3a2-62e0332665c1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow.  We have a strong balance sheet.  We've had time to contemplate this. ", "original_text": "One is we are very \nfocused on maintaining our investment -grade credit rating. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59097b6c3dff0995ecfa4ed465a06e443fd3d4a791cc6e7354d9e4bd10ccfa29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ea94b1e-6c06-49cd-9165-fee7c248ada6", "node_type": "1", "metadata": {"window": "Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow.  We have a strong balance sheet.  We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance. ", "original_text": "We have a strong balance sheet. "}, "hash": "031f6de64f6d85e4158d3f5afab4c1c70196a5a1addb239de24d1417cdc48562", "class_name": "RelatedNodeInfo"}}, "text": "We think we have a business that generates good \ncash flow. ", "start_char_idx": 2577, "end_char_idx": 2637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ea94b1e-6c06-49cd-9165-fee7c248ada6": {"__data__": {"id_": "6ea94b1e-6c06-49cd-9165-fee7c248ada6", "embedding": null, "metadata": {"window": "Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow.  We have a strong balance sheet.  We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance. ", "original_text": "We have a strong balance sheet. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adfc0a97-d783-4f2b-a6c5-7d00829b9e31", "node_type": "1", "metadata": {"window": "A \nThanks, Glen.  Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow.  We have a strong balance sheet.  We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change. ", "original_text": "We think we have a business that generates good \ncash flow. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9eec1275850a381bcc7e449ff64e85e62af1ad514e35afee157a36106b5241ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "762b03e4-349f-441e-be60-504cbe7ff0f2", "node_type": "1", "metadata": {"window": "One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow.  We have a strong balance sheet.  We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business. ", "original_text": "We've had time to contemplate this. "}, "hash": "21a305f03afee06117c1c84b61f266665e403e9956d5313bd581a049cc4f9636", "class_name": "RelatedNodeInfo"}}, "text": "We have a strong balance sheet. ", "start_char_idx": 2637, "end_char_idx": 2669, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "762b03e4-349f-441e-be60-504cbe7ff0f2": {"__data__": {"id_": "762b03e4-349f-441e-be60-504cbe7ff0f2", "embedding": null, "metadata": {"window": "One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow.  We have a strong balance sheet.  We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business. ", "original_text": "We've had time to contemplate this. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ea94b1e-6c06-49cd-9165-fee7c248ada6", "node_type": "1", "metadata": {"window": "Well, you mentioned a couple of things that I'll come back to you in my answer.  One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow.  We have a strong balance sheet.  We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance. ", "original_text": "We have a strong balance sheet. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06329ce1453bc52f01ac058b7585e06c5dfa4bc3eed5e71c0977b64a474267ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d8ddbfc-660c-497b-b640-cbdee8ff40ec", "node_type": "1", "metadata": {"window": "We think we have a business that generates good \ncash flow.  We have a strong balance sheet.  We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend. ", "original_text": "So I think, philosophically, our \napproach to capital deployment will not change. "}, "hash": "d2165e1449ff4f78147a474a3eb8a4a15958eda48c5d2b0694deabcfe8a05b50", "class_name": "RelatedNodeInfo"}}, "text": "We've had time to contemplate this. ", "start_char_idx": 2669, "end_char_idx": 2705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d8ddbfc-660c-497b-b640-cbdee8ff40ec": {"__data__": {"id_": "4d8ddbfc-660c-497b-b640-cbdee8ff40ec", "embedding": null, "metadata": {"window": "We think we have a business that generates good \ncash flow.  We have a strong balance sheet.  We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend. ", "original_text": "So I think, philosophically, our \napproach to capital deployment will not change. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "762b03e4-349f-441e-be60-504cbe7ff0f2", "node_type": "1", "metadata": {"window": "One is we are very \nfocused on maintaining our investment -grade credit rating.  We think we have a business that generates good \ncash flow.  We have a strong balance sheet.  We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business. ", "original_text": "We've had time to contemplate this. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8cdc5685930e02f016c587e0e29f26d18d0c08b1682cfb009ad5e448ac118a63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6bc9e47-1cc3-4aef-a1bd-8b11a424fd47", "node_type": "1", "metadata": {"window": "We have a strong balance sheet.  We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all. ", "original_text": "It will be a balance. "}, "hash": "d2587fc4fd7ff626e6500bb4a23b63133a16497964b58be26a026f721288c9b0", "class_name": "RelatedNodeInfo"}}, "text": "So I think, philosophically, our \napproach to capital deployment will not change. ", "start_char_idx": 2705, "end_char_idx": 2787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6bc9e47-1cc3-4aef-a1bd-8b11a424fd47": {"__data__": {"id_": "c6bc9e47-1cc3-4aef-a1bd-8b11a424fd47", "embedding": null, "metadata": {"window": "We have a strong balance sheet.  We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all. ", "original_text": "It will be a balance. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d8ddbfc-660c-497b-b640-cbdee8ff40ec", "node_type": "1", "metadata": {"window": "We think we have a business that generates good \ncash flow.  We have a strong balance sheet.  We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend. ", "original_text": "So I think, philosophically, our \napproach to capital deployment will not change. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf3f20278cffe1de0900ddb0529ae6c7ee5b1cb4f8433c362b0f0e1388d72bc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96529926-c5d1-424a-b6fc-1669b6c6796e", "node_type": "1", "metadata": {"window": "We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n ", "original_text": "We loo k to make internal investments that we \nthink support growth in the business. "}, "hash": "8f0369907c9b09781c4eca8b3659ef7ff7a971e4c130ea606da51d1f13b33934", "class_name": "RelatedNodeInfo"}}, "text": "It will be a balance. ", "start_char_idx": 2787, "end_char_idx": 2809, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96529926-c5d1-424a-b6fc-1669b6c6796e": {"__data__": {"id_": "96529926-c5d1-424a-b6fc-1669b6c6796e", "embedding": null, "metadata": {"window": "We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n ", "original_text": "We loo k to make internal investments that we \nthink support growth in the business. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6bc9e47-1cc3-4aef-a1bd-8b11a424fd47", "node_type": "1", "metadata": {"window": "We have a strong balance sheet.  We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all. ", "original_text": "It will be a balance. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb7a583f897b8df33a9dac1aacc5a8a96a7410d32238261cc01c36eb0ef78397", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd016f96-fbe7-4dc0-a225-5f936a308e99", "node_type": "1", "metadata": {"window": "So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend. "}, "hash": "7ff953f5088553673f5d55be07ca9e82b51f1b69f785ee9876396370f72a2af3", "class_name": "RelatedNodeInfo"}}, "text": "We loo k to make internal investments that we \nthink support growth in the business. ", "start_char_idx": 2809, "end_char_idx": 2894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd016f96-fbe7-4dc0-a225-5f936a308e99": {"__data__": {"id_": "cd016f96-fbe7-4dc0-a225-5f936a308e99", "embedding": null, "metadata": {"window": "So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96529926-c5d1-424a-b6fc-1669b6c6796e", "node_type": "1", "metadata": {"window": "We've had time to contemplate this.  So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n ", "original_text": "We loo k to make internal investments that we \nthink support growth in the business. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb58aa88589b64b80b156b3868ae6b63fb265f7d38c28999c046994087ec32dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f66c9d5-e784-4613-ab6a-d42820e1a3a5", "node_type": "1", "metadata": {"window": "It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n ", "original_text": "So I don't think our philosophy changes at all. "}, "hash": "94abd335ae5504956ae0b4678717ce5d817e3aae9b558fa8a2f49b67020ad65c", "class_name": "RelatedNodeInfo"}}, "text": "We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend. ", "start_char_idx": 2894, "end_char_idx": 3135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f66c9d5-e784-4613-ab6a-d42820e1a3a5": {"__data__": {"id_": "0f66c9d5-e784-4613-ab6a-d42820e1a3a5", "embedding": null, "metadata": {"window": "It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n ", "original_text": "So I don't think our philosophy changes at all. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd016f96-fbe7-4dc0-a225-5f936a308e99", "node_type": "1", "metadata": {"window": "So I think, philosophically, our \napproach to capital deployment will not change.  It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "938d129a1c018237e5a1a6f4947db3841a3a1156b7ca703c8bc5da1feb71e1b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95016df3-d394-4035-ad94-b2b4f97b3ad8", "node_type": "1", "metadata": {"window": "We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "And I think we \nfeel very comfortable that we have a strong balance sheet.  \n "}, "hash": "71ce9d8e71ade590ddb65fb7614faba6d228d7db908e5ee10b5b8163506fbd11", "class_name": "RelatedNodeInfo"}}, "text": "So I don't think our philosophy changes at all. ", "start_char_idx": 3135, "end_char_idx": 3183, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95016df3-d394-4035-ad94-b2b4f97b3ad8": {"__data__": {"id_": "95016df3-d394-4035-ad94-b2b4f97b3ad8", "embedding": null, "metadata": {"window": "We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "And I think we \nfeel very comfortable that we have a strong balance sheet.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f66c9d5-e784-4613-ab6a-d42820e1a3a5", "node_type": "1", "metadata": {"window": "It will be a balance.  We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n ", "original_text": "So I don't think our philosophy changes at all. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b20303871b1884f39b548166bdc4cc9856075fba5cf0271ec4fb3e3ce89ccb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95a7b89b-ca54-43d5-ad4c-28f2ba2a1b73", "node_type": "1", "metadata": {"window": "We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  "}, "hash": "2ac83e75bba7f25488f4a498d39607c94c5f0e087aa7d80a8ddf590c02d4efd4", "class_name": "RelatedNodeInfo"}}, "text": "And I think we \nfeel very comfortable that we have a strong balance sheet.  \n ", "start_char_idx": 3183, "end_char_idx": 3261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95a7b89b-ca54-43d5-ad4c-28f2ba2a1b73": {"__data__": {"id_": "95a7b89b-ca54-43d5-ad4c-28f2ba2a1b73", "embedding": null, "metadata": {"window": "We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95016df3-d394-4035-ad94-b2b4f97b3ad8", "node_type": "1", "metadata": {"window": "We loo k to make internal investments that we \nthink support growth in the business.  We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "And I think we \nfeel very comfortable that we have a strong balance sheet.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e33e556b0526fbffcf18d88c95aaf8699cecf0df09229d6edea44be5be0d93fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a440587f-b1db-454f-a443-900060df66a3", "node_type": "1", "metadata": {"window": "So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "A \nOperator, next question?  \n "}, "hash": "efa2997876d17e8a8a9b5c2edf18ff5c66ae56815fa541d737e93e16b3bfe782", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "start_char_idx": 361, "end_char_idx": 720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a440587f-b1db-454f-a443-900060df66a3": {"__data__": {"id_": "a440587f-b1db-454f-a443-900060df66a3", "embedding": null, "metadata": {"window": "So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "A \nOperator, next question?  \n ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95a7b89b-ca54-43d5-ad4c-28f2ba2a1b73", "node_type": "1", "metadata": {"window": "We look to make growth investments in M&A where we can find targets that \nare aligned to our strategy and offer a financial return that makes sense vis -\u00e0-vis other ways we can depl oy \ncapital, like buying back shares or paying a dividend.  So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcb47273e0a6e95e72de0405430314603e6afe306af7c5b53d0d657eed5c2992", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ce998a6-b752-4154-b3ae-46ab9d25f98c", "node_type": "1", "metadata": {"window": "And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n "}, "hash": "48312dd5185e8166708a53428653292df5bc688dd61b0cbd1e88db9fe4133f5a", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator, next question?  \n ", "start_char_idx": 3620, "end_char_idx": 3651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ce998a6-b752-4154-b3ae-46ab9d25f98c": {"__data__": {"id_": "0ce998a6-b752-4154-b3ae-46ab9d25f98c", "embedding": null, "metadata": {"window": "And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a440587f-b1db-454f-a443-900060df66a3", "node_type": "1", "metadata": {"window": "So I don't think our philosophy changes at all.  And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "A \nOperator, next question?  \n ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfb5dbbfde4b4fd7a0224351c96ee6a4458a164aa33e5aa62576724d3e472e16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1589ab44-46b2-48f1-9378-375c96feba9a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "da373a0e47e995c787a64aea09e5f4dd5e2c9e37f05e28b84c9e975f2cfa66b4", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n ", "start_char_idx": 3651, "end_char_idx": 3979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1589ab44-46b2-48f1-9378-375c96feba9a": {"__data__": {"id_": "1589ab44-46b2-48f1-9378-375c96feba9a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ce998a6-b752-4154-b3ae-46ab9d25f98c", "node_type": "1", "metadata": {"window": "And I think we \nfeel very comfortable that we have a strong balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e039408d28585e1936feefe7d84f14f54547d0a20b754ee1deaf1dc7f665a9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c8c0636-fc36-4ba4-a9a6-e090676f55c4", "node_type": "1", "metadata": {"window": "A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines. ", "original_text": "LLC  Q \nYeah. "}, "hash": "bcce1c68e81bd24797464846bf560ffb40f9aa105efe9366142a2285dade82e6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 3979, "end_char_idx": 4288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c8c0636-fc36-4ba4-a9a6-e090676f55c4": {"__data__": {"id_": "9c8c0636-fc36-4ba4-a9a6-e090676f55c4", "embedding": null, "metadata": {"window": "A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines. ", "original_text": "LLC  Q \nYeah. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1589ab44-46b2-48f1-9378-375c96feba9a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77166a1cea7e03bf5bd92fafbc24a9ec261c29c74ee9f7a5b439b85b49194e9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49df2a31-8bf3-4874-9dd7-cb1f5a67b6b7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million. ", "original_text": "Hi. "}, "hash": "49dd99f250d00ec4dfca507c3568058de82825ba227117fbc9795b84a43159e3", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah. ", "start_char_idx": 4288, "end_char_idx": 4302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49df2a31-8bf3-4874-9dd7-cb1f5a67b6b7": {"__data__": {"id_": "49df2a31-8bf3-4874-9dd7-cb1f5a67b6b7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million. ", "original_text": "Hi. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c8c0636-fc36-4ba4-a9a6-e090676f55c4", "node_type": "1", "metadata": {"window": "A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines. ", "original_text": "LLC  Q \nYeah. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef916d6c9541d55232e724a72df15afc94bf4dfbd5445ef3faf5c1fc2efa6553", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4751bd56-7c3b-4e6a-b727-e0da2363f568", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance. ", "original_text": "Good morning. "}, "hash": "30194e01a88fd44c8b23b5523c144368097500d83019e058000b219ffe019c78", "class_name": "RelatedNodeInfo"}}, "text": "Hi. ", "start_char_idx": 4302, "end_char_idx": 4306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4751bd56-7c3b-4e6a-b727-e0da2363f568": {"__data__": {"id_": "4751bd56-7c3b-4e6a-b727-e0da2363f568", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance. ", "original_text": "Good morning. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49df2a31-8bf3-4874-9dd7-cb1f5a67b6b7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million. ", "original_text": "Hi. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "099413e55edf7208605ea58a17ae3b88d7c5801a86b016554147cae9e7f2d1e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d054ae2-92c5-4bfb-9267-a0a38b72f36e", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022. ", "original_text": "So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines. "}, "hash": "993b0600d1d8d7fcde3a4e02924d5c9827448639bc2cc0363243ea31e141be64", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 4306, "end_char_idx": 4320, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d054ae2-92c5-4bfb-9267-a0a38b72f36e": {"__data__": {"id_": "4d054ae2-92c5-4bfb-9267-a0a38b72f36e", "embedding": null, "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022. ", "original_text": "So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4751bd56-7c3b-4e6a-b727-e0da2363f568", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance. ", "original_text": "Good morning. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6a39ad7b286777af74d86168acf0969a34cf86e317f4af99e882851daf3aad1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36ec5126-2fe1-4046-a4f6-78ddf7ebba48", "node_type": "1", "metadata": {"window": "Hi.  Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind. ", "original_text": "The CDC guidelines are for about $100 million. "}, "hash": "e8f2182769400c2850ab7221685a1ebbfbbc6aa9f1e72367aefc6ef301e1587a", "class_name": "RelatedNodeInfo"}}, "text": "So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines. ", "start_char_idx": 4320, "end_char_idx": 4431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36ec5126-2fe1-4046-a4f6-78ddf7ebba48": {"__data__": {"id_": "36ec5126-2fe1-4046-a4f6-78ddf7ebba48", "embedding": null, "metadata": {"window": "Hi.  Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind. ", "original_text": "The CDC guidelines are for about $100 million. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d054ae2-92c5-4bfb-9267-a0a38b72f36e", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022. ", "original_text": "So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad872f155e44ff8b456f179a45450b81f2b93dab0acb25580c03e5548d101439", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e03c9af5-bb2a-491d-911e-9a25d76850c0", "node_type": "1", "metadata": {"window": "Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind.  So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n ", "original_text": "So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance. "}, "hash": "82e5b02be9c34da388163d0a98ca1062354d471fdaf6692447e1a7fd956e199b", "class_name": "RelatedNodeInfo"}}, "text": "The CDC guidelines are for about $100 million. ", "start_char_idx": 4431, "end_char_idx": 4478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e03c9af5-bb2a-491d-911e-9a25d76850c0": {"__data__": {"id_": "e03c9af5-bb2a-491d-911e-9a25d76850c0", "embedding": null, "metadata": {"window": "Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind.  So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n ", "original_text": "So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36ec5126-2fe1-4046-a4f6-78ddf7ebba48", "node_type": "1", "metadata": {"window": "Hi.  Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind. ", "original_text": "The CDC guidelines are for about $100 million. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "264993b0d500cc4b891d52daf96a0f1e9db1f071674e0373819dccb0fd0a3074", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96e7dfe3-e0f8-4b5a-9a0e-656456536e68", "node_type": "1", "metadata": {"window": "So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind.  So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022. "}, "hash": "b272d3fc0affdad49c145f0b61f8ed34c162ee356a8ece9b77ebcb288a13c6f6", "class_name": "RelatedNodeInfo"}}, "text": "So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance. ", "start_char_idx": 4478, "end_char_idx": 4596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96e7dfe3-e0f8-4b5a-9a0e-656456536e68": {"__data__": {"id_": "96e7dfe3-e0f8-4b5a-9a0e-656456536e68", "embedding": null, "metadata": {"window": "So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind.  So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e03c9af5-bb2a-491d-911e-9a25d76850c0", "node_type": "1", "metadata": {"window": "Good morning.  So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind.  So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n ", "original_text": "So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a804c0061a0e7ab80d2dff5aa14cb9b6e751aec1ff5953d2daf194e6b262c8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f71adfe7-b3c3-4ddf-9be9-c553f3b2f1ec", "node_type": "1", "metadata": {"window": "The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind.  So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind. "}, "hash": "9376d7f14cfd79459aecbc808d0dd0f9695e34ec2a88f9641931aec421ec0c28", "class_name": "RelatedNodeInfo"}}, "text": "But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022. ", "start_char_idx": 4596, "end_char_idx": 4772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f71adfe7-b3c3-4ddf-9be9-c553f3b2f1ec": {"__data__": {"id_": "f71adfe7-b3c3-4ddf-9be9-c553f3b2f1ec", "embedding": null, "metadata": {"window": "The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind.  So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96e7dfe3-e0f8-4b5a-9a0e-656456536e68", "node_type": "1", "metadata": {"window": "So, taking everything that you said on the vaccine, and I understand that you're basing it \non the guidelines.  The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind.  So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1728b901e343418f51462d6e94df5bec1fa364ac87fa1add05c63b451a0ab500", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4fc8712-998f-432e-a818-7bd78eec8f2c", "node_type": "1", "metadata": {"window": "So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind.  So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n "}, "hash": "385a8d4c858177c4b6f728c25cc4b974994dcc0a9742a5b363ead98c58416ed6", "class_name": "RelatedNodeInfo"}}, "text": "So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind. ", "start_char_idx": 4772, "end_char_idx": 4940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4fc8712-998f-432e-a818-7bd78eec8f2c": {"__data__": {"id_": "d4fc8712-998f-432e-a818-7bd78eec8f2c", "embedding": null, "metadata": {"window": "So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind.  So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f71adfe7-b3c3-4ddf-9be9-c553f3b2f1ec", "node_type": "1", "metadata": {"window": "The CDC guidelines are for about $100 million.  So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind.  So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind. ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d307ac27d1963c3f95de63210e3a43f4d8c683a5a7f011b7d04ce3d7823b857a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "394d53ed-5295-44e8-986a-be25ba243979", "node_type": "1", "metadata": {"window": "But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind.  So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   "}, "hash": "fd969d8f2d97533d98a8188076a8e5916c0a5bd0ef62f166dbb409d860addd15", "class_name": "RelatedNodeInfo"}}, "text": "So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n ", "start_char_idx": 4940, "end_char_idx": 5073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "394d53ed-5295-44e8-986a-be25ba243979": {"__data__": {"id_": "394d53ed-5295-44e8-986a-be25ba243979", "embedding": null, "metadata": {"window": "But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind.  So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a00ecb24338a0106c4fc457b933999fcd6f457cf635571064f927a0cab9dc51d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4fc8712-998f-432e-a818-7bd78eec8f2c", "node_type": "1", "metadata": {"window": "So just wanted to confirm that that's what we \nshould think about as we think about what's included in your guidance.  But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind.  So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37fb470f4a54203828549e3d3ab477725f0ec8f7d90201485a08317cacbf345b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ab3d9b4-032e-44b4-8e75-4b32968d30d3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson. ", "original_text": "McKesson Corp.  "}, "hash": "ce98b2f1c675b2ad62a5dfa4e80350997dda2840fa6f3fd7255aa1aa9c99f879", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "start_char_idx": 361, "end_char_idx": 617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ab3d9b4-032e-44b4-8e75-4b32968d30d3": {"__data__": {"id_": "5ab3d9b4-032e-44b4-8e75-4b32968d30d3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "394d53ed-5295-44e8-986a-be25ba243979", "node_type": "1", "metadata": {"window": "But if we take that and we extrapo late sort \nof what you are guiding for the fourth quarter, we're getting to sort of an average benefit of about [ph] $1 \n(00:58:22) in 2022.  So while I know that it's early to talk about 2022, [ph] you usually (00:58:28) guide in May, but \nmaybe you can \u2013 but clearly, vaccine is going to be a nice tailwind.  So, maybe you can just offer us some color on \nwhat tailwinds and headwinds should we just be considering as we think about 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01cdd73f563fdbe9b7c9a76c83f4b036822a6cc2b0fa752be9a7f059865c8b6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cf9b264-b440-410f-8077-df6cb652c993", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "438d748ff63581404a9670e0faacdc9673b4092dc3e594e17202037a0fce37ae", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cf9b264-b440-410f-8077-df6cb652c993": {"__data__": {"id_": "6cf9b264-b440-410f-8077-df6cb652c993", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ab3d9b4-032e-44b4-8e75-4b32968d30d3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38a692bea186e1c096f7617748d54a9a121eda9c00acf483a42c2a408e262c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f1bde67-8e94-41a5-8536-646fdc2c8fb6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear. ", "original_text": "A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds. "}, "hash": "a5accfd1591e148168b02c86826a0f446204655a45e2a3e197f68076f6a30782", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f1bde67-8e94-41a5-8536-646fdc2c8fb6": {"__data__": {"id_": "2f1bde67-8e94-41a5-8536-646fdc2c8fb6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear. ", "original_text": "A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cf9b264-b440-410f-8077-df6cb652c993", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that. ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c905b62118e3d0ba7f4203c7737cd927f9f9f28eb2d711d91477b0b845bbf572", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0433403-4138-4ec0-aa13-c7286508efce", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n ", "original_text": "First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson. "}, "hash": "30586cf0dfa52d2cb3bb150377a78c5c41289be428f742a4f363f56e312dbc8d", "class_name": "RelatedNodeInfo"}}, "text": "A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds. ", "start_char_idx": 253, "end_char_idx": 389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0433403-4138-4ec0-aa13-c7286508efce": {"__data__": {"id_": "f0433403-4138-4ec0-aa13-c7286508efce", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n ", "original_text": "First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f1bde67-8e94-41a5-8536-646fdc2c8fb6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear. ", "original_text": "A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4085caa258d7cda52a61c1a6e5ffd3db00b63565c92cd4614c525b371b7471cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3b53830-bd44-4235-8b9e-3d7d6e961aee", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that. "}, "hash": "a60e2aa38c7d3b84e1f69b697995afa4590203b3661965644cff8f6af53af15f", "class_name": "RelatedNodeInfo"}}, "text": "First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson. ", "start_char_idx": 389, "end_char_idx": 493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3b53830-bd44-4235-8b9e-3d7d6e961aee": {"__data__": {"id_": "e3b53830-bd44-4235-8b9e-3d7d6e961aee", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0433403-4138-4ec0-aa13-c7286508efce", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n ", "original_text": "First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9410efb4db741f70af8e569a2f3172c60e20f86756fdcd0566427f15a887a20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86f01dbe-db8c-42c9-af2f-12be7cdc77a6", "node_type": "1", "metadata": {"window": "A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "So I just want to make that clear. "}, "hash": "5f954135144be585d61f80d52f14d8464ca60caef2d806fc6e5eaf7939abfc47", "class_name": "RelatedNodeInfo"}}, "text": "We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that. ", "start_char_idx": 493, "end_char_idx": 629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86f01dbe-db8c-42c9-af2f-12be7cdc77a6": {"__data__": {"id_": "86f01dbe-db8c-42c9-af2f-12be7cdc77a6", "embedding": null, "metadata": {"window": "A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "So I just want to make that clear. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3b53830-bd44-4235-8b9e-3d7d6e961aee", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7abec8a20a4e52c318942a106446a4cfecc69840dc0f5316cbb87e17ba8ce244", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11672702-7307-43c1-a91b-a2949bf0a623", "node_type": "1", "metadata": {"window": "First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thank you for the question, Ricky. ", "original_text": "And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n "}, "hash": "4cc28920cbf7245556de8164ce83cd0e1b75529b2417db3ddcc7a20f2cfef51b", "class_name": "RelatedNodeInfo"}}, "text": "So I just want to make that clear. ", "start_char_idx": 629, "end_char_idx": 664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11672702-7307-43c1-a91b-a2949bf0a623": {"__data__": {"id_": "11672702-7307-43c1-a91b-a2949bf0a623", "embedding": null, "metadata": {"window": "First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thank you for the question, Ricky. ", "original_text": "And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86f01dbe-db8c-42c9-af2f-12be7cdc77a6", "node_type": "1", "metadata": {"window": "A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "So I just want to make that clear. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "138f37b51a7c79788a9e30872c900464f34c9c93d959c286f7ed4f4b3d836180", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec38c7d0-f218-4e5c-a56b-8a3c3142d3ab", "node_type": "1", "metadata": {"window": "We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "44a0c936f9e91a66841e4eaad843b685a0ac54b18bc2532b3a151feddf2b0051", "class_name": "RelatedNodeInfo"}}, "text": "And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n ", "start_char_idx": 664, "end_char_idx": 752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec38c7d0-f218-4e5c-a56b-8a3c3142d3ab": {"__data__": {"id_": "ec38c7d0-f218-4e5c-a56b-8a3c3142d3ab", "embedding": null, "metadata": {"window": "We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11672702-7307-43c1-a91b-a2949bf0a623", "node_type": "1", "metadata": {"window": "First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson.  We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thank you for the question, Ricky. ", "original_text": "And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33a727eb754b90e2d79b53b3b7a44da5d922eaeb0064560c753e534d56c33e84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3c9fbcc-c363-4ff6-b818-272b55462028", "node_type": "1", "metadata": {"window": "So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year. ", "original_text": "A \nYeah. "}, "hash": "42b0e2d6354f1fc5de775de2edb921c2dd7a97e869a5b0408d158508a2cbc553", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 752, "end_char_idx": 1098, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3c9fbcc-c363-4ff6-b818-272b55462028": {"__data__": {"id_": "d3c9fbcc-c363-4ff6-b818-272b55462028", "embedding": null, "metadata": {"window": "So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year. ", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec38c7d0-f218-4e5c-a56b-8a3c3142d3ab", "node_type": "1", "metadata": {"window": "We've been working to  that schedule from day one, and that is what we base our forward guide on, \nand we can't really comment on that.  So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ecc0c949adf7e1b0c1504664c8144092a0064f7955d50dc23465b0f3a9f9c782", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15bc7c8e-cb38-48a9-923a-8502aad1f108", "node_type": "1", "metadata": {"window": "And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound. ", "original_text": "Thank you for the question, Ricky. "}, "hash": "7def9f46950c90cd57f6f66396db2991509846e4e0dc4deae207362a24b4d0b8", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 1098, "end_char_idx": 1107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15bc7c8e-cb38-48a9-923a-8502aad1f108": {"__data__": {"id_": "15bc7c8e-cb38-48a9-923a-8502aad1f108", "embedding": null, "metadata": {"window": "And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound. ", "original_text": "Thank you for the question, Ricky. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3c9fbcc-c363-4ff6-b818-272b55462028", "node_type": "1", "metadata": {"window": "So I just want to make that clear.  And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year. ", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a41888aadc462be62aac13f4d1ef80809b9cd07dc2362eb29c6d7f2b449e1a8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d94937d-21fb-4bcb-838f-52bb61bc286a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking. ", "original_text": "I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now. "}, "hash": "e2328a58b5b29c72a9bfed60f092d0b33c25de44df16342750ed4ad079d22a0a", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for the question, Ricky. ", "start_char_idx": 1107, "end_char_idx": 1142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d94937d-21fb-4bcb-838f-52bb61bc286a": {"__data__": {"id_": "9d94937d-21fb-4bcb-838f-52bb61bc286a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking. ", "original_text": "I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15bc7c8e-cb38-48a9-923a-8502aad1f108", "node_type": "1", "metadata": {"window": "And then, Britt, I don't know if you want to \nstart down our list of puts and takes.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound. ", "original_text": "Thank you for the question, Ricky. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7239eb77f97a2bfa08af0bf994c3821ec7d7ac5fd7edb7dffcf8a448fe3567a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38915316-ee1d-4ccf-b40b-015a6a768478", "node_type": "1", "metadata": {"window": "A \nYeah.  Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP. ", "original_text": "We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year. "}, "hash": "c708c2af82f0cb85889cce28999670ccf2d4ca27fd522bfefc89b5d2f88c5767", "class_name": "RelatedNodeInfo"}}, "text": "I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now. ", "start_char_idx": 1142, "end_char_idx": 1314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38915316-ee1d-4ccf-b40b-015a6a768478": {"__data__": {"id_": "38915316-ee1d-4ccf-b40b-015a6a768478", "embedding": null, "metadata": {"window": "A \nYeah.  Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP. ", "original_text": "We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d94937d-21fb-4bcb-838f-52bb61bc286a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExec utive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking. ", "original_text": "I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "38b631db825f84a0a087fa28860232e8a03aeaf5d37ba46fa9a9b39fd89c72ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a0a8b03-ee7c-4e2d-a8e9-5258bfd6b638", "node_type": "1", "metadata": {"window": "Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n", "original_text": "We would expect that the fundamentals of our business \nwill continue to be solid and sound. "}, "hash": "718a4b9850416b22cb08f01f620cfb34f89aece33ba89031b9de2d9cb5a4c6f9", "class_name": "RelatedNodeInfo"}}, "text": "We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year. ", "start_char_idx": 1314, "end_char_idx": 1496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a0a8b03-ee7c-4e2d-a8e9-5258bfd6b638": {"__data__": {"id_": "3a0a8b03-ee7c-4e2d-a8e9-5258bfd6b638", "embedding": null, "metadata": {"window": "Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n", "original_text": "We would expect that the fundamentals of our business \nwill continue to be solid and sound. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38915316-ee1d-4ccf-b40b-015a6a768478", "node_type": "1", "metadata": {"window": "A \nYeah.  Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP. ", "original_text": "We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e21e339b54e60f8919c5e43e1d506ec0c112d11c9fc12c30fefb6501abaf9f67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b65529cd-4665-42b3-aa6e-5fc1af4bc816", "node_type": "1", "metadata": {"window": "I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours. ", "original_text": "And we're starting to see some benefits from the investments that we're \nmaking. "}, "hash": "bf89f8f57be6963890da23b4beda4bb5c58c6fba2a8282aab1f0a68c22647677", "class_name": "RelatedNodeInfo"}}, "text": "We would expect that the fundamentals of our business \nwill continue to be solid and sound. ", "start_char_idx": 1496, "end_char_idx": 1588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b65529cd-4665-42b3-aa6e-5fc1af4bc816": {"__data__": {"id_": "b65529cd-4665-42b3-aa6e-5fc1af4bc816", "embedding": null, "metadata": {"window": "I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours. ", "original_text": "And we're starting to see some benefits from the investments that we're \nmaking. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a0a8b03-ee7c-4e2d-a8e9-5258bfd6b638", "node_type": "1", "metadata": {"window": "Thank you for the question, Ricky.  I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n", "original_text": "We would expect that the fundamentals of our business \nwill continue to be solid and sound. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e6f5548fcc3df870c28ca8e560e66c8709b0e9a6055ae151ae96825d78c1daf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c36ad55-4d09-48a7-9cd5-32b59e2abeec", "node_type": "1", "metadata": {"window": "We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n", "original_text": "Brian talked about AMP. "}, "hash": "02438ee8ef1b4b3cbefbc24c7eb32dcf386f73848e99163446d914075ec2b396", "class_name": "RelatedNodeInfo"}}, "text": "And we're starting to see some benefits from the investments that we're \nmaking. ", "start_char_idx": 1588, "end_char_idx": 1669, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c36ad55-4d09-48a7-9cd5-32b59e2abeec": {"__data__": {"id_": "0c36ad55-4d09-48a7-9cd5-32b59e2abeec", "embedding": null, "metadata": {"window": "We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n", "original_text": "Brian talked about AMP. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b65529cd-4665-42b3-aa6e-5fc1af4bc816", "node_type": "1", "metadata": {"window": "I mean, I'd really start with what I think are some strengths and some \ntailwinds in the business, and we've talked about these really over the last s everal quarters now.  We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours. ", "original_text": "And we're starting to see some benefits from the investments that we're \nmaking. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c65f2405e6c9de3dcaa39d8da7ca6134fc344e314441beab542fb151a893957c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3af7c6ea-7443-4a0d-aab2-7ed7e4be39b9", "node_type": "1", "metadata": {"window": "We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength. ", "original_text": "And clearly, we've talked about the investments we're making in Ontada.  \n \n"}, "hash": "d08eb2cc11bf102f6a6037f1d1e43964e8a8597dd4b844b037ba6d70d2ac7dcc", "class_name": "RelatedNodeInfo"}}, "text": "Brian talked about AMP. ", "start_char_idx": 1669, "end_char_idx": 1693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3af7c6ea-7443-4a0d-aab2-7ed7e4be39b9": {"__data__": {"id_": "3af7c6ea-7443-4a0d-aab2-7ed7e4be39b9", "embedding": null, "metadata": {"window": "We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength. ", "original_text": "And clearly, we've talked about the investments we're making in Ontada.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c36ad55-4d09-48a7-9cd5-32b59e2abeec", "node_type": "1", "metadata": {"window": "We've had good \nmomentum for several quarters now where we're seeing organic growth, and Q3 is a good example of that where \neach of our operating segments grew over the prior year.  We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n", "original_text": "Brian talked about AMP. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "39e576aec3e398ccb8d9d74747eb0a43c620332fbe2f1806268c6cf4b63672b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f10664f2-6582-4fc9-9f0a-f4c09c2e7344", "node_type": "1", "metadata": {"window": "And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet. ", "original_text": "So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours. "}, "hash": "403ff8f82a47efeede1d0a9a15523141fc589cbad04be4cc37966e00df02579d", "class_name": "RelatedNodeInfo"}}, "text": "And clearly, we've talked about the investments we're making in Ontada.  \n \n", "start_char_idx": 1693, "end_char_idx": 1769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f10664f2-6582-4fc9-9f0a-f4c09c2e7344": {"__data__": {"id_": "f10664f2-6582-4fc9-9f0a-f4c09c2e7344", "embedding": null, "metadata": {"window": "And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet. ", "original_text": "So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3af7c6ea-7443-4a0d-aab2-7ed7e4be39b9", "node_type": "1", "metadata": {"window": "We would expect that the fundamentals of our business \nwill continue to be solid and sound.  And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength. ", "original_text": "And clearly, we've talked about the investments we're making in Ontada.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "959b7d8483e937ff33b06b6c6e02c03e0d68b659a35f3a94ae3246176226d399", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "289ecfd9-b73a-406b-a97a-c25123d657ad", "node_type": "1", "metadata": {"window": "Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n", "original_text": "Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n"}, "hash": "ebcfe3ae945b7d3d29c59d61c16cf7b7c3e173ad876c13c874e222277d1bc354", "class_name": "RelatedNodeInfo"}}, "text": "So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours. ", "start_char_idx": 1769, "end_char_idx": 1901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "289ecfd9-b73a-406b-a97a-c25123d657ad": {"__data__": {"id_": "289ecfd9-b73a-406b-a97a-c25123d657ad", "embedding": null, "metadata": {"window": "Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n", "original_text": "Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f10664f2-6582-4fc9-9f0a-f4c09c2e7344", "node_type": "1", "metadata": {"window": "And we're starting to see some benefits from the investments that we're \nmaking.  Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet. ", "original_text": "So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e646c7f27d74479d81fc4e8ca6e44d5ea4a76c752bcb8dbf4944beb8c841ce9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8249943b-6310-4138-bfc4-d9df6f9f65d2", "node_type": "1", "metadata": {"window": "And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that. ", "original_text": "So I think, as you look across our operating segments, we have a lot of good momentum and strength. "}, "hash": "30126df1e7a9b31bb089142e3b07401d2607c4039bd434b34c8e8acd0b52c8cf", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n", "start_char_idx": 1901, "end_char_idx": 2115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8249943b-6310-4138-bfc4-d9df6f9f65d2": {"__data__": {"id_": "8249943b-6310-4138-bfc4-d9df6f9f65d2", "embedding": null, "metadata": {"window": "And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that. ", "original_text": "So I think, as you look across our operating segments, we have a lot of good momentum and strength. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "289ecfd9-b73a-406b-a97a-c25123d657ad", "node_type": "1", "metadata": {"window": "Brian talked about AMP.  And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n", "original_text": "Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0921adecdb6b9319e9de563b6cf6fb120bf6268171ba9639a03a2e38a253a38c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faba3b2a-0e48-4c5e-ab94-96267fec29e1", "node_type": "1", "metadata": {"window": "So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with. ", "original_text": "We have a \nvery strong balance sheet. "}, "hash": "d01d895683fce0f3561ea0370faabf98e56d9fdabb552ba97fe304191b47cc2e", "class_name": "RelatedNodeInfo"}}, "text": "So I think, as you look across our operating segments, we have a lot of good momentum and strength. ", "start_char_idx": 2115, "end_char_idx": 2215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faba3b2a-0e48-4c5e-ab94-96267fec29e1": {"__data__": {"id_": "faba3b2a-0e48-4c5e-ab94-96267fec29e1", "embedding": null, "metadata": {"window": "So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with. ", "original_text": "We have a \nvery strong balance sheet. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8249943b-6310-4138-bfc4-d9df6f9f65d2", "node_type": "1", "metadata": {"window": "And clearly, we've talked about the investments we're making in Ontada.  \n \n So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that. ", "original_text": "So I think, as you look across our operating segments, we have a lot of good momentum and strength. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db2561dc5829ead6c93c3a1e87b32f0bd26df5f866777345505d460b44c0e8c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9e79ab4-368b-400f-ab6c-6aef6df972a9", "node_type": "1", "metadata": {"window": "Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n ", "original_text": "As Brian just mentioned, we've seen consistent cash flow.  \n \n"}, "hash": "e75cfbad62559b0d453c1d8207ebdd32a9ab0ab9317ec5d5ddee059367125ff9", "class_name": "RelatedNodeInfo"}}, "text": "We have a \nvery strong balance sheet. ", "start_char_idx": 2215, "end_char_idx": 2253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9e79ab4-368b-400f-ab6c-6aef6df972a9": {"__data__": {"id_": "e9e79ab4-368b-400f-ab6c-6aef6df972a9", "embedding": null, "metadata": {"window": "Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n ", "original_text": "As Brian just mentioned, we've seen consistent cash flow.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "faba3b2a-0e48-4c5e-ab94-96267fec29e1", "node_type": "1", "metadata": {"window": "So, the strategies and the investments in o ncology and biopharma services, I would expect, will continue to be \nstrengths of ours.  Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with. ", "original_text": "We have a \nvery strong balance sheet. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "47aacdf715cd0f14db7579b0d4df7ca59c1e786cf8a1c1efd38eadd0d1edb49a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "960b5001-63de-4885-9a7b-e056e1e5f6e5", "node_type": "1", "metadata": {"window": "So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that. "}, "hash": "401c55e88b3289389a9e43b5bf9f6a0e42f7d86617a145770ef033e7c0c7d2d9", "class_name": "RelatedNodeInfo"}}, "text": "As Brian just mentioned, we've seen consistent cash flow.  \n \n", "start_char_idx": 2253, "end_char_idx": 2315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "960b5001-63de-4885-9a7b-e056e1e5f6e5": {"__data__": {"id_": "960b5001-63de-4885-9a7b-e056e1e5f6e5", "embedding": null, "metadata": {"window": "So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9e79ab4-368b-400f-ab6c-6aef6df972a9", "node_type": "1", "metadata": {"window": "Obviously, the breadth of our Medical business, as we talked about earlier, the breadth of our \ncustomers, the breadth of services and capabilities across private brand a nd lab will continue to be strong for us. \n So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n ", "original_text": "As Brian just mentioned, we've seen consistent cash flow.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11fa7b895f585c966380c266b3aece3aeb93d5c15a1a4666231710a8d164bf35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57ce940e-3713-4de2-9b3b-933e7e27f9bd", "node_type": "1", "metadata": {"window": "We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n ", "original_text": "I think that will be the thing that we will be challenged with. "}, "hash": "effd00d4af360cc9e5516efaa710ebf06e62d6d1daf749ed6d236b148566cd05", "class_name": "RelatedNodeInfo"}}, "text": "From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that. ", "start_char_idx": 2315, "end_char_idx": 2457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57ce940e-3713-4de2-9b3b-933e7e27f9bd": {"__data__": {"id_": "57ce940e-3713-4de2-9b3b-933e7e27f9bd", "embedding": null, "metadata": {"window": "We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n ", "original_text": "I think that will be the thing that we will be challenged with. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "960b5001-63de-4885-9a7b-e056e1e5f6e5", "node_type": "1", "metadata": {"window": "So I think, as you look across our operating segments, we have a lot of good momentum and strength.  We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62efe1a1b329904a45ef3018d98dfb4a44631da50b362f9fa6c4fe3355b400a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba49fc4d-4753-49b9-91e1-26b904ac4dd5", "node_type": "1", "metadata": {"window": "As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "original_text": "But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n "}, "hash": "bd6a8f37cd6f0cf5d4bf2564ee921bac01a650f28f764a0a3f805020515fd776", "class_name": "RelatedNodeInfo"}}, "text": "I think that will be the thing that we will be challenged with. ", "start_char_idx": 2457, "end_char_idx": 2521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba49fc4d-4753-49b9-91e1-26b904ac4dd5": {"__data__": {"id_": "ba49fc4d-4753-49b9-91e1-26b904ac4dd5", "embedding": null, "metadata": {"window": "As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "original_text": "But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57ce940e-3713-4de2-9b3b-933e7e27f9bd", "node_type": "1", "metadata": {"window": "We have a \nvery strong balance sheet.  As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n ", "original_text": "I think that will be the thing that we will be challenged with. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "703cbdb802b8f6e0cfb84bae0eefaa43c102ca3552408c6776b6daac210c2fb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c8fc4c3-51fb-4b4a-994f-925a99f81315", "node_type": "1", "metadata": {"window": "From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  "}, "hash": "80eb199f9e1df2821c7d10193888831cdca9cc1a776ce9bf29a3176e5135ccf5", "class_name": "RelatedNodeInfo"}}, "text": "But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n ", "start_char_idx": 2521, "end_char_idx": 2684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c8fc4c3-51fb-4b4a-994f-925a99f81315": {"__data__": {"id_": "3c8fc4c3-51fb-4b4a-994f-925a99f81315", "embedding": null, "metadata": {"window": "From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba49fc4d-4753-49b9-91e1-26b904ac4dd5", "node_type": "1", "metadata": {"window": "As Brian just mentioned, we've seen consistent cash flow.  \n \n From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "original_text": "But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85494a84d68d9921d721d2fd7acaefaf48ac4e97fa1d107e18d3a8942a80d59c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "097c8431-f814-4ff7-9224-04d017549088", "node_type": "1", "metadata": {"window": "I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "A \nOperator, we have time for one more question, please.  \n "}, "hash": "2346dddcbcaee49d3bcc8b6954153f571dd383c4230cd0074335e5a6ac0ddbe4", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "start_char_idx": 2684, "end_char_idx": 3043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "097c8431-f814-4ff7-9224-04d017549088": {"__data__": {"id_": "097c8431-f814-4ff7-9224-04d017549088", "embedding": null, "metadata": {"window": "I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "A \nOperator, we have time for one more question, please.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c8fc4c3-51fb-4b4a-994f-925a99f81315", "node_type": "1", "metadata": {"window": "From a headwinds p erspective, I think it will really be how long does the pandemic persist and the unevenness \nand unpredictability of that.  I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42cefc935cac6d3b89dd5fdd496b4185bda957da24cd2f363f656966fe04fa96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6a05654-6339-4fc8-9c45-07c515a85608", "node_type": "1", "metadata": {"window": "But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. "}, "hash": "e4c498b4e1ad1d5f2ee4b86ec71cdbd46c3affeeab402a12183932675abc459c", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator, we have time for one more question, please.  \n ", "start_char_idx": 3043, "end_char_idx": 3103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6a05654-6339-4fc8-9c45-07c515a85608": {"__data__": {"id_": "b6a05654-6339-4fc8-9c45-07c515a85608", "embedding": null, "metadata": {"window": "But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "097c8431-f814-4ff7-9224-04d017549088", "node_type": "1", "metadata": {"window": "I think that will be the thing that we will be challenged with.  But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "A \nOperator, we have time for one more question, please.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94d3b2522bcd7c677c8e2ca638a09e925796ec5593e6d4facd6016a2566ed176", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0959e60f-b45a-4bf8-929e-fdb55116b7d0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n", "original_text": "That question comes from Steven Valiquette with Barclays.  \n "}, "hash": "1b754628c7ba7c817868d49ccaaf978d750f06efcc2e4f6de82abdc92af0a4e5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "start_char_idx": 3103, "end_char_idx": 3384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0959e60f-b45a-4bf8-929e-fdb55116b7d0": {"__data__": {"id_": "0959e60f-b45a-4bf8-929e-fdb55116b7d0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n", "original_text": "That question comes from Steven Valiquette with Barclays.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6a05654-6339-4fc8-9c45-07c515a85608", "node_type": "1", "metadata": {"window": "But as you've seen from \nour results this year, we've been able to mana ge through that quite well and take on some near -term opportunities \nat the same time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3599c0fcd954726d33fc7bb0c888389019ea9f5440d316201b16ea59b6780fc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e1b8fef-719f-4187-9328-68d69ad57b25", "node_type": "1", "metadata": {"window": "A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  "}, "hash": "516646dfee0a11bfb890b999aeef90e07e4c411924881bb64def24d01c2cea7f", "class_name": "RelatedNodeInfo"}}, "text": "That question comes from Steven Valiquette with Barclays.  \n ", "start_char_idx": 3384, "end_char_idx": 3445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e1b8fef-719f-4187-9328-68d69ad57b25": {"__data__": {"id_": "4e1b8fef-719f-4187-9328-68d69ad57b25", "embedding": null, "metadata": {"window": "A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0959e60f-b45a-4bf8-929e-fdb55116b7d0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n", "original_text": "That question comes from Steven Valiquette with Barclays.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d27375f0db779143cabcaf6a392eae20cd58d0cfb5bb763e4cde27926b116bdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6418d3db-4b2d-4fce-9dfd-036cba8c1f9b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n ", "original_text": "Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US? "}, "hash": "097e224a51a70d569338c152aedf20a36b280686b80bfc0a13e400db215d9247", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "start_char_idx": 3445, "end_char_idx": 3757, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6418d3db-4b2d-4fce-9dfd-036cba8c1f9b": {"__data__": {"id_": "6418d3db-4b2d-4fce-9dfd-036cba8c1f9b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n ", "original_text": "Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US? ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e1b8fef-719f-4187-9328-68d69ad57b25", "node_type": "1", "metadata": {"window": "A \nOperator, we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d677af9e26dc54da80bb67ae751a7821858b14ee10fa583155a70ae075cedfad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfc336f4-d4d6-49c4-ab06-45b1d23e716d", "node_type": "1", "metadata": {"window": "That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Just want to confirm that. \n"}, "hash": "1259172b0994e102ebe1935d126dfa2fbd80523a10045f191e4e141d38fa0ae8", "class_name": "RelatedNodeInfo"}}, "text": "Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US? ", "start_char_idx": 3757, "end_char_idx": 3959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfc336f4-d4d6-49c4-ab06-45b1d23e716d": {"__data__": {"id_": "dfc336f4-d4d6-49c4-ab06-45b1d23e716d", "embedding": null, "metadata": {"window": "That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Just want to confirm that. \n", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6418d3db-4b2d-4fce-9dfd-036cba8c1f9b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Certainly.  That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n ", "original_text": "Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US? ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9be7a94725f199a6cf71664a8ea36deeae032d941436dfabac66afe01e50542", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb858eb9-533a-4dd1-8c2a-2b576ae2cda8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start. ", "original_text": "Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022? "}, "hash": "3ceea66a3c670dad70824f6022057e9ec1f25ad04b43f4446d5bd79aeae27659", "class_name": "RelatedNodeInfo"}}, "text": "Just want to confirm that. \n", "start_char_idx": 3959, "end_char_idx": 3987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb858eb9-533a-4dd1-8c2a-2b576ae2cda8": {"__data__": {"id_": "bb858eb9-533a-4dd1-8c2a-2b576ae2cda8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start. ", "original_text": "Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022? ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfc336f4-d4d6-49c4-ab06-45b1d23e716d", "node_type": "1", "metadata": {"window": "That question comes from Steven Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Just want to confirm that. \n", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea13b5b26122761b8373fabcf64c5d3bfcedd79aa9675c3c7544f38c1839786b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3832c4f8-cc3e-4c04-8582-d83c8e1e9d89", "node_type": "1", "metadata": {"window": "Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start.  Great question. ", "original_text": "Thanks.  \n "}, "hash": "2dc5be4bb1edf0821acdbb4d1157fbbf28f410f2bd8e4cac0c636c66c6518bb7", "class_name": "RelatedNodeInfo"}}, "text": "Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022? ", "start_char_idx": 3987, "end_char_idx": 4247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3832c4f8-cc3e-4c04-8582-d83c8e1e9d89": {"__data__": {"id_": "3832c4f8-cc3e-4c04-8582-d83c8e1e9d89", "embedding": null, "metadata": {"window": "Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start.  Great question. ", "original_text": "Thanks.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb858eb9-533a-4dd1-8c2a-2b576ae2cda8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start. ", "original_text": "Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022? ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8de11890e15d20517e92325a30ed88c9b7f0a7754276e80ebadc46508cef93c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4d7bb7e-223a-4668-bd49-3abad361b835", "node_type": "1", "metadata": {"window": "Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start.  Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "bdf9cbcb135bd17ad3fa55dd8bfa8982f6e59d330ce5743ea8865b5e3399a84b", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 4247, "end_char_idx": 4258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4d7bb7e-223a-4668-bd49-3abad361b835": {"__data__": {"id_": "f4d7bb7e-223a-4668-bd49-3abad361b835", "embedding": null, "metadata": {"window": "Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start.  Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3832c4f8-cc3e-4c04-8582-d83c8e1e9d89", "node_type": "1", "metadata": {"window": "Q \nWhen we think about the $0.25 to $0.35 EPS related to COVID vaccine distribution, the additional $0.20 to $0.30 \nfrom the kits and supplies, is the 100% of this combined EPS being derived in the US?  Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start.  Great question. ", "original_text": "Thanks.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5273af0757c177992cfa8b5260a09f4e61a05737f27ec02a2e96f67aeba7b1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2578a559-536c-403f-8807-c91a28743e28", "node_type": "1", "metadata": {"window": "Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start.  Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter.  It's $0.20 to $0.30 from $0.15 to $0.20. ", "original_text": "A \nI'll start. "}, "hash": "16f6aed940f8450aa9463ac13d05da1cfd950f14b4112cdd6715966fddea9e17", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 4258, "end_char_idx": 4603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2578a559-536c-403f-8807-c91a28743e28": {"__data__": {"id_": "2578a559-536c-403f-8807-c91a28743e28", "embedding": null, "metadata": {"window": "Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start.  Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter.  It's $0.20 to $0.30 from $0.15 to $0.20. ", "original_text": "A \nI'll start. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4d7bb7e-223a-4668-bd49-3abad361b835", "node_type": "1", "metadata": {"window": "Just want to confirm that. \n Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start.  Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c0e93cddd912df88404d256e562b58dd6772bb88fd7b8fb7861c650b3d88e7ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d57706ba-8b69-4cb2-84e0-1c8eaeab09ab", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start.  Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter.  It's $0.20 to $0.30 from $0.15 to $0.20.  What we've talked about here both for the vaccine ", "original_text": "Great question. "}, "hash": "24b00815f737cc76ab07747703391c98bf55d8f3bda38b7b603e16fd3ada9789", "class_name": "RelatedNodeInfo"}}, "text": "A \nI'll start. ", "start_char_idx": 4603, "end_char_idx": 4618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d57706ba-8b69-4cb2-84e0-1c8eaeab09ab": {"__data__": {"id_": "d57706ba-8b69-4cb2-84e0-1c8eaeab09ab", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start.  Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter.  It's $0.20 to $0.30 from $0.15 to $0.20.  What we've talked about here both for the vaccine ", "original_text": "Great question. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2578a559-536c-403f-8807-c91a28743e28", "node_type": "1", "metadata": {"window": "Can you remind us about the potential for McKesson to capture international economics on either the COVID \nvaccines or kits in Canada or Europe and where that sta nds either for the remainder of fiscal 2021 or maybe a \ngreater opportunity in your fiscal 2022?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start.  Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter.  It's $0.20 to $0.30 from $0.15 to $0.20. ", "original_text": "A \nI'll start. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c02b7c82bbed05be820beab72b8af35366fe1cba9890b2046433adf362474fa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bcf4294-2772-48f9-a8a5-7b656140eb3c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start.  Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter.  It's $0.20 to $0.30 from $0.15 to $0.20.  What we've talked about here both for the vaccine ", "original_text": "Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter. "}, "hash": "cd6a69056c49b52d79a1251de7fb3ee07ba94cb4773612b595e4d66a314f061c", "class_name": "RelatedNodeInfo"}}, "text": "Great question. ", "start_char_idx": 4618, "end_char_idx": 4634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bcf4294-2772-48f9-a8a5-7b656140eb3c": {"__data__": {"id_": "5bcf4294-2772-48f9-a8a5-7b656140eb3c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start.  Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter.  It's $0.20 to $0.30 from $0.15 to $0.20.  What we've talked about here both for the vaccine ", "original_text": "Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d57706ba-8b69-4cb2-84e0-1c8eaeab09ab", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start.  Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter.  It's $0.20 to $0.30 from $0.15 to $0.20.  What we've talked about here both for the vaccine ", "original_text": "Great question. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d49c7ae50fbdd475bac7e89ba6c705eb765a951c5be74ae99be23e21edcd94a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84b29138-2450-4260-8f0d-2f0e8958a344", "node_type": "1", "metadata": {"window": "A \nI'll start.  Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter.  It's $0.20 to $0.30 from $0.15 to $0.20.  What we've talked about here both for the vaccine ", "original_text": "It's $0.20 to $0.30 from $0.15 to $0.20. "}, "hash": "00ede6ad9b3ac37a2de6c841313715ba7c9690849fcdcb1bc874c8fe329fe296", "class_name": "RelatedNodeInfo"}}, "text": "Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter. ", "start_char_idx": 4634, "end_char_idx": 4747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84b29138-2450-4260-8f0d-2f0e8958a344": {"__data__": {"id_": "84b29138-2450-4260-8f0d-2f0e8958a344", "embedding": null, "metadata": {"window": "A \nI'll start.  Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter.  It's $0.20 to $0.30 from $0.15 to $0.20.  What we've talked about here both for the vaccine ", "original_text": "It's $0.20 to $0.30 from $0.15 to $0.20. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bcf4294-2772-48f9-a8a5-7b656140eb3c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nI'll start.  Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter.  It's $0.20 to $0.30 from $0.15 to $0.20.  What we've talked about here both for the vaccine ", "original_text": "Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dac055c5f646a41e45f6aa3f1f22a0a4378ad9217d3b3075b55836fa44bcee6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df5e9585-ddcf-40eb-a1be-818904c4e066", "node_type": "1", "metadata": {"window": "Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter.  It's $0.20 to $0.30 from $0.15 to $0.20.  What we've talked about here both for the vaccine ", "original_text": "What we've talked about here both for the vaccine "}, "hash": "00ed67b1946db2f28fe83e492d0aa074716d4033f9d06bbe4b24795337b5b2b0", "class_name": "RelatedNodeInfo"}}, "text": "It's $0.20 to $0.30 from $0.15 to $0.20. ", "start_char_idx": 4747, "end_char_idx": 4788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df5e9585-ddcf-40eb-a1be-818904c4e066": {"__data__": {"id_": "df5e9585-ddcf-40eb-a1be-818904c4e066", "embedding": null, "metadata": {"window": "Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter.  It's $0.20 to $0.30 from $0.15 to $0.20.  What we've talked about here both for the vaccine ", "original_text": "What we've talked about here both for the vaccine ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18c221a69702fd6ca221eb7a9307c5d1b44788a234f3b0a3992ae551526ad200", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84b29138-2450-4260-8f0d-2f0e8958a344", "node_type": "1", "metadata": {"window": "A \nI'll start.  Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter.  It's $0.20 to $0.30 from $0.15 to $0.20.  What we've talked about here both for the vaccine ", "original_text": "It's $0.20 to $0.30 from $0.15 to $0.20. ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f27c7ebb9f6e41bf667e4a5eb0286797dff6045719ddd0557d9248c4cc2a38a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31a2d47e-e4b5-4ae3-a178-64ca4cf1dad7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US.  contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n ", "original_text": "McKesson Corp.  "}, "hash": "a711cd188f8ca734aedfeb5870dda2e67b121722e316597225f7dfc040567ba2", "class_name": "RelatedNodeInfo"}}, "text": "What we've talked about here both for the vaccine ", "start_char_idx": 4788, "end_char_idx": 4838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31a2d47e-e4b5-4ae3-a178-64ca4cf1dad7": {"__data__": {"id_": "31a2d47e-e4b5-4ae3-a178-64ca4cf1dad7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US.  contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df5e9585-ddcf-40eb-a1be-818904c4e066", "node_type": "1", "metadata": {"window": "Great question.  Let me just clarify, for the kitti ng component of this, the $0.20 to $0.30 is not incremental \nto last quarter.  It's $0.20 to $0.30 from $0.15 to $0.20.  What we've talked about here both for the vaccine ", "original_text": "What we've talked about here both for the vaccine ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e17885ebf4206c89c1f4f2bc3b7d9f708ed2db06f60a02b357325596b9aadb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f28b034-fb03-4d13-bd27-6ea13ebdb972", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US.  contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US. "}, "hash": "6d9938d2ca179c89be73f5bfd3c80e3ab19b51aa63ae572cb52cbc877aacb934", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f28b034-fb03-4d13-bd27-6ea13ebdb972": {"__data__": {"id_": "1f28b034-fb03-4d13-bd27-6ea13ebdb972", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US.  contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31a2d47e-e4b5-4ae3-a178-64ca4cf1dad7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US.  contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffc21307a5a2ab889988a77fd0fae90a8151d5b8ea6f2e3176a20a5300d57096", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f0f8b98-8dd8-46b5-9ed5-0ff3ac3c28f9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US.  contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "contributions. "}, "hash": "0ca079390e1791b2fdbe4c6b01050f91e03348a30d12ed97f274d5322b3a98c9", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US. ", "start_char_idx": 16, "end_char_idx": 242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f0f8b98-8dd8-46b5-9ed5-0ff3ac3c28f9": {"__data__": {"id_": "5f0f8b98-8dd8-46b5-9ed5-0ff3ac3c28f9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US.  contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "contributions. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f28b034-fb03-4d13-bd27-6ea13ebdb972", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US.  contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "057d4a444445934e07b7b75d9917187d5e7d299f2fa3518ea7a586b1e386ad94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67546e79-7fa5-47b9-8896-920c90537afa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US.  contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n", "original_text": "And I'll let  Brian maybe talk a little bit \nabout our International.  \n "}, "hash": "4158f5deb104cc5df609f0f7a885f7a3307ad2b911a952b3cd59c5ccfd6a2b98", "class_name": "RelatedNodeInfo"}}, "text": "contributions. ", "start_char_idx": 242, "end_char_idx": 257, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67546e79-7fa5-47b9-8896-920c90537afa": {"__data__": {"id_": "67546e79-7fa5-47b9-8896-920c90537afa", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US.  contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n", "original_text": "And I'll let  Brian maybe talk a little bit \nabout our International.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f0f8b98-8dd8-46b5-9ed5-0ff3ac3c28f9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US.  contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "contributions. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b51e368bfb40fff063d67d3b78320d1de02bd3302a3b38288896f3acb81b332", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8036f237-1773-4b5d-8588-c982341e6e93", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US.  contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "408dfc13d9b3ae2e287a9b958871289c57a238ed1d26725a02aa65314a5ab80e", "class_name": "RelatedNodeInfo"}}, "text": "And I'll let  Brian maybe talk a little bit \nabout our International.  \n ", "start_char_idx": 257, "end_char_idx": 330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8036f237-1773-4b5d-8588-c982341e6e93": {"__data__": {"id_": "8036f237-1773-4b5d-8588-c982341e6e93", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US.  contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67546e79-7fa5-47b9-8896-920c90537afa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US.  contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n", "original_text": "And I'll let  Brian maybe talk a little bit \nabout our International.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80a0675e1cbbc79c22e900083e7587961a55a7514298dc801c4a39d515cda961", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93873192-e074-41e5-92db-7127481f1946", "node_type": "1", "metadata": {"window": "contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "A \nYeah. "}, "hash": "1cc2a12e263efc35c153c1ce1f06337bb2cb91991edd90363d2ffbd47238f513", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 330, "end_char_idx": 659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93873192-e074-41e5-92db-7127481f1946": {"__data__": {"id_": "93873192-e074-41e5-92db-7127481f1946", "embedding": null, "metadata": {"window": "contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "A \nYeah. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8036f237-1773-4b5d-8588-c982341e6e93", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US.  contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "70d414d3acb8f04232c2e730a342e7fedf1a0a2a108a333bc43da77be2b8ad20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a09438a8-62e5-48c4-a8fb-10c01e116f66", "node_type": "1", "metadata": {"window": "And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n"}, "hash": "43be5afb3345dbdc736656f31a5e1fb7303cf17f8b1a66dcbbc16713d5a75659", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 659, "end_char_idx": 668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a09438a8-62e5-48c4-a8fb-10c01e116f66": {"__data__": {"id_": "a09438a8-62e5-48c4-a8fb-10c01e116f66", "embedding": null, "metadata": {"window": "And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93873192-e074-41e5-92db-7127481f1946", "node_type": "1", "metadata": {"window": "contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "A \nYeah. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "598d0518b7af80ac71fdab2a8fc55590a024319059c1057e1a4bf41dbd997291", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b18a64b-8edc-4278-b596-461ae0cdcf05", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call. ", "original_text": "They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n "}, "hash": "c3662fbab86cf2e91d7c8f1965bd43754bb17b2c94ba961e65149d540b6cebc8", "class_name": "RelatedNodeInfo"}}, "text": "Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n", "start_char_idx": 668, "end_char_idx": 889, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b18a64b-8edc-4278-b596-461ae0cdcf05": {"__data__": {"id_": "1b18a64b-8edc-4278-b596-461ae0cdcf05", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call. ", "original_text": "They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a09438a8-62e5-48c4-a8fb-10c01e116f66", "node_type": "1", "metadata": {"window": "And I'll let  Brian maybe talk a little bit \nabout our International.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5774060cd18ab3eb17885041e2ffb7333b45d78471ca6b407ca9b3ff3da82b72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c00cd10-ed9f-423d-9604-1e46f4758aff", "node_type": "1", "metadata": {"window": "A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "bcfe612e0bcd8639db3965a66738715d53a9dbca998aa46ac6e49f7362c91a96", "class_name": "RelatedNodeInfo"}}, "text": "They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n ", "start_char_idx": 889, "end_char_idx": 1118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c00cd10-ed9f-423d-9604-1e46f4758aff": {"__data__": {"id_": "4c00cd10-ed9f-423d-9604-1e46f4758aff", "embedding": null, "metadata": {"window": "A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b18a64b-8edc-4278-b596-461ae0cdcf05", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call. ", "original_text": "They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48efac8f4855cbae764bd1aa33c077fd6ff094765fb58fb01e092f46396b1af6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84c8fe53-dba1-4712-a645-2f4c3b92b927", "node_type": "1", "metadata": {"window": "Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program. ", "original_text": "Okay. "}, "hash": "c75974039f123868ddae7e53fccec709581e97b2bc06458ddee047c3aa1c59bb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 1118, "end_char_idx": 1448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84c8fe53-dba1-4712-a645-2f4c3b92b927": {"__data__": {"id_": "84c8fe53-dba1-4712-a645-2f4c3b92b927", "embedding": null, "metadata": {"window": "Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program. ", "original_text": "Okay. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c00cd10-ed9f-423d-9604-1e46f4758aff", "node_type": "1", "metadata": {"window": "A \nYeah.  Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f70f1861d45bf7326fc6311ab8c88fc2812558b606ddfb925d75a69444fda00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7d07c72-e8f3-4c3d-a4e5-52af87b35999", "node_type": "1", "metadata": {"window": "They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market. ", "original_text": "Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call. "}, "hash": "4b3b00bdef643502151d17fe792054705e27de4742ea17e1bcfe79aa6e430434", "class_name": "RelatedNodeInfo"}}, "text": "Okay. ", "start_char_idx": 1448, "end_char_idx": 1454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7d07c72-e8f3-4c3d-a4e5-52af87b35999": {"__data__": {"id_": "c7d07c72-e8f3-4c3d-a4e5-52af87b35999", "embedding": null, "metadata": {"window": "They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market. ", "original_text": "Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84c8fe53-dba1-4712-a645-2f4c3b92b927", "node_type": "1", "metadata": {"window": "Look, our international countries and companies are engaged with local governments either through our \ndistribution capabilities, our retail pharmacy capabilities to help the response of those countries to the pandemic. \n They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program. ", "original_text": "Okay. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84aa9eb1ca81008446d7e69000542050e31022e6b56aa8ea5d89b742ee769161", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33ce3dd9-b950-48d2-a729-4e1a85941c0d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time. ", "original_text": "I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n"}, "hash": "58aca8ddce13c5e4ed0bd04a5c678e4a277c16e08fbb5135a83ff4b5a956d064", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call. ", "start_char_idx": 1454, "end_char_idx": 1543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33ce3dd9-b950-48d2-a729-4e1a85941c0d": {"__data__": {"id_": "33ce3dd9-b950-48d2-a729-4e1a85941c0d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time. ", "original_text": "I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7d07c72-e8f3-4c3d-a4e5-52af87b35999", "node_type": "1", "metadata": {"window": "They I would say as a general characterization are probably from a timeline trailing the US a little bit, but we are \nheavily involved in those discussio ns, but nothing that would be material to our financials at this point.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market. ", "original_text": "Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6401f1dfbdd7dc469d65430a20544c90a156f87990b7125ef5e44b87a236d3dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5534d896-a0c2-4d9d-a69b-7b31bc595fad", "node_type": "1", "metadata": {"window": "Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness. ", "original_text": "Our company's top priority is the vaccination program. "}, "hash": "dc26f76c6575463dd1faf5239bb5c0c87293ffaad62a902e40fde49720bcc723", "class_name": "RelatedNodeInfo"}}, "text": "I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n", "start_char_idx": 1543, "end_char_idx": 1872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5534d896-a0c2-4d9d-a69b-7b31bc595fad": {"__data__": {"id_": "5534d896-a0c2-4d9d-a69b-7b31bc595fad", "embedding": null, "metadata": {"window": "Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness. ", "original_text": "Our company's top priority is the vaccination program. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33ce3dd9-b950-48d2-a729-4e1a85941c0d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time. ", "original_text": "I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0793d734edfdc1ac1456560f7c138d4e99b5f55604c62f5d5bf7f81d0ab250bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27ca605b-db0f-43fe-b818-0932dd2d60c5", "node_type": "1", "metadata": {"window": "Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n ", "original_text": "And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market. "}, "hash": "186b187c4cc268f36297b7ead406fd08d92d844a9733f1fec1e7df404d81feb9", "class_name": "RelatedNodeInfo"}}, "text": "Our company's top priority is the vaccination program. ", "start_char_idx": 1872, "end_char_idx": 1927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27ca605b-db0f-43fe-b818-0932dd2d60c5": {"__data__": {"id_": "27ca605b-db0f-43fe-b818-0932dd2d60c5", "embedding": null, "metadata": {"window": "Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n ", "original_text": "And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5534d896-a0c2-4d9d-a69b-7b31bc595fad", "node_type": "1", "metadata": {"window": "Okay.  Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness. ", "original_text": "Our company's top priority is the vaccination program. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5b3c46d7810fc2fbe1b4cf11b0c1d5302bba766d40c2b615e608e60a15331f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e22c8788-0d43-4123-85d8-f04aa07411ef", "node_type": "1", "metadata": {"window": "I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "original_text": "I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time. "}, "hash": "5d4133e2e75742628e3b44625f6363e778f59869b7977cadfa672449429f2df6", "class_name": "RelatedNodeInfo"}}, "text": "And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market. ", "start_char_idx": 1927, "end_char_idx": 2132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e22c8788-0d43-4123-85d8-f04aa07411ef": {"__data__": {"id_": "e22c8788-0d43-4123-85d8-f04aa07411ef", "embedding": null, "metadata": {"window": "I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "original_text": "I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27ca605b-db0f-43fe-b818-0932dd2d60c5", "node_type": "1", "metadata": {"window": "Thank you, everyone, for your questions, and thank you, Zen, for facilitating this call.  I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n ", "original_text": "And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c0d6515f97158cd73d1e7f36e83dbbbecf8a4c39554ae0c6ae0d9db3735a4bbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06d4a7e9-f84f-4789-a1d8-c36994a5d278", "node_type": "1", "metadata": {"window": "Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "original_text": "We wish you all and your families good health and wellness. "}, "hash": "411f7a178688e4b264925b9e3e842a2ef9da633487d57e5f929dc15d67ac4d05", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time. ", "start_char_idx": 2132, "end_char_idx": 2249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06d4a7e9-f84f-4789-a1d8-c36994a5d278": {"__data__": {"id_": "06d4a7e9-f84f-4789-a1d8-c36994a5d278", "embedding": null, "metadata": {"window": "Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "original_text": "We wish you all and your families good health and wellness. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e22c8788-0d43-4123-85d8-f04aa07411ef", "node_type": "1", "metadata": {"window": "I want to conclude my \nremarks today by once again recognizing and thanking all the frontline healthcare workers across the world who \nare working day in and day out to keep us safe and also acknowledge the great work from our biopharma \nscientific community to have us  at this hopeful moment as it relates to vaccinations.  \n \n Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "original_text": "I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b65c51d1e6d03fbaea1124bc0072bdf6a4fd6b21d21ab15c1796a08b4586574", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c047fd54-4447-4fd5-816e-be69c634e664", "node_type": "1", "metadata": {"window": "And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "original_text": "Thanks again \nfor joining  us today.  \n "}, "hash": "138dfb9dde16367fb37087b28eb033aeb454f0e808dd01a51332f0718cc11882", "class_name": "RelatedNodeInfo"}}, "text": "We wish you all and your families good health and wellness. ", "start_char_idx": 2249, "end_char_idx": 2309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c047fd54-4447-4fd5-816e-be69c634e664": {"__data__": {"id_": "c047fd54-4447-4fd5-816e-be69c634e664", "embedding": null, "metadata": {"window": "And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "original_text": "Thanks again \nfor joining  us today.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06d4a7e9-f84f-4789-a1d8-c36994a5d278", "node_type": "1", "metadata": {"window": "Our company's top priority is the vaccination program.  And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "original_text": "We wish you all and your families good health and wellness. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0817e115c7e279840926c8ff209d099046bea116b455a2b388e233fdc71cb2f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e188928-30da-471f-8f98-ed14c286b090", "node_type": "1", "metadata": {"window": "I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. "}, "hash": "9c90303b7108a8886028d6e9181880182d05a4720281130d92072b44907e80c2", "class_name": "RelatedNodeInfo"}}, "text": "Thanks again \nfor joining  us today.  \n ", "start_char_idx": 2309, "end_char_idx": 2349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e188928-30da-471f-8f98-ed14c286b090": {"__data__": {"id_": "3e188928-30da-471f-8f98-ed14c286b090", "embedding": null, "metadata": {"window": "I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c047fd54-4447-4fd5-816e-be69c634e664", "node_type": "1", "metadata": {"window": "And we look forward to continuing to work with the US \nGovernment to successfully distribute COVID -19 vaccines and stand ready to support the dist ribution of additional \nvaccines as they come to market.  I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "original_text": "Thanks again \nfor joining  us today.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "603c061349bc64f187b6c9a7a99bd976e9a1be66ea7f5728ce5b21ccc755b2c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8160d173-3782-498c-ad6e-295c2be82429", "node_type": "1", "metadata": {"window": "We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n "}, "hash": "e5530a5eb3873dfca22e2800a6e6403ac736c13067067958205e22cfe86b44de", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "start_char_idx": 2349, "end_char_idx": 2666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8160d173-3782-498c-ad6e-295c2be82429": {"__data__": {"id_": "8160d173-3782-498c-ad6e-295c2be82429", "embedding": null, "metadata": {"window": "We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e188928-30da-471f-8f98-ed14c286b090", "node_type": "1", "metadata": {"window": "I want to thank the entire McKesson team for their continued commitment and \nhard work during this challenging time.  We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2eb1e81a56f9af3123772aacce551b2bbfebcd095df4ab81a7d190debb497b30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97550af1-203f-404f-b42e-bacb218358c1", "node_type": "1", "metadata": {"window": "Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n"}, "hash": "1275da8deea5334128d6b23553d4f060930ac95804d41eec7484e24d7cb652e9", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "start_char_idx": 2666, "end_char_idx": 2734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97550af1-203f-404f-b42e-bacb218358c1": {"__data__": {"id_": "97550af1-203f-404f-b42e-bacb218358c1", "embedding": null, "metadata": {"window": "Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8160d173-3782-498c-ad6e-295c2be82429", "node_type": "1", "metadata": {"window": "We wish you all and your families good health and wellness.  Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51493086da696b5043c019b73fdb7a0aebec10aeeb9306dbf848cfcc5d45cedf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d929fa2c-6963-4827-be62-ef63a993609f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. "}, "hash": "7483b909413744c4e3e95c87ffd2ed735c00a1c446ea803d1f9e47f6a8bea139", "class_name": "RelatedNodeInfo"}}, "text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "start_char_idx": 2734, "end_char_idx": 2942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d929fa2c-6963-4827-be62-ef63a993609f": {"__data__": {"id_": "d929fa2c-6963-4827-be62-ef63a993609f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97550af1-203f-404f-b42e-bacb218358c1", "node_type": "1", "metadata": {"window": "Thanks again \nfor joining  us today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfbb0f84a3e10caa4b919efe1a4b0fdea946e49d54bf84c3df3ca095c678ad78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b358b964-0582-4b6b-bb1b-e83a64066cc2", "node_type": "1", "metadata": {"window": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. "}, "hash": "e36bf0d97f05ecdf77b0d8b9557a5d8d7c6840cb1ba3dbda3f6bd25c0b25b4c5", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "start_char_idx": 2942, "end_char_idx": 3064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b358b964-0582-4b6b-bb1b-e83a64066cc2": {"__data__": {"id_": "b358b964-0582-4b6b-bb1b-e83a64066cc2", "embedding": null, "metadata": {"window": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d929fa2c-6963-4827-be62-ef63a993609f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2276e66d6546ad7cefed1e5893b46e92cdce6220bc05f7c5ea60fe4514ce0f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "952f6355-7b85-43ff-8806-969e11acca82", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor. "}, "hash": "8098e91a7af969e1741d0237456368765e6834b54fcf8ce6537639bdb29afb19", "class_name": "RelatedNodeInfo"}}, "text": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "start_char_idx": 3064, "end_char_idx": 3357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "952f6355-7b85-43ff-8806-969e11acca82": {"__data__": {"id_": "952f6355-7b85-43ff-8806-969e11acca82", "embedding": null, "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b358b964-0582-4b6b-bb1b-e83a64066cc2", "node_type": "1", "metadata": {"window": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n  Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0fc0e011d55916f13488155aea6ad0fc1100fbb18ae87551fe094b60b74dba8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a5a9be8-c37c-46c1-be58-7aca8c4f1d97", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. "}, "hash": "2c039f8932268cf3fe725e4692f9228ad415248a811d5a15f3dc480b5828a5e2", "class_name": "RelatedNodeInfo"}}, "text": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "start_char_idx": 3357, "end_char_idx": 3461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a5a9be8-c37c-46c1-be58-7aca8c4f1d97": {"__data__": {"id_": "9a5a9be8-c37c-46c1-be58-7aca8c4f1d97", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "952f6355-7b85-43ff-8806-969e11acca82", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6e6885bcfbcea25785aef06394f68a3ce9873dbac7cced10193a1453fca77cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d55269b-b8d6-45ea-b4bc-f58843bef7d1", "node_type": "1", "metadata": {"window": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. "}, "hash": "dcad480048379c3f99f9271bd5bd90127fd849c4c89108d676add5345fe1a9b3", "class_name": "RelatedNodeInfo"}}, "text": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "start_char_idx": 3461, "end_char_idx": 3719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d55269b-b8d6-45ea-b4bc-f58843bef7d1": {"__data__": {"id_": "4d55269b-b8d6-45ea-b4bc-f58843bef7d1", "embedding": null, "metadata": {"window": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a5a9be8-c37c-46c1-be58-7aca8c4f1d97", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87c2d8926833b30708e12ee6cfcedb3035357dbeffb36f793544eae472f364d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f50d588-0029-4885-8f79-cce9694263b9", "node_type": "1", "metadata": {"window": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. "}, "hash": "68dea3f7c68ad42aef1de3015d8df5455659b0d4cbeeca4cbc6f8f28127097c8", "class_name": "RelatedNodeInfo"}}, "text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "start_char_idx": 3719, "end_char_idx": 3803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f50d588-0029-4885-8f79-cce9694263b9": {"__data__": {"id_": "2f50d588-0029-4885-8f79-cce9694263b9", "embedding": null, "metadata": {"window": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d55269b-b8d6-45ea-b4bc-f58843bef7d1", "node_type": "1", "metadata": {"window": "You  must evaluate, and bear all risks associated wi th, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intended to be used as the primary basis \nof investment decisions.  It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "117bb35ce867c86675e75dbfb888d29c21bc93304228e933c96e56618c7e00dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d978d17-bd9b-499b-b55f-05dc1fc19e99", "node_type": "1", "metadata": {"window": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n"}, "hash": "4ebb17776fe2e6a26b386828757e8a531369e80f4033ada30961be0963e9e72f", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "start_char_idx": 3803, "end_char_idx": 3932, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d978d17-bd9b-499b-b55f-05dc1fc19e99": {"__data__": {"id_": "0d978d17-bd9b-499b-b55f-05dc1fc19e99", "embedding": null, "metadata": {"window": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f50d588-0029-4885-8f79-cce9694263b9", "node_type": "1", "metadata": {"window": "It should not be co nstrued as advice designed to meet the particular investment needs of any investor.  This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc4468d93debd905eadf926a264c0407071d6a3834a4cf4f37c9d52d1d4cce9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ebeee86-b2cc-49ff-af54-ea44a7a7dea1", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. "}, "hash": "18f0e39d05a00795227295f03ed91163e348f3898b53a1a926d92a092dbff2ef", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "start_char_idx": 3932, "end_char_idx": 4095, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ebeee86-b2cc-49ff-af54-ea44a7a7dea1": {"__data__": {"id_": "3ebeee86-b2cc-49ff-af54-ea44a7a7dea1", "embedding": null, "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d978d17-bd9b-499b-b55f-05dc1fc19e99", "node_type": "1", "metadata": {"window": "This report is published solely for infor mation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b9491f69efda3845b092ea39228dcd3cab34e8e44e5ef4362e7db31107bdf3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "064bade1-f77f-4cd5-9e11-c13445b5d3fa", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n"}, "hash": "2c6bae90e9df90334274812ed3f64ae812b3258c5a34fd60ad785382f6242489", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "start_char_idx": 4095, "end_char_idx": 4530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "064bade1-f77f-4cd5-9e11-c13445b5d3fa": {"__data__": {"id_": "064bade1-f77f-4cd5-9e11-c13445b5d3fa", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ebeee86-b2cc-49ff-af54-ea44a7a7dea1", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9dcb62afa0940faefff73ee4e6688aa3ba25dafff805368b80ec9b3076f21ad3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45da7358-3c9e-4d30-ac53-9bc71dfc895a", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. "}, "hash": "336873b54e6b641603df0bb31977526662c684d8214358ce820d89a49bdc9595", "class_name": "RelatedNodeInfo"}}, "text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "start_char_idx": 4530, "end_char_idx": 5209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45da7358-3c9e-4d30-ac53-9bc71dfc895a": {"__data__": {"id_": "45da7358-3c9e-4d30-ac53-9bc71dfc895a", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "064bade1-f77f-4cd5-9e11-c13445b5d3fa", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or  beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6304eea4243f5233792eb86e7a2ee57978d15bc1b6cd8628f73a13f97afc6508", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8d2ff56-ed74-48eb-a03a-dac2ff3ee16a", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. "}, "hash": "65c687c2a6e94cabf10c559e012909afec1d2098e0485a58aafe3f50a936bed5", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "start_char_idx": 5209, "end_char_idx": 5398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8d2ff56-ed74-48eb-a03a-dac2ff3ee16a": {"__data__": {"id_": "f8d2ff56-ed74-48eb-a03a-dac2ff3ee16a", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45da7358-3c9e-4d30-ac53-9bc71dfc895a", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "586ae36f2b9bd6a2ef4aacfdf0d6e7a2faa5b76a6c25bbe9234be5350f5687c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea307088-2e6f-442f-b98d-af61634a18f1", "node_type": "1", "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "1f7d05f09da00904ff4e8b8ef45343e956c843eeb0418f814b00e0087d35a6bb", "class_name": "RelatedNodeInfo"}}, "text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "start_char_idx": 5398, "end_char_idx": 5476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea307088-2e6f-442f-b98d-af61634a18f1": {"__data__": {"id_": "ea307088-2e6f-442f-b98d-af61634a18f1", "embedding": null, "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46ff691097b66c9ab5add3ae2d86189ab8c448375291deb1c62eba1ced3efbe2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8d2ff56-ed74-48eb-a03a-dac2ff3ee16a", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS ,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING  WITHOUT LIMITATION ANY IMPLIE D \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR RE VENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COM PUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVI SED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd2cc080b4944a2a02a79c3c92227cb8fbfa2905488286bb975886c217201855", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 5476, "end_char_idx": 5498, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"38dd1a7d-27ba-4335-9402-e03734054c3c": {"doc_hash": "37a3b76798f75310100252bbcc92e76e708b4833a342b78e722bf99da47fb5c7", "ref_doc_id": "6ce41d2b-3372-41ec-8dc6-18355fe24e8d"}, "aa318a10-2b17-45a0-a4c7-11ca0eb5030d": {"doc_hash": "3bcbeeed735215ee7b91b075d9ef6ef109dd5427cbe08c23767421d816d2b355", "ref_doc_id": "6ce41d2b-3372-41ec-8dc6-18355fe24e8d"}, "b545ce81-cc7e-4fa9-a7b7-bfc56d248bd8": {"doc_hash": "2349f472989e261a2ee02bf67c5fc4115d7f917f33189d829baa5175d2fba653", "ref_doc_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a"}, "71877390-36c8-461c-b0a1-96a746e9ea03": {"doc_hash": "976188d7c592fa267e15cffad687f3967ad178aa40130e43ef8c25ffc259766d", "ref_doc_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a"}, "48c17cbb-eb22-4ffe-8efd-c1227a965b57": {"doc_hash": "74a1ecfebd11ae55b5a5831432d3836c09dd57e990a54a4c068faf6479f9b63e", "ref_doc_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a"}, "d6071895-5869-40fb-b13a-d38dd1a512d8": {"doc_hash": "7c41dc29cdc97fb9a4ff2b3dab4e0ff42b8824612c1e98ab2afc634681e7e5c6", "ref_doc_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a"}, "7b83f4e1-444a-42b3-874e-a7787747e24f": {"doc_hash": "b76a76af83196624d76b18910d66c58cb92f67c5be9e8d9ab0232f55a9a3cb84", "ref_doc_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a"}, "70197d07-7432-4104-8330-93d4f97f51b7": {"doc_hash": "54dd96334c2621683971e7abfe803261bcbd61f838b82a7ab9f24fe35b1e6a6b", "ref_doc_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a"}, "b286532c-a62d-461a-be8b-78fb9bf58770": {"doc_hash": "c3c15a3a6d7fbf56401e0dc364b437c5b2157b9436356b3b9c7b7834882494e5", "ref_doc_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a"}, "ecc443c4-d1f3-4098-aebd-dca88772981e": {"doc_hash": "934674c5adb20c17ea0864d48b611394606304b3a2fc10c5e8cdbeadb82a66a1", "ref_doc_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a"}, "ba51a396-2c18-4f9b-94a0-4233194e9be8": {"doc_hash": "34fe01b1a534a06b3f006f7944b657ed4ffb23f2c401b9fc92c6685d0c16abe0", "ref_doc_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a"}, "7d094fb8-dace-4cba-a878-9a43d07bcebf": {"doc_hash": "9f61da0f2d71f1f975aa3f96acb63e83986d8833fdb7a5b5ae0b68b862a4b30d", "ref_doc_id": "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a"}, "78eb8fd5-0524-4b07-b320-1f7af98185f6": {"doc_hash": "e5b293b7b817b4a52951904b73cb95560f5372d6795e9a9927b367c097c57671", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "82bd315a-fbaa-4d21-a386-2c46c7d0feb0": {"doc_hash": "0e2f79ae5e149d74095d877955b824f1787e6c41da7f3eea0e45d0016fb1895e", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "55b759ef-c781-4fec-ac9f-7b52c205d702": {"doc_hash": "6846dfe877b0948f16ff37e3d7e9fbb84a5f35cd67dd466ead11f4425db1daa9", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "72f54f0b-0978-4278-8f7b-0f1b7008ed0a": {"doc_hash": "6049d9cbf4fa79fab275dee51c79cafb1c2c3d6723d3d9837297661477c66408", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "731545b3-a454-44d6-a58f-dd7ae2b8e975": {"doc_hash": "3703ea312b73bf991be3c95fd5399fe890dffd3dcc653e3742e2c64580bfe432", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "f20d1cfc-94d8-496b-be4d-6a6860a1f210": {"doc_hash": "09bcda42c3257f1ee4dd0213a512e287d843c7077b4e375a61ffdccb63966d64", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "336706fe-f05e-497c-98c1-1c06fb3c86bb": {"doc_hash": "e5589f908cf0d4e4ae9ed88d1ed2548bba682bf108a4d1e4953159f33fdf84b3", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "9a94b739-6aef-4e25-a694-41137a34bb1a": {"doc_hash": "d9d7abec2f962784c90011ae954eb5d4eb61655ba1f7188bf977207b61bd9617", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "228d66c9-2eef-40a6-9187-8678403993b7": {"doc_hash": "e88d9c368979ac57db86760832fe6166fefa07955bc5ebc6a3edd0134d66c4ef", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "db6795b3-6d96-4dee-91d4-db0d010009a3": {"doc_hash": "faa81611bf3f794d2d0f51acbdef5eefa1661691938c929db0dd7ce03b1bdd74", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "0bf2f928-5cc0-4e76-8ede-441a43167d80": {"doc_hash": "64e5f42b382dd54cd95b9a289aa346eae3512bbe760de0707cebc21c5df97ce9", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "74725430-9b72-4525-bf0e-e524b3b7ea14": {"doc_hash": "3728c0a3fa25a8c1dc37a8166634ea8b1d0f09090b01ddc6182d3d5e3f8f622b", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "4809b82a-5848-4f80-af25-d50cd72838c0": {"doc_hash": "11600bf568401e5f7d6c20e07a889ff3cb7ace4a0f50e1df8856deb3c1ede20b", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "6f90bcae-b99f-4f50-ae35-afabb9c6b57f": {"doc_hash": "46377a4bb3351d30436b02746589978c35d198bdfa8111658c0972d011a252e5", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "7fa3900c-7811-452b-9c1e-4b3a086ff437": {"doc_hash": "2a07bb2ea16bcf0dc9dc61cfa2b76f2525dedaeea6089a8d75c5ec48fa45e310", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "d6d0dbb3-be71-4cbb-9e49-82565ac4a6a7": {"doc_hash": "4922dac66997f91bdd725f23564321070af54f143341b9566c5acb8fccc25130", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "8359b3ff-1fdc-455c-b629-162a697b904a": {"doc_hash": "fd6dd637746f2cea4023447dcf2302e237393de0dabfa642067fdf30e4da427a", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "bea181dd-df31-4a25-bca7-0880cbab7b4e": {"doc_hash": "744ea20ebe459ef9e4c3064a9aa5e6b9cdb369da19799f10f57d411c7fdeb3b0", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "0c95631b-be0f-46a2-b842-11b065048fd0": {"doc_hash": "e542511ac2eae5a885d575b271c5401e11a35a6cf202a6a680d14f54eb45bff2", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "f1684d46-5827-4295-90f4-26eb2038a823": {"doc_hash": "0230d499b25dd66b32a75962686ca55160311e3abea1a1f4a78d7d233c2590d6", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "b78783a0-259e-4a47-a841-bb9110ebdd7e": {"doc_hash": "7d8cd676ee72d0cbd35abc6581a049a1151def72f0c2054fa8601aa6c81b2cd7", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "b85a0100-79ab-446e-a517-c41cd67dda83": {"doc_hash": "f7af67149bb039601decd6e0bbd23174a6abc72b95f5f30da99b75af4401b27b", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "a5a6e967-fe33-4f7e-8e6d-b24dc8994b8b": {"doc_hash": "bcf351114ddf3454c86e14392fe735272a84382a935b6323b610ec546d3d426e", "ref_doc_id": "7805d649-c529-4dfb-a2d8-188cd5c185e0"}, "6d3cfddc-4c1e-4c96-808b-9baaae2713db": {"doc_hash": "2631f1bcf845837dbfa298ed49acc863578b7760f9a5d57c60bafef06a0afeca", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "5d104eef-e398-47a3-abe6-0533b9efe8bc": {"doc_hash": "5ba984b20c729114e891301f853d0827dede37090a36c49681c41333a5688ea2", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "6b375ff6-850e-4f61-b00b-56cbe781c5b7": {"doc_hash": "a057051c0d811c75e46a2138c7b723e7a35d1c47ca11a7e82887da5383b0e8b9", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "0915b0c5-28f3-461c-b871-5ed14b2295c6": {"doc_hash": "02085464e3962d416f0df0d360c7d0873540f234bed2f3234856334eaf963071", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "1410ec46-cdb1-46df-bc5a-793e520f19f2": {"doc_hash": "6f58fb02bffbf3eb44ad4b5d5cc053ba15223806d67bf558f25c93d053a22a8a", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "2551dd1c-b3b3-4177-a1ba-2bd472d9e297": {"doc_hash": "f0652b0a11335eb92bd28da30d9db768ea445cb963b0147becb3962e9c7fc848", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "37cbd0c5-42dc-4e62-ba1c-d9114fe303c8": {"doc_hash": "dc7bea54ea7f9f9724d8299e32bcbb7162de155350fe5b2ee3c0db464435dbc6", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "bb141e98-deb4-4dcc-abf1-79b213a9d1f0": {"doc_hash": "5769c90f7718a49506b18309962a175d61013457b6e297018be412f46db72dee", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "3491bef1-5fc2-4917-92da-f170209f7fd7": {"doc_hash": "94dcb80bae4587a95128b41e8462aa00b643fe59f077894455d44c1ac75b186d", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "22d9eb2a-fa9a-42c9-8cdd-c2bc833d2649": {"doc_hash": "5a17e0b77c3f3bf2864f7994ba4aa87097e60c1e8d19af5c1748f1e94528b224", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "b2f8211a-6791-488e-9823-7119f462c48f": {"doc_hash": "be73f1707ccd2deb7b1b9a4f82238b43039483118fc126d1cc10d245b9f7f836", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "87118209-de73-4a6f-ae04-1d608aaff662": {"doc_hash": "27e11254d134bcc75dcb89f22b8b4267c32cbc4a7f7b740d1bac1363302c6560", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "8badf3df-0a70-4584-a279-d2bbb74d3d23": {"doc_hash": "3f102ef6ff43077f90d1d9594e6e124e5686380dee2d49b87264a023bf05dd96", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "92005848-f674-43c7-a41b-f385e000bb14": {"doc_hash": "97c291177539d78f983d94c8e0c023c24bef8c1fa8c786650c9a23c2876a1b41", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "58e27dba-0d9c-4dd6-9727-a9fd32c02945": {"doc_hash": "24e7c8b43b5e30ac5d18a52d4aa1afe8a6adae250b06b0cc14e402c804db496f", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "3e297099-a640-4ce5-8438-879911cf1455": {"doc_hash": "9082ea9131f6096e50a32a543ffbe448877f774eaf4ee9ce6833977edbb4a3d8", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "89bf97d8-e7c5-4637-9696-ad8f90d1086a": {"doc_hash": "04b4dfc381fda786a83639f683e74b8a4151bb91c96fcac40a772786f0f1e76c", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "2339c4db-3cae-439f-bdd4-ad1da6b3836e": {"doc_hash": "a3e9d4ece12e297b6591dee7f78080512bd4c715a4761928bf29b84172b3ce98", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "af70aa23-0324-485b-bb5b-30ee64ffbf45": {"doc_hash": "ab1d284bd10c3abf1cceb834f04184c3ac69d9d729248e18c514d927cf042da5", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "130abf23-737f-470a-846d-dd631ec6bc3b": {"doc_hash": "6ce5ded22a4a73aa9b12a6aa383ce750f53cca2eaa6af7f730c8d3a470054a78", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "f70c8135-7259-41fa-804c-0afa1adc0ddd": {"doc_hash": "f4122bf078214ca1f1db1c5ddb86e5012f5e1c19024046c2d4f8e1d679396d32", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "8a35e73a-bd5d-4e9f-aee8-da6633801f43": {"doc_hash": "54f851ec00790cc89941caab53541c681abb19b5c597af296c9c634f63584cae", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "cf418073-1413-4f4a-add6-0255401b3432": {"doc_hash": "091fe93e3052e23c451b719876d66eda93e259fe9086b8d77bbf14903d84fa34", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "2fd5df00-f307-4d7f-91fe-0e003dcd7ced": {"doc_hash": "82ad3400ed6809b503d2a063e972749fb9b54bf8753a0d9ade9fbdb9efe17b5d", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "61e02dd0-6c4f-4fc7-8ec1-643521f2511f": {"doc_hash": "8187b977a2ea2a70b5b75e09663342bcd725aa022299de867de899607442d1ce", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "f75105bb-e300-42c9-80d9-3d7860047264": {"doc_hash": "009a6642f7263f569e9ce8cf33dc8251042668e9be7cc68fc4200bd4726e9310", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "983f9fb0-ab40-404b-a09a-9a5a668fba92": {"doc_hash": "a5fadf686200973a8d88fa793315ec9b3098c92b59a4df232ccbd0e837bbea75", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "5d7cd32b-154c-4d8b-bfed-70c45ef17e61": {"doc_hash": "69e5d0cec8171eb1aaa4e67f7551d6438e4596171d1bbc6bbe484fbf03a8f007", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "f729234e-bae2-490d-8521-4be6cf24c522": {"doc_hash": "73b6d8799d74894144cf28da25c78737eac02797987e1f790aeceb691a4b7762", "ref_doc_id": "83b04c7e-a941-4553-b3b4-d62f5bd752bd"}, "1eb451b5-bec6-44c7-b643-664b59b5a741": {"doc_hash": "74b2095b82b7be07359310555eaa0eb83aca6a44b05e8e3ed09633e23201d5d3", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "b213a5d9-0827-4a7e-96d6-fa6c524407b7": {"doc_hash": "65172111609a13955359ab3d4012c6481d9129f984a620e324820737838baa7d", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "dab6546f-4a4c-40fa-88a1-8ceca5315f1a": {"doc_hash": "aba259a0dda7ca40695a5af884c2d7e0bde694f155fc1bd65fdf0e1cbcd25177", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "1fe71acd-c9f3-4eed-87a7-46a1410d2c3d": {"doc_hash": "98201ae47d00192aaeeb03f6785d92ecd6598fd3957d57761243364a6cdcb5a8", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "223d73f8-5a91-44d3-b355-10b6ee1b6b82": {"doc_hash": "73ffb5d88808739f0e0d111f93dc07882ba8791701ce3f09de14364bf074acd4", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "169d44ad-5c7b-40a0-8bbe-b1c7cdea53c2": {"doc_hash": "6e8e8a597686e804f6a028f2714b51e78f6ff347274199e37d390c6fe119cbd6", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "47f9a3cb-7cc5-431a-9eee-ef6bbaeeec35": {"doc_hash": "420d01adb3a3b8107afc8407b38fa8e0f9b7e173dca15c978b4187bdc2df9be7", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "32fe518b-d4b9-489b-acde-1385cbf4d8db": {"doc_hash": "d7c534b9982e415ae8e9762ee97dc6f6c28a22d1efb5b6104db0ab0982b1515d", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "eeeb8d89-5094-488b-b0e5-cb70571cd868": {"doc_hash": "1888f36ed51ee3bce80564e935b52ac089d17794dc95e9fdb3758e548b733f1c", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "bd996d7c-0d4c-4812-9ccf-229b5cb55aa2": {"doc_hash": "1b75d05d3d5e982f48344db4a2eb4895fe30bad3934fbc7b81f7c7b54bb6984a", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "1cbb9807-cf80-4155-9fa6-4a06c84a559e": {"doc_hash": "59582a5d357a5b34552a75afea3eefb3e122d0965d4f77a6356580c8b2596394", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "c580e19e-e8a8-4435-9028-87c6a5fc614e": {"doc_hash": "22c9c845f414fee777af22e9afd49359d26ab4d7ac19abffe1ea145217f65114", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "0a141849-6c2f-4f4d-a970-afc044309af7": {"doc_hash": "530820e31f383380de7af72f30146778c1fc5b9b428887b8b3ee6d7ec1f30256", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "8ad5bdb8-cb16-4475-bad3-18884107249d": {"doc_hash": "d8736f72db5f04939403d0c7ca3d47233116a4c05326d2aa2d8ca9f5522912e1", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "bb32dabd-b75b-46bf-93d3-43cf0dbcb18a": {"doc_hash": "c574b90c7fdeea88931e0356c4b2f59652af89e337037d0b9dbe61bab26fc46a", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "da2a37ba-51d3-4021-b240-52aaf3549d19": {"doc_hash": "6966fbb1e42ae21f85061e0b2ba329372d1bc935a4a5631a401334c45b7715dd", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "9260e91b-1c2e-493f-addb-2ad47d9676e5": {"doc_hash": "f54096b85df8d6e2a83834fa22a33d780edde3a9ed1d4e34076f44e1c866ba42", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "2829c412-cb29-4296-b726-ab922a89a8bb": {"doc_hash": "9e9021079127a4d308356a2837aca360f6f7b4ce76fc51b2c898ab882eb0a88e", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "ae887da4-c632-4b65-b84d-2ff58fc892d5": {"doc_hash": "bd842598b19c56ed5f7efd6aef4030b0a464b91abccbb02680898cb022c6f246", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "461c251e-ca4b-46af-91f2-b79600206e97": {"doc_hash": "894842d7c1018174c567c47459e9c3a5d1feb54fd31a6b9c68b3384e771c684d", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "023ca638-e9a0-42e6-9459-3efa8f78ae3f": {"doc_hash": "589a4f71a43d125aeb2331adc1b493c6cb936b315d9e7e197433093b6791a3ce", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "3fc3c390-2a41-41d5-9714-862183684626": {"doc_hash": "46b0ded51c0896f18f8e6c7482a281e68d0a369ac3067bfa114bff5575da217b", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "acc7369d-a4f8-49d5-9940-6cdd3c6dcd89": {"doc_hash": "9ea9df4240a2d420c21462de05c1e506446d826efb5f516899173da4a97bcc0f", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "e681e1ac-99cc-422e-bba2-a417d9795e31": {"doc_hash": "840404c284d33b5b75fbc030c5392cd819adf723f6909497d0a2495464162b2f", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "20d1a6e6-e351-46a6-a9cd-10e589219979": {"doc_hash": "357ae3ed4348d59ff3c692d06fd576ebca2bf790402962327282ef3e61d57259", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "1103d0d2-f102-4b76-b522-ae96c3dab97c": {"doc_hash": "add7fa72efcc1369b0e653df729ce28d4ef6cffc584b0e164f927a30beb58d1a", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "bb4eaa02-42c7-45e1-ab7c-a1aab6a8f55a": {"doc_hash": "b6e1a76b6734b57cd943d52b993c0d03d04692c7941d6dc4b43c038afe596f3a", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "10a9a7a3-aa73-4736-9737-cc5e03c886ba": {"doc_hash": "1cd812f226ad79dfadb203ca8a3d107356eb47819b3bc113f5a7969ad7c18652", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "2cda4f07-45d5-4259-8204-59cabe4df3de": {"doc_hash": "bc174f6f52e91f00c6bed10c44f351f2ff2b7c90db2b83f1d837735bad20dba4", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "1072f645-1500-4d1e-b711-0689730b86d2": {"doc_hash": "954695ce3a32130480135a6d289ffd94c90765dd4181b9091f21b8881631cb2c", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "4519473a-5af9-4e95-ab99-d295ad23a73b": {"doc_hash": "9142c591ed2d38f9e74ebb634a44e4d5036c108c804392d86a1b262275828e70", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "09f93057-a4b8-4d63-bb4f-f35b78390497": {"doc_hash": "d500a94ae937efba5f6c6b97a9ba27cfbcd214946a78334fc1da7cc24462d1f1", "ref_doc_id": "a25013d0-e317-4e07-b596-16a98605d9b3"}, "7717ad48-7ada-4f99-a08c-849776b21e26": {"doc_hash": "7181c258fddf143643e56c08739eefa49bf0e9438e7dc4b0e479a3c32715cefc", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "6a2b0c2e-97bd-492a-bfd6-435db8f74389": {"doc_hash": "fed078f5fab28fad44416c39e17cda88f8575ca5fccee64c2d3fcbf00d2b03c1", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "a00284f0-1b10-47f1-841d-74cd9e5cd82b": {"doc_hash": "67fe4f084e02b5bf6c4c84d08b1e1c543269c691036e84aa7d60fed50205ff19", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "f0b756d4-3a24-411a-81e5-392106092233": {"doc_hash": "6d2eb22ade3f9c011c1aaf0b266f19fc2fa0309301cfaf0a57387b846e32a053", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "44859863-9b82-4c5b-878e-af372dd34020": {"doc_hash": "aae66c1cd666ed888d548ef450bf20d40d0de79998c684fd70c7ea1a033b9f8c", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "3414d6ff-43de-42b5-9a21-5242312b758a": {"doc_hash": "4229d3f1dbe206eb7ac088936e96261a58f6368a595833086771533f6524b1f2", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "d5f77a77-e4cc-4f2e-a859-bfd018591c68": {"doc_hash": "ad869b272e0bc1bc41cbda9ff0bd001cfe6ced10d7620f7b0d9a8bd2658d826f", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "9660841a-7cb6-4b71-87e3-dc8adf067728": {"doc_hash": "96e135c96bbfd2cffbe0ffd71d782b9a6eadb470cef5bb0c786388d477939519", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "9de9ac71-c8e3-4914-974b-d699d94df8ea": {"doc_hash": "70acac1835c81d86922a5502ffabe9916b3720c70e68b0507147de9da950dd55", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "10abb2b2-22a2-433d-875e-30c8b1ea7c08": {"doc_hash": "cee85ea5bd43b505abf08dc452b17e1e601c21ff4f42d2c394445d030fa7aa9d", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "389ac1cb-8ba8-4e20-bdeb-a7ab71d79ddd": {"doc_hash": "2e8b6a23df1eff35093e0d345a5c88b61b4d3542b31fdc61ebc05a5fdc1c572e", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "e750f551-410a-4ae2-8b0c-54ef9df9345a": {"doc_hash": "600fa9aeb3a3c663c2f6f8aadbbaeacdfe7172df7f765edcde755485da696b07", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "fa503a1f-41ff-4234-9fd0-28d148f9a091": {"doc_hash": "abff02f6b5ce26fafa5cd13a5ebd93dd0341bfa5049d0bbcc326e9586da362d8", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "e1f52b15-d6de-4226-ac59-97a810b94af2": {"doc_hash": "421486c962f6aba2ca67c4c56241cf4391cbdb22f2b9529e22b71033a920d400", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "5aebedd8-05a4-43a8-bcad-f69e2f27eda8": {"doc_hash": "adc2ef85bcf4962445ab292d99c6e900024e1c1444ef59d491a084dba9de38ca", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "81fd99b2-1b10-4c8e-8939-6b8b497400ee": {"doc_hash": "a0662525a9a277c21c306dc9c3ef4d9e831f99c4a7421e8833c360ca39a97a04", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "75933a68-1c99-4d0a-a919-3fd78d93e788": {"doc_hash": "fe54f3c6cd97f562d82b225554df8b1182240ab971a1c5422ceb2f0e81129269", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "30548107-4cd4-4a82-8026-74ba719371eb": {"doc_hash": "901b277a3db2dbd7868e489dd80827a26b5591ea6c89bb4f80e5bc94a1151968", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "f41e0699-bf57-4d34-8c6c-fb0a242947e9": {"doc_hash": "261ca2638b9fed61521b696277227f8574c49f0e5d56b36b939b55eec44ef46a", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "38a4a81a-0693-4137-aa1a-3f5c63f70b96": {"doc_hash": "749ef2a2e375dfd7ac6870fdd8cc4aeffffa6b081f6c38f91af9d85ebabe20cf", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "d983ffcc-a2be-42d2-94b6-7920cca7ac50": {"doc_hash": "76e0c70e57977ffc0f183e417de31995a9aa16c4b3c1e991a9d8013b44b1bea1", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "d12f354b-53ff-4b1e-a087-142a17284ca1": {"doc_hash": "fafa9460c8b4ed054aa010d7d6040a3c5f29f07b3f4e70042af15433db4e0655", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "f17bdc66-0d51-4ecd-8945-2f81faa4fe93": {"doc_hash": "dcd390b17e50a97af9f082d984ea9fcca1cd2afb03a174330d49ba123b476398", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "036207f7-043c-4c46-a61f-42afe0ee347f": {"doc_hash": "b307e4ac96668d1f3920be3d4ac902291473744f5a1fe39c25942e7795198027", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "6a847dc3-e47a-4fca-bc90-e8d5935bbd82": {"doc_hash": "a45c7281287cb5e3a25c163c8d13e42cf2afd061492f09c6ec33645550e50e20", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "34e2e5e9-c885-4150-85fe-85a9f0ac953c": {"doc_hash": "187b90967d4ef6d0868f22c9b75b027687a7012039fccbfe5a6efb7bc09cb7c3", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "2313e9d9-0575-410c-aab8-578a5a0266f6": {"doc_hash": "a222e971f48fd5015d89a041f171ac001d9d485f8355f1905e1e3594463880fa", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "9627e903-21b1-42fe-b54a-d14c6134d457": {"doc_hash": "ad22e5a6c01fda4cd35a019638d746f0e5df5504ac6732642047f21c44094e3a", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "1869e5c5-2127-4b7f-8a33-0df08ec856e1": {"doc_hash": "f113453e863b4c6348583c9a573bdbeac270e7e05517519bb9580838eb5ecbea", "ref_doc_id": "cc6cf62f-3b75-40c0-afc0-b39808bb25b3"}, "6879b280-b115-4674-b1b1-a32ae89cc63e": {"doc_hash": "b61c8c6cefb39c43a75ffce2ba62aa6eb5c0b929c0d2a39ae4896db8754a3e17", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "b9290e65-3492-4df4-bc14-948739c70eff": {"doc_hash": "2d9969860aa867647352ba2ae254a03adfc3e0c6a560237c55af0afe45155d1f", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "3f610c91-11ce-4549-96e4-fbac9c666064": {"doc_hash": "230df1a3c235f9a43e99b189edda669e1cfa3009b0895d7319c9e1ff367982fc", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "f2ff38a1-bca3-4c25-a365-9c385137c6bc": {"doc_hash": "9ac48c88bb7495e33f476c83e20554258ebc3d594e1040a19636540cc10f0f3f", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "472a4687-8e10-4211-a3a2-66528be44688": {"doc_hash": "ee3eb0ad5fd3f94f547665a5894844d8bcebcb01045a78b1ce6306870917eaa1", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "aa6005d1-ab09-45d4-ae31-3cf7aba92b03": {"doc_hash": "9bc622031e4beb60f94482f3ca512cf0fe59e9146a3f83c988815f25195e524f", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "873c0758-ec5d-47f7-b70d-e384c2b1cc9f": {"doc_hash": "4757508ddfe6e2574403795772a1eec99a6cfd241159ffc5d3931d62d1895cd6", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "448a3708-c5ae-4f2f-bd4c-e7ebb1620afa": {"doc_hash": "c7274592c283e3bad8a86968c0ae04734e641521b63a0adebe9b31eb50fd585b", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "47f5cb84-60e1-44bc-b272-b033d15a0b27": {"doc_hash": "179051e751215d647f4e4a0a3765d531645532a5862cb5e81b28aefcfb568182", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "168e54a3-a92a-49ad-9af5-8444f439837b": {"doc_hash": "1ad7d217537935aae3c6a65ffa2e991871e0632b23c7cbc8a1c14177c2c0dbcb", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "b13e458f-a59d-4dff-ab66-e322754d6aaa": {"doc_hash": "0c10cb008ba987916fc58c93ee21904d29ad46e6030bbd83700add931d481b11", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "5dfcf625-8962-4772-966d-9500803f76b3": {"doc_hash": "52b7e18e023377f3e222bc281d195ab970ed213b676a156c5f1489e061e0ca84", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "2bc98567-2d2e-49b7-8efc-d347faa2bda9": {"doc_hash": "92ddfe02675dae2b4c49cc5d67ffba2bddb5bbfce3e5ddf3bd668e2a9e752845", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "70995268-93ae-4590-aa54-55cc03e1dce6": {"doc_hash": "4d3a1c24433ae24e1b5b60462d43a7493ba306f235061812b174abc43827aeaa", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "7fc5e98e-4ba8-4e05-a24d-b538382489f7": {"doc_hash": "b78cad15c8358f6d7c1a574eaf8898ee72367f454cfc49ebba79d444c44290c2", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "079cb033-6767-452b-94a6-f73e3b490a85": {"doc_hash": "548de32d25554da1e9c8b3955eebd13a23a236f70bd5bf43dd21e756cfadf6a4", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "9c146540-5fe6-4e50-97ab-6a7edff81ce7": {"doc_hash": "ffcc2af9060391cb9b5dc4857d389b94b56290af412b42fd7b793f0fcf888c4f", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "be270d93-59dc-4349-8cc9-0fce096699ed": {"doc_hash": "a3262d6a137bf0f2ed263fc3d3526ddfd0b6844a1ba1fdaa58d3a798eb488b6f", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "1da4bf30-400e-41bc-b654-1f4202f69933": {"doc_hash": "06ea88faf2a9862f0e364d570774798da30f63f3aef4a25fe16e60b5dd02602c", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "2c1847ea-7574-4802-a972-35d19b99ffe4": {"doc_hash": "5b32f06e9d0df834dab51fa038c913bf07ab5da677a61ca0d213a9327c1b199c", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "1307c4e7-6f91-4010-ae15-d5d6d4a1832e": {"doc_hash": "a188ae837d729d9529b19cdffbb84d32310b43ac22f2d50d7a2627822d90f482", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "3c593057-a76a-4a0c-ba36-a87acb0c74ab": {"doc_hash": "d0830f9c633a4eb04ed60db473131bc667210eb40978182a58ba59c56b792537", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "ab40e5b7-312a-44de-bf09-bcec33df48d0": {"doc_hash": "c1f2b3152b3adbc229939be547ca34aad98c73bf3fd9e36f417d8aee20208b2d", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "0d0e40d5-8ee6-4b0d-8c54-b831017c4c5e": {"doc_hash": "d77de939c55a19ff4d0a4b7414a1b27ef996f70f90e3d14d7cf0f1562cc13055", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "09fb4811-03b4-41e9-92bc-ecac9bb19224": {"doc_hash": "4c0692d5779ffe888984e619df90662d539fbd4470e66907ada628fdf1a83f58", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "bc46cdc1-0f68-4ffa-97fc-53abf040d50e": {"doc_hash": "64fe19225df24655349b648183330f2b9bbfec106cf0993d9efc80053f36fd2e", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "04163cd6-c145-4c3e-953a-59f8d95ece74": {"doc_hash": "2ad0c5a475daddf78747d291251dff70b93332e8ba59ee0b40d8fcc5e42e25eb", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "b97d3d02-3f9a-4c53-917d-b15c7c909e48": {"doc_hash": "97397973beb74b2bd15b6fd411ab4795ad7fee4ae1158935245e3f383b275978", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "4e183617-f898-4d28-aeb8-9dfd1046bac1": {"doc_hash": "67b8be84c25933900e29712949d4c1113b19d1b2c510df3e79a1d64aee2fb045", "ref_doc_id": "87efe71c-a497-4ce2-bcc7-296e354ade52"}, "625159f2-612c-46ca-910e-81b48bef8563": {"doc_hash": "7f0f87e8b032c780bc0a98a42ad42d798aecebd82190f55477abeb15a56e294e", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "e5a9120a-bf19-4160-ae9e-65f0081ed130": {"doc_hash": "61cce72c64287b7e1826b62a67b68fe17e00d2b6445bef25774cbd29a2d5bcc9", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "87ea6fc1-15b8-4604-b069-05cd7a95730a": {"doc_hash": "0e74e3d34274ecc43ecc67453beae3b967d78291d52844d592655241308ee019", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "fddd58d7-dc85-44e0-b61a-f967708d1bab": {"doc_hash": "d75c03e79e7aecc222e86b9fa01ec72ed48c8d31d2a16c61d9146950723deed1", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "a49e850a-4bc5-4ece-836d-774b4bf69c02": {"doc_hash": "34b0b4c9fc6c3ec6a7d144bbc76c4c0408f11549f56f6347364e2abb8954307d", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "e3ced4d1-2673-400c-944e-ff9023211217": {"doc_hash": "c99bb5985e6988fe8daa8f2f0706710c90d1ae7fac1745d238fef1fc3b734179", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "0346339d-d452-4376-ba61-5187b272f758": {"doc_hash": "ce7f8a055ce4a25bf29d056ef3cc9d5fe2ec21032e63a12cf278b8d3a83f7bd9", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "da757c88-f6e3-485e-b88d-e7bfc58be2ea": {"doc_hash": "b89cd6770a12a3ba514d20fde4de157e452bf17b1e1f03479790d546c7a3e273", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "2949101d-26f7-491a-be70-b17d8e14ab5b": {"doc_hash": "e75cd729bd123ef9c5e7861fad8af960c702bd976ed4cc9bb071d1fb182ecda7", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "06bd555d-939c-42fc-97c3-4c6ff56f2244": {"doc_hash": "69fdb10315b7d683e9a1c3da1f7ebeacc383629c44b32aa2ea138e788d2c90fd", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "c2f49db5-c503-403f-b27e-4f4c88a1b084": {"doc_hash": "bb3eaa0706c6c1495595271ae4021027e2ff53dd7457d7cef62713f3da1cdfe9", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "fba1c902-eabd-4727-ad38-6edd637f3c71": {"doc_hash": "875fafc5ac506b1d33f1108f417c43e63a37b0772db8d20163b228cfad8b04ba", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "57c3aa20-12e3-490e-bd67-9a8f938a7fb5": {"doc_hash": "128fd4e844c80ff57c3ace1794d59b5803af0916724239ce69a3fb92b75167a8", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "3da361fe-ca60-4e23-8e46-d8f6fa7c0e58": {"doc_hash": "26c920396fb91ace479d13a512d046a92732b6f2906f41ac35169e0e39677f48", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "5dbbea56-cb4c-4113-9d57-b24bc83e8df5": {"doc_hash": "731fb05442bb36dab1602b784932d6dc6321ea83a12c070204bfe621f10768f7", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "9fb79b84-d94d-4d93-ab80-dbf49768794e": {"doc_hash": "0eb272867ded4e9f033a21fe1fe89b0346d1d9b20d1d6b2748dea571766c9498", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "d68fcda4-ef6f-4f7a-a84c-4236928d4ca7": {"doc_hash": "638d07bd1c7da5bd946914c0768a0b54a98409a9ba28e751091543b0ce2a3880", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "fe6c1024-0450-4cb6-b119-f3f67733da28": {"doc_hash": "340bfb58195ab012380b7d3205544063d70318b4292050aaebcc1414db4d7e62", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "39affadf-f571-4324-b3d2-1b760d740e89": {"doc_hash": "c36c513fa57745efdabf2d9635843f0f5ef2baec74ac60179fd3d8bcb4c814f1", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "2742a2ca-4702-4508-9ace-10586714db58": {"doc_hash": "119ce1fee315ab02375d42564835b0a1d8a93848ecd81b0bf46e6facac204e1f", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "34c67f6b-5cd8-43b7-a75b-b006a0268926": {"doc_hash": "08b013bdb22aef66fd348cabfcd2933e254d8c26ec483b9a9e260807a651b4c9", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "ead0f5d4-cd28-4bc7-9200-a3ef10154920": {"doc_hash": "a04086ec2e77c7b037236a4f38041ddacdecd3db1f58fcdef8a28c46f749f957", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "884a15a3-6a2c-4b9e-92fe-e7e48f8885af": {"doc_hash": "490b4c2311f0bff96f487ec3c930fe4207c5d6e87ced982e8250030e27dbb74f", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "493c94ca-731b-46ed-b8f8-1a8d84a78986": {"doc_hash": "49aa57d9e752be0107fc96b106b151f2b6a14f91ba705b5ac39efc2fcd06bc73", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "d1ad7bfb-cb48-400b-841f-d3fa54023667": {"doc_hash": "474b182224946798a1157a944afe0412ec42d12df4169d3db52b5a143f329425", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "821c90a3-1fb0-4181-a203-02e0f091b7ab": {"doc_hash": "2c99d3bc589de623eaf2f7f2dd5961c33121e1af97850c29a58065659b9462c8", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "d8e9cd68-6724-498f-b281-4c03be7ec71c": {"doc_hash": "8ff3bb54903a5eedcdd5d942557e58e17701e70fde4304a567f286ea33766235", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "dce430b7-7f71-4bcd-82a0-a450810d2e83": {"doc_hash": "8291744c880fa024de5f0a93bd8a79392e3043f228a7e9af9768c6427a0f7c0e", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "eb8c7993-65e1-4157-92c9-21a25c443f09": {"doc_hash": "d436347f42a24e84d5d113b071e1fbe4284c7785fd48d394bb20b613bb0f4547", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "7f787808-d5b5-43de-9d08-adf59c6a0321": {"doc_hash": "948aaf1d31d46b8355c375e77d2affe471b9ff635186a801329d57eb5d16947f", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "5cff03c1-d518-4911-b006-6b60aa089cea": {"doc_hash": "bb612172fda828f5ecddfdc12d0b455bfc6a72ce0975d1b8ab786c2a421fa75e", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "6214e694-d1b2-4bb3-96a0-d7e834fe774e": {"doc_hash": "7a6dc9cbcbbaa359d560e3547a5a525492ce72172f7083907fd7860c865c30f2", "ref_doc_id": "c7818ebb-8d60-40f5-abda-fcc2f11a4afe"}, "3abc02ae-cb43-4cdc-b11d-9619eb01b762": {"doc_hash": "4be161c2ae1ce0b478ab5c5c54a4e483621a16b42ea22ca412b364130409ae7c", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "a7125747-1f13-4759-94a2-1a993149472e": {"doc_hash": "60a0e9b643a91d6fabf41df14962e0caff38f73ea8b657732dbaa2c635ef2f29", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "feed1182-05b5-49a2-b5c8-fea823e9e625": {"doc_hash": "1d55e8bd42e9258ea391bac26fe483f504c88cecc6784400a43bcff3b5e15401", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "6ea17033-66e0-4316-acce-4d5020a5c07a": {"doc_hash": "c61c5e9694445403ca1112ad8e7beb5a6e53f363eaa58c0340b81f5c736f0184", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "9b6ac80c-a2d9-459f-96d0-a1d8e140a66a": {"doc_hash": "5d98d33aad398a0474344d52f5e3d17e9d9dc2c8f45cab5d38c3f429a9877169", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "d97afb29-fb70-4b3a-9a18-9ee4d4fe23fb": {"doc_hash": "dbe923e61eb4c72224400383bccf311738eedf1cbe255db001cbbae350ac268b", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "5a25e308-2007-4955-91e6-6f08b8622ed9": {"doc_hash": "24564f63ae9a3fccd064d3b3a5f760d2a72ed4281f15ef43dab548288db430b5", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "4e6c6d20-f175-4b08-bfb5-f589a63be6eb": {"doc_hash": "a63f52b290b7d6f85df41eccd2c014b9c5a08b0bbbcdf75fce9819d84d86e202", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "76859463-347e-4b41-853e-0c964c0528e8": {"doc_hash": "c27191cd639a6df87f9d95eda7bdb298d89dd2c30bf25e4176b8d04143e92200", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "3dff1ea8-8c1c-4639-9b6a-ab2dc7b8fba0": {"doc_hash": "a54cb806f4d7080b2fc4c5d803f4489637d076420ecb0523a9a7b0b7777fa31c", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "93e4bd42-c8b2-440f-ae0b-b577b84a5bdc": {"doc_hash": "4b9781d7ae2ea7f78749e81a4ab2df7923da17bb90a22fd55c567ab5d5befe4a", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "eb896f3d-b867-4f33-b385-5a48099057b6": {"doc_hash": "c40eb402aee560451d8b4ab0267525679496bf9ae19b4530aa442444ae4f770c", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "8eefe91e-4b88-4ae5-b194-c6c8e6145f1a": {"doc_hash": "4f17daaa4a1b65ae7dbc5a6cda0429006bdbcc3fa30c59afa6ac5f7cedd14f80", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "484ac9d6-a22e-4a0b-b80c-8b05d95d032b": {"doc_hash": "6924ead11acda8736a04c56be2375f095d1ae5857a8de26950da51540df0605e", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "a1e70d42-8466-4cd0-b98e-75deb184d26b": {"doc_hash": "988a34442cfe1f38a531f86b72545215f81791465f9f99897b075dea8c118cd5", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "9c05f315-183f-4c95-a180-83a9a8378c03": {"doc_hash": "e04fba3725435582a3377d2254bac9837d460373702e5f382d1843fa6db0a61f", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "33d49ac4-2de3-4df5-8fc4-dd7e58f15c4c": {"doc_hash": "652e18e499124c2f2da97926b67af8654bd0e0bbe1a28c50ceb98af05b261114", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "5f194c86-af9b-4d24-8be6-96b3b5b140e6": {"doc_hash": "308f3d86b87d8330bfa78b367679d3ad6e2450719dfa95e40d8149f3ec098c91", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "4229859b-965c-4dfc-bf6f-dfba50008773": {"doc_hash": "6ceada53a13800bcd2b6da4cf516cd8ecaf742f2a6358ffb3eeaf2514a1a3dd2", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "b819602e-af52-4235-9db4-670d50d4f1f8": {"doc_hash": "610f762c776dfa12261b56e488afae9ed2f14e830c50ce578637b6ee593b7e94", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "fcd90753-b0af-4d2a-a8ae-4b8dfa614b3e": {"doc_hash": "d71ece2e27050c5c231a88fdb3e4f35d24337696c435569156b1553e791b4306", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "fccbd99b-9584-46cc-a5c2-4c1c29fa3981": {"doc_hash": "ff87d10119663914c6ef7dccc882e44465f224492373f89babbc7ab10dad99c8", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "0cdf0472-da77-4050-9a33-d129d44d5ce3": {"doc_hash": "50350e9d5359296de2baaeefb1148a12bc54ffd4c0525957c5dcefacc59d1c2f", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "bed89a27-1d92-4790-b1c9-1dfbd8edb0a9": {"doc_hash": "3d66d5a9dec7f5747f23cb6e7a363f8aecb52dfe5e7c4b10a855d17ea7292864", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "ad051438-5e2b-49e0-b3d2-0e7ba457c0cf": {"doc_hash": "8348c3947a1379716cb78d3479d3bfe50f65a11120b184994199d756f7958bba", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "2383e33e-604d-459b-b551-07353e8ad9d5": {"doc_hash": "bcbabc5ebd8a841bcbc286a72821af9e8c10a36064ceeb9c2a8d70d17ad4610e", "ref_doc_id": "e55034f1-51be-4c1e-9f52-4a6715b79ec7"}, "518ac18f-81be-40d3-8bf1-c1018e4a9d3a": {"doc_hash": "e732c66136066915b7c1c22d581f67ed1d6caf972fdbe2b1d46a89804f0c4aa4", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "672085d7-3704-4881-a57c-e5f557d2ef46": {"doc_hash": "90474ea99cfe485c340d2fdc117f08d97d76858370fe2c61ff54155f3246b18d", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "296cbf9d-dc10-4f3b-a267-25cec7ec158b": {"doc_hash": "c3fec9547bff6d08e33de82b3e1516081f67e1b9b57aa6a6ca5a75971012ea3b", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "6dd8aa47-43cb-43c4-9ca2-2c8e6b8f3e98": {"doc_hash": "263dfcf2d3940e94d5534ea0dcf58bcecf8bb7f2a9b588e7c0b04452ce241c76", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "1c6c93a1-f84f-45e0-b38f-ebb2ba4ae8e8": {"doc_hash": "80d308409c67f928578998c917829a6e4a9f99cbbd077100b2ce8535774de951", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "36ec6937-7b93-4c9c-999a-2c8c41b2d700": {"doc_hash": "0cf7745e45f1137e621b93a3fb587316138e98a56732b085d43be637be2f99a3", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "8243e97f-ea35-423c-9670-c3c601e2fc39": {"doc_hash": "089c8e7609f7f6e26176c9e6f25f344495d6002dca45af7fe58d92bedcc85455", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "43481d98-90c7-42aa-b3c3-afa00df38dc6": {"doc_hash": "03261014549f9fe47e105937e96e4e8b33c115f62e8d23ada9106c0a72175119", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "fc28ae99-bbab-4f2d-862a-1f35a2640b9c": {"doc_hash": "4e8d928f425f83f976873ab857c07712087147c5f416e6d51f1f791f666d9992", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "f01045c6-86d3-4c0b-8c24-10831cd9d62a": {"doc_hash": "109b293f14dfcfbde0a7a4920a84878b8366591b32f628bed2814b4310a693f2", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "e02f751a-9e50-44bb-92af-ebc5348bd5b6": {"doc_hash": "dd29e0ab7b25937d87d9e9bf6982cab4ebc4abb9b7bda322293a676c1be527a2", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "52ce847a-7030-49bc-8093-7c6875714ffc": {"doc_hash": "72afa9a0f3102608054b3ac4711b0afb1d73f371a90a9a85aee778955d074379", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "527e934f-1928-458a-bc8c-f152e8240234": {"doc_hash": "372e6f902bb2f3fa17f5d174a55839610273219817d62999e617236b2d5bb72c", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "9c2d8e8a-b525-4ab0-bf24-e52b597387de": {"doc_hash": "c760e353ca0548a8d1581b1087949b77834f2b9faaf1b039fc604217db81a969", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "2e4da415-04ec-4fc2-bdf6-c9d75fc60246": {"doc_hash": "99e14d5bdf53a906ff11f07c73942887c01ff00f6d6c793707a458df58a6cd37", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "92addbb9-a3ea-439c-a001-8b93d5493690": {"doc_hash": "652ef3dd8041437a6b866ed1e21075d9942d031a56c29821788110d4dfa3e5c7", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "32cc18c7-26ca-4906-8907-d4630997c146": {"doc_hash": "53cd9ce0d1ecdc22472ab341b4de0e1cc032e51557dc69aa8ea5417e6423f286", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "bd540dba-1f81-4bb7-8f10-37aedc3992f1": {"doc_hash": "9544f2f603b1a66fa8948547d22938fef40f6cc1440a6ff55c586c0aed4e4847", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "8a8ca926-f5da-4cfb-976c-d50ba6402241": {"doc_hash": "caa87b95929b19cfb9a349adaca8555ec66e76823e677b6929d2651c7d6282ca", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "2733f0ca-937e-44f3-801f-45910d9f0bf3": {"doc_hash": "ecfc7dc5f5602e994cac7fc2c561ba598daba26ddb6042d386baeae90a77a51b", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "3448f426-bc04-4d31-b9d4-76b91f5ccaa4": {"doc_hash": "be6a88aa10314621c7b58cbe8a0e4eab330a17237b924d91248d414eb95cae80", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "6abeb063-26d9-4198-8e31-0a11e42fd253": {"doc_hash": "942de5ae47c20c0a5293faa6ad82027481ea6631170dd7d334a17eeffb050b7f", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "f9d6d7eb-6a48-42a2-a1d8-7a68886d732a": {"doc_hash": "fcbd5cf4842d32e0d4f2dae037c19e90019862a06fb21d9831d00c7385080c55", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "5a9238db-6f89-4a03-951b-4f3853c244b3": {"doc_hash": "004165699b8444ebfd050e602034fc736d368fb84811feccf378f277f494edb2", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "5c264609-71f3-4602-95fb-dceef3f8d8c8": {"doc_hash": "dadf39478a550a943a99551c1a397718fa8b3bdf43870209ecb180df454fdc8f", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "30d8ba1f-ca52-4448-8407-cf8984eac727": {"doc_hash": "13832023e9c940670d1425a386362159781b11952d70f4732cf89d2629239b8e", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "148e2572-e7c3-4b0c-bfb9-560cdfcea2d4": {"doc_hash": "4a95c84dcf09b8e3a8c5f6f7679e08f4c85080f1e062ecf448bb1c2265ff6baf", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "b9899304-4164-47de-849b-81eacef93fbc": {"doc_hash": "d3997a79414b0aaef30b0c05834e90697e5b111d159a9c4258273bfdbc10d819", "ref_doc_id": "0f2a9aad-4e4d-4537-a25d-87a978b16b92"}, "8cee55e0-4c35-4e29-9503-92831409e035": {"doc_hash": "4c4a7a34f6467c5837deba5949bfb1472bcb16d6362e3b3f2a5bf4513a1cc651", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "d9cc98ed-14be-44cf-a3ec-28b494cb1de4": {"doc_hash": "b631892b0daf6f92b4250b52856dcfa9aef8b9b15961747066676d8e11a40656", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "e9a75af7-87e4-4c11-976d-1f7391c513b1": {"doc_hash": "af2f7eb2e9bb93f45e4a5114210b9cf3aa118a078ebdad110d990da76f060aa1", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "2b0e9fa8-38f2-415f-adde-c198aa53261e": {"doc_hash": "0a8fda0fcd0f3799308190362bd1bc584e2c755bb5f3de3704c9d94e32311df5", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "7a244f89-d860-4249-959a-dd8aacd28965": {"doc_hash": "f3cc1a5c0d64342a3e3c31bb89cfab771ed972ae1b4bdae632a9c868a001d366", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "ab19a41c-da3c-4c63-a78f-21ecdd816e5d": {"doc_hash": "49effcfea63a7d246e95e45889c0827132fcb226cdc4a91a87fe63a61f75483a", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "3b432f1c-eb11-44ab-ab8a-13303f7430d7": {"doc_hash": "5f141d461420f366e0a31c4fb981e1f71af1a7d2ec84c0cbff2fa7b2c9ad52d1", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "c684f2ae-fc94-415b-8643-5839bd3e97a8": {"doc_hash": "19749de46e6f5f38d72a26c81e0b550362144f30ff4b137d45294a6198e50f75", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "089a3874-e49a-4e77-a26f-35b9b15fd984": {"doc_hash": "54c417eb6f1dd82804455a56acacf0046dd02c56d5457fae5ebd70b434919f24", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "e03d1643-8a00-46f5-91e4-1144c5f0d6a1": {"doc_hash": "d08449ef7296d8cd715864fb6da1d9967f745feb28c4e93001c217116d1a6fee", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "4d75eade-63b6-4030-91ba-60801e38550f": {"doc_hash": "013ee6e2d235775b1c513bb2dfc5c6be99d753b3f06900276ef7cbff17d2d6ec", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "6e001030-53b4-4e9e-9268-d761a7dabdb7": {"doc_hash": "5df14ca1ecf2acba52056116168f80699b73ab54537360c19d3ae0f8f7c10094", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "25aecd66-0ed5-49ab-9227-183bfec04319": {"doc_hash": "ad320a928e2888afdb0b4ff120a6dfbad09a68d35c83c7c1f0bafe298c5c17bf", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "96036f9e-78e4-4dcf-8d58-7677212d81a8": {"doc_hash": "4d19456756cfe7c94c06075165a07ed93333cfb35e7bc2a740cb62e4a81e3fce", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "3b0b0ca8-187e-49df-b525-2559b6248f2b": {"doc_hash": "f00d6d3cb5e3292c4c9e466ec31f04c5ad8d1447b126861017277e276224a5d9", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "367c4f56-1143-4533-a7ff-93d74a92622c": {"doc_hash": "f9ee48805abe0375b079195cd918601d51e3959aa56518e88595309f8c5d7b7d", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "ad46d9cd-7441-48e1-bc2e-7c822bd1a713": {"doc_hash": "a5f31ed257aa4e231cb4063fbc5ae82c62aa176570cf472c48c3be4830cc8f31", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "9cdbe0ae-6ecc-4f77-a19d-8cfa0edb8b66": {"doc_hash": "0d27b8c421e3f7e5b119aa3791d2f0f61839014b27f91dee99b7cfc920324004", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "e28eb4fa-bbb1-4055-9982-e72ad71db54a": {"doc_hash": "1f3ce98e3b2808511d3477ccfb32d4e829f72947a3bc3c9bfe574e0613f64fe6", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "0c07252c-0dfb-4652-b4ce-0a95d850ce9a": {"doc_hash": "27f1df2579927562843ed1e70904f6900a1083dab839c76b02182c97c27eaf40", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "c4fd9bdc-2ec3-4fd0-9f48-75afe01c96de": {"doc_hash": "0d00379c80fa194d55736cac5bf08334310b88f86c3325c9f98116ec66ff761b", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "6baa69fa-618e-497c-832f-bd0c88197fb4": {"doc_hash": "989662a91144f3ffeb9624658c2e6ce6d83598bd8f9f6032cfd5b9a1a297c280", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "c2499827-b829-433a-9a95-b74462551e3d": {"doc_hash": "1a47cf13638f554e2ad366f0570182adb5b4e0b61ca0686242f9d24f6032cc49", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "2da6de91-be19-49a2-bfa5-c441fbc5e715": {"doc_hash": "640ecb0ccb5a16284aeba97ada1f34a8910f1cc30fa6cd7c571af54147de3d99", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "7950d5f3-63be-47a9-9fa8-53c6dbccbf66": {"doc_hash": "48ec88b61f425cff15b8ee0538a0af2a696ecdbe7a2bc06eb9be566da731a397", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "0a78d001-71cc-4644-8cbe-db4f16edd65e": {"doc_hash": "98b6128f1ab856b0dff71bc7bd2cf7e2728775ba49fa53f5963718185003fbbc", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "36828cf7-f5d0-491d-983e-cfc063641b1c": {"doc_hash": "ae2bd2a97424783c79f70c86b0a6be2a2a40c855ff8c4b4721a2b12abe978f41", "ref_doc_id": "145a20f6-59a6-44dc-b2a4-ddb32139b282"}, "e5936876-768b-4e61-847e-2d2f69ee6889": {"doc_hash": "8609ca07a9cd55892869e4aeec8e6ca13bbf21615bfd20b4d8d5e601b087dc20", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "d254eb80-2781-4818-81b9-a10b5e2a3a2a": {"doc_hash": "c41dd286f6dfe9d0d236e907dcac6688b06106c4f256a2d3342ca0885ee19f14", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "b1ff1ca3-9496-4aee-835b-2c2c118eef0a": {"doc_hash": "97bdb514b15c9aecdc776ff1c6bfb9c6c7c1d8d37c7baea078a4d3931cd98a3d", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "d8fb2ab3-5c91-408e-b077-f5dcb129da6b": {"doc_hash": "1fb7bdfe25f494e5eaacffb65daea739b4acc5131d0fa1bbb811b18d5442dc4b", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "18dab790-0e68-4d4f-80f1-c04b6ce4df90": {"doc_hash": "85fa223e7e5117d278279364755633f016bd48ffd24b8c21b6bb7cff22213a8c", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "56ab5f76-6a01-4705-b1f1-5fc535078b9c": {"doc_hash": "a96738d3ff1d94e03aebd9158cb385bb8b581f2fa5aee85f48a05e0ef6951d63", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "ab08f443-2bc5-4a34-86cc-d7efd4739b2c": {"doc_hash": "2a557c392b38201e3dd55e1753edba2455fb388348683278d36b287470aa6a7f", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "fc21e756-1d0e-483a-9f81-33ae387d0cdc": {"doc_hash": "cad3fef938727908be4d5aade6c7a5d31c3faa52e61376bdb0798700b6733c51", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "ec6b21ba-a7f0-4c5d-af68-0698fb90b9c6": {"doc_hash": "aa0fb7f41fa80fa1e9d236b61ea303dfaa71889b50f17c109d2eda20e48f38cd", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "0ebdc7fd-2f8a-4e88-9fa2-f747fd133732": {"doc_hash": "50e9ae21823023d7daae0e1ae64b954725126216f56f4dd18a71bee58ef50263", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "09ac6bb2-16db-41cd-b1ac-cbb32a032bb9": {"doc_hash": "048fcb48ea41c286162b6b15397b19365c2747325ab00462a7a37dab96329180", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "718b230a-aeef-49ae-a2b6-77244d579c85": {"doc_hash": "dbde2f140628133f7601b6f6b3c1d6d096f83896aedf11a4829952137a926525", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "d8208c04-0e27-46ff-90a4-5b1caf9a6313": {"doc_hash": "7b6364d8f66daf5b4854b108fd64a050c240bfa114d0aaec959dae1dc1e0d55d", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "4fbe613b-9c45-4e88-8195-dc43c017467f": {"doc_hash": "d5cc36bd3ad48c12b678f8925dcca333412e2d8e016620e765f93288d908aa67", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "fac9ecaf-cde6-4114-8aa8-27b052876f74": {"doc_hash": "96a28b25c8c775b0c24a3c85f36e35c0b4955f1b937e40a499e87b1b43c1deec", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "93213fdd-9f12-43d8-a375-313ca2868edb": {"doc_hash": "f13dcce1e1eeb8d38e21d555af60cc6853930f4a48bb85155fca1e7e299b4b7e", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "935678a8-88d8-4056-8b91-d9c16c35dcbd": {"doc_hash": "c5bf1bc88d470b6e53492222d8105684f1efb65a75ee178d271381b44af03b6a", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "cb766495-fdfa-4a66-be9d-afec306a30f5": {"doc_hash": "6e5fc587d02d7909fc4569c0ce7c385656625b3bbe4ac731aa2cea2150b170c6", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "adb3dae9-d685-42fe-b238-9dbc984b8cae": {"doc_hash": "7ecd491d698b770a16aac72bd5c023253c28d67809984225d713b7ecf9f1b77d", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "3b197093-1f03-41ef-a52e-420c83a259ea": {"doc_hash": "10af19da751f85a2766b76107c22bd7641492fa52454f048c8d6f859561c733c", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "b806e4cc-79b7-430c-b4f2-8c83fd7bb36e": {"doc_hash": "d23f8f123a19e186e81f7e5c9661411bec8e4e8e0cf16abbba238454032d6d59", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "f1076b4c-5d26-44a5-9d12-b988536e544b": {"doc_hash": "825fee15d62e936fb21964710510c5f6e5000a31ed916ff82c91fcd0a2f7ed0c", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "95f1a12f-6931-4a3e-8138-8f01b9c813ad": {"doc_hash": "3ac6109bcb1eef88e54f2dac83e2a60197cd277021f5a0da8b1015d4d7119953", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "2b555871-fb62-4f8e-bb8b-9b9db9d5ea50": {"doc_hash": "7f9382f1577dc7afffad9d82f8cf3ca31297fe9f3da008ef7aa10b2332d047b2", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "59211d96-3276-49a2-840b-5e0b097ecbb2": {"doc_hash": "78ec705fbcdc25c9fc0feb22b0db3b8aec42bc330f0e8ec7a14904f71130f697", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "08165203-81e7-4c98-8f7a-cc783db97bce": {"doc_hash": "59bcb8cc7f4d083ac0abb6ea4e7195664a09840c55f5f6dddb3fab2374583b46", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "4f9b33c4-304c-4a9a-ad16-42e1ca389ae4": {"doc_hash": "058a837b067fdc69dc819bed9fd6bf67950c1b328f721d435f68a3baf361b4b8", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "cd73d913-59df-46a7-b97e-298dcdffd70e": {"doc_hash": "a41cb320445d18820e7f7cf4cba57827a9addf37a7d1dedac6d7721324026df1", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "5e92e504-a8e6-436b-8b39-a3b480ec14ad": {"doc_hash": "4c90630ee2e19dae4ecb1ace03fed32957969f0c1cccb78db6590e9cd4fde879", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "28c8c488-587e-433f-bd00-409058ae7212": {"doc_hash": "e0ab04675efea64558a62994a485b015a7915c8aa95670b95535264db338d64d", "ref_doc_id": "d0516ff1-c8bb-4fde-926a-6cb9de02b904"}, "9afb920f-0838-4d74-8b85-2e30c41b577d": {"doc_hash": "8b291bd47f831770d41ef6a115ed73268f808324174369621c78ede5948a03d4", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "27371df5-75a0-468b-909f-842e5d0e397d": {"doc_hash": "9d2b065ef746d79930f6cb75f808e1f5121a986f3b7fa9358e0f9f5b8998815c", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "eb333738-60bd-4e45-8bad-9ce7c3588af6": {"doc_hash": "bd65b418eed53f50893bab135d1a71aa1dd134df518fe639d505ac23d2ef6d7c", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "b0fb9584-a411-4e4c-8294-7a90fc0b28f7": {"doc_hash": "38e4b02aba4983e4b05cd459fe4f98fbbf7db21c8512a0a9d5a81858f481bc36", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "c701210c-14e4-45af-b0db-76a0de73fe5e": {"doc_hash": "273977d36e3d14231245541ff371d43bdb81c99223f86f55378d3c7cd0ec9c8f", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "de4c30c6-07ec-42ae-9583-8af050b78834": {"doc_hash": "0de24373e4377ef4c8fe5aabcab193a30af8a2ec0258849551304782658425d9", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "314c0f68-87e3-4f90-a338-d95f278d5c6d": {"doc_hash": "b70a4724f5542fc161251475b6e9814db2c9ab694cb28a9b32bca86802d83e1c", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "52926c40-f213-4065-83bf-77704259f81d": {"doc_hash": "56f8e33b66cc70049abe466e59e163dc4a45bfe57d724fd0b97002b77100f6d6", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "aadc36b2-e8a6-4eee-9157-41cf1b9538cb": {"doc_hash": "afc17fc8a2d64937af4e6d87fb23948450f0a13cff37015322bbb5afccaf37d3", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "69b5e25f-c243-4b61-ba9e-4251491995a2": {"doc_hash": "0df656e12181e01e0a8738e1a269c8164ff40ebd701ff16999fea85067f875f8", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "3d235b88-c9cf-4a80-852b-6ff65d1c9bde": {"doc_hash": "82efcc3d5af00ac5616f5312a9b2a5538e9ac789ae499c184b21a12b10cf1b87", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "93a9f7d6-c223-4b27-9ea8-e2b2b7a3c664": {"doc_hash": "475ef10e5bd7b21dcdd52df6ce56cae5234b1ab762e091eec08c5453c41f8c8a", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "cefdb178-fb58-49c2-8aef-6a225c5f0484": {"doc_hash": "812cd84d908d7c841ad3601b7c371fddfb87c1cce2d867fc7047f1d336f70f3e", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "83b3640b-cde9-4e5c-abec-8d63ea7e738e": {"doc_hash": "b2bba917c1ef64d97a255ecbc3c305fd564142c60acb9d58ec25d8a74f3c3abf", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "59593de9-88c3-46e0-99e1-beac873081f1": {"doc_hash": "7ca350ac352406774678ec5409f21ae6bc3cc0939cabe939c99053c82553ff34", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "a228f731-1d24-4210-b2d6-631581311675": {"doc_hash": "9eea2bfdcff6747741332f0a79d5b19b1134848727c201c07866d5704ef98fb4", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "b1ba0c46-5568-4194-a032-16b118879150": {"doc_hash": "7ae7bd6ae9bb67626835afe37ba277b9bebf52c8b275c1a2c4cbf583ccd07199", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "9170ca6b-c831-4fa1-a555-a7687adde2e0": {"doc_hash": "97c5b2019f4f2d42cbb54989788e7765bf34fe75aaeff458f7341add98516460", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "081e83c4-0ef5-4ca3-91eb-c1df33260efb": {"doc_hash": "8be4e351c387bf71684a2797c4f5e3fdd07262a054cdeebe9d07d798f0593548", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "2a72874d-3f00-4ec2-87b7-59e5221cba70": {"doc_hash": "9c0c35f9e691714df728dc5b065cdf8c9596c4c2f566becd3a105fcacae11fa5", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "db9c89f0-9275-4d37-94b4-ae6ee2e65e48": {"doc_hash": "892e808d1cb312274e2c008c9625e9fe950723c16d756f0284a51fb6008d0be0", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "c9470000-7397-471f-a8d1-d9c404f65f38": {"doc_hash": "e21954ed5ea3bbc3fcda79009af31d4c10911a39034dc93258b0bc66b72b32d8", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "dc3c0d4c-267a-4846-9a3f-8780dd2e6f30": {"doc_hash": "2b682da631f458371b8daa7f4c2d5df7072de055ab7618d1bf7e889dd0d6a608", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "abe2ae4a-91e4-496e-8615-04fc0ade0fdc": {"doc_hash": "c077768ac281c21969f81dd7184fdf9eb6ae70ddb1c19239634d8f55ef45ef47", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "7730d5ba-a801-4c40-a53c-3a3b6f2f2fc7": {"doc_hash": "89d12f3f252758dca1b7e6c06ce406701f359ab0fc4ea74d8f44bb06cfe5b9a2", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "631ae70a-2e90-4f79-8a80-529ceac6aa77": {"doc_hash": "828ed47abfa611524f6d8c6f4c91488d6939138fe167a498a4ea061293ea67f9", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "a841b3d6-81b1-4434-935c-01c523d6ff72": {"doc_hash": "4ac8179d8d8117e2ad9f7f9b81e34f9d72ba12c6d7e0a0bfbd84078fe513859f", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "34d7b68e-a660-41cc-bbb0-d4d8f4091754": {"doc_hash": "3d1616e92f254d414652438fe4f6f4e10697e040232c12b453ed69f19793461d", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "d8b818ff-65fe-4349-b7e5-0680aaefb3f7": {"doc_hash": "06ed097521a94a65f3853a79d6d19f451bfafc3af7c2d69fe2417d38ba507672", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "29182047-0b72-42f4-a9ce-5f22f7c374b5": {"doc_hash": "33e762abf2e9ccd7ea7b33763010fc415578e23c2a3d5e6780cb1685782a9827", "ref_doc_id": "c20f803b-e0d0-435e-8722-82afd7d3dfc0"}, "458e00ca-0ad7-4468-9437-c4f31b16b0ad": {"doc_hash": "2cd886bef09b61306c826113f610370c637a3a9783acb389ff2c2db43f517f9b", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "37197734-21ad-4427-8f67-21b3b00939c1": {"doc_hash": "c6129a7314a09077fdc6d480bcb9d1a1b1046146b2064401eb40256925891a57", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "db0476b2-40f4-4bab-9865-9a8c3c4affca": {"doc_hash": "369ba520ae1792d41416ae957111d442b169d7bcebf714b0985ee907e0a968a2", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "8faf4072-c3c9-480a-9de9-af476c63d9f5": {"doc_hash": "981c57bce8b18059f5663b8d4e1ec6045a6aebb650902e73defff4915c24a6d2", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "2d00a49c-15a4-4e47-be26-c8f32de6e7ea": {"doc_hash": "0ed553624d9ee8a4a827ce11eb83ff786332a533ac3b3b4eff512f1171de91a2", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "7294f7da-0858-4ff8-9345-f88b7578938d": {"doc_hash": "e0bab68962000fffc0c613f5c3c1eb125ec119e3911a25b7424c2bfb01076fa5", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "1beea350-b2f6-4a48-baf1-79f8c0863cf9": {"doc_hash": "79fa89e27bc7395524c7d7f5d5218763b5df318db28947386dcd6a66e9a94fc0", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "46884386-6a01-4c93-a661-4110af3ee4b1": {"doc_hash": "c4a67115a63ed31fa0aeae9ad0f505004a04aa7eb55c97c5d2af231439ddd12a", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "cb24db04-6d3b-4e7c-b374-a4261f3c7c55": {"doc_hash": "2f74ae4a782d9fcc6b5de5f6e81b2eb9722a7350fb3fa96542d101457cfd7900", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "261143c1-57fe-43c5-b975-91e1a3061ebe": {"doc_hash": "5fff875c29a92b82a3ac156c533695a770ebcca4a8f001986e28adc6736bdb7d", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "b99929d5-82fe-4de8-91b3-f3446a01312e": {"doc_hash": "d8176b24c31da4d32f87e2d336ed966aac6221233f5c946a1dc74ab4fe0e94d8", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "b21231a9-411d-4058-acae-7b1969863f22": {"doc_hash": "ade08cf2dd6fc3a2a26d7ae814a87880bf7cfe91f0af43b4d7191b9286e11931", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "cf1f4b2e-4ed0-4ad3-bba9-5246ecc24211": {"doc_hash": "712f09c550ba92aa788840cfdd96ffd1ab2579f1a6f2578646854eea01011556", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "826d38ec-4a0b-4610-b4da-c725b90020fc": {"doc_hash": "4d9cc245cf7542a2aaaa3472c713743e38381c307bac8e8eedb3f385109458d6", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "d099745e-4647-4e6a-ac3e-344fa9c028df": {"doc_hash": "514aec4c226d0758cd4c6171456730d961bc3c1fcfa1f3d1116b871b9082f800", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "ccb860d8-37fc-41ae-b213-535847395450": {"doc_hash": "4709eeeb5275970c5fc8f76ad0a7b2100b3e56c39f5a052af61448b07ecd1206", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "53ec5dd8-0629-4470-959b-e7e6e896a4df": {"doc_hash": "ba198a743c4109abef11068a0a148f618c0c9d5762a724895ff62babc5322e24", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "d1bad39a-148c-4dca-a778-20a2e6dfe58f": {"doc_hash": "18a59747d58d7b3cc9ffa161bcc830aeed6904dd017396fc8e610e30d3fdcd9e", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "6f043f4b-a524-46da-8075-0e37b1fffa36": {"doc_hash": "9e72c713371d0efdaaab2e6f48d2da539550c6f2fc73c53b8f889646e232c573", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "dd200555-38d5-474e-9994-aec798e47a12": {"doc_hash": "e2f00487445dda57e25bd72e98d973d9f5da28459c0a002b250a0268e8edbc69", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "83e2e364-91bd-49d2-9f14-4f81508662bb": {"doc_hash": "efa4f1a9b090c4eb68bbf80897ab1fe6ec065f61a030cea688fb8db9dc47578f", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "b05999c6-c251-4cfb-9d88-1c77a52b1f66": {"doc_hash": "a386e23a7eb715ec5da36f525ba2dfa69447e29da2a08dcc9e275b4fa18cc0c6", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "78c1dff8-b51b-4cfd-a439-546d8ff595a6": {"doc_hash": "899a3aff053972ad8b0b637c5d2b412e20db75f021df75f28d211e1ef6a3e588", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "de5fcaf0-0dee-4ea6-a848-cf31e1ef425c": {"doc_hash": "7961d2ef71aac2b12d861708e4de96550d7639e4fa79326af2b8d9269f0d55ef", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "e39bbe81-f6c7-4640-91dd-dfbea35ffbac": {"doc_hash": "27ebf3439764c079f0b60c6db48025fafa1d59ba4edf11439a933af1f9e454af", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "0f1f4b81-4aba-4c68-9ccd-7fb10f7a4ee9": {"doc_hash": "ce2e1cfb3d3dea913af590ea95bab7ab7a410137ebed3f81901eff3c8fc6c6c7", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "10c0924e-aa0b-4df2-a36e-47d7809ada5d": {"doc_hash": "b78e50439fc1af0adc89ac261adaccb9a8849aff2226821264e1b4b62c4910c9", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "01e82e06-82c8-4492-bde4-f39589738bf4": {"doc_hash": "e12559a6cd1a2538323c7be1d755d17232dc2080c4e8c71854c2f41802975847", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "19a00b6f-c844-4bd8-8387-35bf8a2468a8": {"doc_hash": "b1541924b657d135a3340ad3f01455369f70cc80a8e649c451f2f4050bef5a8f", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "46d5af73-9a78-4cfd-925d-718691676b52": {"doc_hash": "d2826db027e1224e04961979930ae0c712b34ef7426d196d409088443382d4af", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "84d7edc8-008a-4c0e-9ced-bef95cda4016": {"doc_hash": "26d067fcadd2a2841cf9315b31f8eb6e124fc80df1acab4200a88fd5eb79e9a3", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "0470aa4c-1bd0-4076-8f68-cdbb45cb192f": {"doc_hash": "89d149f6c2b2122e66a540b9ff6e300c622118757619797ce444865c2c6d5ff9", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "9ba8d025-cbb4-4d20-9cde-0f6d54bead5e": {"doc_hash": "23b536e1624c2e539d66e75d8e59ffc02cd9bec4f85d3a7d7f0e6463a16e38c1", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "77d07391-a6b6-4cc8-836f-ca9165d75a86": {"doc_hash": "ab71a4c5362078faf1a406fa7c651c9da33e1252b83f2e30d6e7e14984022796", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "c37362aa-966c-4618-ac72-7a4b8d8c93b4": {"doc_hash": "13c3e17993a608b112dcb7bc02e8a3deb4b2df9495b2d08a099588933b7084a5", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "ce6bc3a7-e9f2-4f8a-9111-5f8c11bbb71c": {"doc_hash": "f74b576e4ee5da388f96f94f4c379dedf09930db630814fb44f64393f2832771", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "ce59d728-7ef6-4b22-b7ba-160e02f069b1": {"doc_hash": "f71c05ebfab26563cdf075a497b9a2718d0d3d2dd72a67bb43ce28a5cbf3c06d", "ref_doc_id": "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd"}, "c56dec4c-d24a-4acd-889c-1ebc8fabca29": {"doc_hash": "993ea4f4e25c72cc6ed3834aa6fa4dd3e928a3b3fe4204adf24186ef5965e8a0", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "4516986c-1f8f-45b0-904c-d086db47e723": {"doc_hash": "1fd1df2afa945e14de65f2e96c7bc99ab9c344aa3bb628c9175cdfb5e701832b", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "2ff75f50-6aa3-416e-8d66-9efc3dc3852e": {"doc_hash": "ef58e43abce292cd592f83b21f5cd5d0dd459e2d38d5ad37d3cf723ae16105ec", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "9329efc5-08db-46a2-af91-5eab6274918a": {"doc_hash": "c384c326b6c56a46c7e9d218f1153a9780699618d790c97361a833876a9de22a", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "879eb2da-a5db-463d-bed5-aee8879e3caa": {"doc_hash": "349b844897c1551e1e46598e7a66e553eb2321a6a88f4956e9a39594acb9fa75", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "ba0816f6-fefc-4181-ace5-8332bd802334": {"doc_hash": "d3d785d86e32c92a8e2fe556f2c5a66aee2166a41fd8b6e2b6ba765d0c4ac188", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "32780749-e88f-4b0e-aede-98ba411c93c1": {"doc_hash": "42b200f11b39e87a8a434fa208d961e0d40895bd94ec05cd9e61dd59a331d371", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "56ad9cac-5d95-4b1a-9b7d-6fe57cd60c4b": {"doc_hash": "66e44c35dad76997554d527147adbe4f5c40b94b90b0ee1a0d91a65d9ec248b0", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "5b9414c7-025f-404d-a1d0-5e2c206ecfa3": {"doc_hash": "dffa26cb6b12725dd90d4bc0d1d4e40737346bef1e55c0b5b1803f4eaf07eb60", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "56407c3a-99b8-471e-a575-a4ae019aed8d": {"doc_hash": "f14310815a07ecf277127890ed552e56b90c5c7268ac4acd8165409afc42c9e2", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "83447fdd-d579-4831-bd96-738b39d7878e": {"doc_hash": "15c0d19485d29722c486782980e0636cdf4da9be24a5cf837f121b66e9cc9b7c", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "0021258f-8def-499a-9e95-785cb0d38bd7": {"doc_hash": "4d12aedf7be8e12f216f152cecf98e260659ca809687da78b7904747776c48e3", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "6071aad9-0ecf-4919-89cc-fed50e7f3a75": {"doc_hash": "736b4f53bec6bd4ccb3111ba3bb36f474c3fb186a4ade13e64bdf85876a2d2db", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "8bc4c945-45d3-415f-ace9-827a987e4713": {"doc_hash": "d3215e81afd6ec8ad07898f70c9061ba1bf2d6bf3e6be688d3530e5ceba69c71", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "c3df7df9-22af-489e-bcca-fbd6d11fff3b": {"doc_hash": "b85ab34eb91624d2b5155e14ed09d39e5f7465c3112e500fa85d2922e3c9d533", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "011dc32f-4626-4212-a9f9-0711a89f28c4": {"doc_hash": "864f7c2164f1de2c9f394e5ae28d2791544ba22c783ccc56dbd1fa68868dbd66", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "f6c57703-4d3b-4612-8079-d299ab2304d6": {"doc_hash": "8c124a2936503ea1aa1df4369f0f2159fc9a01f481d6014401f1d18a4e57860d", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "96867894-7617-475d-b58b-90ddba56a198": {"doc_hash": "774b75d1f9ca98b5ced0694b725787ba02f8791f86b78379b57203a7b50179ea", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "3e869dc4-3410-4d64-9d27-2bdc2a33b41d": {"doc_hash": "f172c363c5d407c21131801c49b51c22d641466a0b01f12b33775776fda13f22", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "c32d2f15-ada6-4b6c-8d51-6785310cd077": {"doc_hash": "a2e11c8830ed89d64da7f4d2b20ee21c03d26c9b357dbc5e6592c934111679cc", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "13273932-7196-4122-a499-5d990bef731a": {"doc_hash": "748a77d86ec2177171ff10ae34c48d397e3ae5b2ee8753b57691e729a8f95dd4", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "261941de-fd15-42fb-ab1d-21c0273798f2": {"doc_hash": "199eefe47daffeda5a6549223e896c0ca166f505bb2bc2e47b4338910418cc95", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "6b8071eb-425e-443c-9dc9-2802d36f85ea": {"doc_hash": "1331fb675d36dcb4c6ceeed61f661b58702f39eb669c9cdf580785d37d52ffca", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "741b3698-ef39-4455-af4c-8fd1a1c5f202": {"doc_hash": "d823899002ee2afbef8993b951663ca64dd69358fce2123c5bb38c5542c4561f", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "6cb15c2c-f898-4d91-97d4-ec3c2a6f9675": {"doc_hash": "c649e15502f9614411cd88d7352ce9974bbdfb619cb0a35b0010da1de392ffa4", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "d92d8ef8-c72e-4ccf-9ed7-2d17edaa2328": {"doc_hash": "641e9a96213c0c5c67bd2efdf9ca4d0ef3cc1beac49f2d0aa3d802e806c411d5", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "b6291e14-7d6e-4636-b8fb-b3deaacae94f": {"doc_hash": "8e675dc9fbd6524817a77bc8d353fee39739dd651c20d232bc6b3b23a05ee3a5", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "a18a7f70-8c89-46d4-8dfb-287355e232fe": {"doc_hash": "a5c226209dbedbbb0857b8d792008bba4395318b7614693156bac6fc93a87fcd", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "6ac629a4-a971-4ef4-b882-c3f838db1353": {"doc_hash": "2e9f09167d8ef9217ad2e9b8f95d576f3610171c14081e0db78826afe68dd3a5", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "94a92063-a42d-4b34-a9c3-13d9f47c4883": {"doc_hash": "05facb67d5ecd2fa323619dfe378e6a2390bebfa281cef18d4b8c29c49e5a8a5", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "7d2457c9-bf9f-4957-b59f-89ed8c6b929a": {"doc_hash": "8b4dc1a6d0178be16d96acb1805d170e27c37381afc49c4dc6a3d44d5d28851a", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "be5db252-9361-4cac-b370-4336ba5b0d3a": {"doc_hash": "4f19967b2ab17202f4cf7237b902e33f97f4eaf83dc45aefb138c5080e36be42", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "ac276198-992a-4d4c-bbbd-c0a8e624ebd0": {"doc_hash": "a5f90fdbc6758e8bd0729156e064afb7065462557328c9dffd300ce60be67a68", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "9893cd72-1870-4ad7-be96-31a4c976f33b": {"doc_hash": "ff59a65f0c74a20015706006bfcca41424880ba12a7870374ad487c9bac35f59", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "ea6cca50-1d19-47ac-a17e-9199d40a176e": {"doc_hash": "c062296db720a25b9f2b1c23b7c5ec8f00ac6c5819c22c87c576d3ce668af788", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "3de608f0-57da-4463-b143-7370b7d4d0bc": {"doc_hash": "787d5ffdb17aeb5ca5a459edf729a297632a00748cbaa9430c001507c0fbf437", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "d49cc609-73d6-4657-a3d3-43a03d0afa23": {"doc_hash": "7bc90388053cc719d384d03b663501e38955bdd05639f5867635840f784a7ec7", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "7205682d-975f-4feb-b3bf-ae8f1c717f9e": {"doc_hash": "b6c2c3796dc26ea2316cbc054bfb5d470ff49accce58f4040fd5ff8bdc51ebc4", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "83e7a6df-0b33-408c-ba48-a1de9e15dae8": {"doc_hash": "1cd03ee52485b9fd303ed558b65c89d53e4f717d3e807df4f6c774af94e16439", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "8f609b18-f23b-4590-a1c7-1f9a7aec5640": {"doc_hash": "0e10dbe0f1c0c73279ffce852358ea789b6666ea26642427dd4472a15984748c", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "d38d3531-2acd-4979-9193-ab4a664c993a": {"doc_hash": "87fe38c2e276d0896bc0cb9e53b1bb9c4f7e271760752c626061be03f9491462", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "038e0c0d-96e1-4c5f-9dfd-448425f5a222": {"doc_hash": "a5f2fa4ca2e3c749c7aa69fca1d751279f4eaacbc2cfddcc873c1d3282594220", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "f4240ed4-5d3e-4796-849c-04bd994b746f": {"doc_hash": "86fd99dbb946639cae587bfc18148d48275fed1a76bef7d068f462e3fa80fa67", "ref_doc_id": "10c17b1f-1297-4b9b-b906-6a61e058c790"}, "63faace0-b5fb-4efc-83ad-c54db56cb696": {"doc_hash": "6596e148c7a009788e2b9fa91c766e6bb6ec550251dba597e44adfd937daf40c", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "a7a57b37-57f3-4307-8f80-3cc0836d7482": {"doc_hash": "2923ab7274f9db76d565613310dc895a464350855b546aee4c0c4e4b22cca5b5", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "b83b0ea8-e6ee-4cad-acc1-13961964e231": {"doc_hash": "6ebdfa5e98beb3c38030c8c8e9e86677068f3eb9db7064b38047df7167259db1", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "0eba3e75-d4d6-4da5-8e3d-78eec5a7f589": {"doc_hash": "1b39ae47280c66831960e446762914fe6a8e97ffa51875531efefe7fbc77d1eb", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "d60cbbba-4c11-4903-b7e1-91fe568df2ea": {"doc_hash": "e5573e33ada428a59b12ce8680632c2069a3b0ef4306e50887cb8cbb1a952602", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "eec78512-3fa9-4d11-86a3-c680d6e88ddf": {"doc_hash": "c1c8265ca02b311db60f784c1e14b031e056d377fd0671666034f8c92d633b0c", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "d752a15b-a0b3-408c-8dae-cdf18fb9aee6": {"doc_hash": "52ba9168dbd99d41c30389e54c0eca81e05ffa4c4797281402a30fe73593f051", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "458b2302-05f0-46ef-8ec4-afc858b6b4c9": {"doc_hash": "6fc06163f1018a285bfae0aca66f17334a8a3ad379f48de6a1af499fe9676dfe", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "945a7464-5bb6-4568-8f15-a057043de8c7": {"doc_hash": "fb6432d53b7235d6283969ce28676df624e6f7a9ea83c684108ce0ffcb827eee", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "a86bd9d0-934b-4136-8514-1e151a2017f7": {"doc_hash": "3fdebbca18aa9ff6321c973d56feb39db2e42805cece99536895c4f57b7159f8", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "40779665-dd3f-4f8e-a765-0abb8906ebae": {"doc_hash": "dd6577e78db6fc16e9e10c8ffd860340977e7567f27f1c399804022252311d1c", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "f8bced18-5ec8-4f19-9d77-2a4ca5ea8298": {"doc_hash": "7ce9dd850ad73ae2590b43d951e14db0bbb5adb98f7e0a7a46e2219374764997", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "bdf44eb0-a0b4-4bb8-bac6-f2634aa5d529": {"doc_hash": "3180ed4a8aae7c797e310f59dcd051d27fb9c1fc1ea0114730c78464afa0b65f", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "f5ee7bad-e252-4c3d-bd64-cf672a9a0d6d": {"doc_hash": "4201add44ac40de53a80ca91fe9c58bc6eeda1262a2d0eeb3142559fc106443e", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "738bd9c6-6013-4971-ba69-5f625e4a2331": {"doc_hash": "d346bbe0da949b37d9aabbfbb8949304ecb55f626a9af2cb42d87f8dc84ca0a1", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "dfdc5cfc-1836-4429-b7a9-08bf9ac58f8a": {"doc_hash": "072bec082291bd9bcb8859bb6238c4479859d1125e05b5e673c99b33a53b3cd3", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "fa2bb967-b253-4621-8045-62f09cb99943": {"doc_hash": "a2597cc034de438f54f8b24dfd5054d1d7974fbc4adffd7017d39c64b03cf1ba", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "cf82442a-3740-4c6c-9733-bde2817d8a18": {"doc_hash": "532e430b30b9cca5504ee9a0c9d3f1a61faf7cba4d70290594def53b3dc0f45e", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "879093b7-7d0e-40c6-8a6e-eaac7daeb74a": {"doc_hash": "b1670029e6395ee2f4cb7568b69e0f8f100b9f4445f85a6fe937254d1e196274", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "6e56bb5d-5b09-4b6a-948b-fd34c6569359": {"doc_hash": "c5e7c235e6b4896546a39eea3d5c577cad867634d7b6e3ad13117b58f889bdc9", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "1bd000e7-0600-4222-a271-d6f23b212f8e": {"doc_hash": "13574e5efa9dc59507131b777369a496c87b81272f01932e0940b6265c1cfdb4", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "da0f03e8-560f-490b-a83d-1d0a9ba5d3c3": {"doc_hash": "515fd9a77e7ed7cf57854f496e808976fd9c8229bb4dc9c24e30faea66bb05dc", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "cb82764c-e55d-4833-a434-8b8c5e26f5a6": {"doc_hash": "3a8e061ace89e1e6537df148b328214c8207958bf243de43024a60fff8b3eef1", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "13489f26-1014-480d-badd-9918d31d010e": {"doc_hash": "321bc2e9c57fd06d7a231c4a75ed492fcb2758ed5f5b70947c5ba0d7145645f6", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "0968ce33-e5de-4cf8-98a5-fa6a38231bae": {"doc_hash": "5492c48a11e661a286bb6c0d522afbf5e5f2924a256a0cf0841110c22238ef4a", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "18835154-a547-4a46-b56b-4f0ce8b8b9c7": {"doc_hash": "69d90453d10307d1276572c1b51ad2efc4d0051a6633a5f1a9b9f83fe8bbdbdd", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "5b3e6ad0-875b-4b39-9870-51d907578a08": {"doc_hash": "950dfb96e68ae301e65a46e60d93ff1ed80b85bf1fbd581079a2b0d4b60ce832", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "6bf00cb5-9c25-4536-aa97-0cf9ee27ace8": {"doc_hash": "45e955759ed7c68f97ed01cad5ad49966f8c295c0e3e82cf7786f2f91320613f", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "c8ea22ad-faf6-40a0-a732-90e84ccfddef": {"doc_hash": "faf5e7954feefe319351acd0a557ad05fdbc63af4125faf258ff6c6b4a088ff3", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "2fc77c86-dd04-4533-a63d-c6125b4a61a1": {"doc_hash": "49e43b98ee449170e7e298887cea580406c206025db36b1197d586e8a09558da", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "74581cdb-a03c-4156-b9cf-5612ccbaf73b": {"doc_hash": "ed27b84777866bd49a4965a2a0153a35e93a35160d0ea9d48de338c17159b197", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "3d8d9c82-304c-485a-8089-aa620348d209": {"doc_hash": "f9a251a45ac4ed53de3253c6bb0280744b7a1ccd4e10c6b39aa30ce098628f06", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "0ce1c3cd-41bc-4d3b-9612-fddbcce2f561": {"doc_hash": "de8fa212765836b4a88ace7e06761979cec38815339aaba7b98f44e23d2186cd", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "88b37a4c-a69e-478e-bd53-ca451d3e3427": {"doc_hash": "3afdcc7ec4426936cd1fe88c7e3efd2ac41371c755401050b91697bd5a3bdbb8", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "c3cd5a3f-3023-4ee3-8935-f8b5fe5cd27c": {"doc_hash": "b4ed615f4a8c5efdcab09c31da71c3d81643967d5b3b06300925f0db3b6fc9dd", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "d84385a1-09d0-4510-bac7-ae809864e98e": {"doc_hash": "c73f3bb6aa39fbfc43397362ba291ad45b129a1378db57da075bbe8649ef136b", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "43a40742-a8ff-4377-bd31-3af3907e051b": {"doc_hash": "325ebfdd5efe4808a9c358f99cd3503d5518e8d081da979f090a5cdad766a60f", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "706c5a0d-c012-43dc-b15b-08d281babd14": {"doc_hash": "27c1e5dad0aec9502e6ad6f52eb4156e5ba25ea74a0a2c16cd0ffd320c27f4c9", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "83f9daf7-9d48-422e-9c53-001a775df315": {"doc_hash": "64ac95a8009183b2bac9a966c061a2fbb136b814e911d7da8150da10a0255c45", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "9e99ec59-5e6d-4289-995e-1ed8d29b52ee": {"doc_hash": "bf1d5406521f48aa5df1ff504a265dbe2ffce182c1631d6ffbf9ef762f119323", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "257fa90e-c0de-4af3-a32e-a73dc8ccb24c": {"doc_hash": "a8bce16159fe2ffbb31cc22779b2e79aa23c48bafb2f78ecc07c708ace4f8209", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "959965f5-05b1-4d73-853d-d6ace5c0bfb5": {"doc_hash": "def577f2c886a174146bc52b26f689d66b2b165157aa97bf69ba9dcaee257758", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "5b6b3d61-762a-4bc2-b1cc-ac00487e760e": {"doc_hash": "cdbe2c679fb3cfda8fc00c749840a855892fbfffd12db8c18a66ecbfaa2cafa8", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "98d4bdb2-1997-4edf-bd89-ffa4bc0dbabc": {"doc_hash": "77e5d4ea5c9e87c26b82f429d45ecf7d64e7cb95aae5d7d5b5a40d08f10fbff9", "ref_doc_id": "db8d5d3e-e808-457d-b744-7224d3302f44"}, "007f14c5-b700-4aed-ac00-8f491a8bb0bd": {"doc_hash": "40df69c4dfb0cd72c4e89b7f199cfc3021e91f2b40649ec9a530dfd03cb70010", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "01dcb3f5-1bf8-432d-93fc-6714bbc12adb": {"doc_hash": "dc99e4d3472a3c355fe66f5d57acbb5976f62955bbc8a04d6530d5b8329bcb46", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "aa19da2c-66c9-45b4-a8ad-37079f5dc49d": {"doc_hash": "610cc9ef23c7308a8bcd128de380c7e0433c6b49378bcbcd2ca135ff1efd3ca7", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "746b1be4-c714-402e-a860-80867612c7ab": {"doc_hash": "a875f01ee9d19c9a59a85ce86d1d69923004b7acb5eb38d87d24a4dea0bfc846", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "c7b78c38-4a6e-4aa8-a8f5-d8a7f2c4c439": {"doc_hash": "6379e313fad8c5a4cf46112f4f9d35c166dca734f2277617ebe9f1c989e2fcd9", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "e1167720-6c1e-4484-b12b-c63e7f371c9c": {"doc_hash": "8eb4ddfab7e6592c0c9f1d0f6088e683478fb4621417523b7343712170687d3e", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "336868d9-1fe3-49b5-817d-4de1527ed823": {"doc_hash": "6c05d7baadda8d8223eee0ecb3a83ab98d84f9b075914c78aee4c6cfba2d477b", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "ab7b1257-f0fb-475e-b646-22d8df98c2e4": {"doc_hash": "5ccf52d98d1db0bbd0c96ec15af357958c10d1ff8cf2e9dec17b756213274b1e", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "2a99e7d9-1b22-4abc-a5bf-a969bc08f4fc": {"doc_hash": "2f622eb3ab1c785d9791d845fac5e87157242f669b14efe5b0c159e69d71721b", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "1d7f9c74-86e9-43c5-9665-8fc8c320610a": {"doc_hash": "5944db7fc5bcf2e567143c245f038ae86a69e2f4fd24786ddb997cd983858002", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "14937692-3fbf-416d-8ffb-254d0a5f11fc": {"doc_hash": "823d6bf0e776017957e708932da49d166174ebe075f878022319f3e78ba39203", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "ae5afb72-1e8c-4113-8cef-e110892ea113": {"doc_hash": "ded4a3be831a3fe2bfd43855a77fc0146e627dd04471c87c9f9a18e6ea26460b", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "f5b3294c-0265-4446-a13a-e15c9fd0819b": {"doc_hash": "c6c1f97cb360795daaebb008da0bbe3888cdafa945f54ef58723517f5ef38cc5", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "35f1e843-6b11-42f5-8745-9748746172e3": {"doc_hash": "6da00fe3f38393f148d31eb30c14ba763519f018e6ea7fe1342bdfe4a5745ce4", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "87ff3ef5-72d4-4399-91ec-6e6c8965b2a1": {"doc_hash": "54b70ce3ffc9e8becd9d2359fac68b6ee5caf9ca1676b999158acb62a8f68d86", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "f84ac324-769e-4f8f-ab0b-fc95929857f4": {"doc_hash": "38b860151b0d1499ea1430f390db2f550e88bca3cbaf77b64e12bc971e212cce", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "8967fef5-a0b8-4566-bec8-b525901e3546": {"doc_hash": "08b7453e77f06fddfecf3843b34a811cf0f9e66d0ac6d2341252eae9f360250f", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "07505390-43df-483e-a725-241d9728f5ed": {"doc_hash": "3a2c36c7cdc29f57a7cf3977f23291ba956ab171ce2ed6ba58c7c26e8d0248d0", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "5e580d55-ae1c-4dfb-8959-211fcd59b729": {"doc_hash": "2918113795e3d4f495e896c1c9c2dba68604180614eefd18887e27f79a4ed9e6", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "3386d0ce-2af5-4161-b300-cdb7ea023af8": {"doc_hash": "f545ed25003232bb22738eed85554b5d68dfa1815bf9b36212d6fa9e14fbb36b", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "012aa14c-e413-4dfb-9e87-737e0a079c78": {"doc_hash": "24b17a2b0a53c7d651458954195892ebf2a558c69f5be0d04bd5c803785e70cf", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "66ced4c7-c53b-4403-8881-f84d28003b71": {"doc_hash": "72fc99f893a6533fdcceec4d2e0d4cb615f2eb14fa6a96ae2dce3cc1d38d26b9", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "77e418c5-a50a-4408-a9cc-78d452b50711": {"doc_hash": "de49ced0bd7b4667cfc45e68255e636efa2781e0cbde99a668073bfc3eac7773", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "b9b771be-b39e-4bbb-b516-6a8976ce07b0": {"doc_hash": "865090e77ebf81ce6f78046a2f09932d32b0102136c94ecf720967104985a17f", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "6aafa541-8a5b-41e1-8a8b-ce23e053abc2": {"doc_hash": "1b670bef25d423dd1bfa1ede0753071578c5c5d31678147eea6ebc27c1530b63", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "3aa3a2dc-4ae4-47ea-97ad-dcaca633c35c": {"doc_hash": "05aeea3def9f36eb42134bbfe628093895a43c5913dd1185f8abdfa09a44ffc3", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "bbce21b6-0302-4cef-bc4d-4a5414bd69b8": {"doc_hash": "1cbecc299d8df81348e8580dcb3db50d9b26cfe4554f008e5a5285e051ff66b8", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "6c5c3ce4-1cdf-474d-a560-c2fc0940539f": {"doc_hash": "5e048955d4c220736445dac863f64feeff88afb4fce5410d2658df7d5df73e11", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "3efe36e7-2d83-40a7-bf43-8c170c240c32": {"doc_hash": "07382bf9d02841cc8dd1a564be62455500c1152858fd66916d529b538630f973", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "c238d40b-3ed5-4eb0-aeff-7bdd3d12d4b8": {"doc_hash": "cb0339592446569ffd1c928608e39095e6b7b076415fa1c20c415add34598d14", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "052a07c2-4934-4e1a-b382-14625813f28f": {"doc_hash": "0dbe54c60d93bf663d5a33b5d1dbaf9e979b1821ecbd34d7e8283b5e10f97afb", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "44e59188-6206-471e-8e35-773d911c9f41": {"doc_hash": "ee2f50e0426b17b2a428c242edb2415786792de1ff454606d1ee08c789844a72", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "9b388715-3c35-40d0-be46-4fb2efe5dd3a": {"doc_hash": "baaadb62b38543acd8eb1cb03f8f5b015b70b12eecc9522b92ac2230e23a5ee1", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "4ab76461-0ff0-47a9-8077-4797d7ffc09d": {"doc_hash": "241a98da2afafcf52c6a4782c73ca7df6c002f7ea5a7c518afc67eff219e3a47", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "dc1119d1-d8f0-4ef5-b9ee-196341296ee4": {"doc_hash": "ceace362a50af20f046472e0cd0f8bdf4531d1bd0d17629dc5d30f3d6f0a09f4", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "62ba9b61-5f6a-4bdd-b13e-b1583599fbc2": {"doc_hash": "df8f239cba8880bd0985164dd679561feb9a692ed1ecbb2b1e1d2ecac886c0d1", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "90303622-fa9b-440f-b52e-1fdc4ac9bd14": {"doc_hash": "b967cb430c407205d261f170055d522854bb3c40500f2ba6994c296ef8e9acc0", "ref_doc_id": "6ac7948c-840a-4576-910f-d22be89beb77"}, "7385dc4b-bfc8-4367-9e7b-2a74901ff8b9": {"doc_hash": "61c35de7490185467b69585d60a45fa7813dcf0d9bed331a418aeefa9865deaf", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "061d8647-7deb-4841-829f-be3c4817fbe1": {"doc_hash": "c2ad673dae4596a43741153038ac14b432975f7b1d6332879e335b066c345369", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "7075bd82-20b2-44b1-9fe8-2d2c3d9f31d9": {"doc_hash": "98cc7f959198a2799581a986a250306d71e36b20aac0b7e0f3e86c0be0c5a227", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "0f008790-2956-4f15-a24b-23ea3642fcd9": {"doc_hash": "8266693ed16a79cb4c4de4abd637094cd3cc5e462eda2f6bde14c212b1d72ecd", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "6d808a5f-61d7-461a-a2f8-e9e7c9561848": {"doc_hash": "2f284c09fa2dcd42418575b51eda6e3b0a55312271a9fde3e7168c40e8787081", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "f8fbfa72-d7b7-430c-a0b2-3ad8aed3a9f6": {"doc_hash": "aeb6dcf5a71c2a6c158200a4d62068086009675e3c0c4bb5a87f3bdfde56f1b2", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "98ff77b7-6305-422b-b23a-9b7a3e5410af": {"doc_hash": "e0c4c7cdfcbf45e0c518388a8b261323d4a8265b4a8a0287fe306006e16882bb", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "c437555c-ae45-4464-b1fc-8c4a10c64589": {"doc_hash": "970161d5624148816997a360b0a9c0f342418c16767083156330e752d6ec13de", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "28562d13-8f29-4fa6-a4e5-5dc1039d86e8": {"doc_hash": "1c4d75bce574377b1c5e210107d5e8c3bdf6b9dc325848b8e375bf1a01deaceb", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "eb1ad679-1325-4aba-9537-d0789c6db02f": {"doc_hash": "251fea56355613101d239379141e2a0c36b897afe5da77d2a98086cee170a106", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "3bce4caf-96e2-4d4a-85f2-ed5903073431": {"doc_hash": "a9989945c3529931c0450d424c1cf2c8fd1cad1c791621569a6ba890dd82381e", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "e0f3bb48-c5e1-4251-ab73-f7d3378f5e64": {"doc_hash": "53469acd513f8ebf46d373e172b9e094751122d000ff3b205a8b05dc175113f4", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "3c48e2f1-4589-4b05-8661-d9b18626aa61": {"doc_hash": "49672a82fb8e023060e06a6eed98ad91c2fa25fc41a94c6693bee3c519ffaae3", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "91cb59b5-69f4-484f-8cd9-dcb239558665": {"doc_hash": "45f5e8671be14d7dd5662cfb25a6bb42abfed173652f56b94bf857a3a62b2741", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "9030b909-e0bc-402f-8845-2919423f31fa": {"doc_hash": "a96534c66dc048ce2467f978862ff26a499ed885e5008fb2437cf2056add04ba", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "5f13086f-348a-4042-860e-eb5f7e99628e": {"doc_hash": "12dd82808073aea13d62bdd4453a87a38d8bf3c61b5216963e0fa2f6d200193f", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "fca98014-73f4-4b8f-a3a2-62e0332665c1": {"doc_hash": "59097b6c3dff0995ecfa4ed465a06e443fd3d4a791cc6e7354d9e4bd10ccfa29", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "adfc0a97-d783-4f2b-a6c5-7d00829b9e31": {"doc_hash": "9eec1275850a381bcc7e449ff64e85e62af1ad514e35afee157a36106b5241ce", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "6ea94b1e-6c06-49cd-9165-fee7c248ada6": {"doc_hash": "06329ce1453bc52f01ac058b7585e06c5dfa4bc3eed5e71c0977b64a474267ad", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "762b03e4-349f-441e-be60-504cbe7ff0f2": {"doc_hash": "8cdc5685930e02f016c587e0e29f26d18d0c08b1682cfb009ad5e448ac118a63", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "4d8ddbfc-660c-497b-b640-cbdee8ff40ec": {"doc_hash": "cf3f20278cffe1de0900ddb0529ae6c7ee5b1cb4f8433c362b0f0e1388d72bc0", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "c6bc9e47-1cc3-4aef-a1bd-8b11a424fd47": {"doc_hash": "cb7a583f897b8df33a9dac1aacc5a8a96a7410d32238261cc01c36eb0ef78397", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "96529926-c5d1-424a-b6fc-1669b6c6796e": {"doc_hash": "fb58aa88589b64b80b156b3868ae6b63fb265f7d38c28999c046994087ec32dd", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "cd016f96-fbe7-4dc0-a225-5f936a308e99": {"doc_hash": "938d129a1c018237e5a1a6f4947db3841a3a1156b7ca703c8bc5da1feb71e1b1", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "0f66c9d5-e784-4613-ab6a-d42820e1a3a5": {"doc_hash": "0b20303871b1884f39b548166bdc4cc9856075fba5cf0271ec4fb3e3ce89ccb3", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "95016df3-d394-4035-ad94-b2b4f97b3ad8": {"doc_hash": "e33e556b0526fbffcf18d88c95aaf8699cecf0df09229d6edea44be5be0d93fa", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "95a7b89b-ca54-43d5-ad4c-28f2ba2a1b73": {"doc_hash": "bcb47273e0a6e95e72de0405430314603e6afe306af7c5b53d0d657eed5c2992", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "a440587f-b1db-454f-a443-900060df66a3": {"doc_hash": "cfb5dbbfde4b4fd7a0224351c96ee6a4458a164aa33e5aa62576724d3e472e16", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "0ce998a6-b752-4154-b3ae-46ab9d25f98c": {"doc_hash": "5e039408d28585e1936feefe7d84f14f54547d0a20b754ee1deaf1dc7f665a9b", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "1589ab44-46b2-48f1-9378-375c96feba9a": {"doc_hash": "77166a1cea7e03bf5bd92fafbc24a9ec261c29c74ee9f7a5b439b85b49194e9a", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "9c8c0636-fc36-4ba4-a9a6-e090676f55c4": {"doc_hash": "ef916d6c9541d55232e724a72df15afc94bf4dfbd5445ef3faf5c1fc2efa6553", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "49df2a31-8bf3-4874-9dd7-cb1f5a67b6b7": {"doc_hash": "099413e55edf7208605ea58a17ae3b88d7c5801a86b016554147cae9e7f2d1e1", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "4751bd56-7c3b-4e6a-b727-e0da2363f568": {"doc_hash": "c6a39ad7b286777af74d86168acf0969a34cf86e317f4af99e882851daf3aad1", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "4d054ae2-92c5-4bfb-9267-a0a38b72f36e": {"doc_hash": "ad872f155e44ff8b456f179a45450b81f2b93dab0acb25580c03e5548d101439", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "36ec5126-2fe1-4046-a4f6-78ddf7ebba48": {"doc_hash": "264993b0d500cc4b891d52daf96a0f1e9db1f071674e0373819dccb0fd0a3074", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "e03c9af5-bb2a-491d-911e-9a25d76850c0": {"doc_hash": "9a804c0061a0e7ab80d2dff5aa14cb9b6e751aec1ff5953d2daf194e6b262c8f", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "96e7dfe3-e0f8-4b5a-9a0e-656456536e68": {"doc_hash": "1728b901e343418f51462d6e94df5bec1fa364ac87fa1add05c63b451a0ab500", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "f71adfe7-b3c3-4ddf-9be9-c553f3b2f1ec": {"doc_hash": "d307ac27d1963c3f95de63210e3a43f4d8c683a5a7f011b7d04ce3d7823b857a", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "d4fc8712-998f-432e-a818-7bd78eec8f2c": {"doc_hash": "37fb470f4a54203828549e3d3ab477725f0ec8f7d90201485a08317cacbf345b", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "394d53ed-5295-44e8-986a-be25ba243979": {"doc_hash": "01cdd73f563fdbe9b7c9a76c83f4b036822a6cc2b0fa752be9a7f059865c8b6a", "ref_doc_id": "c71a55c1-c8cb-4ff3-991a-01b42e116eb4"}, "5ab3d9b4-032e-44b4-8e75-4b32968d30d3": {"doc_hash": "c38a692bea186e1c096f7617748d54a9a121eda9c00acf483a42c2a408e262c6", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "6cf9b264-b440-410f-8077-df6cb652c993": {"doc_hash": "c905b62118e3d0ba7f4203c7737cd927f9f9f28eb2d711d91477b0b845bbf572", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "2f1bde67-8e94-41a5-8536-646fdc2c8fb6": {"doc_hash": "4085caa258d7cda52a61c1a6e5ffd3db00b63565c92cd4614c525b371b7471cf", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "f0433403-4138-4ec0-aa13-c7286508efce": {"doc_hash": "e9410efb4db741f70af8e569a2f3172c60e20f86756fdcd0566427f15a887a20", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "e3b53830-bd44-4235-8b9e-3d7d6e961aee": {"doc_hash": "7abec8a20a4e52c318942a106446a4cfecc69840dc0f5316cbb87e17ba8ce244", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "86f01dbe-db8c-42c9-af2f-12be7cdc77a6": {"doc_hash": "138f37b51a7c79788a9e30872c900464f34c9c93d959c286f7ed4f4b3d836180", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "11672702-7307-43c1-a91b-a2949bf0a623": {"doc_hash": "33a727eb754b90e2d79b53b3b7a44da5d922eaeb0064560c753e534d56c33e84", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "ec38c7d0-f218-4e5c-a56b-8a3c3142d3ab": {"doc_hash": "ecc0c949adf7e1b0c1504664c8144092a0064f7955d50dc23465b0f3a9f9c782", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "d3c9fbcc-c363-4ff6-b818-272b55462028": {"doc_hash": "a41888aadc462be62aac13f4d1ef80809b9cd07dc2362eb29c6d7f2b449e1a8b", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "15bc7c8e-cb38-48a9-923a-8502aad1f108": {"doc_hash": "7239eb77f97a2bfa08af0bf994c3821ec7d7ac5fd7edb7dffcf8a448fe3567a2", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "9d94937d-21fb-4bcb-838f-52bb61bc286a": {"doc_hash": "38b631db825f84a0a087fa28860232e8a03aeaf5d37ba46fa9a9b39fd89c72ea", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "38915316-ee1d-4ccf-b40b-015a6a768478": {"doc_hash": "e21e339b54e60f8919c5e43e1d506ec0c112d11c9fc12c30fefb6501abaf9f67", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "3a0a8b03-ee7c-4e2d-a8e9-5258bfd6b638": {"doc_hash": "1e6f5548fcc3df870c28ca8e560e66c8709b0e9a6055ae151ae96825d78c1daf", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "b65529cd-4665-42b3-aa6e-5fc1af4bc816": {"doc_hash": "c65f2405e6c9de3dcaa39d8da7ca6134fc344e314441beab542fb151a893957c", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "0c36ad55-4d09-48a7-9cd5-32b59e2abeec": {"doc_hash": "39e576aec3e398ccb8d9d74747eb0a43c620332fbe2f1806268c6cf4b63672b1", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "3af7c6ea-7443-4a0d-aab2-7ed7e4be39b9": {"doc_hash": "959b7d8483e937ff33b06b6c6e02c03e0d68b659a35f3a94ae3246176226d399", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "f10664f2-6582-4fc9-9f0a-f4c09c2e7344": {"doc_hash": "3e646c7f27d74479d81fc4e8ca6e44d5ea4a76c752bcb8dbf4944beb8c841ce9", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "289ecfd9-b73a-406b-a97a-c25123d657ad": {"doc_hash": "0921adecdb6b9319e9de563b6cf6fb120bf6268171ba9639a03a2e38a253a38c", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "8249943b-6310-4138-bfc4-d9df6f9f65d2": {"doc_hash": "db2561dc5829ead6c93c3a1e87b32f0bd26df5f866777345505d460b44c0e8c9", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "faba3b2a-0e48-4c5e-ab94-96267fec29e1": {"doc_hash": "47aacdf715cd0f14db7579b0d4df7ca59c1e786cf8a1c1efd38eadd0d1edb49a", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "e9e79ab4-368b-400f-ab6c-6aef6df972a9": {"doc_hash": "11fa7b895f585c966380c266b3aece3aeb93d5c15a1a4666231710a8d164bf35", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "960b5001-63de-4885-9a7b-e056e1e5f6e5": {"doc_hash": "62efe1a1b329904a45ef3018d98dfb4a44631da50b362f9fa6c4fe3355b400a8", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "57ce940e-3713-4de2-9b3b-933e7e27f9bd": {"doc_hash": "703cbdb802b8f6e0cfb84bae0eefaa43c102ca3552408c6776b6daac210c2fb4", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "ba49fc4d-4753-49b9-91e1-26b904ac4dd5": {"doc_hash": "85494a84d68d9921d721d2fd7acaefaf48ac4e97fa1d107e18d3a8942a80d59c", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "3c8fc4c3-51fb-4b4a-994f-925a99f81315": {"doc_hash": "42cefc935cac6d3b89dd5fdd496b4185bda957da24cd2f363f656966fe04fa96", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "097c8431-f814-4ff7-9224-04d017549088": {"doc_hash": "94d3b2522bcd7c677c8e2ca638a09e925796ec5593e6d4facd6016a2566ed176", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "b6a05654-6339-4fc8-9c45-07c515a85608": {"doc_hash": "3599c0fcd954726d33fc7bb0c888389019ea9f5440d316201b16ea59b6780fc3", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "0959e60f-b45a-4bf8-929e-fdb55116b7d0": {"doc_hash": "d27375f0db779143cabcaf6a392eae20cd58d0cfb5bb763e4cde27926b116bdf", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "4e1b8fef-719f-4187-9328-68d69ad57b25": {"doc_hash": "d677af9e26dc54da80bb67ae751a7821858b14ee10fa583155a70ae075cedfad", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "6418d3db-4b2d-4fce-9dfd-036cba8c1f9b": {"doc_hash": "d9be7a94725f199a6cf71664a8ea36deeae032d941436dfabac66afe01e50542", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "dfc336f4-d4d6-49c4-ab06-45b1d23e716d": {"doc_hash": "ea13b5b26122761b8373fabcf64c5d3bfcedd79aa9675c3c7544f38c1839786b", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "bb858eb9-533a-4dd1-8c2a-2b576ae2cda8": {"doc_hash": "a8de11890e15d20517e92325a30ed88c9b7f0a7754276e80ebadc46508cef93c", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "3832c4f8-cc3e-4c04-8582-d83c8e1e9d89": {"doc_hash": "d5273af0757c177992cfa8b5260a09f4e61a05737f27ec02a2e96f67aeba7b1d", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "f4d7bb7e-223a-4668-bd49-3abad361b835": {"doc_hash": "c0e93cddd912df88404d256e562b58dd6772bb88fd7b8fb7861c650b3d88e7ff", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "2578a559-536c-403f-8807-c91a28743e28": {"doc_hash": "c02b7c82bbed05be820beab72b8af35366fe1cba9890b2046433adf362474fa1", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "d57706ba-8b69-4cb2-84e0-1c8eaeab09ab": {"doc_hash": "0d49c7ae50fbdd475bac7e89ba6c705eb765a951c5be74ae99be23e21edcd94a", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "5bcf4294-2772-48f9-a8a5-7b656140eb3c": {"doc_hash": "dac055c5f646a41e45f6aa3f1f22a0a4378ad9217d3b3075b55836fa44bcee6a", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "84b29138-2450-4260-8f0d-2f0e8958a344": {"doc_hash": "8f27c7ebb9f6e41bf667e4a5eb0286797dff6045719ddd0557d9248c4cc2a38a", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "df5e9585-ddcf-40eb-a1be-818904c4e066": {"doc_hash": "8e17885ebf4206c89c1f4f2bc3b7d9f708ed2db06f60a02b357325596b9aadb8", "ref_doc_id": "6fd10df3-08f5-453d-8e6d-b74e7052fe44"}, "31a2d47e-e4b5-4ae3-a178-64ca4cf1dad7": {"doc_hash": "ffc21307a5a2ab889988a77fd0fae90a8151d5b8ea6f2e3176a20a5300d57096", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "1f28b034-fb03-4d13-bd27-6ea13ebdb972": {"doc_hash": "057d4a444445934e07b7b75d9917187d5e7d299f2fa3518ea7a586b1e386ad94", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "5f0f8b98-8dd8-46b5-9ed5-0ff3ac3c28f9": {"doc_hash": "9b51e368bfb40fff063d67d3b78320d1de02bd3302a3b38288896f3acb81b332", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "67546e79-7fa5-47b9-8896-920c90537afa": {"doc_hash": "80a0675e1cbbc79c22e900083e7587961a55a7514298dc801c4a39d515cda961", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "8036f237-1773-4b5d-8588-c982341e6e93": {"doc_hash": "70d414d3acb8f04232c2e730a342e7fedf1a0a2a108a333bc43da77be2b8ad20", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "93873192-e074-41e5-92db-7127481f1946": {"doc_hash": "598d0518b7af80ac71fdab2a8fc55590a024319059c1057e1a4bf41dbd997291", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "a09438a8-62e5-48c4-a8fb-10c01e116f66": {"doc_hash": "5774060cd18ab3eb17885041e2ffb7333b45d78471ca6b407ca9b3ff3da82b72", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "1b18a64b-8edc-4278-b596-461ae0cdcf05": {"doc_hash": "48efac8f4855cbae764bd1aa33c077fd6ff094765fb58fb01e092f46396b1af6", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "4c00cd10-ed9f-423d-9604-1e46f4758aff": {"doc_hash": "4f70f1861d45bf7326fc6311ab8c88fc2812558b606ddfb925d75a69444fda00", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "84c8fe53-dba1-4712-a645-2f4c3b92b927": {"doc_hash": "84aa9eb1ca81008446d7e69000542050e31022e6b56aa8ea5d89b742ee769161", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "c7d07c72-e8f3-4c3d-a4e5-52af87b35999": {"doc_hash": "6401f1dfbdd7dc469d65430a20544c90a156f87990b7125ef5e44b87a236d3dc", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "33ce3dd9-b950-48d2-a729-4e1a85941c0d": {"doc_hash": "0793d734edfdc1ac1456560f7c138d4e99b5f55604c62f5d5bf7f81d0ab250bd", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "5534d896-a0c2-4d9d-a69b-7b31bc595fad": {"doc_hash": "f5b3c46d7810fc2fbe1b4cf11b0c1d5302bba766d40c2b615e608e60a15331f6", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "27ca605b-db0f-43fe-b818-0932dd2d60c5": {"doc_hash": "c0d6515f97158cd73d1e7f36e83dbbbecf8a4c39554ae0c6ae0d9db3735a4bbf", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "e22c8788-0d43-4123-85d8-f04aa07411ef": {"doc_hash": "3b65c51d1e6d03fbaea1124bc0072bdf6a4fd6b21d21ab15c1796a08b4586574", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "06d4a7e9-f84f-4789-a1d8-c36994a5d278": {"doc_hash": "0817e115c7e279840926c8ff209d099046bea116b455a2b388e233fdc71cb2f8", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "c047fd54-4447-4fd5-816e-be69c634e664": {"doc_hash": "603c061349bc64f187b6c9a7a99bd976e9a1be66ea7f5728ce5b21ccc755b2c6", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "3e188928-30da-471f-8f98-ed14c286b090": {"doc_hash": "2eb1e81a56f9af3123772aacce551b2bbfebcd095df4ab81a7d190debb497b30", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "8160d173-3782-498c-ad6e-295c2be82429": {"doc_hash": "51493086da696b5043c019b73fdb7a0aebec10aeeb9306dbf848cfcc5d45cedf", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "97550af1-203f-404f-b42e-bacb218358c1": {"doc_hash": "dfbb0f84a3e10caa4b919efe1a4b0fdea946e49d54bf84c3df3ca095c678ad78", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "d929fa2c-6963-4827-be62-ef63a993609f": {"doc_hash": "e2276e66d6546ad7cefed1e5893b46e92cdce6220bc05f7c5ea60fe4514ce0f3", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "b358b964-0582-4b6b-bb1b-e83a64066cc2": {"doc_hash": "0fc0e011d55916f13488155aea6ad0fc1100fbb18ae87551fe094b60b74dba8a", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "952f6355-7b85-43ff-8806-969e11acca82": {"doc_hash": "d6e6885bcfbcea25785aef06394f68a3ce9873dbac7cced10193a1453fca77cc", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "9a5a9be8-c37c-46c1-be58-7aca8c4f1d97": {"doc_hash": "87c2d8926833b30708e12ee6cfcedb3035357dbeffb36f793544eae472f364d3", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "4d55269b-b8d6-45ea-b4bc-f58843bef7d1": {"doc_hash": "117bb35ce867c86675e75dbfb888d29c21bc93304228e933c96e56618c7e00dc", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "2f50d588-0029-4885-8f79-cce9694263b9": {"doc_hash": "bc4468d93debd905eadf926a264c0407071d6a3834a4cf4f37c9d52d1d4cce9f", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "0d978d17-bd9b-499b-b55f-05dc1fc19e99": {"doc_hash": "8b9491f69efda3845b092ea39228dcd3cab34e8e44e5ef4362e7db31107bdf3c", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "3ebeee86-b2cc-49ff-af54-ea44a7a7dea1": {"doc_hash": "9dcb62afa0940faefff73ee4e6688aa3ba25dafff805368b80ec9b3076f21ad3", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "064bade1-f77f-4cd5-9e11-c13445b5d3fa": {"doc_hash": "6304eea4243f5233792eb86e7a2ee57978d15bc1b6cd8628f73a13f97afc6508", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "45da7358-3c9e-4d30-ac53-9bc71dfc895a": {"doc_hash": "586ae36f2b9bd6a2ef4aacfdf0d6e7a2faa5b76a6c25bbe9234be5350f5687c9", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "f8d2ff56-ed74-48eb-a03a-dac2ff3ee16a": {"doc_hash": "fd2cc080b4944a2a02a79c3c92227cb8fbfa2905488286bb975886c217201855", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}, "ea307088-2e6f-442f-b98d-af61634a18f1": {"doc_hash": "e75a5ac89adcc0b09700bcea7876e061c10e6ec2abae7cee260e62a359715aa7", "ref_doc_id": "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827"}}, "docstore/ref_doc_info": {"6ce41d2b-3372-41ec-8dc6-18355fe24e8d": {"node_ids": ["38dd1a7d-27ba-4335-9402-e03734054c3c", "aa318a10-2b17-45a0-a4c7-11ca0eb5030d"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n02-Feb-2021  \nMcKesson Corp.   (MCK ) \nQ3 2021 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n02-Feb-2021  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "4a4d1c47-ffc7-4f60-8f04-ab974a39b49a": {"node_ids": ["b545ce81-cc7e-4fa9-a7b7-bfc56d248bd8", "71877390-36c8-461c-b0a1-96a746e9ea03", "48c17cbb-eb22-4ffe-8efd-c1227a965b57", "d6071895-5869-40fb-b13a-d38dd1a512d8", "7b83f4e1-444a-42b3-874e-a7787747e24f", "70197d07-7432-4104-8330-93d4f97f51b7", "b286532c-a62d-461a-be8b-78fb9bf58770", "ecc443c4-d1f3-4098-aebd-dca88772981e", "ba51a396-2c18-4f9b-94a0-4233194e9be8", "7d094fb8-dace-4cba-a878-9a43d07bcebf"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "7805d649-c529-4dfb-a2d8-188cd5c185e0": {"node_ids": ["78eb8fd5-0524-4b07-b320-1f7af98185f6", "82bd315a-fbaa-4d21-a386-2c46c7d0feb0", "55b759ef-c781-4fec-ac9f-7b52c205d702", "72f54f0b-0978-4278-8f7b-0f1b7008ed0a", "731545b3-a454-44d6-a58f-dd7ae2b8e975", "f20d1cfc-94d8-496b-be4d-6a6860a1f210", "336706fe-f05e-497c-98c1-1c06fb3c86bb", "9a94b739-6aef-4e25-a694-41137a34bb1a", "228d66c9-2eef-40a6-9187-8678403993b7", "db6795b3-6d96-4dee-91d4-db0d010009a3", "0bf2f928-5cc0-4e76-8ede-441a43167d80", "74725430-9b72-4525-bf0e-e524b3b7ea14", "4809b82a-5848-4f80-af25-d50cd72838c0", "6f90bcae-b99f-4f50-ae35-afabb9c6b57f", "7fa3900c-7811-452b-9c1e-4b3a086ff437", "d6d0dbb3-be71-4cbb-9e49-82565ac4a6a7", "8359b3ff-1fdc-455c-b629-162a697b904a", "bea181dd-df31-4a25-bca7-0880cbab7b4e", "0c95631b-be0f-46a2-b842-11b065048fd0", "f1684d46-5827-4295-90f4-26eb2038a823", "b78783a0-259e-4a47-a841-bb9110ebdd7e", "b85a0100-79ab-446e-a517-c41cd67dda83", "a5a6e967-fe33-4f7e-8e6d-b24dc8994b8b"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Good morning, and  welcome, everyone, to McKesson's Third Quarter Fiscal 2021 Earnings Call.  Today, I'm \njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "83b04c7e-a941-4553-b3b4-d62f5bd752bd": {"node_ids": ["6d3cfddc-4c1e-4c96-808b-9baaae2713db", "5d104eef-e398-47a3-abe6-0533b9efe8bc", "6b375ff6-850e-4f61-b00b-56cbe781c5b7", "0915b0c5-28f3-461c-b871-5ed14b2295c6", "1410ec46-cdb1-46df-bc5a-793e520f19f2", "2551dd1c-b3b3-4177-a1ba-2bd472d9e297", "37cbd0c5-42dc-4e62-ba1c-d9114fe303c8", "bb141e98-deb4-4dcc-abf1-79b213a9d1f0", "3491bef1-5fc2-4917-92da-f170209f7fd7", "22d9eb2a-fa9a-42c9-8cdd-c2bc833d2649", "b2f8211a-6791-488e-9823-7119f462c48f", "87118209-de73-4a6f-ae04-1d608aaff662", "8badf3df-0a70-4584-a279-d2bbb74d3d23", "92005848-f674-43c7-a41b-f385e000bb14", "58e27dba-0d9c-4dd6-9727-a9fd32c02945", "3e297099-a640-4ce5-8438-879911cf1455", "89bf97d8-e7c5-4637-9696-ad8f90d1086a", "2339c4db-3cae-439f-bdd4-ad1da6b3836e", "af70aa23-0324-485b-bb5b-30ee64ffbf45", "130abf23-737f-470a-846d-dd631ec6bc3b", "f70c8135-7259-41fa-804c-0afa1adc0ddd", "8a35e73a-bd5d-4e9f-aee8-da6633801f43", "cf418073-1413-4f4a-add6-0255401b3432", "2fd5df00-f307-4d7f-91fe-0e003dcd7ced", "61e02dd0-6c4f-4fc7-8ec1-643521f2511f", "f75105bb-e300-42c9-80d9-3d7860047264", "983f9fb0-ab40-404b-a09a-9a5a668fba92", "5d7cd32b-154c-4d8b-bfed-70c45ef17e61", "f729234e-bae2-490d-8521-4be6cf24c522"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nToday we are raising and narrowing our fiscal 2021 adjusted earnings per diluted share guidance range to $16.95 \nto $17.25 per diluted share.  This is up from our previous range of $16 to $16.50 per diluted share.  This update \nreflects  our solid performance in the quarter and improved outlook across the businesses, including the \nanticipated contribution from our work distributing COVID -19 vaccines and assembling and distributing ancillary \nsupply kits.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "a25013d0-e317-4e07-b596-16a98605d9b3": {"node_ids": ["1eb451b5-bec6-44c7-b643-664b59b5a741", "b213a5d9-0827-4a7e-96d6-fa6c524407b7", "dab6546f-4a4c-40fa-88a1-8ceca5315f1a", "1fe71acd-c9f3-4eed-87a7-46a1410d2c3d", "223d73f8-5a91-44d3-b355-10b6ee1b6b82", "169d44ad-5c7b-40a0-8bbe-b1c7cdea53c2", "47f9a3cb-7cc5-431a-9eee-ef6bbaeeec35", "32fe518b-d4b9-489b-acde-1385cbf4d8db", "eeeb8d89-5094-488b-b0e5-cb70571cd868", "bd996d7c-0d4c-4812-9ccf-229b5cb55aa2", "1cbb9807-cf80-4155-9fa6-4a06c84a559e", "c580e19e-e8a8-4435-9028-87c6a5fc614e", "0a141849-6c2f-4f4d-a970-afc044309af7", "8ad5bdb8-cb16-4475-bad3-18884107249d", "bb32dabd-b75b-46bf-93d3-43cf0dbcb18a", "da2a37ba-51d3-4021-b240-52aaf3549d19", "9260e91b-1c2e-493f-addb-2ad47d9676e5", "2829c412-cb29-4296-b726-ab922a89a8bb", "ae887da4-c632-4b65-b84d-2ff58fc892d5", "461c251e-ca4b-46af-91f2-b79600206e97", "023ca638-e9a0-42e6-9459-3efa8f78ae3f", "3fc3c390-2a41-41d5-9714-862183684626", "acc7369d-a4f8-49d5-9940-6cdd3c6dcd89", "e681e1ac-99cc-422e-bba2-a417d9795e31", "20d1a6e6-e351-46a6-a9cd-10e589219979", "1103d0d2-f102-4b76-b522-ae96c3dab97c", "bb4eaa02-42c7-45e1-ab7c-a1aab6a8f55a", "10a9a7a3-aa73-4736-9737-cc5e03c886ba", "2cda4f07-45d5-4259-8204-59cabe4df3de", "1072f645-1500-4d1e-b711-0689730b86d2", "4519473a-5af9-4e95-ab99-d295ad23a73b", "09f93057-a4b8-4d63-bb4f-f35b78390497"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nto-date we have assembled enough kits to support over 250 million doses.  It's  our great privilege to have been \nselected to serve the US Government for these roles and we've been engaged with the new administration's \ntransition team and stand ready to fulfill our commitments in the ongoing battle against COVID -19. \n \n Now, let's get to  the business. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "cc6cf62f-3b75-40c0-afc0-b39808bb25b3": {"node_ids": ["7717ad48-7ada-4f99-a08c-849776b21e26", "6a2b0c2e-97bd-492a-bfd6-435db8f74389", "a00284f0-1b10-47f1-841d-74cd9e5cd82b", "f0b756d4-3a24-411a-81e5-392106092233", "44859863-9b82-4c5b-878e-af372dd34020", "3414d6ff-43de-42b5-9a21-5242312b758a", "d5f77a77-e4cc-4f2e-a859-bfd018591c68", "9660841a-7cb6-4b71-87e3-dc8adf067728", "9de9ac71-c8e3-4914-974b-d699d94df8ea", "10abb2b2-22a2-433d-875e-30c8b1ea7c08", "389ac1cb-8ba8-4e20-bdeb-a7ab71d79ddd", "e750f551-410a-4ae2-8b0c-54ef9df9345a", "fa503a1f-41ff-4234-9fd0-28d148f9a091", "e1f52b15-d6de-4226-ac59-97a810b94af2", "5aebedd8-05a4-43a8-bcad-f69e2f27eda8", "81fd99b2-1b10-4c8e-8939-6b8b497400ee", "75933a68-1c99-4d0a-a919-3fd78d93e788", "30548107-4cd4-4a82-8026-74ba719371eb", "f41e0699-bf57-4d34-8c6c-fb0a242947e9", "38a4a81a-0693-4137-aa1a-3f5c63f70b96", "d983ffcc-a2be-42d2-94b6-7920cca7ac50", "d12f354b-53ff-4b1e-a087-142a17284ca1", "f17bdc66-0d51-4ecd-8945-2f81faa4fe93", "036207f7-043c-4c46-a61f-42afe0ee347f", "6a847dc3-e47a-4fca-bc90-e8d5935bbd82", "34e2e5e9-c885-4150-85fe-85a9f0ac953c", "2313e9d9-0575-410c-aab8-578a5a0266f6", "9627e903-21b1-42fe-b54a-d14c6134d457", "1869e5c5-2127-4b7f-8a33-0df08ec856e1"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nInvestments we've made into our lab business over the last few years have given us additional expe rtise and \nreach around lab testing solutions.  So, as COVID testing emerged, we have been well -positioned to expand our \nexisting partnerships and quickly drive these products into the community provider channels.  \n \n We strategically built this business to suc ceed at moments like this. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "87efe71c-a497-4ce2-bcc7-296e354ade52": {"node_ids": ["6879b280-b115-4674-b1b1-a32ae89cc63e", "b9290e65-3492-4df4-bc14-948739c70eff", "3f610c91-11ce-4549-96e4-fbac9c666064", "f2ff38a1-bca3-4c25-a365-9c385137c6bc", "472a4687-8e10-4211-a3a2-66528be44688", "aa6005d1-ab09-45d4-ae31-3cf7aba92b03", "873c0758-ec5d-47f7-b70d-e384c2b1cc9f", "448a3708-c5ae-4f2f-bd4c-e7ebb1620afa", "47f5cb84-60e1-44bc-b272-b033d15a0b27", "168e54a3-a92a-49ad-9af5-8444f439837b", "b13e458f-a59d-4dff-ab66-e322754d6aaa", "5dfcf625-8962-4772-966d-9500803f76b3", "2bc98567-2d2e-49b7-8efc-d347faa2bda9", "70995268-93ae-4590-aa54-55cc03e1dce6", "7fc5e98e-4ba8-4e05-a24d-b538382489f7", "079cb033-6767-452b-94a6-f73e3b490a85", "9c146540-5fe6-4e50-97ab-6a7edff81ce7", "be270d93-59dc-4349-8cc9-0fce096699ed", "1da4bf30-400e-41bc-b654-1f4202f69933", "2c1847ea-7574-4802-a972-35d19b99ffe4", "1307c4e7-6f91-4010-ae15-d5d6d4a1832e", "3c593057-a76a-4a0c-ba36-a87acb0c74ab", "ab40e5b7-312a-44de-bf09-bcec33df48d0", "0d0e40d5-8ee6-4b0d-8c54-b831017c4c5e", "09fb4811-03b4-41e9-92bc-ecac9bb19224", "bc46cdc1-0f68-4ffa-97fc-53abf040d50e", "04163cd6-c145-4c3e-953a-59f8d95ece74", "b97d3d02-3f9a-4c53-917d-b15c7c909e48", "4e183617-f898-4d28-aeb8-9dfd1046bac1"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nfundamentals continue to be stable and execution has improved.  Success in the core enables strong cash flow \ngeneration, which we can use to reinvest back into the business and return to our shareholders.  \n \n While the pandemic has brought an unprecedented level of uncertainty, it has not paused our strategic priorities, \nand we will continue to invest to differentiate and innovate our service o fferings to our customers. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c7818ebb-8d60-40f5-abda-fcc2f11a4afe": {"node_ids": ["625159f2-612c-46ca-910e-81b48bef8563", "e5a9120a-bf19-4160-ae9e-65f0081ed130", "87ea6fc1-15b8-4604-b069-05cd7a95730a", "fddd58d7-dc85-44e0-b61a-f967708d1bab", "a49e850a-4bc5-4ece-836d-774b4bf69c02", "e3ced4d1-2673-400c-944e-ff9023211217", "0346339d-d452-4376-ba61-5187b272f758", "da757c88-f6e3-485e-b88d-e7bfc58be2ea", "2949101d-26f7-491a-be70-b17d8e14ab5b", "06bd555d-939c-42fc-97c3-4c6ff56f2244", "c2f49db5-c503-403f-b27e-4f4c88a1b084", "fba1c902-eabd-4727-ad38-6edd637f3c71", "57c3aa20-12e3-490e-bd67-9a8f938a7fb5", "3da361fe-ca60-4e23-8e46-d8f6fa7c0e58", "5dbbea56-cb4c-4113-9d57-b24bc83e8df5", "9fb79b84-d94d-4d93-ab80-dbf49768794e", "d68fcda4-ef6f-4f7a-a84c-4236928d4ca7", "fe6c1024-0450-4cb6-b119-f3f67733da28", "39affadf-f571-4324-b3d2-1b760d740e89", "2742a2ca-4702-4508-9ace-10586714db58", "34c67f6b-5cd8-43b7-a75b-b006a0268926", "ead0f5d4-cd28-4bc7-9200-a3ef10154920", "884a15a3-6a2c-4b9e-92fe-e7e48f8885af", "493c94ca-731b-46ed-b8f8-1a8d84a78986", "d1ad7bfb-cb48-400b-841f-d3fa54023667", "821c90a3-1fb0-4181-a203-02e0f091b7ab", "d8e9cd68-6724-498f-b281-4c03be7ec71c", "dce430b7-7f71-4bcd-82a0-a450810d2e83", "eb8c7993-65e1-4157-92c9-21a25c443f09", "7f787808-d5b5-43de-9d08-adf59c6a0321", "5cff03c1-d518-4911-b006-6b60aa089cea", "6214e694-d1b2-4bb3-96a0-d7e834fe774e"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nWell, thank you, Brian, and good morning, everyone.  I'm pleased to speak to you about another solid quarter for \nMcKesson.  Against a dynamic and challenging macroeconomic backdrop,  we continued to respond to the \nevolving demand brought on by the pandemic, leveraging the breadth and scale of our distribution and services \ncapabilities.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e55034f1-51be-4c1e-9f52-4a6715b79ec7": {"node_ids": ["3abc02ae-cb43-4cdc-b11d-9619eb01b762", "a7125747-1f13-4759-94a2-1a993149472e", "feed1182-05b5-49a2-b5c8-fea823e9e625", "6ea17033-66e0-4316-acce-4d5020a5c07a", "9b6ac80c-a2d9-459f-96d0-a1d8e140a66a", "d97afb29-fb70-4b3a-9a18-9ee4d4fe23fb", "5a25e308-2007-4955-91e6-6f08b8622ed9", "4e6c6d20-f175-4b08-bfb5-f589a63be6eb", "76859463-347e-4b41-853e-0c964c0528e8", "3dff1ea8-8c1c-4639-9b6a-ab2dc7b8fba0", "93e4bd42-c8b2-440f-ae0b-b577b84a5bdc", "eb896f3d-b867-4f33-b385-5a48099057b6", "8eefe91e-4b88-4ae5-b194-c6c8e6145f1a", "484ac9d6-a22e-4a0b-b80c-8b05d95d032b", "a1e70d42-8466-4cd0-b98e-75deb184d26b", "9c05f315-183f-4c95-a180-83a9a8378c03", "33d49ac4-2de3-4df5-8fc4-dd7e58f15c4c", "5f194c86-af9b-4d24-8be6-96b3b5b140e6", "4229859b-965c-4dfc-bf6f-dfba50008773", "b819602e-af52-4235-9db4-670d50d4f1f8", "fcd90753-b0af-4d2a-a8ae-4b8dfa614b3e", "fccbd99b-9584-46cc-a5c2-4c1c29fa3981", "0cdf0472-da77-4050-9a33-d129d44d5ce3", "bed89a27-1d92-4790-b1c9-1dfbd8edb0a9", "ad051438-5e2b-49e0-b3d2-0e7ba457c0cf", "2383e33e-604d-459b-b551-07353e8ad9d5"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating expenses increased 2% year -over-year, led by higher operating expenses to support growth in \nstrategic investment s across the business, partially offset by the contribution of our German wholesale business \nto the joint venture with Walgreens Boots Alliance and a reduction in operating expenses due to the impact of \nCOVID -19. \n \n Adjusted operating profit was $1.1 billion  for the quarter, an increase of 11% compared to the prior year.  When \nexcluding the $51 million contributed by Change Healthcare in the prior year, which was previously recorded in \nOther, adjusted operating profit grew 18%, exceeding our expectations.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "0f2a9aad-4e4d-4537-a25d-87a978b16b92": {"node_ids": ["518ac18f-81be-40d3-8bf1-c1018e4a9d3a", "672085d7-3704-4881-a57c-e5f557d2ef46", "296cbf9d-dc10-4f3b-a267-25cec7ec158b", "6dd8aa47-43cb-43c4-9ca2-2c8e6b8f3e98", "1c6c93a1-f84f-45e0-b38f-ebb2ba4ae8e8", "36ec6937-7b93-4c9c-999a-2c8c41b2d700", "8243e97f-ea35-423c-9670-c3c601e2fc39", "43481d98-90c7-42aa-b3c3-afa00df38dc6", "fc28ae99-bbab-4f2d-862a-1f35a2640b9c", "f01045c6-86d3-4c0b-8c24-10831cd9d62a", "e02f751a-9e50-44bb-92af-ebc5348bd5b6", "52ce847a-7030-49bc-8093-7c6875714ffc", "527e934f-1928-458a-bc8c-f152e8240234", "9c2d8e8a-b525-4ab0-bf24-e52b597387de", "2e4da415-04ec-4fc2-bdf6-c9d75fc60246", "92addbb9-a3ea-439c-a001-8b93d5493690", "32cc18c7-26ca-4906-8907-d4630997c146", "bd540dba-1f81-4bb7-8f10-37aedc3992f1", "8a8ca926-f5da-4cfb-976c-d50ba6402241", "2733f0ca-937e-44f3-801f-45910d9f0bf3", "3448f426-bc04-4d31-b9d4-76b91f5ccaa4", "6abeb063-26d9-4198-8e31-0a11e42fd253", "f9d6d7eb-6a48-42a2-a1d8-7a68886d732a", "5a9238db-6f89-4a03-951b-4f3853c244b3", "5c264609-71f3-4602-95fb-dceef3f8d8c8", "30d8ba1f-ca52-4448-8407-cf8984eac727", "148e2572-e7c3-4b0c-bfb9-560cdfcea2d4", "b9899304-4164-47de-849b-81eacef93fbc"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nGerman wholesale business, segment revenue increased 4% year -over-year and was flat on a n FX -adjusted \nbasis.  \n \n Adjusted operating profit increased 9% year -over-year to $158 million.  On an FX -adjusted basis, adjusted \noperating profit increased 3% to $150 million, primarily driven by two additional sell days in the European \nbusiness compared to the prior year.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "145a20f6-59a6-44dc-b2a4-ddb32139b282": {"node_ids": ["8cee55e0-4c35-4e29-9503-92831409e035", "d9cc98ed-14be-44cf-a3ec-28b494cb1de4", "e9a75af7-87e4-4c11-976d-1f7391c513b1", "2b0e9fa8-38f2-415f-adde-c198aa53261e", "7a244f89-d860-4249-959a-dd8aacd28965", "ab19a41c-da3c-4c63-a78f-21ecdd816e5d", "3b432f1c-eb11-44ab-ab8a-13303f7430d7", "c684f2ae-fc94-415b-8643-5839bd3e97a8", "089a3874-e49a-4e77-a26f-35b9b15fd984", "e03d1643-8a00-46f5-91e4-1144c5f0d6a1", "4d75eade-63b6-4030-91ba-60801e38550f", "6e001030-53b4-4e9e-9268-d761a7dabdb7", "25aecd66-0ed5-49ab-9227-183bfec04319", "96036f9e-78e4-4dcf-8d58-7677212d81a8", "3b0b0ca8-187e-49df-b525-2559b6248f2b", "367c4f56-1143-4533-a7ff-93d74a92622c", "ad46d9cd-7441-48e1-bc2e-7c822bd1a713", "9cdbe0ae-6ecc-4f77-a19d-8cfa0edb8b66", "e28eb4fa-bbb1-4055-9982-e72ad71db54a", "0c07252c-0dfb-4652-b4ce-0a95d850ce9a", "c4fd9bdc-2ec3-4fd0-9f48-75afe01c96de", "6baa69fa-618e-497c-832f-bd0c88197fb4", "c2499827-b829-433a-9a95-b74462551e3d", "2da6de91-be19-49a2-bfa5-c441fbc5e715", "7950d5f3-63be-47a9-9fa8-53c6dbccbf66", "0a78d001-71cc-4644-8cbe-db4f16edd65e", "36828cf7-f5d0-491d-983e-cfc063641b1c"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs I mentioned on our second quarter call, it's difficult to predict when gains or losses on our venture portfolio \ncompanies may occur and, therefore, our practice has been and will continue to be not include ventures portfolio \nimpacts in our guidance.  And  finally, we reported opioid -related litigation expenses of $34 million in the quarter \nand for fiscal 2021 we anticipate that opioid -related costs will be approximately $160 million.  \n \n Turning now to cash which can be found on slide 11. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "d0516ff1-c8bb-4fde-926a-6cb9de02b904": {"node_ids": ["e5936876-768b-4e61-847e-2d2f69ee6889", "d254eb80-2781-4818-81b9-a10b5e2a3a2a", "b1ff1ca3-9496-4aee-835b-2c2c118eef0a", "d8fb2ab3-5c91-408e-b077-f5dcb129da6b", "18dab790-0e68-4d4f-80f1-c04b6ce4df90", "56ab5f76-6a01-4705-b1f1-5fc535078b9c", "ab08f443-2bc5-4a34-86cc-d7efd4739b2c", "fc21e756-1d0e-483a-9f81-33ae387d0cdc", "ec6b21ba-a7f0-4c5d-af68-0698fb90b9c6", "0ebdc7fd-2f8a-4e88-9fa2-f747fd133732", "09ac6bb2-16db-41cd-b1ac-cbb32a032bb9", "718b230a-aeef-49ae-a2b6-77244d579c85", "d8208c04-0e27-46ff-90a4-5b1caf9a6313", "4fbe613b-9c45-4e88-8195-dc43c017467f", "fac9ecaf-cde6-4114-8aa8-27b052876f74", "93213fdd-9f12-43d8-a375-313ca2868edb", "935678a8-88d8-4056-8b91-d9c16c35dcbd", "cb766495-fdfa-4a66-be9d-afec306a30f5", "adb3dae9-d685-42fe-b238-9dbc984b8cae", "3b197093-1f03-41ef-a52e-420c83a259ea", "b806e4cc-79b7-430c-b4f2-8c83fd7bb36e", "f1076b4c-5d26-44a5-9d12-b988536e544b", "95f1a12f-6931-4a3e-8138-8f01b9c813ad", "2b555871-fb62-4f8e-bb8b-9b9db9d5ea50", "59211d96-3276-49a2-840b-5e0b097ecbb2", "08165203-81e7-4c98-8f7a-cc783db97bce", "4f9b33c4-304c-4a9a-ad16-42e1ca389ae4", "cd73d913-59df-46a7-b97e-298dcdffd70e", "5e92e504-a8e6-436b-8b39-a3b480ec14ad", "28c8c488-587e-433f-bd00-409058ae7212"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nNow moving to the segments.  In our U.S.  Pharmaceutical segment, we continue to expect revenue growth of 3% \nto 6% and now expect adjusted operating profit to grow 2% to 5% compared to the prior year. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c20f803b-e0d0-435e-8722-82afd7d3dfc0": {"node_ids": ["9afb920f-0838-4d74-8b85-2e30c41b577d", "27371df5-75a0-468b-909f-842e5d0e397d", "eb333738-60bd-4e45-8bad-9ce7c3588af6", "b0fb9584-a411-4e4c-8294-7a90fc0b28f7", "c701210c-14e4-45af-b0db-76a0de73fe5e", "de4c30c6-07ec-42ae-9583-8af050b78834", "314c0f68-87e3-4f90-a338-d95f278d5c6d", "52926c40-f213-4065-83bf-77704259f81d", "aadc36b2-e8a6-4eee-9157-41cf1b9538cb", "69b5e25f-c243-4b61-ba9e-4251491995a2", "3d235b88-c9cf-4a80-852b-6ff65d1c9bde", "93a9f7d6-c223-4b27-9ea8-e2b2b7a3c664", "cefdb178-fb58-49c2-8aef-6a225c5f0484", "83b3640b-cde9-4e5c-abec-8d63ea7e738e", "59593de9-88c3-46e0-99e1-beac873081f1", "a228f731-1d24-4210-b2d6-631581311675", "b1ba0c46-5568-4194-a032-16b118879150", "9170ca6b-c831-4fa1-a555-a7687adde2e0", "081e83c4-0ef5-4ca3-91eb-c1df33260efb", "2a72874d-3f00-4ec2-87b7-59e5221cba70", "db9c89f0-9275-4d37-94b4-ae6ee2e65e48", "c9470000-7397-471f-a8d1-d9c404f65f38", "dc3c0d4c-267a-4846-9a3f-8780dd2e6f30", "abe2ae4a-91e4-496e-8615-04fc0ade0fdc", "7730d5ba-a801-4c40-a53c-3a3b6f2f2fc7", "631ae70a-2e90-4f79-8a80-529ceac6aa77", "a841b3d6-81b1-4434-935c-01c523d6ff72", "34d7b68e-a660-41cc-bbb0-d4d8f4091754", "d8b818ff-65fe-4349-b7e5-0680aaefb3f7", "29182047-0b72-42f4-a9ce-5f22f7c374b5"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nour role in the pandemic response, working to get vaccines and ancillary supplies into the communities that need \nthem.  \n \n And with that, Holly, let me turn the call back over to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e58db0dc-c8ed-43f1-b6f3-af4ea9774bfd": {"node_ids": ["458e00ca-0ad7-4468-9437-c4f31b16b0ad", "37197734-21ad-4427-8f67-21b3b00939c1", "db0476b2-40f4-4bab-9865-9a8c3c4affca", "8faf4072-c3c9-480a-9de9-af476c63d9f5", "2d00a49c-15a4-4e47-be26-c8f32de6e7ea", "7294f7da-0858-4ff8-9345-f88b7578938d", "1beea350-b2f6-4a48-baf1-79f8c0863cf9", "46884386-6a01-4c93-a661-4110af3ee4b1", "cb24db04-6d3b-4e7c-b374-a4261f3c7c55", "261143c1-57fe-43c5-b975-91e1a3061ebe", "b99929d5-82fe-4de8-91b3-f3446a01312e", "b21231a9-411d-4058-acae-7b1969863f22", "cf1f4b2e-4ed0-4ad3-bba9-5246ecc24211", "826d38ec-4a0b-4610-b4da-c725b90020fc", "d099745e-4647-4e6a-ac3e-344fa9c028df", "ccb860d8-37fc-41ae-b213-535847395450", "53ec5dd8-0629-4470-959b-e7e6e896a4df", "d1bad39a-148c-4dca-a778-20a2e6dfe58f", "6f043f4b-a524-46da-8075-0e37b1fffa36", "dd200555-38d5-474e-9994-aec798e47a12", "83e2e364-91bd-49d2-9f14-4f81508662bb", "b05999c6-c251-4cfb-9d88-1c77a52b1f66", "78c1dff8-b51b-4cfd-a439-546d8ff595a6", "de5fcaf0-0dee-4ea6-a848-cf31e1ef425c", "e39bbe81-f6c7-4640-91dd-dfbea35ffbac", "0f1f4b81-4aba-4c68-9ccd-7fb10f7a4ee9", "10c0924e-aa0b-4df2-a36e-47d7809ada5d", "01e82e06-82c8-4492-bde4-f39589738bf4", "19a00b6f-c844-4bd8-8387-35bf8a2468a8", "46d5af73-9a78-4cfd-925d-718691676b52", "84d7edc8-008a-4c0e-9ced-bef95cda4016", "0470aa4c-1bd0-4076-8f68-cdbb45cb192f", "9ba8d025-cbb4-4d20-9cde-0f6d54bead5e", "77d07391-a6b6-4cc8-836f-ca9165d75a86", "c37362aa-966c-4618-ac72-7a4b8d8c93b4", "ce6bc3a7-e9f2-4f8a-9111-5f8c11bbb71c", "ce59d728-7ef6-4b22-b7ba-160e02f069b1"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAnd as I talked about, we invested about 2% of headwind year -over-year in Ontada.  So I think as this continues to \npersist, as our vaccine distribution begins to take hold, we feel comfortable that the business is stable and is \nshowing good \u2013 the fundamentals of it are strong and the growth is still there.  And again, that  allows us to \ncontinue to make investments for further growth going forward.  \n ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "10c17b1f-1297-4b9b-b906-6a61e058c790": {"node_ids": ["c56dec4c-d24a-4acd-889c-1ebc8fabca29", "4516986c-1f8f-45b0-904c-d086db47e723", "2ff75f50-6aa3-416e-8d66-9efc3dc3852e", "9329efc5-08db-46a2-af91-5eab6274918a", "879eb2da-a5db-463d-bed5-aee8879e3caa", "ba0816f6-fefc-4181-ace5-8332bd802334", "32780749-e88f-4b0e-aede-98ba411c93c1", "56ad9cac-5d95-4b1a-9b7d-6fe57cd60c4b", "5b9414c7-025f-404d-a1d0-5e2c206ecfa3", "56407c3a-99b8-471e-a575-a4ae019aed8d", "83447fdd-d579-4831-bd96-738b39d7878e", "0021258f-8def-499a-9e95-785cb0d38bd7", "6071aad9-0ecf-4919-89cc-fed50e7f3a75", "8bc4c945-45d3-415f-ace9-827a987e4713", "c3df7df9-22af-489e-bcca-fbd6d11fff3b", "011dc32f-4626-4212-a9f9-0711a89f28c4", "f6c57703-4d3b-4612-8079-d299ab2304d6", "96867894-7617-475d-b58b-90ddba56a198", "3e869dc4-3410-4d64-9d27-2bdc2a33b41d", "c32d2f15-ada6-4b6c-8d51-6785310cd077", "13273932-7196-4122-a499-5d990bef731a", "261941de-fd15-42fb-ab1d-21c0273798f2", "6b8071eb-425e-443c-9dc9-2802d36f85ea", "741b3698-ef39-4455-af4c-8fd1a1c5f202", "6cb15c2c-f898-4d91-97d4-ec3c2a6f9675", "d92d8ef8-c72e-4ccf-9ed7-2d17edaa2328", "b6291e14-7d6e-4636-b8fb-b3deaacae94f", "a18a7f70-8c89-46d4-8dfb-287355e232fe", "6ac629a4-a971-4ef4-b882-c3f838db1353", "94a92063-a42d-4b34-a9c3-13d9f47c4883", "7d2457c9-bf9f-4957-b59f-89ed8c6b929a", "be5db252-9361-4cac-b370-4336ba5b0d3a", "ac276198-992a-4d4c-bbbd-c0a8e624ebd0", "9893cd72-1870-4ad7-be96-31a4c976f33b", "ea6cca50-1d19-47ac-a17e-9199d40a176e", "3de608f0-57da-4463-b143-7370b7d4d0bc", "d49cc609-73d6-4657-a3d3-43a03d0afa23", "7205682d-975f-4feb-b3bf-ae8f1c717f9e", "83e7a6df-0b33-408c-ba48-a1de9e15dae8", "8f609b18-f23b-4590-a1c7-1f9a7aec5640", "d38d3531-2acd-4979-9193-ab4a664c993a", "038e0c0d-96e1-4c5f-9dfd-448425f5a222", "f4240ed4-5d3e-4796-849c-04bd994b746f"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Eric Coldwell from  Baird.  \n ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "db8d5d3e-e808-457d-b744-7224d3302f44": {"node_ids": ["63faace0-b5fb-4efc-83ad-c54db56cb696", "a7a57b37-57f3-4307-8f80-3cc0836d7482", "b83b0ea8-e6ee-4cad-acc1-13961964e231", "0eba3e75-d4d6-4da5-8e3d-78eec5a7f589", "d60cbbba-4c11-4903-b7e1-91fe568df2ea", "eec78512-3fa9-4d11-86a3-c680d6e88ddf", "d752a15b-a0b3-408c-8dae-cdf18fb9aee6", "458b2302-05f0-46ef-8ec4-afc858b6b4c9", "945a7464-5bb6-4568-8f15-a057043de8c7", "a86bd9d0-934b-4136-8514-1e151a2017f7", "40779665-dd3f-4f8e-a765-0abb8906ebae", "f8bced18-5ec8-4f19-9d77-2a4ca5ea8298", "bdf44eb0-a0b4-4bb8-bac6-f2634aa5d529", "f5ee7bad-e252-4c3d-bd64-cf672a9a0d6d", "738bd9c6-6013-4971-ba69-5f625e4a2331", "dfdc5cfc-1836-4429-b7a9-08bf9ac58f8a", "fa2bb967-b253-4621-8045-62f09cb99943", "cf82442a-3740-4c6c-9733-bde2817d8a18", "879093b7-7d0e-40c6-8a6e-eaac7daeb74a", "6e56bb5d-5b09-4b6a-948b-fd34c6569359", "1bd000e7-0600-4222-a271-d6f23b212f8e", "da0f03e8-560f-490b-a83d-1d0a9ba5d3c3", "cb82764c-e55d-4833-a434-8b8c5e26f5a6", "13489f26-1014-480d-badd-9918d31d010e", "0968ce33-e5de-4cf8-98a5-fa6a38231bae", "18835154-a547-4a46-b56b-4f0ce8b8b9c7", "5b3e6ad0-875b-4b39-9870-51d907578a08", "6bf00cb5-9c25-4536-aa97-0cf9ee27ace8", "c8ea22ad-faf6-40a0-a732-90e84ccfddef", "2fc77c86-dd04-4533-a63d-c6125b4a61a1", "74581cdb-a03c-4156-b9cf-5612ccbaf73b", "3d8d9c82-304c-485a-8089-aa620348d209", "0ce1c3cd-41bc-4d3b-9612-fddbcce2f561", "88b37a4c-a69e-478e-bd53-ca451d3e3427", "c3cd5a3f-3023-4ee3-8935-f8b5fe5cd27c", "d84385a1-09d0-4510-bac7-ae809864e98e", "43a40742-a8ff-4377-bd31-3af3907e051b", "706c5a0d-c012-43dc-b15b-08d281babd14", "83f9daf7-9d48-422e-9c53-001a775df315", "9e99ec59-5e6d-4289-995e-1ed8d29b52ee", "257fa90e-c0de-4af3-a32e-a73dc8ccb24c", "959965f5-05b1-4d73-853d-d6ace5c0bfb5", "5b6b3d61-762a-4bc2-b1cc-ac00487e760e", "98d4bdb2-1997-4edf-bd89-ffa4bc0dbabc"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nother ancillary COVID -related supplies.  But I am just wondering even taking that out, it was a particularly strong \nresult, just given where that business has been and I know utilizat ion hasn't exactly been even or strong in this \nenvironment.  So I was hoping maybe you could just talk a little bit about what's driving the growth kind of ex the \nvaccine kitting related items that you quantified.  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "6ac7948c-840a-4576-910f-d22be89beb77": {"node_ids": ["007f14c5-b700-4aed-ac00-8f491a8bb0bd", "01dcb3f5-1bf8-432d-93fc-6714bbc12adb", "aa19da2c-66c9-45b4-a8ad-37079f5dc49d", "746b1be4-c714-402e-a860-80867612c7ab", "c7b78c38-4a6e-4aa8-a8f5-d8a7f2c4c439", "e1167720-6c1e-4484-b12b-c63e7f371c9c", "336868d9-1fe3-49b5-817d-4de1527ed823", "ab7b1257-f0fb-475e-b646-22d8df98c2e4", "2a99e7d9-1b22-4abc-a5bf-a969bc08f4fc", "1d7f9c74-86e9-43c5-9665-8fc8c320610a", "14937692-3fbf-416d-8ffb-254d0a5f11fc", "ae5afb72-1e8c-4113-8cef-e110892ea113", "f5b3294c-0265-4446-a13a-e15c9fd0819b", "35f1e843-6b11-42f5-8745-9748746172e3", "87ff3ef5-72d4-4399-91ec-6e6c8965b2a1", "f84ac324-769e-4f8f-ab0b-fc95929857f4", "8967fef5-a0b8-4566-bec8-b525901e3546", "07505390-43df-483e-a725-241d9728f5ed", "5e580d55-ae1c-4dfb-8959-211fcd59b729", "3386d0ce-2af5-4161-b300-cdb7ea023af8", "012aa14c-e413-4dfb-9e87-737e0a079c78", "66ced4c7-c53b-4403-8881-f84d28003b71", "77e418c5-a50a-4408-a9cc-78d452b50711", "b9b771be-b39e-4bbb-b516-6a8976ce07b0", "6aafa541-8a5b-41e1-8a8b-ce23e053abc2", "3aa3a2dc-4ae4-47ea-97ad-dcaca633c35c", "bbce21b6-0302-4cef-bc4d-4a5414bd69b8", "6c5c3ce4-1cdf-474d-a560-c2fc0940539f", "3efe36e7-2d83-40a7-bf43-8c170c240c32", "c238d40b-3ed5-4eb0-aeff-7bdd3d12d4b8", "052a07c2-4934-4e1a-b382-14625813f28f", "44e59188-6206-471e-8e35-773d911c9f41", "9b388715-3c35-40d0-be46-4fb2efe5dd3a", "4ab76461-0ff0-47a9-8077-4797d7ffc09d", "dc1119d1-d8f0-4ef5-b9ee-196341296ee4", "62ba9b61-5f6a-4bdd-b13e-b1583599fbc2", "90303622-fa9b-440f-b52e-1fdc4ac9bd14"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nThank you.  So, in Medical, I think a lot of questions on kitting, vaccine.  Am I wrong to expect that this is really \ntesting -driven strength? ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c71a55c1-c8cb-4ff3-991a-01b42e116eb4": {"node_ids": ["7385dc4b-bfc8-4367-9e7b-2a74901ff8b9", "061d8647-7deb-4841-829f-be3c4817fbe1", "7075bd82-20b2-44b1-9fe8-2d2c3d9f31d9", "0f008790-2956-4f15-a24b-23ea3642fcd9", "6d808a5f-61d7-461a-a2f8-e9e7c9561848", "f8fbfa72-d7b7-430c-a0b2-3ad8aed3a9f6", "98ff77b7-6305-422b-b23a-9b7a3e5410af", "c437555c-ae45-4464-b1fc-8c4a10c64589", "28562d13-8f29-4fa6-a4e5-5dc1039d86e8", "eb1ad679-1325-4aba-9537-d0789c6db02f", "3bce4caf-96e2-4d4a-85f2-ed5903073431", "e0f3bb48-c5e1-4251-ab73-f7d3378f5e64", "3c48e2f1-4589-4b05-8661-d9b18626aa61", "91cb59b5-69f4-484f-8cd9-dcb239558665", "9030b909-e0bc-402f-8845-2919423f31fa", "5f13086f-348a-4042-860e-eb5f7e99628e", "fca98014-73f4-4b8f-a3a2-62e0332665c1", "adfc0a97-d783-4f2b-a6c5-7d00829b9e31", "6ea94b1e-6c06-49cd-9165-fee7c248ada6", "762b03e4-349f-441e-be60-504cbe7ff0f2", "4d8ddbfc-660c-497b-b640-cbdee8ff40ec", "c6bc9e47-1cc3-4aef-a1bd-8b11a424fd47", "96529926-c5d1-424a-b6fc-1669b6c6796e", "cd016f96-fbe7-4dc0-a225-5f936a308e99", "0f66c9d5-e784-4613-ab6a-d42820e1a3a5", "95016df3-d394-4035-ad94-b2b4f97b3ad8", "95a7b89b-ca54-43d5-ad4c-28f2ba2a1b73", "a440587f-b1db-454f-a443-900060df66a3", "0ce998a6-b752-4154-b3ae-46ab9d25f98c", "1589ab44-46b2-48f1-9378-375c96feba9a", "9c8c0636-fc36-4ba4-a9a6-e090676f55c4", "49df2a31-8bf3-4874-9dd7-cb1f5a67b6b7", "4751bd56-7c3b-4e6a-b727-e0da2363f568", "4d054ae2-92c5-4bfb-9267-a0a38b72f36e", "36ec5126-2fe1-4046-a4f6-78ddf7ebba48", "e03c9af5-bb2a-491d-911e-9a25d76850c0", "96e7dfe3-e0f8-4b5a-9a0e-656456536e68", "f71adfe7-b3c3-4ddf-9be9-c553f3b2f1ec", "d4fc8712-998f-432e-a818-7bd78eec8f2c", "394d53ed-5295-44e8-986a-be25ba243979"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsupport those strategies.  So I would say that a portion of that is to support the infrastructure, but a larger portion \nof that is really to support ongoing growth initiatives.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "6fd10df3-08f5-453d-8e6d-b74e7052fe44": {"node_ids": ["5ab3d9b4-032e-44b4-8e75-4b32968d30d3", "6cf9b264-b440-410f-8077-df6cb652c993", "2f1bde67-8e94-41a5-8536-646fdc2c8fb6", "f0433403-4138-4ec0-aa13-c7286508efce", "e3b53830-bd44-4235-8b9e-3d7d6e961aee", "86f01dbe-db8c-42c9-af2f-12be7cdc77a6", "11672702-7307-43c1-a91b-a2949bf0a623", "ec38c7d0-f218-4e5c-a56b-8a3c3142d3ab", "d3c9fbcc-c363-4ff6-b818-272b55462028", "15bc7c8e-cb38-48a9-923a-8502aad1f108", "9d94937d-21fb-4bcb-838f-52bb61bc286a", "38915316-ee1d-4ccf-b40b-015a6a768478", "3a0a8b03-ee7c-4e2d-a8e9-5258bfd6b638", "b65529cd-4665-42b3-aa6e-5fc1af4bc816", "0c36ad55-4d09-48a7-9cd5-32b59e2abeec", "3af7c6ea-7443-4a0d-aab2-7ed7e4be39b9", "f10664f2-6582-4fc9-9f0a-f4c09c2e7344", "289ecfd9-b73a-406b-a97a-c25123d657ad", "8249943b-6310-4138-bfc4-d9df6f9f65d2", "faba3b2a-0e48-4c5e-ab94-96267fec29e1", "e9e79ab4-368b-400f-ab6c-6aef6df972a9", "960b5001-63de-4885-9a7b-e056e1e5f6e5", "57ce940e-3713-4de2-9b3b-933e7e27f9bd", "ba49fc4d-4753-49b9-91e1-26b904ac4dd5", "3c8fc4c3-51fb-4b4a-994f-925a99f81315", "097c8431-f814-4ff7-9224-04d017549088", "b6a05654-6339-4fc8-9c45-07c515a85608", "0959e60f-b45a-4bf8-929e-fdb55116b7d0", "4e1b8fef-719f-4187-9328-68d69ad57b25", "6418d3db-4b2d-4fce-9dfd-036cba8c1f9b", "dfc336f4-d4d6-49c4-ab06-45b1d23e716d", "bb858eb9-533a-4dd1-8c2a-2b576ae2cda8", "3832c4f8-cc3e-4c04-8582-d83c8e1e9d89", "f4d7bb7e-223a-4668-bd49-3abad361b835", "2578a559-536c-403f-8807-c91a28743e28", "d57706ba-8b69-4cb2-84e0-1c8eaeab09ab", "5bcf4294-2772-48f9-a8a5-7b656140eb3c", "84b29138-2450-4260-8f0d-2f0e8958a344", "df5e9585-ddcf-40eb-a1be-818904c4e066"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, let me talk about your opening comments on the vaccine itself and then maybe Britt can give us a few \nheadwinds and tailwinds.  First, just to reiterate, our guidance is based on the schedule that the CDC has provided \nto McKesson. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "a2d80b70-52a1-4d7a-b5d0-de64cf3d1827": {"node_ids": ["31a2d47e-e4b5-4ae3-a178-64ca4cf1dad7", "1f28b034-fb03-4d13-bd27-6ea13ebdb972", "5f0f8b98-8dd8-46b5-9ed5-0ff3ac3c28f9", "67546e79-7fa5-47b9-8896-920c90537afa", "8036f237-1773-4b5d-8588-c982341e6e93", "93873192-e074-41e5-92db-7127481f1946", "a09438a8-62e5-48c4-a8fb-10c01e116f66", "1b18a64b-8edc-4278-b596-461ae0cdcf05", "4c00cd10-ed9f-423d-9604-1e46f4758aff", "84c8fe53-dba1-4712-a645-2f4c3b92b927", "c7d07c72-e8f3-4c3d-a4e5-52af87b35999", "33ce3dd9-b950-48d2-a729-4e1a85941c0d", "5534d896-a0c2-4d9d-a69b-7b31bc595fad", "27ca605b-db0f-43fe-b818-0932dd2d60c5", "e22c8788-0d43-4123-85d8-f04aa07411ef", "06d4a7e9-f84f-4789-a1d8-c36994a5d278", "c047fd54-4447-4fd5-816e-be69c634e664", "3e188928-30da-471f-8f98-ed14c286b090", "8160d173-3782-498c-ad6e-295c2be82429", "97550af1-203f-404f-b42e-bacb218358c1", "d929fa2c-6963-4827-be62-ef63a993609f", "b358b964-0582-4b6b-bb1b-e83a64066cc2", "952f6355-7b85-43ff-8806-969e11acca82", "9a5a9be8-c37c-46c1-be58-7aca8c4f1d97", "4d55269b-b8d6-45ea-b4bc-f58843bef7d1", "2f50d588-0029-4885-8f79-cce9694263b9", "0d978d17-bd9b-499b-b55f-05dc1fc19e99", "3ebeee86-b2cc-49ff-af54-ea44a7a7dea1", "064bade1-f77f-4cd5-9e11-c13445b5d3fa", "45da7358-3c9e-4d30-ac53-9bc71dfc895a", "f8d2ff56-ed74-48eb-a03a-dac2ff3ee16a", "ea307088-2e6f-442f-b98d-af61634a18f1"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2021 Earnings Call  Corrected Transcript  \n02-Feb-2021   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ncontribution and the kitting and supply contribution are US.  contributions.  And I'll let  Brian maybe talk a little bit \nabout our International.  \n ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY21-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 382773, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}